
<html lang="en"     class="pb-page"  data-request-id="d1a0c990-02c9-4a79-b2ee-8a349db9cd54"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-22;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.8b01467;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity" /></meta><meta name="dc.Creator" content="Yue-Mei  Zhang" /></meta><meta name="dc.Creator" content="Michael N.  Greco" /></meta><meta name="dc.Creator" content="Mark J.  Macielag" /></meta><meta name="dc.Creator" content="Christopher A.  Teleha" /></meta><meta name="dc.Creator" content="Renee L.  DesJarlais" /></meta><meta name="dc.Creator" content="Yuting  Tang" /></meta><meta name="dc.Creator" content="George  Ho" /></meta><meta name="dc.Creator" content="Cuifen  Hou" /></meta><meta name="dc.Creator" content="Cailin  Chen" /></meta><meta name="dc.Creator" content="Shuyuan  Zhao" /></meta><meta name="dc.Creator" content="Jack  Kauffman" /></meta><meta name="dc.Creator" content="Raul  Camacho" /></meta><meta name="dc.Creator" content="Jenson  Qi" /></meta><meta name="dc.Creator" content="William  Murray" /></meta><meta name="dc.Creator" content="Keith  Demarest" /></meta><meta name="dc.Creator" content="James  Leonard" /></meta><meta name="dc.Description" content="A novel series of 6-benzhydryl-4-amino-quinolin-2-ones was discovered as cannabinoid type 1 receptor (CB1R) inverse agonists based on the high-throughput screening hit, compound 1a. Structure–activ..." /></meta><meta name="Description" content="A novel series of 6-benzhydryl-4-amino-quinolin-2-ones was discovered as cannabinoid type 1 receptor (CB1R) inverse agonists based on the high-throughput screening hit, compound 1a. Structure–activ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 19, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01467" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01467" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01467" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01467" /></link>
        
    
    

<title>6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01467" /></meta><meta property="og:title" content="6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0001.jpeg" /></meta><meta property="og:description" content="A novel series of 6-benzhydryl-4-amino-quinolin-2-ones was discovered as cannabinoid type 1 receptor (CB1R) inverse agonists based on the high-throughput screening hit, compound 1a. Structure–activity relationships were studied to improve in vitro/in vivo pharmacology and restrict distribution to the peripheral circulation. We adopted several strategies such as increasing topological polar surface area, incorporating discrete polyethylene glycol side chains, and targeting P-glycoprotein (P-gp) to minimize access to the brain. Compound 6a is a P-gp substrate and a potent and highly selective CB1R inverse agonist, demonstrating excellent in vivo metabolic stability and a low brain to plasma ratio. However, brain receptor occupancy studies showed that compound 6a may accumulate in brain with repeat dosing. This was evidenced by compound 6a inhibiting food intake and inducing weight loss in diet-induced obese mice. Thus, a strategy based on P-gp efflux may not be adequate for peripheral restriction of the disclosed quinolinone series." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01467"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01467">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01467&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01467&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01467&amp;href=/doi/10.1021/acs.jmedchem.8b01467" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 10276-10298</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01433" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01487" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB<sub>1</sub>) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yue-Mei Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yue-Mei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 1-215-628-7923. E-mail: <a href="/cdn-cgi/l/email-protection#6811120009060f5d28011c1b46020602460b0705"><span class="__cf_email__" data-cfemail="e990938188878edca9809d9ac7838783c78a8684">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yue-Mei++Zhang">Yue-Mei Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6052-8120" title="Orcid link">http://orcid.org/0000-0001-6052-8120</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael N. Greco</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael N. Greco</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+N.++Greco">Michael N. Greco</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark J. Macielag</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark J. Macielag</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+J.++Macielag">Mark J. Macielag</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher A. Teleha</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher A. Teleha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+A.++Teleha">Christopher A. Teleha</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Renee L. DesJarlais</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Renee L. DesJarlais</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Renee+L.++DesJarlais">Renee L. DesJarlais</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuting Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuting Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuting++Tang">Yuting Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">George Ho</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">George Ho</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=George++Ho">George Ho</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cuifen Hou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cuifen Hou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cuifen++Hou">Cuifen Hou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cailin Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cailin Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cailin++Chen">Cailin Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuyuan Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuyuan Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuyuan++Zhao">Shuyuan Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jack Kauffman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jack Kauffman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jack++Kauffman">Jack Kauffman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raul Camacho</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raul Camacho</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raul++Camacho">Raul Camacho</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jenson Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jenson Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jenson++Qi">Jenson Qi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William Murray</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William Murray</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William++Murray">William Murray</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keith Demarest</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keith Demarest</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keith++Demarest">Keith Demarest</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">James Leonard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Leonard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Leonard">James Leonard</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01467&amp;href=/doi/10.1021%2Facs.jmedchem.8b01467" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 10276–10298</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 19, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 September 2018</li><li><span class="item_label"><b>Published</b> online</span>19 October 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 21 November 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01467" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01467</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10276%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYue-Mei%2BZhang%252C%2BMichael%2BN.%2BGreco%252C%2BMark%2BJ.%2BMacielag%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D22%26contentID%3Dacs.jmedchem.8b01467%26title%3D6-Benzhydryl-4-amino-quinolin-2-ones%2Bas%2BPotent%2BCannabinoid%2BType%2B1%2B%2528CB1%2529%2BReceptor%2BInverse%2BAgonists%2Band%2BChemical%2BModifications%2Bfor%2BPeripheral%2BSelectivity%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10298%26publicationDate%3DNovember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01467"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1169</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01467" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yue-Mei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;N. Greco&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;J. Macielag&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;A. Teleha&quot;},{&quot;first_name&quot;:&quot;Renee&quot;,&quot;last_name&quot;:&quot;L. DesJarlais&quot;},{&quot;first_name&quot;:&quot;Yuting&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Ho&quot;},{&quot;first_name&quot;:&quot;Cuifen&quot;,&quot;last_name&quot;:&quot;Hou&quot;},{&quot;first_name&quot;:&quot;Cailin&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Shuyuan&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Jack&quot;,&quot;last_name&quot;:&quot;Kauffman&quot;},{&quot;first_name&quot;:&quot;Raul&quot;,&quot;last_name&quot;:&quot;Camacho&quot;},{&quot;first_name&quot;:&quot;Jenson&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;Murray&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;Demarest&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Leonard&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;10276-10298&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01467&quot;},&quot;abstract&quot;:&quot;A novel series of 6-benzhydryl-4-amino-quinolin-2-ones was discovered as cannabinoid type 1 receptor (CB1R) inverse agonists based on the high-throughput screening hit, compound 1a. Structure–activity relationships were studied to improve in vitro/in vivo pharmacology and restrict distribution to the peripheral circulation. We adopted several strategies such as increasing topological polar surface area, incorporating discrete polyethylene glycol side chains, and targeting P-glycoprotein (P-gp) to minimize access to the brain. Compound 6a is a P-gp substrate and a potent and highly selective CB1R inverse agonist, demonstrating excellent in vivo metabolic stability and a low brain to plasma ratio. However, brain receptor occupancy studies showed that compound 6a may accumulate in brain with repeat dosing. This was evidenced by compound 6a inhibiting food intake and inducing weight loss in diet-induced obese mice. Thus, a strategy based on P-gp efflux may not be adequate for peripheral restriction of the disclos&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01467&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01467" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01467&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01467" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01467&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01467" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01467&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01467&amp;href=/doi/10.1021/acs.jmedchem.8b01467" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01467" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01467" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01467%26sid%3Dliteratum%253Aachs%26pmid%3D30339387%26genre%3Darticle%26aulast%3DZhang%26date%3D2018%26atitle%3D6-Benzhydryl-4-amino-quinolin-2-ones%2Bas%2BPotent%2BCannabinoid%2BType%2B1%2B%2528CB1%2529%2BReceptor%2BInverse%2BAgonists%2Band%2BChemical%2BModifications%2Bfor%2BPeripheral%2BSelectivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D22%26spage%3D10276%26epage%3D10298%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/jmcmar.2018.61.issue-22/20181121/jmcmar.2018.61.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of 6-benzhydryl-4-amino-quinolin-2-ones was discovered as cannabinoid type 1 receptor (CB<sub>1</sub>R) inverse agonists based on the high-throughput screening hit, compound <b>1a</b>. Structure–activity relationships were studied to improve in vitro/in vivo pharmacology and restrict distribution to the peripheral circulation. We adopted several strategies such as increasing topological polar surface area, incorporating discrete polyethylene glycol side chains, and targeting P-glycoprotein (P-gp) to minimize access to the brain. Compound <b>6a</b> is a P-gp substrate and a potent and highly selective CB<sub>1</sub>R inverse agonist, demonstrating excellent in vivo metabolic stability and a low brain to plasma ratio. However, brain receptor occupancy studies showed that compound <b>6a</b> may accumulate in brain with repeat dosing. This was evidenced by compound <b>6a</b> inhibiting food intake and inducing weight loss in diet-induced obese mice. Thus, a strategy based on P-gp efflux may not be adequate for peripheral restriction of the disclosed quinolinone series.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57633" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57633" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cannabinoid type 1 receptor (CB<sub>1</sub>R) is the most abundant 7-transmembrane, G protein-coupled receptor (GPCR) in the brain and is also widely expressed in peripheral tissues such as liver, adipose, pancreas, and skeletal muscle.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> CB<sub>1</sub>R may be up-regulated in some disease states such as liver fibrosis and obesity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> CB<sub>1</sub>R antagonists/inverse agonists (CB<sub>1</sub>RAs/CB<sub>1</sub>RIAs) have been shown in the clinic to induce weight loss and improve metabolism in obese dyslipidemic<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and diabetic patients.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> However, the occurrence of severe neuropsychiatric liabilities such as depression, anxiety, and suicidality, led to market withdrawal of the CB<sub>1</sub>RIA, rimonabant, as well as the termination of clinical development programs for several other brain penetrant CB<sub>1</sub>RIAs (ibipinabant, taranabant, and otenabant).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Nevertheless, the weight loss independent benefits of rimonabant on hepatic steatosis and improvement of other metabolic parameters,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> including elevation of HDL cholesterol and plasma adiponectin, reduction of plasma triglycerides and LDL cholesterol, and improvement of insulin sensitivity, suggest that a peripherally restricted CB<sub>1</sub>RIA could be of benefit in the treatment of type 2 diabetes. Moreover, a potential role of CB<sub>1</sub>R in the inflammatory response associated with nonalcoholic steatohepatitis (NASH) has been suggested by the reduction of liver inflammation in obese rats following treatment with CB<sub>1</sub>RIAs.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> A clinical case study also demonstrated improvement of liver enzymes, metabolic parameters, and hepatic mitochondrial function of a NASH patient treated with a CB<sub>1</sub>RIA.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> CB<sub>1</sub>R may also play a role in pathological renal conditions. Treatment with CB<sub>1</sub>RIAs dramatically reduced the development of renal fibrosis in mice.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The contribution of the CB<sub>1</sub>R to the development of renal fibrosis was recently demonstrated in human nephropathies and correlates with kidney function.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Thus, the potential utility of peripherally restricted CB<sub>1</sub>RAs or CB<sub>1</sub>RIAs for the treatment of metabolic disorders and its associated complications remains.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Various CB<sub>1</sub>RIAs with low brain-penetration have been disclosed, including molecules designed around the 2,3-diarylpyrazole (rimonabant), 2,3-diaryl-dihydropyrazole (ibipinabant), or diphenyl purine (otenabant) templates.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11−14)</a> The 2,3-diaryl-dihydropyrazole-based peripherally restricted CB<sub>1</sub>RIA JD5037 is to enter the PhI trial for the treatment of NASH.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">In an attempt to discover peripherally restricted CB<sub>1</sub>RIAs, a 4-styrylquinolin-2-one compound <b>1a</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <b>1a</b>) emerged from an internal high throughput screening (HTS) campaign as a highly selective and structurally distinct CB<sub>1</sub>RIA with modest in vitro potency. Initial lead optimization around this scaffold (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, scaffold <b>1</b>) focused on three aspects prior to enhancing peripheral restriction properties: (1) improving CB<sub>1</sub>R in vitro inverse agonism potency, (2) diminishing cytochrome P450 (CYP450) inhibition by replacing the imidazolyl group with a suitable R<sup>4</sup> substituent<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (C6 position); and (3) removing the styryl moiety with potential chemical instability and in vivo metabolism liabilities (C4 position). The specific sites modified in SAR studies of scaffold <b>1</b> are outlined in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of rimonabant, quinoline-2-one-based HTS hit <b>1a</b>, and the generic scaffold <b>1</b> with sites of modification labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61866" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61866" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> outlines the general synthesis of quinolones in series <b>5</b>, <b>6</b>, and <b>9</b> in which the imidazolyl or C4 styryl moieties of compound <b>1a</b> are replaced and in series <b>7</b> and <b>8</b> in which N1 or C2 respectively are substituted. The key intermediate <b>2</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> was treated with an organolithium or Grignard reagent at −78 °C to give compound <b>3</b>. Deoxygenation of <b>3</b> in an aqueous SnCl<sub>2</sub>/HCl solution gave compound <b>10</b> which underwent Suzuki coupling to provide compounds <b>5b</b>–<b>e</b> . Buchwald amination of <b>10</b> or <b>3</b> with various amines followed by acidic deoxygenation if required led to compounds <b>5p</b>–<b>r</b> and the compounds in series <b>9</b>. Further derivatizing C4 amino-piperidinyl ring of compound <b>5n</b> and <b>11</b> with various polar electrophiles resulted in compounds <b>5m</b>, <b>5o</b>, <b>9c</b>,<b>d</b>, and <b>9e</b>,<b>f</b>. Alternatively, Buchwald amination of compound <b>2</b> with 1-trifluoromethylsulfonylpiperidin-4-amine yielded compound <b>12</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Compounds in Series <b>5</b>, <b>6</b>, <b>7</b>, <b>8</b>, and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) R<sup>4</sup>Li or R<sup>4</sup> MgBr, −78 °C, THF; (b) SnCl<sub>2</sub>·2H<sub>2</sub>O, HCl, AcOH; (c) Pd(OAc)<sub>2</sub>, SPhos, K<sub>3</sub>PO<sub>4</sub>, 35 °C, THF; (d) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, 100 °C, Cs<sub>2</sub>CO<sub>3</sub>, dioxane; (e) Et<sub>3</sub>SiH, TFA/CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) 48% HBr, 100 °C, 96%; (g) ClSO<sub>2</sub>R′, BrR′, TEA, CH<sub>2</sub>Cl<sub>2</sub>; or R′CHO, NaBH<sub>3</sub>CN, MeOH, AcOH; (h) aq NaOH, THF/MeOH; (i) NH<sub>4</sub>Cl, DIEA, HATU, DMF, 47%; (j) R<sup>1</sup>Br or R<sup>1</sup>OTs, Cs<sub>2</sub>CO<sub>3</sub>, 80 °C, CH<sub>3</sub>CN.</p></p></figure><div class="NLM_p">In a similar fashion, treatment of compound <b>12</b> with heteroaryl lithium or Grignard reagents and subsequent deoxygenation furnished compounds in series <b>6</b> with a variety of R<sup>4</sup> substituents. The final target compounds in series <b>6</b> can be further derivatized to a mixture of compounds in series <b>7</b> and <b>8</b> by <i>SN2</i> displacement reactions. We found the regioselectivity toward formation of compounds <b>8</b> (<i>O</i>- vs <i>N</i>-alkylation) was enhanced by increasing the size of the electrophiles. Compounds <b>5g</b> and <b>5j</b>–<b>l</b> can be prepared from intermediate <b>4</b> via Suzuki coupling or Buchwald amination followed by conversion of the secondary hydroxyl group to an imidazolyl group by treatment with imidazole and carbonyldiimidazole (CDI) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> describes the synthesis of compounds <b>5h</b> and <b>5i</b>, prepared from the common intermediate <b>13</b>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Silver-mediated <i>O</i>-alkylation of compound <b>13</b> with benzyl bromide provided the ketone <b>17</b>, which was converted to the corresponding 2-quinolone derivative <b>18</b> with <i>m</i>-CPBA followed by treatment with tosyl chloride and potassium carbonate. Reduction of the ketone followed by conversion of the alcohol to target compound <b>5h</b> was conducted as described previously. Compound <b>5i</b> was prepared in a similar fashion except that copper-catalyzed amidation was used for C4 elaboration to give intermediate <b>15</b>. Compounds <b>6i</b> and <b>6k</b> were synthesized from intermediate <b>19</b> via a two-step sequence (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Mitsunobu reaction of compound <b>19</b> with 4-chlorophenol in the presence of PPh<sub><b>3</b></sub> and diethyl azodicarboxylate (DEAD) followed by deprotection of the <i>t</i>-butyl ether gave compound <b>6i</b>. Compound <b>6k</b> was obtained by treating compound <b>19</b> with thionyl chloride and SN2 displacement of the resulting chloride with <i>N</i>-phenyl piperazine. Grignard addition of compound <b>12</b> followed by deoxygenation gave a mixture of <i>E</i>,<i>Z</i>-6-(diarylvinyl)quinolinone, which was reduced via hydrogenation in the presence of PtO<sub>2</sub> to provide compound <b>6j</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Compounds in Series <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:5), rt, 92%; (b) NaBH<sub>4</sub>, MeOH, 92%; (c) R<sup>3</sup>B(OH)<sub>2</sub> or R<sup>3</sup>Bpin, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 80 °C, dioxane/H<sub>2</sub>O; (d) Imidazole, CDI, rt, CH<sub>2</sub>Cl<sub>2</sub>; (e) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, 100 °C, Cs<sub>2</sub>CO<sub>3</sub>, dioxane.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>5h</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BnBr, Ag<sub>2</sub>CO<sub>3</sub>, 100 °C, toluene, 65%; (b) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 100%; (c) TsCl, K<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 60–80%; (d) NaBH<sub>4</sub>, MeOH, rt, 84–91%; (e) imidazole, CDI, rt, CH<sub>2</sub>Cl<sub>2</sub>; (f) PBr<sub>3</sub>, DMF, rt, 80%; (g) PhCONH<sub>2</sub>, CuI, <i>trans</i>-<i>N</i>,<i>N</i>-dimethylcyclohexane-1,2-diamine, K<sub>3</sub>PO<sub>4</sub>, 100 °C, toluene, 54%.</p></p></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>6b</b>, <b>6i</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, 99%; (b) 4-ClPhOH, PPh<sub>3</sub>, DEAD, CH<sub>2</sub>Cl<sub>2</sub>; (c) TFA, CH<sub>2</sub>Cl<sub>2,</sub> rt; (d) SOCl<sub>2</sub>; (e) 1-phenylpiperazine, TEA, CH<sub>2</sub>Cl<sub>2</sub>; (f) Et<sub>3</sub>SiH, TFA/CH<sub>2</sub>Cl<sub>2</sub>, rt; (g) 4-F-BnMgBr, −78 °C, THF; (h) PtO<sub>2</sub>, MeOH, H<sub>2</sub>, rt; 22%.</p></p></figure><div class="NLM_p">The analogues with C-linked or N-linked substituents in the C8 position were prepared as shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Tribromoquinoline <b>20</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> was treated with potassium <i>t</i>-butoxide or sodium methoxide and the resulting 2-alkoxy-quinoline reacted with 4-chlorophenyl magnesium bromide at low temperature to yield compound <b>21a</b> and <b>21b</b>. Pd-catalyzed amination of 4,8-bisbromoquinolones <b>21a</b>,<b>b</b> yielded the intermediates <b>22a</b>,<b>b</b> with high regioselectivity (<b>22a</b>,<b>b</b>/bis-amination byproduct = 9:1 based on the crude proton NMR analysis). A second Pd-catalyzed amination provided compounds <b>7d</b>–<b>f</b> with various amino substituents in the C8 position. The C8 alkyl side chain in compound <b>7c</b> was installed via Suzuki coupling followed by hydrogenation. The resulting 2-methoxyquinoline was heated in aqueous HCl to give quinolinone <b>7c</b>.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>7c</b>, <b>7e</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) KOBu<sup>t</sup> or NaOMe, 65 °C, toluene; (b) 4-ClPhMgBr, 0 °C, THF; (c) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, 85–100 °C, Cs<sub>2</sub>CO<sub>3</sub>, dioxane; (d) Et<sub>3</sub>SiH, TFA/CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 80 °C, dioxane/H<sub>2</sub>O, 66%; (f) PtO<sub>2</sub>, H<sub>2</sub>, rt, 70%; (g) 4 N HCl, 100 °C, 59%; (h) aq NaOH, THF/MeOH.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a> describes the synthesis of another set of quinoline compounds <b>8a</b>–<b>g</b> with O-linked substituents in the C8 position. The 4-bromo-8-methoxyquinoline <b>24</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> was treated with excess Grignard reagent under reflux and the resulting bis(4-chlorophenyl)methanol was deoxygenated with Et<sub>3</sub>SiH and TFA to give compound <b>25</b>. The 8-hydroxyquinoline <b>8a</b> was obtained by Buchwald amination of compound <b>25</b> and subsequent BBr<sub>3</sub> demethylation. Quinolines <b>8b</b>–<b>g</b> bearing C8 alkoxy side chains were then prepared from the key intermediate <b>8a</b> via SN2 displacement with various alkyl tosylates or halides.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>8a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-ClPhMgBr, THF, reflux, 63%; (b) Et<sub>3</sub>SiH, TFA/CH<sub>2</sub>Cl<sub>2</sub>, rt, 90%; (c) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C, 48%; (d) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, 72%; (e) R<sup>5</sup>Br or R<sup>5</sup>OTs, Cs<sub>2</sub>CO<sub>3,</sub> 60 °C, DMF; (f) aq NaOH, THF/MeOH; (g) NH<sub>4</sub>Cl, HATU, DIEA, DMF, rt, 29%; (h) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:10), rt.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The CB<sub>1</sub>RIA activity of quinolones <b>5a</b>–<b>r</b> with modifications in the C4 position (R<sup>3</sup>) and the R<sup>4</sup> portion was evaluated in a cell-based cyclic adenosine monophosphate (cAMP) functional assay. The structure–activity relationships (SARs) are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The R<sup>4</sup> substituent is essential for CB<sub>1</sub>RIA potency. Replacing the imidazolyl group of <b>1a</b> with a hydroxyl group diminished in vitro activity of compound <b>5a</b>. However, a 2-thiazolyl group appeared to be a suitable replacement for the <i>N</i>-imidazolyl to maintain modest in vitro potency while removing CYP450 inhibitory activity (<b>5d</b>) (IC<sub>50</sub> > 10 μM for isoforms 3A4, 2C9, 2D6, 1A2, 2C19, in CYP450 human liver microsome assay). Keeping the R<sup>4</sup> imidazolyl substituent constant, compounds with a diverse array of C4 substituents (<b>5g</b>–<b>l</b>) were investigated, yielding a range of in vitro CB<sub>1</sub>RIA potencies. The structure and orientation of the C4 group had a significant effect on CB<sub>1</sub>R inverse agonism activity. Analogues with a C–C bond (<b>1a</b>, <b>5g</b>), an ether linkage (<b>5h</b>), and an amide bond (<b>5i</b>) as a linking moiety or an analogue with a more rigid C4 group (<b>5r</b>) exhibited moderate to poor CB<sub>1</sub>R inverse agonism activity. We identified compound <b>5l</b> with a 4-amino-<i>N</i>-(trifluoromethyl)sulfonyl)piperidinyl R<sup>3</sup> substituent as a potent CB<sub>1</sub>RIA. Furthermore, the related 2-thiazolyl analogue <b>5m</b> exhibited moderate in vitro liver microsome stability and excellent in vitro functional activity. Compound <b>5m</b> also has a high affinity for the CB<sub>1</sub>R, as demonstrated in a competitive binding assay that employed [<sup>3</sup>H] CP-55,940 as radioligand and human CB<sub>1</sub>R expressed in CHO cell membranes (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Both the <i>N</i><sup>1</sup>-substituent on the piperidinyl ring (<b>5n</b>, <b>5o</b>) and the nature of the C4 amino substituent (<b>5p</b>,<b>q</b>) are important for in vitro potency and metabolic stability. Compound <b>5p</b> with a 3-aminopyrrolidinyl-<i>N</i>-trifluoromethylsulfonyl R<sup>3</sup> substituent showed lower liver microsome stability than <b>5m</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of the Compound <b>5</b> Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0012.gif" alt="" id="gr8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0013.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data represent the mean of at least two independent experiments performed in duplicate.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Microsome Stability, CYP450 Inhibitory Activity, and Binding Affinity of <b>5m</b> and <b>5p</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">% rem @ 10 min</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="."><i>h</i></th><th class="colsep0 rowsep0" align="center" char="."><i>r</i></th><th class="colsep0 rowsep0" align="center" char="."><i>m</i></th><th class="colsep0 rowsep0" align="center">CYP450 IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">CB<sub>1</sub> IC<sub>50</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="char" char=".">62.2</td><td class="colsep0 rowsep0" align="char" char=".">60.1</td><td class="colsep0 rowsep0" align="char" char=".">47.8</td><td class="colsep0 rowsep0" align="left">3A4, 2C9, 2D6, 1A4 >10; 2C19 ≈ 8</td><td class="colsep0 rowsep0" align="left">0.0044</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5p</b></td><td class="colsep0 rowsep0" align="char" char=".">20.4</td><td class="colsep0 rowsep0" align="char" char=".">27.9</td><td class="colsep0 rowsep0" align="char" char=".">19.1</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">NT</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">[<sup>3</sup>H] CP-55,940 as CB<sub>1</sub>R radioligand</p></div></div></div><div class="NLM_p">After identifying a viable C4 substituent, we further investigated the SAR of the R<sup>4</sup> portion in the compound <b>6</b> series to improve potency and in vitro metabolic stability (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>6a</b> with a 4-chlorophenyl R<sup>4</sup> substituent has comparable in vitro potency to rimonabant and excellent liver microsome stability (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Noteworthy, the results of the selected compounds from <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> in the liver microsome stability studies suggested that the R<sup>4</sup> substituent had a moderate impact on in vitro metabolic stability in series <b>6</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf" class="ext-link">Supporting Information</a>). As noted in the compound <b>5</b> series, compound <b>6b</b> without an R<sup>4</sup> substituent is 40-fold less potent than compound <b>6a</b>, indicating the importance of this pharmacophoric element. While a variety of substituted phenyl and heteroaryl groups are well tolerated (<b>6c</b>–<b>g</b>), larger R<sup>1</sup> (<b>6h</b>) and more flexible R<sup>4</sup> substituents (<b>6i</b>–<b>k</b>) are detrimental to in vitro potency. Given its excellent potency, in vitro stability, and lack of chirality, a bis(4-Cl-phenyl)methyl group in the C6 position was chosen as a key molecular feature for additional SAR studies of other positions.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of Compounds in Series <b>6</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0014.gif" alt="" id="GRAPHIC-d7e1569-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0015.gif" alt="" id="GRAPHIC-d7e1570-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Data represent the mean of at least two independent experiments performed in duplicate</p></div></div><div></div></div><div class="NLM_p">Next, we sought to incorporate physical properties to enhance peripheral exposure but limit the blood–brain barrier penetration of the 4-aminoquinoline-2-one scaffold. Several physicochemical properties such as lipophilicity, molecular weight, polar surface area (PSA), acidity, and hydrogen bonding play an important role in blood–brain barrier (BBB) permeability for passive diffusion compounds.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Additionally, high selectivity for peripheral receptor action has been achieved by modifying BBB penetrant drugs with a discrete polyethylene glycol (dPEG) moiety,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> resulting in analogues with high molecular weight and increased hydrodynamic radius. The challenge for all of these strategies is to identify tolerant sites for chemical modifications that will retain bioactivity. We utilized empirical and computational modeling approaches to define solvent exposed regions in the 6-benzhydryl-4-aminoquinolin-2-one scaffold for incorporating H-bond donors, polar groups, or dPEG side chains (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure. <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). At the time of this SAR exercise, no CB<sub>1</sub>R crystal structures were available. We established a ligand-based model using the “Flexible Superposition” method in MOE.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> With rimonabant as the template, we flexibly superimposed the series of quinolones described here. <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A shows the resulting overlay of compound <b>6a</b> and rimonabant. Abundant SARs around the rimonabant series and our proposed superposition provided helpful information on potential solvent exposed sites of compound <b>6a</b>. In the rimonabant series, the methyl on the pyrazolyl ring and the piperidinyl moiety, which overlay with the C8 position and C4 amino piperidinyl moiety of compound <b>6a</b>, respectively, have been extensively explored for peripheral modifications.<a onclick="showRef(event, 'ref11 ref21'); return false;" href="javascript:void(0);" class="ref ref11 ref21">(11,21)</a> This approach identified C4 and C8 of the quinoline-2-one scaffold as potential positions for incorporating additional functionalities. Later, a crystal structure was reported of CB<sub>1</sub>R in complex with the antagonist AM6538, a close analogue of rimonabant.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We used this structure along with our overlay model to define a predicted binding pose for our quinolone series (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Starting from the conformation used in the flexible overlay, the pyrazole core of rimonabant along with the two pendant phenyl rings were superimposed on the matching atoms of AM6538 from the crystal structure (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). The transformation matrix determined from this superposition was applied to the pose of compound <b>6a</b> from the flexible overlay to orient <b>6a</b> in the ligand binding site of the CB<sub>1</sub>R crystal structure. This process preserves the overlay from the flexible superposition while orienting both rimonabant and compound <b>6a</b> in CB<sub>1</sub>R. The torsion connecting the piperidinyl-aminocarbonyl group of rimonabant to the pyrazole core required adjustment of about 45 deg to match AM6538. Corresponding changes in torsions of the aminopiperidine substituent of the quinolone series were made. Adjustments to the torsion angles of side chains M103, I105, F170, F174, H178, and M384 were required to relieve steric clashes with the quinoline carbonyl oxygen and the trifuoromethylsulfonyl piperidinyl substituent (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf" class="ext-link">Supporting Information</a> for coordinates of the model). This binding pose confirmed the solvent accessibility predicted by our ligand-based model.</div><figure id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0003.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Overlay model of rimonabant (cyan carbons) and compound <b>6a</b> (pink carbons). Arrows indicate positions on the 4-aminoquinolinone scaffold that were explored to increase peripheral restriction. (B) The same overlay, with minor adjustments as described in the text, in the context of the CB<sub>1</sub>R-AM6538 crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TGZ">5TGZ</a>). CB<sub>1</sub>R is shown with white carbons, AM6538 with purple carbons, and compound <b>6a</b> with pink carbons. The blue arrow indicates the C8 position and the tunnel toward solvent. (C) Atoms in red were used to superimpose the rimonabant conformation from the flexible overlay onto AM6538 from the cocrystal structure with CB<sub>1</sub>R (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TGZ">5TGZ</a>)<a onclick="showRef(event, 'cit22a'); return false;" href="javascript:void(0);" class="ref cit22a">(22a)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We probed the N1, C2 carbonyl, and C8 positions with substituents containing polar groups, H-bonding (especially H-bond donors or HBDs), or short discrete PEG side chains while maintaining the amino <i>N</i>-trifluoromethylsulfonyl piperidinyl moiety in the C4 position. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, in the compound <b>7</b> subseries, R<sup>1</sup> substituents larger than a methyl group reduce in vitro potency (<b>7b</b>), and charged R<sup>5</sup> substituents are not well tolerated (<b>7e</b>,<b>f</b>) although topological polar surface areas (tPSA) are increased. On the other hand, small, polar C8 substituents maintain CB<sub>1</sub>RIA potency but enhance CB<sub>2</sub> inverse agonist activity (<b>7c</b>,). In the compound <b>8</b> series, the in vitro CB<sub>1</sub>RIA potency is inversely correlated to dPEG length in the C2 position (<b>8h</b>–<b>j</b>). We also prepared several quinolines with polar groups or dPEGs in the C8 position (<b>8a</b>–<b>g</b>). The CB<sub>1</sub>RIA potencies are improved for the compounds with the polar or charged groups distant from the quinoline core (<b>8c</b> vs <b>8d</b>,<b>e</b>) and a similar SAR was observed in the 2-alkoxy-quinoline series (<b>8k</b> vs <b>8l</b>). However, the introduction of hydrocarbon spacers in the compound <b>8</b> series greatly increases clogP values beyond a drug-like range. A long dPEG side chain was tolerated in this case as predicted by our modeling of the receptor binding mode, but CB<sub>1</sub>/CB<sub>2</sub> R selectivity was compromised (<b>8g</b>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of Compounds <b>7</b> and <b>8</b> and in Silico Properties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0016.gif" alt="" id="gr13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0017.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Data represent the mean of at least two independent experiments performed in duplicate.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Calculated values.</p></div></div><div></div></div><div class="NLM_p">Because incorporating polar groups or dPEGs into the N1, C2, and C8 positions of the quinoline-2-one scaffold while maintaining CB<sub>1</sub>RIA potency and high CB<sub>1</sub>/CB<sub>2</sub>R selectivity was not successful, we turned our attention to modification of the C4 amino piperidinyl moiety. <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> summarizes in vitro potencies of the compound <b>9</b> series with various hydrophobic or polar R substituents. The calculated cLogP and tPSA values of the compound <b>9</b> series analogues are also included for estimating passive molecular transport through membranes.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compounds containing carboxylic acids are generally considered to have low BBB permeability.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, carboxylic acid or carboxamide functional groups increase tPSA and lower cLogP values as expected but significantly reduce CB<sub>1</sub>R in vitro potency (<b>9c</b>,<b>d</b> vs <b>9b</b>, <b>9i</b>,<b>j</b> vs <b>9h</b>). In contrast, the ester analogue <b>9h</b> retains in vitro potency. Similar SAR has been reported previously.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> Arylation of the piperidinyl nitrogen with a pyrimidine leads to a potent CB<sub>1</sub>RIA <b>9l</b>. However, compound <b>9l</b> has the lowest calculated tPSA value (70.2 Å<sup>2</sup>) among all compounds in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The tPSA of brain penetrant molecules is typically found to be less than 70 Å<sup>2</sup>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and compounds with high tPSA, usually greater than 100 Å<sup>2</sup>, have lower BBB permeability.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR of Compounds <b>9a</b>–<b>l</b> and Their cLogP and tPSA Values</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0018.gif" alt="" id="gr15" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0019.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">In vitro functional data represent the mean from at least two independent experiments performed in duplicate.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Calculated value.</p></div></div><div></div></div><div class="NLM_p">Although BBB permeability can be controlled by varying tPSA and lipophilicity, boosting affinity for efflux transporters may be used as an alternative strategy to decrease central nervous system (CNS) exposure. P-Glycoprotein (P-gp), also known as the multidrug resistance (MDR1) protein, is one of the most important CNS efflux transporters and has been utilized to reduce central exposure in the development of drugs with neuropsychiatric side effects.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> Assessment of CB<sub>1</sub>RIAs as P-gp substrates can be done using a variety of in vitro assays measuring bidirectional transport across polarized cell monolayers.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The Madin–Darby canine kidney (MDCK)-MDR1 assay was employed to predict brain permeability of the quinoline-2-one compounds but low compound recovery possibly due to nonspecific binding complicated interpretation of the assay results. As an alternative, compounds <b>6a</b> and <b>9l</b>, which have excellent in vitro potency and reasonable metabolic stability, were subjected to a plasma/brain distribution study in mice (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Following oral administration of 20 mg/kg, the B/P ratio of compound <b>9l</b> increased slightly from 1 to 4 h although its plasma concentration decreased, suggesting it was in the elimination phase. In contrast, compound <b>6a</b> had good plasma exposure and a low B/P ratio at both time points (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf" class="ext-link">Supporting Information</a> for CNS activity). The in vitro pharmacology and safety profiles of compound <b>6a</b> were further assessed and summarized in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Tables <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. Compound <b>6a</b> is a selective CB<sub>1</sub>RIA with high CB<sub>1</sub>R binding affinity and its in vitro CB<sub>1</sub>R potency is comparable to rimonabant. The CYP450 inhibition liability exhibited by screening hit <b>1a</b> was eliminated in compound <b>6a</b>. The plasma protein binding (PPB) of compound <b>6a</b> was very high, likely due to its high lipophilicity (cLogP = 6.15).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mouse Plasma/Brain Distribution<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> of Compounds <b>6a</b> and <b>9l</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">% rem @10 min<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="."><i>h</i></th><th class="colsep0 rowsep0" align="center" char="."><i>m</i></th><th class="colsep0 rowsep0" align="center" char="."><i>r</i></th><th class="colsep0 rowsep0" align="center" char=".">time (h)</th><th class="colsep0 rowsep0" align="center" char="±">plasma<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (nmol/mL)</th><th class="colsep0 rowsep0" align="center">brain<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (nmol/g)</th><th class="colsep0 rowsep0" align="center">B/P</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char="±">1.72 ± 0.20</td><td class="colsep0 rowsep0" align="center">0.012 ± 0.004</td><td class="colsep0 rowsep0" align="center">0.0073</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char="±">1.94 ± 0.24</td><td class="colsep0 rowsep0" align="center">0.019 ± 0.015</td><td class="colsep0 rowsep0" align="center">0.0099</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left">      </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9l</b></td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">57</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char="±">4.16 ± 1.84</td><td class="colsep0 rowsep0" align="center">BLOQ</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char="±">2.89 ± 0.017</td><td class="colsep0 rowsep0" align="center">0.107 ± 0.096</td><td class="colsep0 rowsep0" align="center">0.037</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">20 mg/kg (po) in C57bl/6j mouse (perfused brain); vehicle: 10%PEG400/10%solutol; BLOQ = below level of quantitation; NA = not applicable.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Percentage remaining after 10 min in human, mouse, and rat liver microsomes.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Mean conc (nmol/mL) ± std dev (nmol/mL).</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Mean conc (nmol/g) ± std dev (nmol/g).</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro Profile of Compound <b>6a</b> and Rimonabant</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">hCB<sub>1</sub> EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">hCB<sub>2</sub> EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">hCB<sub>1</sub> IC<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">hCB<sub>1</sub> IC<sub>50</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rimonabant</td><td class="colsep0 rowsep0" align="char" char=".">0.0041</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.0069</td><td class="colsep0 rowsep0" align="char" char=".">0.0046</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0083</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.0012</td><td class="colsep0 rowsep0" align="char" char=".">0.0013</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">[<sup>3</sup>H] CP-55,940 as CB<sub>1</sub>R radioligand;</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">[<sup>3</sup>H] rimonabant as CB<sub>1</sub>R radioligand; NA = not available</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vitro Off-Target and Safety Screening of Compound <b>6a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">CYP450 IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">PPB (%)</th><th class="colsep0 rowsep0" align="center" char=".">Cerep panel (μM)</th><th class="colsep0 rowsep0" align="center" char=".">invitrogen kinase panel (μM)</th><th class="colsep0 rowsep0" align="center" char=".">hERG (μM)</th><th class="colsep0 rowsep0" align="center">Ames</th><th class="colsep0 rowsep0" align="center">glutathione conjugation</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4, 2C9, 2C19, 2D6, 1A2 >10</td><td class="colsep0 rowsep0" align="char" char=".">99.99</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>50</td><td class="colsep0 rowsep0" align="center">negative</td><td class="colsep0 rowsep0" align="center">negative</td></tr></tbody></table></div></div><div class="NLM_p">To better understand the mechanism by which compound <b>6a</b> was restricted to the periphery, the plasma and brain exposures were measured in the P-gp knockout (KO) mouse model following oral administration of 20 mg/kg (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). The plasma levels of compound <b>6a</b> in both P-gp KO and wild type (WT) mice were similar. However, the B/P ratio in P-gp KO animals was increased ∼26-fold (0.72 compared to 0.027 for the WT animal), indicating that compound <b>6a</b> indeed is a P-gp substrate in mice, and its low brain concentration is due to P-gp efflux. Although the SAR of P-gp substrates is not well understood, it is believed that substrates must be lipophilic, given the importance of interaction with the biological membrane prior to binding to P-gp.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Compound <b>6a</b> is highly lipophilic and bears a terminal sulfonamide group, which is a well-described recognition motif for P-gp substrates.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> Compound <b>6a</b> showed a long half-life following both oral and iv dosing, low clearance, and a low volume of distribution in a mouse PK study (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf" class="ext-link">Supporting Information</a> for additional PK data). The moderate oral bioavailability of <b>6a</b> may be partially due to a P-gp efflux effect negatively impacting gut epithelial uptake.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Plasma and Brain Exposures<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a> of Compound <b>6a</b> in P-gp KO Mice 2 h Post-Dose</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center" char="±">plasma<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a> (nmol/mL)</th><th class="colsep0 rowsep0" align="center" char="±">brain<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a> (nmol/g)</th><th class="colsep0 rowsep0" align="center" char=".">B/P</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P-gp KO<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±">4.95 ± 0.78</td><td class="colsep0 rowsep0" align="char" char="±">3.49 ± 0.92</td><td class="colsep0 rowsep0" align="char" char=".">0.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WT<a class="ref internalNav" href="#t9fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char="±">3.92 ± 1.05</td><td class="colsep0 rowsep0" align="char" char="±">0.104 ± 0.027</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">20 mg/kg dose (po); perfused brain; each group mice <i>n</i> = 4; vehicle, 10% PEG400/10% solutol.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">Mean conc (nmol/mL) ± std dev (nmol/mL); blood samples were collected at day 1.</p></div><div class="footnote" id="t9fn3"><sup><sup>c</sup></sup><p class="last">Mean conc (nmol/g) ± std dev (nmol/g), brain tissue were removed at day 2.</p></div><div class="footnote" id="t9fn4"><sup><sup>d</sup></sup><p class="last">MDR1a KO male CF-1 mice from Charles River.</p></div><div class="footnote" id="t9fn5"><sup><sup>e</sup></sup><p class="last">Male CF-1 mice.</p></div></div></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Mouse Pharmacokinetics of Compound <b>6a</b><a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">oral <i>C</i><sub>max</sub> (nmol/mL)</th><th class="colsep0 rowsep0" align="center" char=".">oral AUC<sub>last</sub> (h·nmol/mL)</th><th class="colsep0 rowsep0" align="center" char=".">oral <i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">iv <i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vss (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">3.70</td><td class="colsep0 rowsep0" align="char" char=".">28.45</td><td class="colsep0 rowsep0" align="char" char=".">7.26</td><td class="colsep0 rowsep0" align="char" char=".">6.97</td><td class="colsep0 rowsep0" align="char" char=".">2.21</td><td class="colsep0 rowsep0" align="char" char=".">0.456</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">5 mg/kg dose for iv and 20 mg/kg for po, in C57bl/6j mouse; vehicle, 10% PEG400/10% solution.</p></div></div></div><div class="NLM_p">To compare the pharmacology of this P-gp substrate to a brain penetrant CB<sub>1</sub>RIA, compound <b>6a</b> (30 mg/kg) or rimonabant (10 mg/kg) were dosed for 5 days to diet-induced obese (DIO) mice. Both compound <b>6a</b> and rimonabant decreased food intake (FI) and body weight (BW) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B). Because FI inhibition is mediated by antagonism of brain CB<sub>1</sub>R directly<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> or indirectly,<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> these results suggest that compound <b>6a</b> may be engaging CB<sub>1</sub>R in the brain. A tissue distribution and brain CB<sub>1</sub> receptor occupancy (RO) study (conducted with nonperfused brain) was performed to assess brain penetrance of compound <b>6a</b>. After 5 days of dosing (30 mg/kg), brain tissues were collected (2 h after the last dose) and RO was determined in a competitive binding assay using [<sup>3</sup>H]CP-55940 as the radioligand. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>, compound <b>6a</b> achieved high plasma exposure (18.49 nmol/mL) and a low B/P ratio (0.024). Although FI reduction could be induced by peripherally restricted CB<sub>1</sub>RIAs resensitizing endogenous leptin in DIO mice<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> or acting on CB<sub>1</sub>Rs expressed in afferent vagal nerve terminals involved in gut–brain signaling,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> the high RO for compound <b>6a</b> (71.6% versus 81.7% for rimonabant) suggests that the observed time-dependent FI reduction and BW loss may be mediated primarily (or could at least partially) by brain CB<sub>1</sub>R engagement. Thus, despite the large difference in the B/P ratio (0.024 vs 0.98) and the absolute brain concentration (0.36 vs 1.46 nmol/g) between compound <b>6a</b> and rimonabant, their RO values are not significantly different. This may be due to the fact that compound <b>6a</b> demonstrated a 6-fold higher CB<sub>1</sub>R binding affinity than rimonabant in the competitive binding assay using the same radiligand [<sup>3</sup>H]CP-55940 as in the RO studies (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). The secondary CB<sub>1</sub>R binding assay showed that compound <b>6a</b> fully competes with [<sup>3</sup>H]rimonabant binding to hCB<sub>1</sub>R (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), suggesting that compound <b>6a</b> binds hCB<sub>1</sub>R at the same site as rimonabant but with higher affinity. Although cross-contamination of brain tissue with drug from the plasma compartment cannot be ruled out, the long in vivo half-life, low clearance, and high CB<sub>1</sub>R binding affinity of compound <b>6a</b> could potentially lead to increased drug accumulation and high RO in the brain.</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0004.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Efficacy of compound <b>6a</b> (30 mg/kg, daily) in DIO mice. (A) Daily food intake. (B) Percent body weight change.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Plasma and Brain Exposures<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a> of <b>6a</b> in the DIO Mouse Model at Day 5, 2 h Post Last Dose</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±">plasma<a class="ref internalNav" href="#t11fn2" aria-label="b">b</a> (nmol/mL)</th><th class="colsep0 rowsep0" align="center" char="±">brain<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a> (nmol/g)</th><th class="colsep0 rowsep0" align="center" char=".">B/P</th><th class="colsep0 rowsep0" align="center" char=".">CB<sub>1</sub> RO<a class="ref internalNav" href="#t11fn4" aria-label="d">d</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rimonabant</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="±">1.50 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">1.46 ± 0.18</td><td class="colsep0 rowsep0" align="char" char=".">0.98</td><td class="colsep0 rowsep0" align="char" char=".">81.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char="±">18.49 ± 1.33</td><td class="colsep0 rowsep0" align="char" char="±">0.357 ± 0.028</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td><td class="colsep0 rowsep0" align="char" char=".">71.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">Perfused brain; vehicle: 10% PEG400/10% solutol.</p></div><div class="footnote" id="t11fn2"><sup><sup>b</sup></sup><p class="last">Mean conc (nmol/mL) ± std dev (nmol/mL).</p></div><div class="footnote" id="t11fn3"><sup><sup>c</sup></sup><p class="last">Mean conc (nmol/g) ± std dev (nmol/g).</p></div><div class="footnote" id="t11fn4"><sup><sup>d</sup></sup><p class="last">Nonperfused brain.</p></div></div></div><div class="NLM_p">In light of the high plasma concentration (18.49 nmol/mL) achieved with the 30 mg/kg dose, a chronic study of compound <b>6a</b> was conducted at lower doses to test efficacy in DIO mice with lower brain concentrations (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Daily dosing of DIO mice with compound <b>6a</b> for 23 days resulted in significant inhibition of FI and decreases in BW (measured for 17 days only) at the 3 and 10 mg/kg doses (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B). Without pair-fed controls and measurement of energy expenditure during the course of the study, we cannot draw conclusions regarding the relative contribution of peripheral and central mechanisms to weight loss. However, even though statistically significant FI reduction at the 3 mg/kg dose (vs vehicle) occurred only at days 8 and 15, progressive weight loss of compound <b>6a</b> (vs vehicle) suggests alternate FI-independent mechanisms, including those in the periphery, as possibly contributing to body weight loss at lower doses.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In agreement with the weight loss, the 3 and 10 mg/kg doses also significantly decreased 4 h fasting insulin, liver fat, and cholesterol as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C–E. The study confirmed that compound <b>6a</b> was efficacious in attenuating obesity and improving insulin sensitivity at a dose as low as 3 mg/kg. The exposures of compound <b>6a</b> in the PK arms 2 h after dosing were assessed with plasma samples on day 1 and day 22 and with brain tissues on day 2 and day 23 (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). Although B/P ratios remained low at all doses (<0.072), brain concentrations tended to increase over the course of the study, suggesting that compound <b>6a</b> may accumulate in brain as observed in the 5-day DIO mouse study, which raised concerns about the safety of compound <b>6a</b> as a therapeutic agent.</div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0005.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dose–response DIO mouse efficacy of compound <b>6a</b> over 23-day treatment. (A) Food intake was measured daily for 5 days, twice weekly thereafter until 17 days, and every 3 days for the last 6 days. Data for last 6 days not shown. (B) Body weight was measured daily for 5 days and twice weekly thereafter for 10 days with oral dosing of 1, 3, and 10 mpk. (C) Fasting insulin at day 26. (D) liver fat. (E) cholesterol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Plasma and Brain Exposures<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a> of Compound <b>6a</b> in Chronic DIO Mouse Model 2 h Post Dose</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">plasma<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a> (nmol/mL) @time (d)</th><th class="colsep0 rowsep0" align="center">brain<a class="ref internalNav" href="#t12fn3" aria-label="c">c</a> (nmol/g) @time (d)</th><th class="colsep0 rowsep0" align="center">B/P</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="center">0.508 ± 0.079 @ d1</td><td class="colsep0 rowsep0" align="center">BLOQ @ d2</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="center">1.24 ± 0.17 @ d1</td><td class="colsep0 rowsep0" align="center">BLOQ @ d2</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="center">4.08 ± <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f5c5dbccc2b5">[email protected]</a> d1</td><td class="colsep0 rowsep0" align="center">0.102 ± 0.11 @ d2</td><td class="colsep0 rowsep0" align="center">0.026</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="center">0.843 ± 0.16 @ d22</td><td class="colsep0 rowsep0" align="center">0.060 ± 0.135 @ d23</td><td class="colsep0 rowsep0" align="center">0.072</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="center">2.55 ± 0.35 @ d22</td><td class="colsep0 rowsep0" align="center">0.164 ± 0.016 @ d23</td><td class="colsep0 rowsep0" align="center">0.065</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="center">8.65 ± 1.22 @ d22</td><td class="colsep0 rowsep0" align="center">0.329 ± 0.036 @ d23</td><td class="colsep0 rowsep0" align="center">0.038</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">Perfused brain; vehicle: 10% PEG400/10% solutol.</p></div><div class="footnote" id="t12fn2"><sup><sup>b</sup></sup><p class="last">Mean conc (nmol/mL) ± std dev (nmol/mL).</p></div><div class="footnote" id="t12fn3"><sup><sup>c</sup></sup><p class="last">Mean conc (nmol/g) ± std dev (nmol/g); BLOQ <4 ng/mL.</p></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We discovered a novel chemical class of 6-benzhydryl-4-aminoquinolin-2-ones as potent and selective CB<sub>1</sub>RIAs. We undertook a variety of approaches to improve peripheral selectivity, including increasing tPSA, incorporation of discrete PEG side chains, and leveraging the P-gp efflux mechanism. The optimized lead compound <b>6a</b> is a P-gp substrate that is restricted to the periphery, as evidenced by low B/P ratios in mice. Nevertheless, studies of compound <b>6a</b> in mice suggested the effects on FI may be mediated by binding to brain CB<sub>1</sub>R, as receptor occupancy values of >70% were measured in brain after an oral dose of 30 mg/kg for 5 days. Chronic efficacy studies showed that compound <b>6a</b> was efficacious in attenuating obesity and improving insulin sensitivity at lower doses, which may be mediated by a combination of central and peripheral mechanisms. However, compound <b>6a</b> showed time-dependent brain accumulation, possibly due to its high affinity for the CB<sub>1</sub>R and extended half-life. This work illustrates the challenges associated with restricting 6-benzhydryl-4-aminoquinolin-2-one CB<sub>1</sub>RIAs to the periphery and in developing such a small molecule therapeutic agent for metabolic complications utilizing this mechanism.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55772" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55772" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Chemistry</h3><div class="NLM_p last">Reagents available commercially were purchased and used as supplied. Proton (<sup>1</sup>H NMR) spectra were recorded on a Bruker Avance II 300 and Avance III 400 NMR spectrometer. For NMR sprectra obtained in CDCl<sub>3</sub>, DMSO-<i>d<sub>6</sub></i>, and CD<sub>3</sub>OD, the residual protons (7.27, 2.50, and 3.31 ppm) were used as the internal reference. Chemical shifts are given in ppm (δ scale) upfield from tetramethylsilane. Coupling constants (<i>J</i>) are expressed in Hz. Low-resolution mass spectra were obtained using an Agilent 1260 high performance liquid chromatograph (HPLC) linked to an Agilent 6140 quadrupole mass spectrometer or an Shimadzu LC20AD HPLC linked to an Shimadzu LCMS2020 quadrupole mass spectrometer (LC-MS) with simultaneous UV (220 and 254 nM) and TIC detection. High-resolution mass spectra (HRMS) analysis was performed using a Triple TOF API5600 instrument (Sciex). Elemental analyses were performed by Intertek Pharmaceutical Services (Whitehouse, NJ). Silica gel chromatography was performed either with a CombiFlash (Teledyne Isco) or Isolera (Biotage) purification system. Yields refer to isolated pure products and were not maximized. All final compounds were purified and are ≥95% pure. The purity was assessed (UV 254 nM) by a Shimadzu LC20AD HPLC linked to an Shimadzu LCMS2020 quadrupole mass spectrometer (method A, Shim-pack XR-ODS, 3 mm × 50 mm, 2.2 μm; Column temp, 40 °C; 5.6 min @ 1 mL/min with a linear gradient from 15% to 95% of acetonitrile (0.05% TFA) in water (0.05% TFA); method B, AtlantisT3-C18, 4.6 mm × 100 mm, 3.5 μm, 15 min @ 1 mL/min with a linear gradient from 5% to 100% of acetonitrile (0.05% TFA) in water (0.05% TFA)), or an Agilent 1260 high performance liquid chromatograph (HPLC) linked to an Agilent 6140 quadrupole mass spectrometer (method C, Agilent Poroshell 120 EC-C18, 3 mm × 50 mm, 2.7 μm; Column temp, 30 °C; 8 min @ 0.65 mL/min with a linear gradient from 10% to 100% of acetonitrile (0.1% TFA) in water (0.1% TFA)).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure A: Suzuki Coupling Using Pd(OAc)<sub>2</sub></h3><div class="NLM_p last">To a mixture of 4-bromoquinolin-2(1<i>H</i>)-one or 4-bromo-quinoline (1 equiv), boronic acid (1.5equiv), SPhos (0.14 equiv), tripotassium phosphate (2 equiv), and palladium acetate (0.065 equiv) was added to 1,4-dioxane (0.1M), and the resulting mixture was stirred for 4–6 h under N<sub>2</sub> atmosphere at 35 °C and rt overnight. The reaction mixture was diluted with water and EtOAc. The organic phase was washed with water and saturated sodium bicarbonate and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was triturated with Et<sub>2</sub>O to yield desired product. without further purification.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure B: Buchwald Amination</h3><div class="NLM_p last">A solution of 4-bromoquinoline or 4-bromoquinolin-2(1<i>H</i>)-one (1 equiv), Cs<sub>2</sub>CO<sub>3</sub> (2 equiv), amine (1.7 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.1 equiv), and DPPF (0.35 equiv) in 1,4-dioxane (0.02–0.1M) was heated to 90–100 °C under Ar<sub>2</sub> overnight. The reaction was diluted with water and EtOAc. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was purified by a silica gel column.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Procedure C: Organolithium Addition to Ketones</h3><div class="NLM_p last">To a solution of thiazole (2 equiv) in THF (0.2 M) was dropwise added <i>n</i>-BuLi (1.65 equiv) with stirring at −78 °C under N<sub>2</sub>. The resulting solution was stirred for 50 min at −78 °C, and then a solution of a (4-chlorophenyl)methanone (1 equiv) in THF (0.3 M) was added dropwise. The reaction mixture was stirred for an additional 40 min at −78 °C and warmed to 0 °C for 30 min. The reaction was quenched by water and extracted with EtOAc. The combined organics were washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by a silica gel column or RP-HPLC.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Procedure D: Deoxygenation with SnCl<sub>2</sub></h3><div class="NLM_p last">A solution of a (4-chlorophenyl)quinolinomethanol (1 equiv) and tin(II) chloride dihydrate (3–4 equiv) in a mixture solvent of HCl (36 wt %)/AcOH (1:20, 0.03 M) was heated to 110 °C for 45 min. The reaction was cooled to rt and concentrated. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub>, washed with saturated NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude product was purified by RP-HPLC.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure E: Suzuki Coupling Using PdCl<sub>2</sub> (dppf)<sub>2</sub></h3><div class="NLM_p last">A mixture of 4-bromoquinolone (1 equiv), boronic acid (1.5 equiv), PdCl<sub>2</sub>(dppf).CH<sub>2</sub>Cl<sub>2</sub> (0.1 equiv), and K<sub>2</sub>CO<sub>3</sub> (2 equiv) in THF/H<sub>2</sub>O (0.1M, 10:1) was heated to 60–80 °C under N<sub>2</sub> overnight. The reaction mixture was diluted with EtOAc and water. The organic layer was concentrated and purified by silica column.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure F: Deoxygenation with Et<sub>3</sub>SiH/TFA</h3><div class="NLM_p last">To a solution of a (4-chlorophenyl)quinolinomethanol (1 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (0.05 M) was added Et<sub>3</sub>SiH (5–7 equiv) and trifluoroacetic acid (20–25 equiv) under N<sub>2</sub>. The resulting solution was stirred at room temperature overnight. The pH value of the solution was adjusted to 7–8 with aq NaHCO<sub>3</sub>. The reaction mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to yield the reduced product.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure G: Grignard Addition to Ketones</h3><div class="NLM_p last">To a solution of a (4-chlorophenyl)methanone (1 equiv) in THF (0.03–0.15 M) was dropwise added Grignard reagent (0.9–4 equiv) with stirring at 0 °C under N<sub>2</sub>. The resulting solution was stirred for 2 h at 0 °C and then quenched by water and extracted with ethyl acetate. The combined organic layers were washed with water and brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The residue was purified by silica gel chromatography.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>E</i>)-6-((4-Chlorophenyl)(hydroxy)methyl)-4-styrylquinolin-2(1<i>H</i>)-one (<b>5a</b>)</h3><div id="sec5_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step 1: 4-Bromo-6-(4-chlorobenzoyl)quinolin-2(1<i>H</i>)-one</h4><div class="NLM_p last">To a solution of <b>2</b><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (400 mg, 0.95 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added 4 mL of trifluoroacetic acid (TFA). The mixture was stirred for 5 h at rt and concentrated. The crude material was triturated with hexane to yield 316 mg of the titled compound as an off-white solid. 1H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.42 (br s, 1H), 8.12–8.29 (m, 1H), 7.94–8.08 (m, 1H), 7.79 (d, <i>J</i> = 8.3 Hz, 2H), 7.67 (d, <i>J</i> = 8.3 Hz, 2H), 7.41–7.55 (m, 1H), 7.16 (s, 1H), 6.97 (s, 1H). ES, <i>m</i>/<i>z</i>: 362.0, 363.9 [M + H] <sup>+</sup>.</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 2: 4-Bromo-6-((4-chlorophenyl)(hydroxy) methyl)quinoline-2(1<i>H</i>)-one (<b>4</b>)</h4><div class="NLM_p last">To a suspension of 4-bromo-6-(4-chlorobenzoyl)quinolin-2(1<i>H</i>)-one from step 1 (700 mg, 1.93 mmol) in dry MeOH (10 mL) was dropwise added NaBH<sub>4</sub> (7.72 mL, 0.5 M in THF) at 0 °C. The resulting reaction mixture slowly turned clear and was stirred at 0 °C for 1 h, when the precipitates were slowly formed. The reaction mixture was then concentrated. Washed the crude product with water and EtOAc/Et<sub>2</sub>O (1:10) to give 649 mg of compound <b>4</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.02 (br s, 1H), 7.86 (s, 1H), 7.52 (d, <i>J</i> = 10.3 Hz, 1H), 7.33–7.43 (m, 4H), 7.29 (d, <i>J</i> = 8.6 Hz, 1H), 7.02 (s, 1H), 6.17 (d, <i>J</i> = 3.9 Hz, 1H), 5.83 (d, <i>J</i> = 3.9 Hz, 1H). ES, <i>m</i>/<i>z</i>: 347.6 (−OH), 365.6 [M + H] <sup>+</sup>.</div></div><div id="sec5_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 3: (<i>E</i>)-6-((4-Chlorophenyl)(hydroxy)methyl)-4-styrylquinolin-2(1<i>H</i>)-one (<b>5a</b>)</h4><div class="NLM_p last">Compound <b>5a</b> (56.3 mg) was synthesized according to general procedure A (without further purification) from <b>4</b> (70 mg, 0.192 mol), <i>trans</i>-2-phenylvinyl boronic acid (42.6 mg, 0.288 mmol), SPhos (11.03 mg, 0.027 mmol), tripotassium phosphate (81.5 mg, 0.384 mmol), and palladium acetate (3.0 mg, 0.013 mmol. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.71 (s, 1H), 8.11 (s, 1H), 7.65–7.86 (m, 3H), 7.18–7.54 (m, 10H), 6.79 (s, 1H), 6.07 (d, <i>J</i> = 3.9 Hz, 1H), 5.84 (d, <i>J</i> = 3.7 Hz, 1H). HRMS (C<sub>24</sub>H<sub>18</sub>ClNO<sub>2</sub> + H<sup>+</sup>), ESI, <i>m</i>/<i>z</i>: calcd 388.1104, found 388.1097 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.65 min (method C), 97.2%.</div></div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>E</i>)-6-((4-Chlorophenyl)(thiphen-2-yl)methyl)-4-(4-styryl)quinolin-2(1<i>H</i>)-one (<b>5b</b>)</h3><div class="NLM_p last">Synthesized in a similar fashion as <b>5c</b> except replacing thiazolyl lithium with thiophenyl magnesium bromide in step 1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.24 (br s, 1 H), 7.65 (s, 1 H), 7.51 (d, <i>J</i> = 8.15 Hz, 2 H), 7.36–7.44 (m, 5H), 7.22–7.24 (m, 2 H) 7.28–7.32 (m, 3 H), 7.15–7.18 (m, 2H), 6.96 (dd, <i>J</i> = 5.01, 3.55 Hz, 1 H), 6.90 (s, 1 H), 6.69 (d, <i>J</i> = 3.42 Hz, 1 H), 5.76 (s, 1 H). ES, <i>m</i>/<i>z</i>: 454, 456 [M + H] <sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.94 min (method C), 98.3%.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>E</i>)-6-((4-Chlorophenyl)(thiazol-2-yl)methyl)-4-(4-styryl)quinolin-2(1<i>H</i>)-one (<b>5c</b>)</h3><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step 1: (4-Bromo-2-<i>tert</i>-butoxyquinolin-6-yl)(4-chlorophenyl)(thiazol-2-yl)methanol (<b>3c</b>)</h4><div class="NLM_p last">Compound <b>3c</b> was synthesized according to general procedure C from thiazole (255 mg, 3.00 mmol), <i>n</i>-BuLi (1 mL, 2.5 M), and <b>2</b> (630 mg, 1.50 mmol). Purification: silica gel column (ethyl acetate/petroleum ether = 1:4). Yield 98.7%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 (d, <i>J</i> = 2.0 Hz, 1H), 7.82 (d, <i>J</i> = 3.2 Hz, 1H), 7.73 (d, <i>J</i> = 8.8 Hz, 1H), 7.62 (dd, <i>J</i> = 2.2, 8.8 Hz, 1H), 7.28–7.38 (m, 5H), 7.14 (s, 1H), 4.54 (s, 1H), 1.59–1.74 (m, 9H). ES, <i>m</i>/<i>z</i>: 446.9, 449.0 [M – Bu<sup>t</sup>]<sup>+</sup>.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Step 2: 4-Bromo-6-[(4-chlorophenyl)(thiazol-2-yl)methyl]quinolin-2-one (<b>10c</b>)</h4><div class="NLM_p last">Compound <b>10c</b> was prepared according to general procedure D from <b>3c</b> (5.5 g, 10.92 mmol), SnCl<sub>2</sub>·2H<sub>2</sub>O (7.4 g, 32.80 mmol). Purification: silica gel column eluted with CH<sub>2</sub>Cl<sub>2</sub>:MeOH (10:1). Yield 80% (3.78 g). ES, <i>m</i>/<i>z</i>: 433.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step 3: (<i>E</i>)-6-((4-Chlorophenyl)(thiazol-2-yl)methyl)-4-(4-(trifluoromethyl)styryl)quinolin-2(1<i>H</i>)-one (<b>5c</b>)</h4><div class="NLM_p last">Compound <b>5c</b> (51.3 mg) was synthesized according to general procedure A from <b>10c</b> (80 mg, 0.185 mol), <i>trans</i>-2-phenylvinylboronic acid (54 mg, 0.371 mmol), SPhos (15.5 mg, 0.037 mmol), tripotassium phosphate (78.7 mg, 0.371 mmol), and palladium acetate (4.2 mg, 0.019 mmol). Purification: RP-HPLC (C18 column). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.74 (s, 1H), 7.98 (d, <i>J</i> = 1.71 Hz 1H), 7.86 (d, <i>J</i> = 8.15 Hz, 2H), 7.70–7.77 (m, 4H), 7.59 (d, <i>J</i> = 3.30 Hz 1H), 7.50 (d, <i>J</i> = 8.15 Hz, 1H), 7.35–7.40 (m, 4H), 7.32 (m, 2H), 6.80 (s, 1H), 6.10 (s, 1H). HRMS (C<sub>27</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>S</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 455.0984, found 455.0949 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.16 min (method C), 100%.</div></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>E</i>)-6-((4-Chlorophenyl)(thiphen-2-yl)methyl)-4-(4-styryl)quinolin-2(1<i>H</i>)-one (<b>5d</b>)</h3><div class="NLM_p last">Synthesized in a similar fashion as <b>5c</b> except replacing <i>trans</i>-2-phenylvinylboronic acid with <i>trans</i>-2-(4-trifluoromethylphenyl)vinylboronic acid in step 2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.98 (s, 1H), 7.87 (d, <i>J</i> = 8.11 Hz, 2H), 7.68–7.79 (m, 4H), 7.59 (d, <i>J</i> = 3.29 Hz, 1H), 7.50 (d, <i>J</i> = 8.11 Hz, 1H), 7.34–7.41 (m, 4H), 7.26–7.33 (m, 2H), 6.80 (s, 1H), 6.08 (s, 1H). HRMS (C<sub>28</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>2</sub>OS + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 523.0859, found 523.0822 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.40 min (method C), 99.3%.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 6-[(4-Chlorophenyl)(phenyl)methyl]-4-{(<i>E</i>)-2-[4-(trifluoromethyl)phenyl]ethenyl}quinoline-2(1<i>H</i>)-one (<b>5e</b>)</h3><div class="NLM_p last">Synthesized in a similar fashion as <b>5c</b> except replacing thiazolyl lithium with phenyl magnesium bromide in step 1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.07 (s, 1H), 7.62–7.70 (m, 2H), 7.56 (d, <i>J</i> = 8.31 Hz, 2H), 7.49 (s, 1H), 7.39 (t, <i>J</i> = 8.07 Hz, 1H), 7.26–7.33 (m, H), 7.18 (s, 1H), 7.14 (s, 1H), 7.10 (d, <i>J</i> = 8.0 Hz, 2H), 7.05 (d, <i>J</i> = 12.0 Hz, 2H), 6.89 (s, 1H), 5.64 (s, 1H). HRMS (C<sub>31</sub>H<sub>21</sub>ClF<sub>3</sub>NO + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 516.1342, found 516.1332 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.83 min (method C), 98.6%.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 4-(3-Chlorophenethyl)-6-((4-chlorophenyl)(thiazol-2-yl)methyl)quinolin-2(1<i>H</i>)-one (<b>5f</b>)</h3><div id="sec5_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Step 1: 4-(3-Chlorophenethyl)-6-((4-chlorophenyl)(hydroxy)(thiazol-2-yl)methyl)quinolin-2(1<i>H</i>)-one</h4><div class="NLM_p last">The titled compound was prepared according to general procedure C from thiazole (201 mg, 2.37 mmol), <i>n</i>-BuLi (1.6 M in hexanes, 1.50 mL, 2.39 mmol), and 6-(4-chlorobenzoyl)-4-(3-chlorophenethyl)quinolin-2(1<i>H</i>)-one (250 mg, 0.592 mmol, prepared as described in PCT Publication WO2002/051835) in HMPA (4 mL). Purification: RP-HPLC (C18 column) MeOH–CH<sub>2</sub>Cl<sub>2</sub> (0–10%). Yield 50% (150 mg). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.65 (s, 1H), 7.84 (s, 1H), 7.64 (s, 1H), 7.48–7.55 (m, 1H), 7.33–7.45 (m, 6H), 7.24–7.30 (m, 2H), 7.16 (d, <i>J</i> = 7.09 Hz, 2H), 7.01 (br s, 1H), 6.41 (s, 1H), 2.90–2.93 (m, 2H), 2.81–2.85 (m, 2H). ES, <i>m</i>/<i>z</i>: 507, 509 [M + H]<sup>+</sup>.</div></div><div id="sec5_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Step 2. 4-(3-Chlorophenethyl)-6-((4-chlorophenyl)(thiazol-2-yl)methyl)quinolin-2(1<i>H</i>)-one <b>(5f)</b></h4><div class="NLM_p last">Compound <b>5f</b> was synthesized according to general procedure D from 4-(3-chlorophenethyl)-6-((4-chlorophenyl)(hydroxy)(thiazol-2-yl)methyl)-1-methylquinolin-2(1<i>H</i>)-one from step 1 (68 mg, 0.134 mmol), tin(II) chloride dihydrate (121 mg, 0.536 mmol). Purification: HPLC (C18 column) MeOH–CH<sub>2</sub>Cl<sub>2</sub> (0–10%). Yield 28% (19 mg). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.84 (d, <i>J</i> = 8.2 Hz 1H), 7.76 (d, <i>J</i> = 7.2 Hz, 1H), 7.69 (s, 1H), 7.48–7.27 (m, 9H), 7.16 (d, <i>J</i> = 7.2 Hz, 1H), 6.42 (s, 1H), 6.16 (s, 1H), 3.02–2.98 (m, 2H), 2.87–2.83 (m, 2H). ES, <i>m</i>/<i>z</i>: 491, 493 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.25 min (method C), 100%.</div></div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-4-phenethylquinolin-2(1<i>H</i>)-one (<b>5g</b>)</h3><div id="sec5_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Step 1: 6-((4-Chlorophenyl)(hydroxy)methyl)-4-phenethylquinolin-2(1<i>H</i>)-one</h4><div class="NLM_p last">The titled compound was synthesized according to general procedure E from <b>4</b> (40 mg, 0.11 mmol), phenylethyl boronic acid (24.7 mg, 0.165 mmol), PdCl<sub>2</sub>(dppf).CH<sub>2</sub>Cl<sub>2</sub> (8.96 mg, 0.011 mmol), and K<sub>2</sub>CO<sub>3</sub> (30.32 mg, 0.22 mmol). Purification: silica column (80% EtOAc/heptane). Yield 68% (29 mg). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.60 (br s, 1H), 7.79 (s, 1H), 7.11–7.54 (m, 11H), 6.36 (s, 1H), 6.07 (d, <i>J</i> = 3.67 Hz, 1H), 5.82 (br s, 1H), 2.97–3.16 (m, 2H), 2.84–2.94 (m, 2H). ES, <i>m</i>/<i>z</i>: 390.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Step 2. 6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-4-phenethylquinolin-2(1<i>H</i>)-one (<b>5g</b>)</h4><div class="NLM_p last">A suspension of 6-((4-chlorophenyl)(hydroxy)methyl)-4-phenethylquinolin-2(1<i>H</i>)-one from step 1 (15 mg, 0.0385 mmol), imidazole (10.48 mg, 0.154 mmol), and CDI (18.72 mg, 0.115 mmol) in MeCN (1 mL) was heated to 90 °C in a sealed vial for 6 h. The reaction turned into clear solution. The reaction mixture was concentrated and diluted with CH<sub>2</sub>Cl<sub>2</sub> and water. The organics were washed with water twice and then concentrated. The crude product was purified by silica column (elute with 5–8% MeOH/EtOAc) to give 10 mg of <b>5g</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.75 (br s, 1H), 7.71 (s, 1H), 7.45–7.57 (m, 3H), 7.24–7.39 (m, 4H), 7.07–7.22 (m, 6H), 7.00 (br d, <i>J</i> = 4.65 Hz, 2H), 6.44 (s, 1H), 2.88–3.03 (m, 2H), 2.77 (br s, 2H). HRMS (C<sub>27</sub>H<sub>22</sub>ClN<sub>3</sub>O + H<sup>+</sup>) [M + H]<sup>+</sup>: calcd 440.1529, found 440.1526 (ESI, <i>m</i>/<i>z</i>). HPLC <i>R</i><sub>t</sub> = 3.05 min (method C), 96.5%.</div></div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 4-(Benzyloxy)-6-((4-chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)quinolin-2(1<i>H</i>)-one (<b>5h</b>)</h3><div id="sec5_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Step 1. (4-(Benzyloxy)quinolin-6-yl)(4-chlorophenyl)methanone (<b>17</b>)</h4><div class="NLM_p last">A mixture of <b>13</b> (674 mg, 2.376 mmol), benzyl bromide (0.367 mL, 3.088 mmol), and Ag<sub>2</sub>CO<sub>3</sub> (852 mg, 3.088 mmol) in 25 mL of toluene was heated to 100 °C in a sealed reaction vessel for 4 h. The resulting reaction mixture was filtered through a pad of Celite. The filtrate was concentrated and purified by silica chromatography (elute with 20% EtOAc/heptane) to give 578 mg of compound <b>17</b> as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.84 (d, <i>J</i> = 5.14 Hz, 1H), 8.71 (d, <i>J</i> = 1.71 Hz, 1H), 8.06–8.23 (m, 2H), 7.82 (d, <i>J</i> = 8.31 Hz, 2H), 7.34–7.55 (m, 7H), 6.89 (d, <i>J</i> = 5.38 Hz, 1H), 5.36 (s, 2H). ES, <i>m</i>/<i>z</i>: 374.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Step 2: 4-(Benzyloxy)-6-(4-chlorobenzoyl)quinoline-1-oxide</h4><div class="NLM_p last">A mixture of <b>17</b> (180 mg, 0.481 mmol) and <i>m</i>-CPBA (216 mg, 0.963 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was stirred at rt for 1.5 h. The reaction mixture was diluted with EtOAc and water. The organics were washed with water, dried over anhydrous Mg<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude product was used in next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.86 (d, <i>J</i> = 9.05 Hz, 1H), 8.69 (d, <i>J</i> = 1.47 Hz, 1H), 8.55 (d, <i>J</i> = 6.85 Hz, 1H), 8.15 (dd, <i>J</i> = 1.59, 8.93 Hz, 1H), 7.80 (d, <i>J</i> = 8.31 Hz, 2H), 7.51 (d, <i>J</i> = 8.31 Hz, 2H), 7.36–7.46 (m, 5H), 6.78 (d, <i>J</i> = 7.09 Hz, 1H), 5.34 (s, 2H). (ES, <i>m</i>/<i>z</i>) 390.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_16_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Step 3: 4-(Benzyloxy)-6-(4-chlorobenzoyl)quinolin-2(1<i>H</i>)-one <b>(18)</b></h4><div class="NLM_p last">A solution of 4-methylbenzenesulfonyl chloride (86.27 mg, 0.452 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added slowly at rt to a solution of 4-(benzyloxy)-6-(4-chlorobenzoyl)quinoline 1-oxide from step 2 (147 mg, 0.377 mmol) in a 10% K<sub>2</sub>CO<sub>3</sub> (3 mL) aqueous solution and CH<sub>2</sub>Cl<sub>2</sub> (3 mL). The resulting mixture was stirred at rt for 30 min. A small amount of EtOAc/heptanes (1:5) were added and filtered off. The precipitates were washed with heptane and evaporated to dryness to yield 117.6 mg of compound <b>18</b>, which was used directly to next step. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 8.19 (d, <i>J</i> = 1.47 Hz, 1H), 7.95 (dd, <i>J</i> = 1.83, 8.68 Hz, 1H), 7.76 (d, <i>J</i> = 8.31 Hz, 2H), 7.65 (d, <i>J</i> = 8.56 Hz, 2H), 7.29–7.53 (m, 6H), 6.10 (s, 1H), 5.30 (s, 2H). ES, <i>m</i>/<i>z</i>: 390.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_16_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Step 4: 4-(Benzyloxy)-6-((4-chlorophenyl)(hydroxy)methyl)quinolin-2(1<i>H</i>)-one</h4><div class="NLM_p last">The titled compound was prepared (91% yield) according to procedure described in synthesis of <b>5a</b> step 2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.37 (br s, 1H), 7.80 (s, 1H), 7.33–7.53 (m, 10H), 7.22 (d, <i>J</i> = 8.07 Hz, 1H), 5.91–6.13 (m, 2H), 5.77 (br s, 1H), 5.27 (s, 2H). ES, <i>m</i>/<i>z</i>: 392.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_16_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Step 5: 4-(Benzyloxy)-6-((4-chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)quinolin-2(1<i>H</i>)-one (<b>5h</b>)</h4><div class="NLM_p last">The titled compound was prepared (54% yield) according to the procedure described in synthesis of compound <b>5g</b>, step 2. <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.65 (br d, <i>J</i> = 5.38 Hz, 2H), 7.33–7.47 (m, 9H), 7.15 (d, <i>J</i> = 8.31 Hz, 2H), 7.05 (br d, <i>J</i> = 3.91 Hz, 2H), 6.93 (s, 1H), 6.09 (s, 1H), 5.22 (s, 2H). HRMS (C<sub>26</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>2</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 442.1322, found 442.1320 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.04 min (method C), 96.0%.</div></div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl) benzamide (<b>5i</b>)</h3><div id="sec5_17_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Step 1: (4-Bromoquinolin-6-yl)(4-chlorophenyl)methanone (<b>14</b>)</h4><div class="NLM_p last">To a suspension of <b>13</b> (1.26 g, 4.45 mmol) in DMF (8 mL) at rt was added slowly phosphorus tribromide (0.44 mL, 4.67 mmol). The resulting mixture was stirred under Ar<sub>2</sub> for 30 min, at which point HPLC indicated all consumption of the starting material. The reaction mixture was made basic by the addition of solid NaHCO<sub>3</sub> until pH was greater than 10. The resulting solution was diluted with water and filtered. The product as an off-white solid was washed with water and dried to yield 1.23 g of compound <b>14</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.80 (d, <i>J</i> = 4.89 Hz, 1H), 8.60 (d, <i>J</i> = 1.47 Hz, 1H), 8.22–8.30 (m, 1H), 8.14–8.21 (m, 1H), 7.78–7.89 (m, 3H), 7.53 (d, <i>J</i> = 8.56 Hz, 2H). ES, <i>m</i>/<i>z</i>: 345.9, 348.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_17_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Step 2: <i>N</i>-(6-(4-Chlorobenzoyl)quinolin-4-yl)benzamide (<b>15</b>)</h4><div class="NLM_p last">A mixture of <b>14</b> (200 mg, 0.577 mmol), benzamide (83.88 mg, 0.692 mmol), CuI (16.48 mg, 0.0866 mmol), and K<sub>3</sub>PO<sub>4</sub> (244.96 mg, 1.15 mmol) were put in a sealed reaction tube and back-flushed with Ar<sub>2</sub>. (1<i>S</i>,2<i>S</i>)-<i>N</i>1,<i>N</i>2-Dimethylcyclohexane-1,2-diamine (0.041 mL, 0.26 mmol) was added via syringe followed by toluene (2 mL). The reaction mixture was stirred at rt for 1 min and then heated at 100 °C overnight. The reaction was cooled and diluted with CH<sub>2</sub>Cl<sub>2</sub> and water. The organics were concentrated and purified by silica column (50–60% EtOAc/heptanes) to give 120.6 mg of compound <b>15</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.03 (d, <i>J</i> = 5.13 Hz, 1H), 8.67 (br s, 1H), 8.54 (d, <i>J</i> = 4.89 Hz, 1H), 8.43 (s, 1H), 8.27 (d, <i>J</i> = 8.31 Hz, 1H), 8.06 (d, <i>J</i> = 8.80 Hz, 1H), 7.96 (d, <i>J</i> = 7.58 Hz, 2H), 7.82 (d, <i>J</i> = 8.56 Hz, 2H), 7.49–7.59 (m, 1H), 7.44–7.68 (m, 5H). ES, <i>m</i>/<i>z</i>: 387.0, 389.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_17_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Step 3: 4-Benzamido-6-(4-chlorobenzoyl)quinoline-1-oxide</h4><div class="NLM_p last">The titled compound was prepared from compound <b>15</b> from step 2 (202 mg, 0.522 mmol) according to the procedure described in synthesis of compound <b>5h</b>, step 2. Yield 90% (189 mg). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.91 (d, <i>J</i> = 9.05 Hz, 1H), 8.74 (br s, 1H), 8.63 (d, <i>J</i> = 6.51 Hz, 1H), 8.43 (s, 1H), 8.37 (d, <i>J</i> = 6.64 Hz, 1H), 8.09 (d, <i>J</i> = 9.05 Hz, 1H), 7.96 (d, <i>J</i> = 7.82 Hz, 2H), 7.80 (d, <i>J</i> = 8.07 Hz, 2H), 7.63–7.68 (m, 1H), 7.49–7.60 (m, 4H). ES, <i>m</i>/<i>z</i>: 403.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_17_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Step 4: <i>N</i>-(6-(4-Chlorobenzoyl)-2-oxo-1,2-dihydrquinolin-4-yl)benzamide (<b>16</b>)</h4><div class="NLM_p last">Compound <b>16</b> was prepared from 4-benzamido-6-(4-chlorobenzoyl)quinoline 1-oxide from step 3 (100 mg, 0.25 mmol) according to the procedure described in synthesis of compound <b>5h</b>, step 3. ES, <i>m</i>/<i>z</i>: 403.0 [M + H]<sup>+</sup>. Yield 60% (60 mg). The crude product was immediately used for next step.</div></div><div id="sec5_17_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Step 5: <i>N</i>-(6-((4-Chlorophenyl)(hydroxy)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)benzamide</h4><div class="NLM_p last">The titled compound was prepared (21 mg, 83.6% yield) with compound <b>16</b> (25 mg, 0.062 mmol) according to the procedure described in synthesis of compound <b>5a</b>, step 2. ES, <i>m</i>/<i>z</i>: 405.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_17_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Step 6: <i>N</i>-(6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)benzamide (<b>5i</b>)</h4><div class="NLM_p last">Compound <b>5i</b> was prepared (16 mg, 67.8% yield) from <i>N</i>-(6-((4-chlorophenyl)(hydroxy)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)benzamide (from step 5, 21 mg, 0.052 mmol) according to the procedure described in synthesis of compound <b>5g</b>, step 2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (br s, 1H), 10.36 (s, 1H), 7.83 (d, <i>J</i> = 7.34 Hz, 2H), 7.70 (s, 1H), 7.62–7.68 (m, 2H), 7.53–7.62 (m, 2H), 7.42–7.50 (m, 3H), 7.34–7.39 (m, 1H), 7.10–7.19 (m, 3H), 6.98 (s, 3H). HRMS (C<sub>26</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 455.1275, found 455.1272 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.90 min (method C), 95.2%.</div></div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-4-(4-(trifluoromethoxy)benzyl)quinolin-2(1<i>H</i>)-one (<b>5j</b>)</h3><div id="sec5_18_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Step 1: 6-((4-Chlorophenyl)(hydroxy)methyl)-4-(4-(trifluoromethoxy)benzyl)quinolin-2(1<i>H</i>)-one</h4><div class="NLM_p last">The titled compound was synthesized according to general procedure E from <b>4</b> (40 mg, 0.11 mmol), 4,4,5,5-tetramethyl-2-(4-(trifluoromethoxy)benzyl)-1,3,2-dioxaborolane (49.71 mg, 0.165 mmol), Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (8.96 mg, 0.011 mmol), and Na<sub>2</sub>CO<sub>3</sub> (23.3 mg, 0.219 mmol). Purification: silica column chromatography (80% EtOAc/hexanes). Yield 78% (39 mg). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.91 (br s, 1H), 7.61 (s, 1H), 7.47 (d, <i>J</i> = 7.82 Hz, 1H), 7.28–7.35 (m, 3H), 7.13–7.24 (m, 6H), 6.43 (s, 1H), 5.85 (br s, 1H), 4.14 (s, 2H), 2.26 (br s, 1H). ES, <i>m</i>/<i>z</i>: 460.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_18_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Step 2: 6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-4-(4-(trifluoromethoxy)benzyl)quinoline-2(1<i>H</i>)-one (<b>5j</b>)</h4><div class="NLM_p last">The titled compound was prepared using the procedure described in synthesis of compound <b>5g</b>, step 2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 7.62 (s, 1H), 7.38–7.46 (m, 3H), 7.34 (q, <i>J</i> = 8.56 Hz, 2H), 7.21 (s, 4H), 7.02–7.09 (m, 3H), 6.96 (s, 1H), 6.89 (s, 1H), 6.43 (s, 1H), 3.90–4.27 (m, 2H). HRMS (C<sub>26</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 510.1196, found 510.1183[M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.12 min (method C), 95.3%.</div></div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-4-((1<i>R</i>,2<i>S</i>)-2-phenylcyclopropyl)quinolin-2(1<i>H</i>)-one (<b>5k</b>)</h3><div id="sec5_19_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Step 1: 6-((4-Chlorophenyl)(hydroxy)methyl)-4-(<i>trans</i>-(1,2)-2-phenylcyclopropyl)quinolin-2(1<i>H</i>)-one</h4><div class="NLM_p last">The titled compound was prepared according to general procedure E. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.60 (br s, 1H), 7.77 (s, 1H), 7.45–7.50 (m, 1H), 7.32–7.41 (m, 3H), 7.23–7.29 (m, 7H), 6.30 (br s, 1H), 5.98 (d, <i>J</i> = 3.91 Hz, 1H), 5.63 (d, <i>J</i> = 3.91 Hz, 1H), 2.43–2.48 (m, 1H), 2.14–2.23 (m, 1H), 1.51–1.61 (m, 2H). ES, <i>m</i>/<i>z</i>: 402.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_19_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Step 2: 6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-4-((1<i>R</i>,2<i>S</i>)-2-phenylcyclopropyl)quinolin-2(1<i>H</i>)-one (<b>5k</b>)</h4><div class="NLM_p last">The titled compound was prepared using the procedure described in synthesis of compound <b>5g</b>, step 2. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 12.46 (br s, 1H), 7.42–7.52 (m, 2H), 7.24–7.34 (m, 7H), 7.20 (d, <i>J</i> = 8.31 Hz, 1H), 7.02 (d, <i>J</i> = 6.85 Hz, 2H), 6.93 (d, <i>J</i> = 8.31 Hz, 1H), 6.83 (d, <i>J</i> = 8.56 Hz, 1H), 6.59–6.62 (m, 1H), 6.53 (s, 1H), 6.45 (d, <i>J</i> = 11.00 Hz, 1H), 2.16–2.27 (m, 1H), 1.97–2.04 (m, 1H), 1.59–1.68 (m, 1H), 1.48–1.52 (m, 1H). HRMS (C<sub>28</sub>H<sub>22</sub>ClN<sub>3</sub>O+H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 452.1529, found 452.1528 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.07 min (method C), 95.8%.</div></div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 6-((4-Chlorophenyl)(1<i>H</i>-imidazol-1-yl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>5l</b>)</h3><div class="NLM_p last">A mixture of <b>19</b> from step 1 of synthesis of compound <b>6i</b> (75 mg, 0.193 mmol), imidazole (52.4 mg, 0.752 mmol), and CDI (93.6 mg, 0.57 mmol) in MeCN (5 mL) was heated to 90 °C in a sealed vial for 6 h. The reaction mixture was concentrated and diluted with CH<sub>2</sub>Cl<sub>2</sub> and water. The organics were washed with water twice and then concentrated. The crude product was dissolved in 15 mL of 10% TFA in CH<sub>2</sub>Cl<sub>2</sub>, and the resulting solution was stirred at rt overnight. The reaction was concentrated and dissolved in EtOAc. The organics were washed with satd NaHCO<sub>3</sub> and concentrated. The residue was purified by silica column (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 72.1 mg of compound <b>5l</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.88 (s, 1H), 8.01 (s, 1H), 7.67 (s, 1H), 7.46 (d, <i>J</i> = 8.50 Hz, 2H), 7.23 (s, 2H), 7.16 (s, 1H), 7.06 (d, <i>J</i> = 8.40 Hz, 2H), 6.98 (s, 1H), 6.79 (s, 1H), 6.57 (br d, <i>J</i> = 7.84 Hz, 1H), 5.50 (s, 1H), 3.86 (br d, <i>J</i> = 12.84 Hz, 2H), 3.71–3.79 (m, 1H), 3.37–3.50 (m, 2H), 2.08 (br d, <i>J</i> = 11.52 Hz, 2H), 1.49–1.69 (m, 2H). HRMS (C<sub>25</sub>H<sub>23</sub>ClF<sub>3</sub>N5O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 566.1240, found 566.1212 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.27 min (method C), 96.0%.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 6-((4-Chlorophenyl)(thiazol-2-yl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>5m</b>)</h3><div class="NLM_p last">To a solution of <b>5n</b> (20 mg, 0.044 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was added triethyl amine (0.034 mL, 0.246 mmol) at −20 °C under Ar<sub>2</sub> followed by trifluoromethanesulfonic anhydride (Tf<sub>2</sub>O) (0.088 mL, 1 M in CH<sub>2</sub>Cl<sub>2</sub>). The reaction was slowly warmed to 0 °C and stirred for 2 h at 0 °C. A 1N NaOH solution (0.5 mL) and MeOH (0.5 mL) were added, and the mixture was stirred for 2 h. The reaction mixture was concentrated and purified by prep-TLC (100% EtOAc) to yield the titled compound (24.9% yield). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.83 (s, 1H), 8.06 (s, 1H), 7.83 (d, <i>J</i> = 3.3 Hz, 1H), 7.70 (d, <i>J</i> = 3.0 Hz, 1H), 7.30–7.44 (m, 5H), 7.22 (d, <i>J</i> = 8.7 Hz, 1H), 6.57 (d, <i>J</i> = 7.5 Hz, 1H), 5.92 (s, 1H), 5.50 (s, 1H), 3.88 (d, <i>J</i> = 12.6 Hz, 2H), 3.77 (br, 1H), 3.42–3.46 (m, 2H), 2.10(d, <i>J</i> = 12.6 Hz, 2H), 1.60–1.64 (m, 2H). HRMS (C<sub>25</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 583.0852, found 583.0816 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.18 min (method A), 96.9%.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 6-((4-Chlorophenyl)(thiazol-2-yl)methyl)-4-(piperidin-4-ylamino)quinolin-2(1<i>H</i>)-one (<b>5n</b>)</h3><div id="sec5_22_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Step 1: Ethyl 4-((2-(<i>tert</i>-Butoxy)-6-((4-chlorophenyl)(hydroxy)(thiazol-2-yl)methyl)quinolin-4-yl)amino)piperidine-1-carboxylate</h4><div class="NLM_p last">The titled compound was synthesized according to general procedure B from <b>3c</b> (184 mg, 0.365 mmol), Cs<sub>2</sub>CO<sub>3</sub> (237.97 mg, 0.73 mmol), ethyl 4-aminopiperidine-1-carboxylate (0.106 mL, 0.621 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (33.44 mg, 0.0365 mmol), and DPPF (70.86 mg, 0.126 mmol). Purification: silica gel column (25% EtOAc/heptanes). Yield 85%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83 (d, <i>J</i> = 3.81 Hz, 1H), 7.64 (d, <i>J</i> = 8.80 Hz, 1H), 7.40 (dd, <i>J</i> = 1.47, 8.80 Hz, 1H), 7.36 (d, <i>J</i> = 3.18 Hz, 1H), 7.29 (m, 4H), 5.87 (s, 1H), 4.56 (br d, <i>J</i> = 7.09 Hz, 1H), 4.38 (s, 1H), 4.14 (q, <i>J</i> = 7.09 Hz, 4H), 3.49–3.71 (m, 1H), 2.86–3.11 (m, 2H), 2.00–2.22 (m, 2H), 1.67 (s, 9H), 1.36–1.55 (m, 2H), 1.27 (t, <i>J</i> = 7.09 Hz, 3H). ES, <i>m</i>/<i>z</i>: 595.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_22_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Step 2: Ethyl 4-((6-((4-Chlorophenyl)(thiazol-2-yl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)amino)piperidine-1-carboxylate</h4><div class="NLM_p last">The titled compound was synthesized according to general procedure D from ethyl 4-((2-(<i>tert</i>-butoxy)-6-((4-chlorophenyl)(hydroxy)(thiazol-2-yl)methyl)quino-line-4-yl)amino)piperidine-1-carboxylate from step 1 (167 mg, 0.281 mmol), SnCl<sub>2</sub>·2H<sub>2</sub>O (253.3 mg, 1.12 mmol). Purification: silica gel column (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). Yield 85%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.17 (br s, 1H),7.82 (d, <i>J</i> = 3.18 Hz, 1H), 7.35–7.40 (m, 2H), 7.28–7.33 (m, 4H), 7.17 (d, <i>J</i> = 8.31 Hz, 2H), 5.87 (s, 1H), 5.70 (s, 1H), 4.66–4.72 (m, 1H), 4.11–4.15 (m, 2H), 3.51–3.64 (m, 1H), 2.88–3.05 (m, 2H), 2.14 (br d, <i>J</i> = 11.74 Hz, 2H), 1.78–1.95 (m, 2H), 1.40–1.57 (m, 2H), 1.20–1.27 (m, 3H). ES, <i>m</i>/<i>z</i>: 523.0 [M + H] <sup>+</sup>.</div></div><div id="sec5_22_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Step 3: 6-((4-Chlorophenyl)(thiazol-2-yl)methyl)-4-(piperidin-4-ylamino)quinolin-2(1<i>H</i>)-one (<b>5n</b>)</h4><div class="NLM_p last">A 114 mg of ethyl 4-((6-((4-chlorophenyl)(thiazol-2-yl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)amino)piperidine-1-carboxylate (0.218 mmol) was dissolved in HBr (1.5 mL, 48%), and the mixture was heated to 100 °C for 2 h. The reaction was cooled to rt and concentrated to a yellow slurry. The residue was neutralized carefully under cooling temperature. The precipitates were formed. Filtration and washing with water to give the titled compound as a tan solid (95.6% yield). The product was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.05 (s, 1H), 7.80 (d, <i>J</i> = 3.42 Hz, 1H), 7.55 (d, <i>J</i> = 3.42 Hz, 1H), 7.16–7.45 (m, 6H), 5.97 (s, 1H), 5.59 (s, 1H), 3.49–3.67 (m, 1H), 3.12 (br d, <i>J</i> = 10.51 Hz, 2H), 2.66–2.89 (m, 2H), 2.07 (br d, <i>J</i> = 12.72 Hz, 2H), 1.55–1.61 (m, 2H). HRMS (C<sub>24</sub>H<sub>23</sub>ClN<sub>4</sub>OS + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 451.1359, found 451.1340 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.89 min (method C), 99.4%.</div></div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 6-((4-Chlorophenyl)(thiazol-2-yl)methyl)-4-((1-(isopropylsulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>5o</b>)</h3><div class="NLM_p last">The titled compound was prepared using the procedure described in synthesis of compound <b>5m</b> by replacing Tf<sub>2</sub>O with <i>i</i>-propyl sulfonyl chloride. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.05 (s, 1H), 7.80 (d, <i>J</i> = 2.69 Hz, 1H), 7.55 (d, <i>J</i> = 3.18 Hz, 1H), 7.40 (d, <i>J</i> = 8.56 Hz, 1H), 7.35 (d, <i>J</i> = 8.31 Hz, 2H), 7.29 (d, <i>J</i> = 8.56 Hz, 1H), 7.24 (d, <i>J</i> = 8.31 Hz, 2H), 6.67 (br d, <i>J</i> = 7.58 Hz, 1H), 5.96 (s, 1H), 5.62 (s, 1H), 3.85 (br d, <i>J</i> = 12.96 Hz, 2H), 3.57–3.76 (m, 1H), 3.23–3.38 (m, 1H), 3.12 (br t, <i>J</i> = 12.23 Hz, 2H), 2.11 (br d, <i>J</i> = 12.23 Hz, 2H), 1.57–1.80 (m, 2H), 1.33 (d, <i>J</i> = 6.85 Hz, 6H). ES, <i>m</i>/<i>z</i>: 557.0 [M + H] <sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.09 min (method C), 100%.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 6-[(4-Chlorophenyl)(1,3-thiazol-2-yl)methyl]-4-({(3<i>R</i>)-1-[(trifluoromethyl)sulfonyl]pyrrolidine-3-yl}amino)quinolin-2(1<i>H</i>)-one (<b>5p</b>)</h3><div class="NLM_p last">The titled compound was prepared using the procedure described in synthesis of compound <b>5n</b> except skipping step 3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.93 (s, 1H), 8.03 (s, 1H), 7.82 (s, 1H), 7.81 (s, 1H), 7.69 (s, 1H), 7.42–7.28 (m, 5H), 7.22 (d, <i>J</i> = 6.6 Hz,1H), 6.73 (br, 1H), 5.92 (s, 1H), 5.43 (s, 1H), 4.32–4.33 (m, 1H), 3.83–3.87 (m, 1H), 3.77–3.75 (m, 1H), 3.64–3.66 (m, 1H), 3.53–3.55 (m, 1H), 2.34–2.41 (m, 1H), 2.17–2.21 (m, 1H). HRMS (C<sub>24</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 569.0695, found 569.0670 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 1.94 min (method A), 96.7%.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>tert</i>-Butyl-3-[({6-[(4-chlorophenyl)(1,3-thiazol-2-yl)methyl]-2-oxo-1,2-dihydroquinolin-4-yl}amino)methyl]azetidine-1-carboxylate (<b>5q</b>)</h3><div class="NLM_p last">The titled compound was prepared using the procedure described in synthesis of compound <b>5n</b> except skipping step 3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79 (s, 1H), 7.96 (s, 1H), 7.81 (d, <i>J</i> = 3.42 Hz, 1H), 7.69 (d, <i>J</i> = 2.93 Hz, 1H), 7.39–7.43 (m, 2H), 7.29–7.36 (m, 3H), 7.19 (d, <i>J</i> = 8.56 Hz, 1H), 6.96 (br s, 1H), 5.90 (s, 1H), 5.33 (s, 1H), 3.85–3.95 (m, 2H), 3.53–3.64 (m, 2H), 3.30–3.41 (m, 2H), 2.76–2.92 (m, 1H), 1.37 (s, 9H). HRMS (C<sub>28</sub>H<sub>29</sub>ClN<sub>4</sub>O<sub>3</sub>S+ H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 537.1727, found 537.1711 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.74 min (method C), 100%.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 6-[(4-Chlorophenyl)(1,3-thiazol-2-yl)methyl]-4-{4-[(trifluoromethyl)sulfonyl]piperazin-1-yl}quinolin-2(1<i>H</i>)-one (<b>5r</b>)</h3><div class="NLM_p last">The titled compound was prepared using the procedure described in synthesis of compound <b>5n</b> except skipping step 3. <sup>1</sup>H NMR (400 Hz, CDCl<sub>3</sub>) δ 11.55 (br s, 1H), 7.83 (d, <i>J</i> = 3.4 Hz, 1H), 7.37–7.42 (m, 1H), 7.33 (d, <i>J</i> = 8.6 Hz, 5H), 7.19 (d, <i>J</i> = 8.3 Hz, 2H), 6.10 (s, 1H), 5.90 (s, 1H), 3.55 (m, 4H), 3.12 (m, 4H). ES, <i>m</i>/<i>z</i>: 569.0 [M + H]<sup>+</sup>. HRMS (C<sub>24</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 569.0695, found 569.0663 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.90 min (method C), 99.9%.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 6-(Bis(4-chlorophenyl)methyl)-4-(1-(trifluoromethylsulfonyl)piperidin-4-ylamino)quinolin-2(1<i>H</i>)-one (<b>6a</b>)</h3><div id="sec5_27_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Step 1: (4-Bromo-2-<i>tert</i>-butoxyquinolin-6-yl)bis(4-chlorophenyl) methanol (<b>3a</b>)</h4><div class="NLM_p last">Compound <b>3a</b> was synthesized according to general procedure G from <b>2</b> (4 g, 9.55 mmol), (4-chlorophenyl)magnesium bromide (8.2 mL, 1 M in THF). Purification: silica gel column (20% EtOAc/petroleum ether). Yield 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.88 (d, <i>J</i> = 2.02 Hz, 1H), 7.67–7.77 (m, 1H), 7.50–7.59 (m, 1H), 7.41 (d, <i>J</i> = 8.59 Hz, 4H), 7.30 (s, 1H), 7.26 (d, <i>J</i> = 9.09 Hz, 4H), 6.90–6.97 (m, 1H), 1.64 (s, 9H). ES, <i>m</i>/<i>z</i>: 532.0 [M + H] <sup>+</sup>.</div></div><div id="sec5_27_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Step 2: 4-Bromo-6-(bis(4-chlorophenyl)methyl)quinolin-2-ol</h4><div class="NLM_p last">The titled compound was synthesized according to general procedure F from <b>3a</b> (1.5 g, 2.82 mmol), Et<sub>3</sub>SiH (1.3 g), and trifluoroacetic acid (8 g, 70.77 mmol). Yield 96%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.21 (s, 1H), 7.62 (s, 1H), 7.29 (m, 6H), 7.09 (s, 1H), 7.03 (d, <i>J</i> = 8.07 Hz, 4H), 5.59 (s, 1H). ES, <i>m</i>/<i>z</i>: 459.9, 461.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_27_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Step 3: 6-(Bis(4-chlorophenyl)methyl)-4-(1-(trifluoromethylsulfonyl)piperidin-4-ylamino)quinolin-2(1<i>H</i>)-one <b>(6a)</b></h4><div class="NLM_p last">The titled compound was synthesized according to general procedure B from 6-[bis(4-chlorophenyl)methyl]-4-bromoquinolin-2-ol (3.4 g, 7.40 mmol), 1-(trifluoro methane)sulfonyl-piperidin-4-amine hydrochloride (3.4 g, 12.65 mmol), Pd(dba)<sub>3</sub> (680 mg), dppf (1.44 g, 2.60 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (6.05 g). Purification: silica gel column (10% CH<sub>2</sub>Cl<sub>2</sub>/MeOH). The resulting product <b>6a</b> was concentrated and recrystallized from CH<sub>3</sub>CN. Yield 71%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79 (s, 1H), 7.93 (s, 1H), 7.39–7.42 (m, 4H), 7.13–7.22 (m, 6H), 6.54 (d, <i>J</i> = 7.8 Hz, 1H), 5.63 (s,1H), 5.49 (s, 1H), 3.87 (d, <i>J</i> = 13.2 Hz, 2H), 3.37 (br s, 1H), 3.41–3.45 (m, 2H), 2.07–2.11 (m, 2H), 1.56–1.66 (m, 2H). HRMS (C<sub>28</sub>H<sub>24</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 610.0945, found 610.0944 [M + H]<sup>+</sup>. Elemental Analysis Calcd for C<sub>28</sub>H<sub>24</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S·0.4H<sub>2</sub>O: C, 54.45; H, 4.05; N, 6.80; Cl, 11.48; F, 9.23; S, 5.19; KF, 1.17. Found: C, 54.73; H, 3.84; N, 6.64; Cl, 11.19; F, 9.03; S, 5.28; KF, 1.18%.</div></div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 6-(4-Chlorobenzyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>6b</b>)</h3><div class="NLM_p last">The titled compound was prepared according to general procedure F from compound <b>19</b>. Yield 91%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (s, 1H), 7.92 (s, 1H), 7.05–7.42 (m, 7H), 6.54 (br d, <i>J</i> = 7.74 Hz, 1H), 5.47 (s, 1H), 3.96 (s, 3H), 3.88 (br d, <i>J</i> = 13.22 Hz, 2H), 3.65–3.80 (m, 1H), 3.37–3.47 (m, 2H), 2.10 (br d, <i>J</i> = 12.37 Hz, 2H), 1.53–1.73 (m, 2H). HRMS (C<sub>22</sub>H<sub>21</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 500.1022, found 500.1000 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.10 min (method A), 97.1%.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 6-((4-Chlorophenyl)(4-methoxyphenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>6c</b>)</h3><div id="sec5_29_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Step 1: 2-(<i>tert</i>-Butoxy)-6-[(4-chlorophenyl)carbonyl]-<i>N</i>-[1-(trifluoromethane)sulfonyl piperidin-4-yl]quinolin-4-amine (<b>12</b>)</h4><div class="NLM_p last">Compound <b>12</b> was synthesized according to general procedure B from <b>2</b> (20 g, 47.77 mmol), 1-(trifluoromethane)sulfonylpiperidin-4-amine hydrochloride (22 g, 81.88 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (4.92 g), DPPF (9.2 g, 16.60 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (38.8 g, 119.08 mmol). Purification: silica gel column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 20:1). Yield 88%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.65 (s, 1H), 7.78–7.85 (m, 2H), 7.62–7.68 (m, 3H), 7.48–7.52 (m, 1H), 7.07 (d, <i>J</i> = 8.1 Hz, 1H), 6.01 (s, 1H), 3.88 (brd, <i>J</i> = 12.3 Hz, 3H), 3.39–3.47 (m, 2H), 2.45–2.53 (m, 2H), 2.01–2.09 (m, 2H), 1.66 (s, 9H). ES, <i>m</i>/<i>z</i>: 570.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_29_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Step 2: (2-<i>tert</i>-Butoxy-4-(1-(trifluoromethylsulfonyl)piperidin-4-ylamino)quinolin-6-yl)(4-chlorophenyl)(4-methoxyphenyl)methanol</h4><div class="NLM_p last">The titled compound was synthesized according to general procedure G from <b>12</b> (300 mg, 0. 526 mmol) in THF (15 mL) and (4-methoxyphenyl) magnesium bromide (2 mL, 1.0 M in THF). The compound was used in next step without further purification. ES, <i>m</i>/<i>z</i>: 678.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_29_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Step 3: 6-((4-Chlorophenyl)(4-methoxyphenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl) piperidin-4-yl)amino) quinolin-2(1<i>H</i>)-one (<b>6c</b>)</h4><div class="NLM_p last">Compound <b>6c</b> was synthesized according to general procedure F from [2-(<i>tert</i>-butoxy)-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]quinolin-6-yl](4-chlorophenyl)(4-methoxyphenyl)methanol (200 mg, 0.29 mmol), Et<sub>3</sub>SiH (840 mg), and TFA (137 mg, 1.21 mmol). Purification: silica gel column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 30:1). Yield 82%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (s, 1H), 7.91 (s, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.01–7.19 (m, 6H), 6.89 (d, <i>J</i> = 8.7 Hz, 2H), 6.54 (d, <i>J</i> = 7.2 Hz, 1H), 5.54 (s, 1H), 5.47 (s, 1H), 3.84–3.88 (m, 2H), 3.60–3.80 (m, 4H), 3.44–3.35 (m, 2H), 2.09–2.06 (m, 2H), 1.61–1.58 (m, 2H). HRMS (C<sub>29</sub>H<sub>27</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 606.1441, found 606.1425 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.34 min (method A), 98.4%.</div></div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 6-{(4-Chlorophenyl)[4-(trifluoromethyl)phenyl]methyl}-4-({1-[(trifluoromethyl)sulfonyl]piperidin-4-yl}amino)quinolin-2(1<i>H</i>)-one (<b>6d</b>)</h3><div class="NLM_p last">Synthesized in a similar fashion as <b>6c</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.78 (s, 1H), 7.94 (s, 1H), 7.69 (d, <i>J</i> = 8.1 Hz, 2H), 7.32–7.42 (m, 4H), 7.12–7.22 (m, 4H), 6.52 (d, <i>J</i> = 7.8 Hz, 1H), 5.72 (s, 1H), 5.47 (s, 1H), 3.72–3.87 (m, 3H), 3.33–3.43 (m, 2H), 2.05–2.09 (m, 2H), 1.52–1.64 (m, 2H). HRMS (C<sub>29</sub>H<sub>24</sub>ClF<sub>6</sub>N<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 644.1209, found 644.1189 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.35 min (method A), 96.2%.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 6-[(4-Chlorophenyl)(3,4-dichlorophenyl)methyl]-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]-1,2-dihydroquinolin-2-one (<b>6e</b>)</h3><div class="NLM_p last">Synthesized in a similar fashion as <b>6c</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79 (s, 1H), 7.90 (s, 1H), 7.59(d, <i>J</i> = 8.4 Hz, 1H), 7.35–7.41 (m, 3H), 7.08–7.22 (m, 5H), 6.53 (d, <i>J</i> = 7.5 Hz,1H), 5.65 (s, 1H), 5.48 (s, 1H), 3.83–3.87 (m, 2H),3.73 (brs, 1H), 3.35–3.43 (m, 2H), 2.05–2.09 (m, 2H), 1.53–1.64 (m, 2H). HRMS (C<sub>28</sub>H<sub>23</sub>Cl<sub>3</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 644.0556, found 644.0578 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.53 min (method A), 96.7%.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 6-[1,3-Benzodioxol-5-yl(4-chlorophenyl)methyl]-4-({1-[(trifluoromethyl)sulfonyl]piperidin-4-yl}amino)quinolin-2(1<i>H</i>)-one (<b>6f</b>)</h3><div class="NLM_p last">Synthesized in a similar fashion as <b>6c</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (s, 1H), 7.89 (s, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.10–7.20 (m, 4H), 6.85 (d, <i>J</i> = 8.1 HZ, 1H), 6.68 (s, 1H), 6.53- 6.57 (m, 2H), 5.99 (s, 2H), 5.52 (s, 1H), 5.47 (s, 2H), 3.84–3.88 (m, 2H), 3.74 (brs, 1H), 3.40–3.44 (m, 2H), 2.06–2.10 (m, 2H), 1.55–1.67 (m, 2H). HRMS (C<sub>29</sub>H<sub>25</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 620.1233, found 620.1206 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.18 min (method A), 99.3%.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 6-[(4-Chlorophenyl)(6-chloropyridin-3-yl)methyl]-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]-1,2-dihydroquinolin-2-one (<b>6g</b>)</h3><div id="sec5_33_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Step 1. (2-(<i>tert</i>-Butoxy)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-6-yl)(4-chlorophenyl)(6-chloropyridin-3-yl) methanol</h4><div class="NLM_p last">The titled compound was synthesized according to general procedure C from 5-bromo-2-chloropyridine (250 mg, 1.30 mmol), <i>n</i>-BuLi (1.1 mL, 1 M in THF), <b>12</b> (250 mg, 0.44 mmol). The resulting residue was used in the next step without further purification. ES, <i>m</i>/<i>z</i>: 683.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_33_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Step 2. 6-[(4-Chlorophenyl)(6-chloropyridin-3-yl)methyl]-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]-1,2-dihydroquinolin-2-one (<b>6g</b>)</h4><div class="NLM_p last">Compound <b>6g</b> was synthesized according to general procedure D from [2-(<i>tert</i>-butoxy)-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]quinolin-6-yl](4-chlorophenyl)(6-chloropyridin-3-yl)methanol (350 mg, 0.51 mmol) and SnCl<sub>2</sub> (380 mg, 2.00 mmol). Purification: silica gel column (CH<sub>2</sub>Cl<sub>2</sub>:MeOH 20:1). The desired product was concentrated and recrystallized from EtOAc:<i>n</i>-hexane (1:5). Yield 34% (116 mg). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79 (s, 1H), 8.22 (s, 1H), 7.90 (s, 1H), 7.57–7.61 (m, 1H), 7.47–7.50 (m, 1H), 7.42–7.39 (m, 2H), 7.22–7.14 (m, 4H), 6.50–6.53 (m, 1H), 5.69 (s, 1H), 5.48 (s, 1H), 3.88–3.83 (m, 2H), 3.72 (brs, 1H), 3.39–3.43 (m, 2H), 2.05–2.09 (m, 2H), 1.53–1.64 (m, 2H). HRMS (C<sub>27</sub>H<sub>23</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 611.0898, found 611.0875 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.93 min (method A), 95.9%.</div></div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 6-[1,3-Benzothiazol-2-yl(4-chlorophenyl)methyl]-4-({1-[(trifluoromethyl)sulfonyl] piperidin-4-yl}amino)quinoline-2(1<i>H</i>)-one (<b>6h</b>)</h3><div class="NLM_p last">Synthesized in a similar fashion as <b>6g</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.83 (s, 1H), 8.11 (s, 1H), 8.05 (d, <i>J</i> = 6.9 Hz, 1H), 7.957 (d, <i>J</i> = 7.8 Hz, 1H), 7.53–7.33 (m, 7H), 7.23 (d, <i>J</i> = 8.7 Hz, 1H), 6.57 (d, <i>J</i> = 7.5 Hz,1H), 6.03 (s, 1H), 5.49 (s, 1H), 3.88–3.83 (m, 2H), 3.76–3.74 (m, 1H), 3.44–3.33 (m, 2H), 2.10–2.06 (m, 2H), 1.64–1.54 (m, 2H). HRMS (C<sub>29</sub>H<sub>24</sub>ClF<sub>3</sub>N4O<sub>3</sub>S<sub>2</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 633.1008, found 633.0984 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.27 min (method A), 96.8%.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 6-[4-Chlorophenoxy(4-chlorophenyl)methyl]-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]-1,2-dihydroquinolin-2-one (<b>6i</b>)</h3><div id="sec5_35_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> Step 1. [2-(<i>tert</i>-Butoxy)-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]quinolin-6-yl](4-chlorophenyl)methanol (<b>19</b>)</h4><div class="NLM_p last">To a solution of <b>12</b> (1.14 g, 2.00 mmol) in MeOH (40 mL) was NaBH<sub>4</sub> (60 mg, 1.59 mmol) under N<sub>2</sub>. The resulting solution was stirred for 2 h at room temperature and then quenched by water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum to yield 1.13 g of compound <b>19</b> (Yield 99%). ES, <i>m</i>/<i>z</i>: 572.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_35_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Step 2. 2-(<i>tert</i>-Butoxy)-6-((4-chlorophenoxy)(4-chlorophenyl)methyl)-<i>N</i>-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)quinolin-4-amine</h4><div class="NLM_p last">To a solution of <b>19</b> (250 mg, 0.44 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL) was added 4-chlorophenol (60 mg, 0.47 mmol), PPh<sub>3</sub> (150 mg), and DEAD (100 mg, 0.57 mmol). The resulting solution was stirred for 3 h at room temperature, quenched by water, and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude residue was used in the next step directly. ES, <i>m</i>/<i>z</i>: 682.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_35_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Step 3. 6-[4-Chlorophenoxy(4-chlorophenyl)methyl]-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]-1,2-dihydroquinolin-2-one (<b>6i</b>)</h4><div class="NLM_p last">A mixture of 2-(<i>tert</i>-butoxy)-6-[4-chlorophenoxy(4-chlorophenyl)methyl]-<i>N</i>-[1-(tri fluoromethane)sulfonylpiperidin-4-yl]quinolin-4-amine (250 mg, 0.37 mmol) and TFA (1 mL) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred overnight at room temperature and then extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. Purification: silica gel column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 20:1). Yield 47%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (s, 1H), 8.07 (s, 1H), 7.37–7.44 (m, 5H), 7.21–7.24 (m, 2H), 7.11–7.14 (m, 1H), 6.94–6.97 (m, 2H), 6.53–6.56 (m, 1H), 6.38 (s, 1H), 5.42 (s, 1H), 3.79–3.84 (m, 2H), 3.68 (br, 1H), 3.36–3.46 (m, 2H), 1.92–2.03 (m, 2H), 1.55–1.59 (m, 2H). ES, <i>m</i>/<i>z</i>: 626.0 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.43 min (method A), 99.5%.</div></div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> 6-(1-(4-Chlorophenyl)-2-(4-fluorophenyl)ethyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinoline-2(1<i>H</i>)-one (<b>6j</b>)</h3><div id="sec5_36_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> Step 1: 1-(2-(<i>tert</i>-Butoxy)-4-((1-((trifluoro methyl)sulfonyl)piperidin-4-yl)amino)quinolin-6-yl)-1-(4-chlorophenyl)-2-(4-fluorophenyl)ethanol</h4><div class="NLM_p last">Synthesized according to general procedure G compound <b>12</b> by using 4-fluorobenzyl magnesium bromide. (ES, <i>m</i>/<i>z</i>): 680.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_36_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Step 2: 6-(1-(4-Chlorophenyl)-2-(4-fluorophenyl)ethyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>6j</b>)</h4><div class="NLM_p last">A solution of 1-(2-(<i>tert</i>-butoxy)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-6-yl)-1-(4-chlorophenyl)-2-(4-fluorophenyl) ethanol from step 1 (150 mg, 0.22 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was treated with Et<sub>3</sub>SiH (100 mg) and TFA (600 mg, 5.31 mmol) for 3 h at rt and then concentrated to dryness. The residue was purified by silica column eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (30:1) to afford a 150 mg of a mixture of (<i>E</i>)- and (<i>Z</i>)-6-(1-(4-chlorophenyl)-2-(4-fluorophenyl)vinyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one as a white solid (ES, <i>m</i>/<i>z</i>: 606.0 [M + H]<sup>+</sup>). In an evacuated flask was placed a solution of the above mixture (150 mg, 0.25 mmol) in MeOH (15 mL), PtO<sub>2</sub> (150 mg). The flask was charged with an atmosphere of H<sub>2</sub>, and the resulting mixture was stirred overnight at room temperature. The reaction was filtered and the filtrate was concentrated. The residue was applied onto a silica gel column eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (20:1) to yield 33 mg of compound <b>6j</b> (yield 22%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.70 (s, 1H), 7.92 (s, 1H), 7.44 (d, <i>J</i> = 8.4 Hz, 1H), 7.27–7.39 (m, 4H), 7.12–7.20 (m, 3H), 6.98–7.02 (m, 2H), 6.52 (d, <i>J</i> = 7.6 Hz, 1H), 5.46 (s, 1H), 4.30–4.34 (m, 1H), 3.88–3.91 (m, 2H), 3.76 (br, 1H), 3.31–3.48 (m, 4H), 2.10–2.13 (m, 2H), 1.63–1.66 (m, 2H). ES, <i>m</i>/<i>z</i>: 608.0 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 6.59 min (method B), 95.6%.</div></div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> 6-((4-Chlorophenyl)(4-phenylpiperazin-1-yl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinoline-2(1<i>H</i>)-one (<b>6k</b>)</h3><div id="sec5_37_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Step 1: 6-(Chloro(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one</h4><div class="NLM_p last">To a solution <b>19</b> (200 mg, 0.37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added thionyl dichloride (450 mg, 3.78 mmol) dropwise with stirring at 0 °C and then stirred for 2 h at 45 °C. The cooled reaction mixture was quenched by saturated NaHCO<sub>3</sub> and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was applied onto a silica gel column (EtOAc/petroleum ether 1:2) to yield 0.1 g of the titled compound. ES, <i>m</i>/<i>z</i>: 534.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_37_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> Step 2: 6-((4-Chlorophenyl)(4-phenylpiperazin-1-yl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>6k</b>)</h4><div class="NLM_p last">To a solution of 6-[chloro(4-chlorophenyl)methyl]-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]-1,2-dihydroquinolin-2-one (100 mg, 0.19 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added 1-phenylpiperazine (55 mg, 0.34 mmol) and TEA (51 mg, 0.50 mmol). The resulting solution was stirred overnight at room temperature, quenched by water, and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was applied onto a silica gel column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 20:1) to yield 30 mg of compound <b>6k</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (s, 1H), 7.99 (s, 1H), 7.51–7.55 (m, 3H), 7.38–7.41 (m, 2H), 7.17–7.22 (m, 3H), 6.88–6.91 (m, 2H), 6.74–6.78 (m, 1H), 6.56 (d, <i>J</i> = 7.5 Hz, 1H), 5.46 (s, 1H), 4.32 (s, 1H), 3.86- 3.91 (m, 2H), 3.75 (br, 1H), 3.32–3.45 (m, 2H), 3.16–3.22- (m, 4H), 2.35–2.45 (m, 4H), 2.09–2.19 (m, 2H), 1.62–1.70 (m, 2H). HRMS (C<sub>32</sub>H<sub>33</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 660.2023, found 660.2013 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.70 min (method A), 96.9%.</div></div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 6-[Bis(4-chlorophenyl)methyl]-1-methyl-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]-1,2-dihydroquinolin-2-one (<b>7a</b>)</h3><div class="NLM_p last">A mixture of <b>6a</b> (92.5 mg, 0.152 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.149g, 0.456 mmol), and CH<sub>3</sub>I (0.033 g) in DMF (5 mL) was stirred for 1 h at rt and then quenched by water. The resulting mixture was extracted with EtOAc). The combined organic layers were washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was applied onto a silica gel column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 20:1). The desired product was recrystallized from EtOAc:<i>n</i>-hexane (1:5) to yield 88 mg of compound <b>7a</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.02 (s, 1H), 7.38–7.41 (m, 5H), 7.12–7.23 (m, 5H), 6.58 (d, <i>J</i> = 7.5 Hz, 1H), 5.66–5.67 (m, 2H), 3.84–3.88 (m, 2H), 3.76 (br, 1H), 3.56 (s, 3H), 3.44–3.48 (m, 2H), 2.08 (d, <i>J</i> = 12.3 Hz, 2H), 1.55–1.65 (m, 2H). HRMS (C<sub>29</sub>H<sub>26</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 624.1102, found 624.1075 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.48 min (method A), 96.3%.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 6-(Bis(4-chlorophenyl)methyl)-1-(2-methoxyethyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>7b</b>) and 6-(Bis(4-chlorophenyl)methyl)-2-(2-methoxyethoxy)-<i>N</i>-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)quinolin-4-amine (<b>8h</b>)</h3><div class="NLM_p last">A mixture of <b>6a</b> (66.7 mg, 0.109 mmol) and 1-bromo-2-methoxyethane (0.0123 mL, 0.131 mmol) in CH<sub>3</sub>CN (2 mL) was heated at 75 °C overnight. Additional 1-bromo-2-methoxyethane (0.006 mL) was added, and the reaction mixture stirred for another 24 h. The reaction mixture was diluted with EtOAc and water. The aqueous layer was extracted with EtOAc twice. The combined organics were concentrated and purified by silica column to yield 23 mg of compound <b>8h</b> (25% EtOAc/hexanes) and a 38 mg of compound <b>7b</b> (80% EtOAc/hexanes). For compound <b>7b</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.49 (d, <i>J</i> = 9.09 Hz, 1H), 7.28 (d, <i>J</i> = 8.08 Hz, 4H), 7.18–7.24 (m, 2H), 7.01 (d, <i>J</i> = 8.08 Hz, 4H), 5.71 (s, 1H), 5.57 (s, 1H), 4.38–4.48 (m, 2H), 3.90–4.05 (m, 2H), 3.68 (t, <i>J</i> = 5.81 Hz, 2H), 3.55–3.62 (m, 1H), 3.33 (s, 3H), 3.10–3.35 (m, 2H), 2.18–2.33 (m, 2H), 1.54–1.67 (m, 2H). HRMS (C<sub>31</sub>H<sub>30</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 668.1364, found 668.1340 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.72 min (method C), 100%. For compound <b>8h</b>: <sup>1</sup>H NMR (400 Hz, CDCl<sub>3</sub>) δ 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.29 (d, <i>J</i> = 8.1, 4H), 7.25 (m, 2H), 7.04 (d, <i>J</i> = 8.1 Hz, 4H), 6.02 (s, 1H), 5.64 (s, 1H), 4.56–4.67 (m, 2H), 4.46 (d, <i>J</i> = 7.1 Hz, 1H), 4.00 (m, 2H), 3.71–3.85 (m, 2H), 3.62 (m, 1H), 3.46 (s, 3H), 3.11–3.33 (m, 2H), 2.27 (br d, <i>J</i> = 11.12 Hz, 2H), 1.59–1.70 (m, 2H). HRMS (C<sub>31</sub>H<sub>30</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 668.1364, found 668.1348 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.30 min (method C), 99.5%. The structures of the two regioisomers were confirmed by NOESY (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> 6-(Bis(4-chlorophenyl)methyl)-8-(3-methoxypropyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>7c</b>)</h3><div id="sec5_40_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Step 1: Bis(4-chlorophenyl)(4,8-dibromo-2-methoxyquinolin-6-yl)methanol (<b>21b</b>)</h4><div class="NLM_p last">To a solution of <b>20</b><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (2 g, 3.97 mmol) in toluene (20 mL) and cosolvent THF (2 mL) was added NaOMe (1.28g, 23.78 mmol). The resulting solution was stirred at 80 °C for 5 h and then quenched by saturated NaHCO<sub>3</sub>. The resulting solution was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum to yield 1.5 g of 4,8-dibromo-6-[(4-chlorophenyl)carbonyl]-2-methoxyquinoline (product was confirmed by LCMS (ES, <i>m</i>/<i>z</i>) 456.4 [M + H]<sup>+</sup>), which was used to synthesize compound <b>21b</b> according to general procedure G with (4-chlorophenyl)magnesium bromide (9.87 mL, 1 M in THF). Purification: silica gel column (EtOAc/petroleum ether 1:9). Yield 85% (1.58g). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.96 (d, <i>J</i> = 1.8 Hz, 1H), 7.81 (d, <i>J</i> = 2.1 Hz, 1H), 7.59 (s, 1H), 7.43 (d, <i>J</i> = 8.7 Hz, 4H), 7.26 (d, J = 8.7 Hz, 4H), 7.07 (s, 1H), 4.05 (s, 3H). ES, <i>m</i>/<i>z</i>: 568.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_40_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Step 2: (8-Bromo-2-methoxy-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]quinolin-6-yl)bis(4-chlorophenyl)methanol (<b>22b</b>)</h4><div class="NLM_p last">Compound <b>22b</b> was synthesized according to general procedure B from bis(4-chloro phenyl)(4,8-dibromo-2-methoxyquinolin-6-yl)methanol (1.3 g, 2.29 mmol), dppf (216 mg, 0.39 mmol), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (114 mg, 0.11 mmol), Cs<sub>2</sub>CO<sub>3</sub> (2.99 g, 9.18 mmol), and 1-(trifluoromethane)sulfonylpiperidin-4-amine hydrochloride (1.23 g, 4.58 mmol). Purification: silica gel column (EtOAc/petroleum ether 1:9) to yield 1.4 g of <b>22b</b> (Yield 85%). ES, <i>m</i>/<i>z</i>: 720.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_40_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Step 3: 6-(Bis(4-chlorophenyl)methyl)-8-bromo-2-methoxy-<i>N</i>-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)quinolin-4-amine</h4><div class="NLM_p last">The titled compound was prepared from compound <b>22b</b> (300 mg, 0.42 mmol) according to general procedure F. Yield 90%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (s, 1H), 7.55 (s, 1H), 7.41 (d, <i>J</i> = 6.3 Hz, 4H), 7.17 (d, <i>J</i> = 6.3 Hz, 2H), 6.81 (d, <i>J</i> = 8.0 Hz, 1H), 6.12 (s, 1H), 5.73 (s, 1H), 3.99 (s, 3H), 3.80–3.94 (m, 3H), 3.36–3.42 (m, 2H), 2.07–2.10 (m, 2H), 1.55–1.64 (m, 2H). ES, <i>m</i>/<i>z</i>: 704.0 [M + H]<sup>+</sup>;</div></div><div id="sec5_40_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Step 4: 6-(Bis(4-chlorophenyl)methyl)-2-methoxy-8-(3-methoxyprop-1-en-1-yl)-<i>N</i>-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)quinolin-4-amine (<b>23</b>)</h4><div class="NLM_p last">Compound <b>23</b> was synthesized according to general procedure F from <b>22b</b> (50 mg, 0.07 mmol), 2-[(1<i>E</i>)-3-methoxyprop-1-en-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (16 mg, 0.08 mmol), Pd(dppf)Cl<sub>2</sub> (5 mg), and K<sub>2</sub>CO<sub>3</sub> (30 mg, 0.22 mmol). Purification: silica gel column (EtOAc:petroleum ether 1:4). Yield 66% (32 mg). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.92 (s, 1H), 7.51–7.42 (m, 2H),7.43 (d, <i>J</i> = 8.4 Hz, 4H), 7.12 (d, <i>J</i> = 8.4 Hz, 4H), 6.60–6.65 (m, 1H), 6.26–6.38 (m, 1H), 6.00 (s, 1H), 5.63 (s, 1H), 4.01–4.07 (m, 2H), 3.77–3.85 (m, 6H), 3.33–3.34 (m, 2H), 3.22 (s, 3H), 1.98–2.08 (m, 2H), 1.52–1.65 (m, 2H). ES, <i>m</i>/<i>z</i>: 694.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_40_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Step 5: 6-[Bis(4-chlorophenyl)methyl]-2-methoxy-8-(3-methoxypropyl)-<i>N</i>-[1-(trifluoromethane)sulfonylpiperidin-4-yl]quinolin-4-amine</h4><div class="NLM_p last">To a solution of <b>23</b> (100 mg, 0.14 mmol) in MeOH (20 mL) was added PtO<sub>2</sub> (5 mg). The flask was charged with H<sub>2</sub> and stirred overnight at 25 °C. The reaction mixture was filtered and concentrated under vacuum. The residue was applied onto a silica gel column eluting with ethyl EtOAc/petroleum ether (1:4) to yield 68 mg of the titled compound (70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.91 (d, <i>J</i> = 0.8 Hz,1H), 7.39 (d, <i>J</i> = 8.2 Hz, 4H), 7.14 (d, <i>J</i> = 8.2 Hz, 4H), 7.71 (s, 1H), 6.61 (d, <i>J</i> = 8.0 Hz, 1H), 6.03 (s, 1H), 5.66 (s, 1H), 3.88 (s, 3H), 3.74–3.84 (m,3H), 3.40–3.43 (m, 2H), 3.19–3.29 (m, 2H), 3.12 (s, 3H), 2.95–2.99 (m, 2H), 2.07–2.09 (m, 2H), 1.80–1.87 (m, 2H), 1.62–1.66 (m, 2H). ES, <i>m</i>/<i>z</i>: 696.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_40_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Step 6: 6-(Bis(4-chlorophenyl)methyl)-8-(3-methoxypropyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>7c</b>)</h4><div class="NLM_p last">A solution of 6-[bis(4-chlorophenyl)methyl]-2-methoxy-8-(3-methoxypropyl)-<i>N</i>-[1-(trifluoromethane)sulfonylpiperidin-4-yl]quinolin-4-amine (8 mg, 0.01 mmol) in 1,4-dioxane (2 mL) and 4 N HCl (2 mL) was stirred overnight at 100 °C. The reaction was cooled and concentrated under vacuum. The residue was applied onto a silica gel column with EtOAc/petroleum ether (1:2) to yield 4 mg of <b>7c</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.82 (s, 1H), 7.73 (s, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 4H), 7.06 (d, <i>J</i> = 8.4 Hz, 4H), 6.86 (s, 1H), 6.46 (d, <i>J</i> = 10.5 Hz, 1H), 5.53 (s, 1H), 5.43 (s, 1H), 3.76–3.85 (m,3H), 3.26–3.32 (m, 2H), 3.05–3.13 (m, 5H), 2.70–2.75 (m, 2H), 1.98–2.05 (m, 2H), 1.54–1.59 (m, 4H). HRMS (C<sub>32</sub>H<sub>32</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 682.1520, found 682.1507 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.64 min (method A), 99.0%.</div></div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> 6-(Bis(4-chlorophenyl)methyl)-8-((2-methoxyethyl)amino)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>7d</b>)</h3><div id="sec5_41_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Step 1: Bis(4-chlorophenyl)[4,8-dibromo-2-(<i>tert</i>-butoxy)quinolin-6-yl]methanol (<b>21a</b>)</h4><div class="NLM_p last">To a solution of <b>20</b><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (1.0 g, 1.98 mmol) in toluene (30 mL) was added KO<i>t</i>-Bu (2.18 mL, 1 M in THF) under argon. The reaction was stirred for 1.5 h at 65 °C, cooled, and diluted with saturated NaCl. The resulting mixture was extracted with EtOAc. The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was applied onto a silica gel column eluting with EtOAc/petroleum ether (5:95) to yield 0.87 g of 4,8-dibromo-2-(<i>tert</i>-butoxy)-6-[(4-chlorophenyl)carbonyl]quinoline (ES, <i>m</i>/<i>z</i> 497.9 [M + H]<sup>+</sup>), which was used to synthesize compound <b>21a</b> according to general procedure G with (4-chlorophenyl)magnesium bromide. Yield 81%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.91 (d, <i>J</i> = 2.1 Hz, 1H), 7.77 (d, <i>J</i> = 1.8 Hz, 1H), 7.39–7.43 (m, 5H), 7.26 (d, <i>J</i> = 9.0 Hz, 4H), 7.04 (s, 1H), 1.69 (s, 9H). ES, <i>m</i>/<i>z</i>: 609.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_41_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Step 2: [8-Bromo-2-(<i>tert</i>-butoxy)-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]quinolin-6-yl]bis(4-chlorophenyl)methanol (<b>22a</b>)</h4><div class="NLM_p last">The titled compound was prepared according to general procedure B. Yield 80%. ES, <i>m</i>/<i>z</i>: 760.0, 762.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_41_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Step 3: (2-(<i>tert</i>-Butoxy)-8-((2-methoxyethyl)amino)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-6-yl)bis(4-chlorophenyl)methanol</h4><div class="NLM_p last">A mixture of <b>22a</b> (58 mg, 0.0762 mmol), 2-methoxyethanamine, Pd<sub>2</sub>(dba)<sub>3</sub> (6.98 mg, 0.0076 mmol), XPhos (15.98 mg, 0.0335 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (74.45 mg, 0.229 mmol) in 1,4-dioxane (0.7 mL) was heated to 100 °C for 3 h under Ar<sub>2</sub>. The reaction was diluted with EtOAc and water. The aqueous layer was extracted with EtOAc. The combined organics were concentrated and purified by silica column (15% EtOAc/hexanes) to yield 34 mg of the titled compound. ES, <i>m</i>/<i>z</i>: 755.0, 757.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_41_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> Step 4: 6-(Bis(4-chlorophenyl)methyl)-8-((2-methoxyethyl)amino)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>7d</b>)</h4><div class="NLM_p last">Compound <b>7d</b> was prepared according to general procedure F from (2-(<i>tert</i>-butoxy)-8-((2-methoxyethyl)amino)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-6-yl)bis(4-chlorophenyl)methanol. Yield 90%. <sup>1</sup>H NMR (400 Hz, CDCl<sub>3</sub>) δ 11.59 (br s, 1H), 7.21–7.36 (m, 4H), 7.03 (d, <i>J</i> = 8.1 Hz, 4H), 6.45 (s, 1H), 6.47 (s, 1H), 5.61 (s, 2H), 5.49 (s, 1H), 4.54 (d, <i>J</i> = 6.6 Hz, 1H), 3.97 (m, 2H), 3.51–3.70 (m, 3H), 3.36 (s, 3H), 3.11–3.31 (m, 4H), 2.25 (m, 2H), 1.53–1.74 (m, 2H). HRMS (C<sub>31</sub>H<sub>31</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 683.1473, found 683.1463 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.85 min (method C), 100%.</div></div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> 8-((4-Aminobutyl)amino)-6-(bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>7e</b>)</h3><div class="NLM_p last">The titled compound was prepared according to the procedure described in synthesis of compound <b>7d</b> except <i>step 3</i> and <i>step 4</i> were executed as follows. <i>Step 3</i>: <i>tert</i>-Butyl <i>N</i>-[4-([6-[bis(4-chlorophen-yl)(hydroxy)methyl]-2-(<i>tert</i>-butoxy)-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]quinolin-8-yl]amino)butyl] carbamate. A mixture of <b>22a</b> (200 mg, 0.26 mmol) <i>tert</i>-butyl <i>N</i>-(4-aminobutyl)carbamate (98 mg, 0.52 mmol), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (13 mg, 0.01 mmol), Cs<sub>2</sub>CO<sub>3</sub> (254 mg, 0.78 mmol), and Xantphos (25 mg, 0.04 mmol) in 1,4-dioxane (2 mL) was stirred overnight at 90 °C under N<sub>2</sub> and then cooled. The reaction was quenched by saturated NaHCO<sub>3</sub> and extracted with EtOAc. The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered. The filtrate was concentrated under vacuum. The residue was applied onto a silica gel column (EtOAc/petroleum ether 1:6) to yield 200 mg of the titled compound. ES, <i>m</i>/<i>z</i>: 868.0 [M + H]<sup>+</sup>. <i>Step 4</i>: 8-((4-Aminobutyl)amino)-6-(bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>7e</b>). To a solution of <i>tert</i>-butyl <i>N</i>-[4-([6-[bis(4-chlorophenyl)(hydroxy)methyl]-2-(<i>tert</i>-butoxy)-4-[[1-(trifluoromethane)sulfonylpiperidin-4-yl]amino]quinolin-8-yl]amino)butyl]carbamate (200 mg, 0.23 mmol) in degassed CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added Et<sub>3</sub>SiH (3.66 mL) and TFA (0.7 mL). The resulting mixture was stirred for 8 h at room temperature under N<sub>2</sub>. The reaction was diluted with saturated NaHCO<sub>3</sub> and was extracted with EtOAc. The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered. The filtrate was concentrated and purified by Prep-HPLC with the following conditions (Waters 2767-1, Column, X-Bridge Prep C18, 5 μm, 19 mm × 100 mm; mobile phase, phase A, water with 0.05% TFA; phase B, CH<sub>3</sub>CN; linear gradient 35% CH<sub>3</sub>CN up to 95% in 12 min) to yield 59 mg of <b>7e</b> as a TFA. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.23–7.19 (m, 5H), 7.02 (d, <i>J</i> = 8.4 Hz, 4H), 6.41 (s, 1H), 5.56 (s, 1H), 5.51 (s, 1H), 3.89–3.86 (m, 2H), 3.68–3.62 (m, 1H), 3.26–3.22 (m, 2H), 3.03–2.97 (m, 2H), 2.86–2.80 (m, 2H), 2.07–2.04 (m, 2H), 1.65–1.53 (m, 6H). ES, <i>m</i>/<i>z</i>: 696.0 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 8.29 min (method B), 95.5%.</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> 4-((6-(Bis(4-chlorophenyl)methyl)-2-oxo-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)-1,2-dihydroquinolin-8-yl)amino)butanoic Acid (<b>7f</b>)</h3><div id="sec5_43_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Step 1: Ethyl 4-((6-(Bis(4-chlorophenyl)methyl)-2-oxo-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)-1,2-dihydroquinolin-8-yl)amino)butanoate</h4><div class="NLM_p last">The titled compound prepared in a similar fashion as compound <b>7d</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.62 (br s, 1H), 7.29 (d, d, <i>J</i> = 8.08 Hz, 4H), 7.04 (d, <i>J</i> = 8.08 Hz, 4H), 6.39 (s, 1H), 6.32 (s, 1H), 6.00–6.12 (m, 1H), 5.85 (s, 1H), 5.49 (s, 1H), 4.49 (br d, <i>J</i> = 6.57 Hz, 1H), 4.08 (q, <i>J</i> = 7.24 Hz, 2H), 3.95–4.03 (m, 2H), 3.75–3.88 (m, 1H), 3.37 (br t, <i>J</i> = 11.62 Hz, 2H), 3.05 (br s, 2H), 2.61 (br t, <i>J</i> = 7.83 Hz, 2H), 2.28 (br d, <i>J</i> = 12.63 Hz, 2H), 2.08–2.19 (m, 2H), 1.54–1.65 (m, 2H), 1.24 (t, <i>J</i> = 6.82 Hz, 3H). ES, <i>m</i>/<i>z</i>: 739.0, 741.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_43_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> Step 2. 4-((6-(Bis(4-chlorophenyl)methyl)-2-oxo-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)-1,2-dihydroquinolin-8-yl)amino)butanoic Acid (<b>7f</b>)</h4><div class="NLM_p last">To a solution of ethyl 4-((6-(bis(4-chlorophenyl)methyl)-2-oxo-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)-1,2-dihydroquinolin-8-yl)amino)butanoate (20 mg, 0.027 mmol) in 2 mL of THF was added 0.11 mL of NaOH (1 M in H<sub>2</sub>O). The mixture was stirred at rt for 2.5 h and then concentrated. The residue was neutralized to pH 5 and extracted with CH<sub>3</sub>Cl three times. The organics were concentrated and purified by silica column chromatography (elute with 10% MeOH/EtOAc) to yield 8 mg of compound <b>7f</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.02 (s, 1H), 7.37 (d, <i>J</i> = 8.08 Hz, 4H), 7.15 (d, <i>J</i> = 8.59 Hz, 6H), 6.36–6.50 (m, 1H), 6.31 (s, 1H), 5.74–5.93 (m, 1H), 5.51 (s, 1H), 5.47 (s, 1H), 3.83–3.86 (m, 2H), 3.63–3.78 (m, 1H), 3.37–3.45 (m, 2H), 2.91–2.94 (m, 2H), 2.30 (br t, <i>J</i> = 7.33 Hz, 2H), 2.05 (d, <i>J</i> = 12.13 Hz, 2H), 1.70–1.80 (m, 2H), 1.54–1.66 (m, 2H). ES, <i>m</i>/<i>z</i>: 710.3, 711.2 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.28 min (method C), 98.5%.</div></div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> 6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoro-methyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-ol (<b>8a</b>)</h3><div id="sec5_44_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> Step 1: (4-Bromo-8-methoxyquinolin-6-yl)bis(4-chlorophenyl)methanol</h4><div class="NLM_p last">To a solution of methyl 4-bromo-8-methoxyquinoline-6-carboxylate <b>24</b><a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (13 g, 43.90 mmol) in THF (500 mL) was added (4-chlorophenyl) magnesium bromide (220 mL, 1 M in THF), and the resulting solution was stirred for 3 h at refluxing temperature. The reaction was quenched by water, and the aqueous layer was extracted with ethyl acetate. The organic combined layers were dried over anhydrous sodium sulfate and filtered through a pad of Celite. The filtrate was concentrated and applied onto a silica gel column with ethyl acetate/petroleum ether (2:1) to yield 13.5 g of the titled compound as a yellow solid. ES, <i>m</i>/<i>z</i>: 487.0, 489.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_44_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Step 2: 6-[Bis(4-chlorophenyl)methyl]-4-bromo-8-methoxyquinoline (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> was synthesized according to general procedure F from (4-bromo-8-methoxyquinolin-6-yl)bis(4-chlorophenyl)methanol (6 g, 12.27 mmol), Et<sub>3</sub>SiH (8 mL), and TFA (24 mL) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL). Purification: silica gel column (EtOAc:petroleum ether 1:1) to yield 5.2 g of compound <b>25</b>. ES, <i>m</i>/<i>z</i>: 471.0, 473.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_44_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> Step 3: 6-[Bis(4-chlorophenyl)methyl]-8-methoxy-<i>N</i>-[1-(trifluoromethane)sulfonylpiperidin-4-yl]quinolin-4-amine</h4><div class="NLM_p last">The titled compound was synthesized according to general procedure B from <b>25</b> (500 mg, 1.06 mmol), 1-(trifluoromethane)sulfonylpiperidin-4-amine hydrochloride (425 mg, 1.58 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (55 mg, 0.05 mmol), dppf (100 mg, 0.18 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (1g, 3.07 mmol). Purification: silica gel column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 5:1) to yield 314 mg of the titled compound. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 5.4 Hz, 1H), 7.72 (s, 1H), 7.39 (d, <i>J</i> = 8.4HZ, 4H), 7.22 (d, <i>J</i> = 8.4 Hz, 4H), 6.80 (s, 1H), 6.76 (d, <i>J</i> = 7.8 Hz, 1H), 6.64 (d, <i>J</i> = 5.7 Hz, 1H), 5.69 (s,1H), 3.85–3.90 (m, 3H), 3.77 (s, 3H), 3.32–3.44 (m, 2H), 2.07–2.11 (m, 2H), 1.65–1.71 (m, 2H), 1.27–1.30 (m, 2H). ES, <i>m</i>/<i>z</i>: 624 [M + H]<sup>+</sup>.</div></div><div id="sec5_44_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Step 4: 6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-ol (<b>8a</b>)</h4><div class="NLM_p last">To a solution of 6-[bis(4-chlorophenyl)methyl]-8-methoxy-<i>N</i>-[1-(trifluoromethane)sulfonylpiperidin-4-yl]quinolin-4-amine (1 g, 1.60 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added BBr<sub>3</sub> (1.6 g, 6.40 mmol) dropwise with stirring at −78 °C under N<sub>2</sub>. The reaction was stirred overnight at rt and then was quenched by the addition of water. The organics were concentrated and applied onto a silica gel column eluting with 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> to yield 702 mg of compound <b>8a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (s, 1H), 7.65 (s, 1H), 7.40 (d, <i>J</i> = 8.31 Hz, 4H), 7.16 (d, <i>J</i> = 8.31 Hz, 4H), 6.90 (br s, 1H), 6.66–6.67 (m, 2H), 5.66 (s, 1H), 3.77–3.98 (m, 3H), 3.32–3.53 (m, 2H), 1.98–2.19 (m, 2H), 1.49–1.77 (m, 2H). HRMS (C<sub>28</sub>H<sub>24</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 610.0945, found 610.0925 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 7.37 min (method B), 96.2%.</div></div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> Ethyl 2-((6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-yl)oxy)acetate (<b>8b</b>)</h3><div class="NLM_p last">A mixture of <b>8a</b> (61 mg, 0.10 mmol), ethyl 2-bromoacetate (0.0133 mL, 0.12 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (39.07 mg, 0.12 mmol) in DMF (1 mL) was heated to 50 °C for 3 h. The reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub> and water. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organics were concentrated and was purified by silica column chromatography (0–5% MeOH/DCM) to give a 39.7 mg of compound <b>8b</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.48 (s, 1H), 7.23–7.35 (m, 5H), 7.03 (br d, <i>J</i> = 7.58 Hz, 4H), 6.56–6.66 (m, 1H), 6.45–6.54 (m, 1H), 5.65 (br s, 1H), 5.31 (s, 1H), 4.72 (s, 2H), 4.12 (q, <i>J</i> = 7.41 Hz, 2H), 3.99 (br d, <i>J</i> = 10.61 Hz, 2H), 3.69–3.75 (m, 1H), 3.42–3.48 (m, 2H), 2.12–2.28 (m, 2H), 1.59–1.85 (m, 2H), 1.18 (t, <i>J</i> = 7.33 Hz, 3H). ES, <i>m</i>/<i>z</i>: 696.0 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.36 min (method C), 99.7%.</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> 2-((6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-yl)oxy)acetic Acid (<b>8c</b>)</h3><div class="NLM_p last">To a solution of <b>8b</b> (27 mg, 0.039 mmol) in 2 mL of THF was added 0.6 mL of aqueous NaOH (1M). The mixture was vigorously stirred at rt for 2 h. The reaction was acidified by 1 N HCl solution. The solid was filtered, washed with water, and dried under high vacuum to give a 22.7 mg of compound <b>8c</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (d, <i>J</i> = 5.56 Hz, 1H), 7.96 (s, 1H), 7.52 (br s, 2H), 7.40 (d, <i>J</i> = 8.08 Hz, 4H), 7.18 (d, <i>J</i> = 8.59 Hz, 4H), 7.00 (s, 1H), 6.80 (d, <i>J</i> = 5.56 Hz, 1H), 5.72 (s, 1H), 4.53 (s, 2H), 3.95–4.07 (m, 1H), 3.89 (d, <i>J</i> = 13.14 Hz, 2H), 3.37 (br s, 2H), 2.10 (d, <i>J</i> = 12.63 Hz, 2H), 1.67 (d, <i>J</i> = 10.11 Hz, 2H). HRMS (C<sub>30</sub>H<sub>26</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 668.1000, found 668.0964 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.16 min (method C), 99.2%.</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> 5-((6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-yl)oxy)pentanoic Acid (<b>8d</b>)</h3><div class="NLM_p last">The titled compound was prepared in a similar fashion as compound <b>8c</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 5.4 Hz, 1H),7.72 (s, 1H), 7.39 (d, <i>J</i> = 8.4 Hz, 4H), 7.20 (d, <i>J</i> = 8.4 Hz, 4H), 6.72–6.80 (m, 2H), 6.65 (d, <i>J</i> = 5.7 Hz, 1H), 5.68 (s,1H), 3.86–3.99 (m, 5H), 3.35–3.55 (m, 2H), 2.27–2.34 (m, 2H), 2.08–2.11 (m, 2H), 1.57–1.74 (m, 6H). HRMS (C<sub>33</sub>H<sub>32</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 710.1470, found 710.1434 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.81 min (method A), 97.7%.</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> 5-((6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-yl)oxy)pentanamide (<b>8e</b>)</h3><div class="NLM_p last">A mixture of <b>8d</b> (100 mg, 0.14 mmol), NH<sub>4</sub>Cl (38 mg, 0.71 mmol), HATU (80 mg, 0.21 mmol), and DIEA (0.5 mL) in DMF (10 mL) was stirred overnight at 25 °C. The resulting solution was diluted with water (50 mL). The solids were collected by filtration. The residue was applied onto a silica gel column with 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> to yield 29 mg of compound <b>8e</b> as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 6.9 Hz, 1H), 7.91 (s, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 4H), 7.23 (d, <i>J</i> = 8.4 Hz, 4H), 7.13 (s, 1H), 6.98 (d, <i>J</i> = 6.9 Hz, 1H), 5.77 (s,1H), 4.10–4.12 (m, 3H), 3.85–3.95 (m, 4H), 3.35–3.43 (m, 2H), 2.10–2.19 (m, 4H), 1.68–1.80 (m, 6H). HRMS (C<sub>33</sub>H<sub>33</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 709.1629, found 709.1589 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 7.70 min (method B), 95.0%.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> 8-(4-Aminobutoxy)-6-(bis(4-chlorophenyl)methyl)-<i>N</i>-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)quinolin-4-amine, Trifluoroacetic Acid Salt (<b>8f</b>)</h3><div id="sec5_49_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> Step 1. <i>tert</i>-Butyl (4-((6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-yl) oxy)butyl)carbamate</h4><div class="NLM_p last">A mixture of <b>8a</b> (200 mg, 0.33 mmol), Cs<sub>2</sub>CO<sub>3</sub> (320 mg, 0.98 mmol), and <i>tert</i>-butyl <i>N</i>-(4-bromobutyl)carbamate (88 mg, 0.35 mmol) in DMF (20 mL) was stirred for 3 h at 60 °C. The resulting solution was diluted with water (150 mL). The solids were collected by filtration and applied onto a silica gel column eluting with 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> to yield 120 mg of the titled compound as a light-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (d, <i>J</i> = 5.6 Hz, 1H), 7.79 (s, 1H), 7.41 (d, <i>J</i> = 8.4 Hz, 4H), 7.21 (d, <i>J</i> = 8.4 Hz, 4H), 6.70–7.04 (brm, 2H), 5.71 (s, 1H), 3.88–4.01 (m, 5H), 3.31–3.44 (m, 2H), 2.95–3.00 (m, 2H), 2.08–2.11 (m, 2H), 1.65–1.76 (m, 6H), 1.37 (s, 9H). ES, <i>m</i>/<i>z</i>: 781 [M + H]<sup>+</sup>.</div></div><div id="sec5_49_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> Step 2: 8-(4-Aminobutoxy)-6-[bis(4-chlorophenyl)methyl]-<i>N</i>-[1-(trifluoromethane)sulfonylpiperidin-4-yl]quinoline-4-amine, Trifluoroacetic Acid Salt (<b>8f</b>)</h4><div class="NLM_p last">A solution of <i>tert</i>-butyl(4-((6-(bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-yl)oxy)butyl)carbamate (120 mg) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and TFA (1 mL) was stirred at rt for 2 h and then concentrated. The solid was washed with heptanes to yield 60 mg of compound <b>8f</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (d, <i>J</i> = 7.2 Hz, 1H), 8.41 (s, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 4H), 7.22–7.25 (m, 5H), 7.09 (d, <i>J</i> = 7.2 Hz, 1H), 5.79 (s, 1H), 4.15–4.19 (m, 3H), 3.92–3.96 (m, 2H), 3.36–3.44 (m, 2H), 2.84–2.89 (m, 2H), 2.09–2.13 (m, 2H), 1.77–1.85 (m, 6H). HRMS (C<sub>32</sub>H<sub>33</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 681.1680, found 681.1647 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 7.73 min (method B), 96.9%.</div></div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> 1-((6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-8-yl)oxy)-3,6,9,12,15,18,21,24,27,30,33,36-dodeca-oxanonatriacontan-39-oic Acid (<b>8g</b>)</h3><div class="NLM_p last">The titled compound was prepared in a similar fashion as compound <b>8f</b> by replacing <i>tert</i>-butyl <i>N</i>-(4-bromobutyl)carbamate with <i>tert</i>-butyl 1-(tosyloxy)-3,6,9,12,15,18,21,24, 27,30,33,36-dodecaoxanonatriacontan-39-oate in step 1 (overall yield 29% in two steps). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.38 (d, <i>J</i> = 7.07 Hz, 1H), 7.95 (s, 1H), 7.31–7.40 (m, 4H), 7.17 (d, <i>J</i> = 8.59 Hz, 4H), 7.05 (d, <i>J</i> = 7.07 Hz, 1H), 5.80 (s, 1H), 5.49 (s, 1H), 4.33 (dd, <i>J</i> = 3.28, 5.31 Hz, 2H), 4.12–4.22 (m, 1H), 4.01–4.10 (m, 2H), 3.88–3.97 (m, 2H), 3.66–3.72 (m, 4H), 3.52–3.65 (m, 44H), 3.32–3.39 (m, 2H), 2.50–2.53 (m, 2H), 2.20 (br d, <i>J</i> = 11.12 Hz, 2H), 1.72–1.96 (m, 2H). ES, <i>m</i>/<i>z</i>: 1212.3 [M + H]<sup>+</sup>, 1234.2 [M + Na]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.94 min (method C), 95.5%.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> 2-((2,5,8,11-Tetraoxatridecan-13-yl)oxy)-6-(bis(4-chlorophenyl)methyl)-<i>N</i>-(1-((trifluoro methyl)sulfonyl)piperidin-4-yl)quinolin-4-amine (<b>8i</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>8h</b> (see the synthesis of <b>7b</b>) from <b>6a</b> (66.7 mg, 0.109 mmol), 13-bromo-2,5,8,11-tetraoxatridecane (35.5 mg, 0.131 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (71.2 mg, 0.218 mmol). Yield 35.2% (30.7 mg). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (d, <i>J</i> = 9.09 Hz, 1H), 7.23–7.31 (m, 6H), 7.03 (d, <i>J</i> = 8.59 Hz, 4H), 5.98 (s, 1H), 5.63 (s, 1H), 4.56–4.65 (m, 2H), 4.47 (d, <i>J</i> = 7.07 Hz, 1H), 3.99 (br d, <i>J</i> = 12.63 Hz, 2H), 3.85–3.91 (m, 2H), 3.61–3.76 (m, 10H), 3.52–3.58 (m, 2H), 3.37 (s, 3H), 3.21–3.31 (m, 2H), 2.26 (br d, <i>J</i> = 11.12 Hz, 2H), 1.55–1.67 (m, 2H). HRMS (C<sub>37</sub>H<sub>42</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>7</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 800.2150, found 800.2119 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 4.31 min (method C), 99.8%.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> 2-((2,5,8,11,14,17,20-Heptaoxadocosan-22-yl)oxy)-6-(bis(4-chlorophenyl)methyl)-<i>N</i>-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)quinolin-4-amine (<b>8j</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>8h</b> from <b>6a</b> (70 mg, 0.115 mmol), 2,5,8,11,14,17,20-heptaoxadocosan-22-yl 4-methylbenzenesulfonate (62.4 mg, 0.126 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (74.7 mg, 0.229 mmol). Yield 52.3% (56.7 mg). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 (d, <i>J</i> = 8.59 Hz, 1H), 7.18–7.33 (m, 6H), 7.03 (d, <i>J</i> = 8.59 Hz, 4H), 5.98 (s, 1H), 5.63 (s, 1H), 4.56–4.63 (m, 2H), 4.51 (d, <i>J</i> = 7.07 Hz, 1H), 3.99 (br d, <i>J</i> = 12.63 Hz, 2H), 3.79–3.94 (m, 2H), 3.58–3.77 (m, 22H), 3.53–3.58 (m, 2H), 3.37 (s, 3H), 3.15–3.33 (m, 2H), 2.26 (br d, <i>J</i> = 11.12 Hz, 2H), 1.62 (br d, <i>J</i> = 10.61 Hz, 2H). HRMS (C<sub>43</sub>H<sub>54</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>10</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 932.2937, found 932.2923 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.78 min (method C), 97.1%.</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> 2-((6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoro-methyl)sulfonyl)piperidin-4-yl)amino)quinolin-2-yl)oxy)acetic Acid (<b>8k</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>8c</b>, except beginning with compound <b>6a</b> instead of <b>8a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.62 (d, <i>J</i> = 8.59 Hz, 1H), 7.23–7.29 (m, 6H), 7.03 (d, <i>J</i> = 8.59 Hz, 4H), 5.92–6.08 (m, 1H), 5.57–5.68 (m, 1H), 4.87 (s, 2H), 4.48–4.63 (m, 1H), 3.87–4.03 (m, 2H), 3.46–3.65 (m, 1H), 3.09–3.28 (m, 2H), 2.10–2.30 (m, 2H), 1.53–1.68 (m, 2H). HRMS (C<sub>30</sub>H<sub>26</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>) [M + H]<sup>+</sup>: calcd 668.1001, found 668.1003 (ESI, <i>m</i>/<i>z</i>). HPLC <i>R</i><sub>t</sub> = 3.67 min (method C), 100%.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> 6-((6-(Bis(4-chlorophenyl)methyl)-4-((1-((trifluoromethyl)sulfonyl)piperidin-4-yl)amino)quinolin-2-yl)oxy)hexanoic Acid (<b>8l</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>8c</b>, except beginning with compound <b>6a</b> instead of <b>8a</b> and using methyl 6-bromohexanoate in place of ethyl 2-bromoacetate. <sup>1</sup>H NMR (400 MHz, CDCl3) δ 7.59–7.77 (m, 1H), 7.19–7.32 (m, 6H), 6.94–7.09 (m, 4H), 5.91 (s, 1H), 5.64 (s, 1H), 4.29–4.56 (m, 2H), 3.89–4.16 (m, 2H), 3.55–3.65 (m, 1H), 3.17–3.43 (m, 2H), 2.31–2.35 (m, 2H), 2.21–2.30 (m, 2H), 1.60–1.93 (m, 6H), 1.45–1.54 (m, 2H). HRMS (C<sub>34</sub>H<sub>34</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 724.1626, found 724.1625 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 3.65 min (method C), 99.0%.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> 6-[Bis(4-chlorophenyl)methyl]-4-{[1-(methylsulfonyl)piperidin-4-yl]amino}quinolin-2(1<i>H</i>)-one (<b>9a</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>6a</b>, except the order of steps 2 and 3 was reversed. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (s, 1H), 7.93 (s, 1H), 7.39 (d, <i>J</i> = 8.1 Hz, 4H), 7.11–7.20 (m, 6H), 6.50 (d, <i>J</i> = 7.2 Hz, 1H), 5.61 (s, 1H), 5.40 (s, 1H), 3.54–3.62 (m, 3H), 2.88–2.94 (m, 5H), 1.99–2.04 (m, 2H), 1.54–1.64 (m, 2H). HRMS (C<sub>28</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 556.1228, found 556.1214 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.21 min (method A), 99.5%.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> 6-[Bis(4-chlorophenyl)methyl]-4-{[1-(phenylsulfonyl)piperidin-4-yl]amino}quinolin-2(1<i>H</i>)-one (<b>9b</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>6a</b>, except the order of steps 2 and 3 was reversed. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (s, 1H), 7.89 (s, 1H), 7.64–7.77 (m, 5H), 7.37–7.39 (m, 4H), 7.08–7.17 (m, 6H), 6.43 (d, <i>J</i> = 7.5 Hz, 1H), 5.60 (s, 1H), 5.35 (s, 1H), 3.68 (d, <i>J</i> = 12.0 Hz, 2H), 3.41–3.42 (m, 1H), 2.42–2.50 (m, 2H), 1.97–2.01 (m, 1H), 1.57–1.63 (m, 2H). HRMS (C<sub>33</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 618.1384, found 618.1406 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.27 min (method A), 97.5%.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> 4-((4-((6-(Bis(4-chlorophenyl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)amino)piperidin-1-yl)sulfonyl)benzoic Acid (<b>9c</b>)</h3><div id="sec5_57_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> Step 1: 6-[Bis(4-chlorophenyl)methyl]-4-[(piperidin-4-yl)amino]-1,2-dihydroquinolin-2-one (<b>11</b>)</h4><div class="NLM_p last">Compound <b>11</b> was prepared in a similar fashion as <b>5n.</b><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.44 (s, 1H), 7.28 (d, <i>J</i> = 8.1 Hz, 4H), 7.22 (d, <i>J</i> = 4.0 Hz, 1H), 7.16 (d, <i>J</i> = 4.0 Hz, 1H), 7.09 (s, 1H), 7.02 (d, <i>J</i> = 12.0 Hz, 4H), 5.67 (s, 1H), 5.56 (s, 1H), 4.49 (m, 1H), 3.43–3.52 (m, 1H), 3.09–3.14 (m, 2H), 2.72 (br t, <i>J</i> = 10.9 Hz, 2H), 2.05–2.17 (m, 2H), 1.37–1.46 (m, 2H). ES, <i>m</i>/<i>z</i>: 478.1 [M + H] <sup>+</sup>.</div></div><div id="sec5_57_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> Step 2: 4-((4-((6-(Bis(4-chlorophenyl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)amino)piperidin-1-yl)sulfonyl)benzoic Acid (<b>9c</b>)</h4><div class="NLM_p last">To a solution of <b>11</b> (150 mg, 0.31 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added 4-(chlorosulfonyl)benzoic acid (103.77 mg, 0.47 mmol) and triethylamine (98.28 mg, 0.95 mmol). The resulting solution was stirred overnight at rt and then concentrated to dryness. The residue was purified by Prep-HPLC with the following conditions: column, Sunfire Prep C18 OBD 5 μm, 19 mm × 150 mm; mobile phase, phase A, water (0.05% NH<sub>4</sub>HCO<sub>3</sub>); phase B, CH<sub>3</sub>CN, linear gradient 20% CH<sub>3</sub>CN up to 65% in 8 min); detector, UV 220 and 254 nm to yield 35 mg of compound <b>9c</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.70 (s, 1H), 8.18 (d, <i>J</i> = 8.40 Hz, 2H), 7.85–7.89 (m, 3H), 7.38 (d, <i>J</i> = 8.40 Hz, 4H), 7.02–7.24 (m, 6H), 6.44 (d, <i>J</i> = 7.18 Hz, 1H), 5.60 (s, 1H), 5.35 (s, 1H), 3.61–3.83 (m, 2H), 3.38–3.53 (m, 1H), 2.39–2.51 (m, 2H), 1.84–2.13 (m, 2H), 1.44–1.70 (m, 2H). HRMS (C<sub>34</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 662.1283, found 662.1266 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.30 min (method A), 98.4%.</div></div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> 3-{[4-({6-[Bis(4-chlorophenyl)methyl]-2-oxo-1,2-dihydroquinolin-4-yl}amino)piperidin-1-yl]sulfonyl}benzoic Acid (<b>9d</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>9c</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.70 (s, 1H), 8.09–8.36 (m, 2H), 7.97–8.02 (m, 1H), 7.89 (s, 1H), 7.70–7.84 (m, 1H), 7.38 (d, <i>J</i> = 8.03 Hz, 4H), 7.06–7.20 (m, 5H), 6.38–6.47 (m, 1H), 5.60 (s, 1H), 5.36 (s, 1H), 3.70 (br d, <i>J</i> = 10.54 Hz, 2H), 3.40–3.52 (m, 1H), 2.43–2.49 (m, 2H), 1.95–2.05 (m, 2H), 1.51–1.70 (m, 2H). HRMS (C<sub>34</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 662.1283, found 662.1264 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 8.99 min (method B), 95.7%.</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> 3-((4-((6-(Bis(4-chlorophenyl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)amino)piperidin-1-yl)methyl)benzoic Acid (<b>9e</b>)</h3><div id="sec5_59_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> Step 1: Methyl 3-[[4-([6-[Bis(4-chlorophenyl)methyl]-2-hydroxyquinolin-4-yl]amino)piperidin-1-yl]methyl]benzoate</h4><div class="NLM_p last">To a solution of <b>11</b> (100 mg, 0.21 mmol) in MeOH (10 mL), methyl 3-formylbenzoate (68 mg, 0.41 mmol), NaBH<sub>3</sub>CN (66 mg, 1.03 mmol), and acetic acid (0.1 mL). The resulting solution was stirred overnight at 25 °C and then concentrated under vacuum. The residue was applied onto a silica gel column eluting with 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> to yield 80 mg of the titled compound as a yellow solid. ES, <i>m</i>/<i>z</i>: 626.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_59_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> Step 2: 3-[[4-([6-[Bis(4-chlorophenyl)methyl]-2-hydroxyquinolin-4-yl]amino)piperidin-1-yl]methyl]benzoic Acid (<b>9e</b>)</h4><div class="NLM_p last">A solution of methyl 3-[[4-([6-[bis(4-chloro-phenyl)methyl]-2-hydroxyquinolin-4-yl]amino)piperidin-1-yl]methyl]benzoate (80 mg, 0.13 mmol) in 20 mL of MeOH and 20 mL of 1 M NaOH was stirred overnight at 30 °C and then the pH value of the solution was adjusted to 5–6 with 10% HCl. The organic solvent was removed and the solids were collected by filtration to yield 61 mg of compound <b>9e</b> as a white solid. <sup>1</sup>H NMR (300 MHz, MeOD) δ 8.02 (s, 1H), 7.98 (d, <i>J</i> = 7.53 Hz, 1H), 7.90 (s, 1H), 7.50–7.58 (m, 1H), 7.41–7.49 (m, 1H), 7.26–7.34 (m, 5H), 7.16–7.25 (m, 2H), 7.09 (d, <i>J</i> = 8.48 Hz, 4H), 5.66 (s, 1H), 5.58 (s, 1H), 3.97 (s, 2H), 3.56–3.71 (m, 1H), 3.46–3.40 (m, 2H), 2.69–2.75 (m, 2H), 2.13–2.19 (d, <i>J</i> = 11.87 Hz, 2H), 1.74–1.86 (m, 2H). HRMS (C<sub>35</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 612.1820, found 612.1817 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 1.65 min (method A), 95.5%.</div></div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> 4-{[4-({6-[Bis(4-chlorophenyl)methyl]-2-oxo-1,2-dihydroquinolin-4-yl}amino)piperidin-1-yl]methyl}benzoic Acid (<b>9f</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>9e.</b><sup>1</sup>H NMR (300 MHz, MeOD) δ 8.10 (d, <i>J</i> = 8.10 Hz, 2H), 7.92 (s, 1H), 7.60 (d, <i>J</i> = 8.10 Hz, 2H), 7.17–7.37 (m, 7H), 7.10 (d, <i>J</i> = 8.48 Hz, 4H), 5.68 (s, 1H), 5.61 (s, 1H), 4.25 (s, 2H), 3.66–3.83 (m, 1H), 3.42 (d, <i>J</i> = 12.24 Hz, 2H), 2.95–3.14 (m, 2H), 2.27 (d, <i>J</i> = 12.81 Hz, 2H), 1.84–1.95 (m, 2H). ES, <i>m</i>/<i>z</i>: 612.1 [M + H] <sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 1.72 min (method A), 95.3%.</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i150" class="anchor-spacer"></div><h3 class="article-section__title" id="_i150"> 4-(4-((6-(Bis(4-chlorophenyl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)amino)cyclohexane-1-carbon-yl)benzoic Acid (<b>9g</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>6a</b>, except the order of steps 2 and 3 was reversed. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (s, 1H), 7.96–7.98 (m, 3H), 7.39 (d, <i>J</i> = 8.53 Hz, 6H), 7.01–7.25 (m, 6H), 6.51 (br d, <i>J</i> = 7.78 Hz, 1H), 5.62 (s, 1H), 5.45 (s, 1H), 4.39–4.62 (m, 1H), 3.59–3.73 (m, 2H), 2.97–3.19 (m, 2H), 1.79–2.14 (m, 2H), 1.34–1.65 (m, 2H). HRMS (C<sub>35</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>4</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 626.1613, found 626.1594 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 1.97 min (method A), 97.0%.</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i151" class="anchor-spacer"></div><h3 class="article-section__title" id="_i151"> Ethyl 3-[4-({6-[Bis(4-chlorophenyl)methyl]-2-oxo-1,2-dihydroquinolin-4-yl}amino)piperidin-1-yl]-3-oxopro-panoate (<b>9h</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>6a</b>, except the order of steps 2 and 3 was reversed. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.22 (t, <i>J</i> = 6.9 Hz, 3H), 1.36–1.52 (m, 2H), 1.92–1.97 (m, 2H), 2.73–2.80 (m, 1H), 3.15–3.23 (m,1H), 3.54 (s, 2H), 3.60–3.68 (m, 1H), 3.77–3.81 (m, 1H), 4.06–4.11 (q, <i>J</i> = 6.9 Hz, 2H), 4.34–4.38 (m, 1H), 5.44 (s, 1H), 5.60 (s,1H), 6.46 (d, <i>J</i> = 7.8 Hz,1H), 7.11–7.19 (m, 6H), 7.38 (d, <i>J</i> = 8.7 Hz, 4H), 7.93 (s,1H), 10.72 (s,1H). ES, <i>m</i>/<i>z</i>: 592.0 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.06 min (method A), 98.8%.</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i152" class="anchor-spacer"></div><h3 class="article-section__title" id="_i152"> 3-[4-({6-[Bis(4-chlorophenyl)methyl]-2-oxo-1,2-dihydroquinolin-4-yl}amino)piperidin-1-yl]-3-oxopropanoic Acid (<b>9i</b>)</h3><div class="NLM_p last">A solution of <b>9h</b> (60 mg, 0.097 mmol) in ethanol (15 mL) and NaOH (1N, 2 mL) was stirred for 4 h at room temperature. The resulting mixture was concentrated and acidified to pH3–4 with 1 N HCl. The solids were collected by filtration. The resulting residue was purified by recrystallization from methanol to yield 19 mg of <b>9i</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.55 (br s, 1H), 10.72 (s, 1H), 7.94 (s, 1H), 7.38 (d, <i>J</i> = 8.50 Hz, 4H), 7.03–7.27 (m, 6H), 6.47 (br d, <i>J</i> = 7.55 Hz, 1H), 5.60 (s, 1H), 5.44 (s, 1H), 4.38 (d, <i>J</i> = 12.46 Hz, 1H), 3.82 (d, <i>J</i> = 13.12 Hz, 1H), 3.60–3.74 (m, 1H), 3.45 (d, <i>J</i> = 1.98 Hz, 2H), 3.19 (t, <i>J</i> = 12.13 Hz, 1H), 2.62–2.84 (m, 1H), 1.85–2.04 (m, 2H), 1.30–1.58 (m, 3H). HRMS (C<sub>30</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>4</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 564.1456, found 564.1426 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 7.37 min (method B), 95.0%.</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i153" class="anchor-spacer"></div><h3 class="article-section__title" id="_i153"> 3-(4-((6-(Bis(4-chlorophenyl)methyl)-2-oxo-1,2-dihydroquinolin-4-yl)amino)piperidin-1-yl)-3-oxo-propanamide (<b>9j</b>)</h3><div class="NLM_p last">A mixture of <b>9i</b> (20 mg, 0.03 mmol), NH<sub>4</sub>Cl (9.48 mg, 0.18 mmol), DIEA (45.7 mg, 0.35 mmol), and HATU (20.2 mg, 0.05 mmol) in DMF (3 mL) was stirred overnight at rt. The resulting solution was diluted with water and extracted with EtOAc. The combined organic layers were concentrated to dryness. The residue was applied onto a silica gel column eluting with 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> to yield 8 mg of compound <b>9j</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (s, 1H), 7.95 (s, 1H), 7.35–7.46 (m, 5H), 7.08–7.19 (m, 5H), 6.97 (br s, 1H), 6.46 (br d, <i>J</i> = 7.36 Hz, 1H), 5.59 (s, 1H), 5.43 (s, 1H), 4.38 (br d, <i>J</i> = 12.75 Hz, 1H), 3.90 (br d, <i>J</i> = 14.26 Hz, 1H), 3.58–3.74 (m, 1H), 3.27 (d, <i>J</i> = 3.49 Hz, 2H), 3.12–3.26 (m, 2H), 2.69–2.77 (m, 2H), 1.88–1.99 (m, 2H), 1.53 (br d, <i>J</i> = 10.76 Hz, 1H), 1.31–1.44 (m, 1H). HRMS (C<sub>30</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 563.1616, found 563.1590 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 1.84 min (method A), 99.6%.</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i154" class="anchor-spacer"></div><h3 class="article-section__title" id="_i154"> [4-({6-[Bis(4-chlorophenyl)methyl]-2-oxo-1,2-dihydroquinolin-4-yl}amino)piperidin-1-yl]acetic Acid (<b>9k</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>6a</b>, except the order of steps 2 and 3 was reversed. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.90 (s, 1H), 9.88 (brs, 1H), 8.00 (s, 1H), 7.39 (d, <i>J</i> = 8.1 Hz, 4H), 7.21 (d, <i>J</i> = 8.1 Hz, 1H), 7.11–7.14 (m, 5H), 5.62 (s, 1H), 5.48 (s, 1H), 4.12–4.14 (m, 2H), 3.62–3.69 (m, 1H), 3.57 (s, 2H), 3.19–3.25 (m, 2H), 2.12–2.19 (m, 2H), 1.84–1.92 (m, 2H). HRMS (C<sub>29</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 536.1507, found 536.1473 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 5.98 min (method B), 95.0%.</div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i155" class="anchor-spacer"></div><h3 class="article-section__title" id="_i155"> 6-(Bis(4-chlorophenyl)methyl)-4-((1-(pyrimidin-2-yl)piperidin-4-yl)amino)quinolin-2(1<i>H</i>)-one (<b>9l</b>)</h3><div class="NLM_p last">The titled compound was synthesized in a similar fashion as compound <b>6a</b>, except the order of steps 2 and 3 was reversed. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ10.75 (s, 1H), 8.39 (d, <i>J</i> = 4.5 Hz, 2H), 7.93 (s, 1H), 7.38–7.40 (m, 4H), 7.12–7.21 (m, 6H), 6.61–6.64 (m, 1H), 6.45 (d, <i>J</i> = 7.8 Hz, 1H), 5.60 (s, 1H), 5.48 (s, 1H),4.67–4.72 (m, 2H), 3.76 (br, 1H), 3.04–3.13 (m, 2H), 1.98–2.02 (d, <i>J</i> = 11.1 Hz, 2H), 1.47–1.54 (m, 2H). HRMS (C<sub>31</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>5</sub>O + H<sup>+</sup>) (ESI, <i>m</i>/<i>z</i>): calcd 556.1671, found 556.1682 [M + H]<sup>+</sup>. HPLC <i>R</i><sub>t</sub> = 2.13 min (method A), 95.9%.</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i156" class="anchor-spacer"></div><h3 class="article-section__title" id="_i156"> Biology</h3><div class="NLM_p">All animal experiments were performed in compliance with institutional guidelines defined by Institutional Animal Care and Use Committee for US institutions.</div><div id="sec5_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> CB<sub>1</sub>R and CB<sub>2</sub>R cAMP Functional Assays</h4><div class="NLM_p last">HEK-293 cells stably overexpressing hCB1R or hCB1R (DiscoveRx, Fremont, CA) were maintained in DMEM supplemented with 10% fetal bovine serum, 0.2 mg/mL Hygromycin B, and 600 μg/mL G418. After cell expansion, aliquots were cryostored in media containing 5% DMSO. One day prior to the experiment, cells were plated at 8000 cells/well into 384-well PDL white solid-bottom plates. Stimulation of cAMP by CB<sub>1</sub>RIVs or CB<sub>2</sub>RIVs was determined using the CISBIO cAMP homogenous time-resolved fluorescence resonance energy transfer (FRET) (HTRF) assay according to the manufacturer’s instructions (Cisbio Assays, Bedford, MA). Tested compounds and control compound CB1RIA 1-(2,4-dichlorophenyl)-7-[(4-fluorophenyl)methylene]-4,5,6,7-tetrahydro-<i>N</i>-1-piperidinyl-1<i>H</i>-indazole-3-carboxamide or CB2RIA AM630 (also known as [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1<i>H</i>-indol-3-yl](4-methoxyphenyl)-methanone) were added to the cell plate at the indicated concentrations followed by addition of forskolin (250 nM final concentration). The cell plate was incubated for 30 min at the room temperature. In parallel, the cAMP standard dilutions were added in duplicates to the cell plate. After incubation, a 6 μL of each d2 labeled cAMP and Anti-cAMP (CisBio HTRF Detection Kit) were added to all wells of the cell plate, mixed, centrifuged, and incubated for 60 min in the dark at the room temperature. The cell plate was read in HTRF mode (fluorescence at 665 and 620 nm) on an Envision plate reader (PerkinElmer, Waltham, MA). Amount of cAMP in nM was calculated for each well from a cAMP standard curve located on each plate. EC<sub>50</sub> values were determined from a 4-point fit (Hill equation) of 11-point compound concentrations. The details of the assay protocols were described previously.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div><div id="sec5_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> CB<sub>1</sub>R Membrane Binding Assay Using Radioligand [3H] CP-55,940</h4><div class="NLM_p last">The assay was performed in hCB1-CHO-K1 membrane as described previously.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div><div id="sec5_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> CB<sub>1</sub>R Membrane Binding Assay Using Radioligand [3H]-Rimonabant</h4><div class="NLM_p last">The hCB<sub>1</sub> membranes were prepared from CHO-CB<sub>1</sub> cells. The binding assay was carried out in a 96-well plate containing 2 nM radioligand 3H-rimonabant, indicated concentration of the tested compounds, and 7.5 μg/well hCB1 membrane suspension in a total volume of 100 μL. The plate was incubated for 60 min at room temperature with gentle shaking. The binding buffer is 50 mM Hepes, pH 7.4, 5 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 0.2% BSA. Binding assays were terminated by separating bound and free radioligand by collecting membrane-bound fractions onto GF/B filterplates impregnated with PEI 0.5% and prewet with binding buffer and washed five times with ice-cold wash buffer (50 mM Hepes, pH 7.4, 500 mM NaCl, 0.1% BSA) using a Harvester Filtermate 96 (PerkinElmer). Filterplates were dried for 2 h, and 50 μL of Microscint O was added to each well. Radioactivity retained was counted using the Topcount</div></div><div id="sec5_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> Liver Microsome Stability Assay</h4><div class="NLM_p last">The stability of compounds in the presence of human, rat, and mouse liver microsomes was determined by measuring the percent of the parent compound remaining after incubation of the compound under the following conditions: 100 mM phosphate buffer, 1 mg/mL microsomal protein, 1 mM NADPH, 1 μM substrate concentration. Analysis of data: The ratio of peak area of compound of interest to an internal standard is calculated, % parent remaining at 10 min = peak area ratio at 10 min × 100</div></div><div id="sec5_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> CYP450 Drug–Drug Interaction Assay</h4><div class="NLM_p last">Test compounds are incubated at seven concentrations with human liver microsomes and chemical probe substrates for each of the six isoforms (1A2 phenacetin, 2C9 tolbutamide, 2C19 S-mephenytoin, 2D6 dextromethorphan, 3A4 midazolam, and testosterone) to estimate the IC<sub>50</sub> for inhibition of the probe substrate by the test inhibitor. Reference incubations in which the test compound is a reference inhibitor (α-naphthoflavone for 1A2, sulfaphenazole for 2C9, +<i>N</i>-3-benzyl-phenobarbital for 2C19, quinidine for 2D6, ketoconazole for 3A4) are also included. After the defined incubation time (10–30 min), the reaction is terminated; samples are centrifuged and prepared for analysis by LC/MS. The percent inhibition of the metabolite formation by the probe substrate is plotted against inhibitor concentration and an estimated IC50 value is calculated.</div></div><div id="sec5_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> Mouse Plasma/Brain Distribution Study</h4><div class="NLM_p last">Male C57bl/6j mice (<i>N</i> = 3) were administered test compounds orally at 20 mg/kg (formulated in 10% PEG400 and 10% solutol). At 1 and 4 h after dosing, the mice were anesthetized and blood was collected via retro-orbital bleeding, and then they were perfused with heparinized saline and whole brain without cerebellum was collected. Wet brain weight was recorded before freezing. Brains were homogenized in saline and sent for analysis for determination of concentration of test compound.</div></div><div id="sec5_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> Mouse Full PK Study</h4><div class="NLM_p last">C57bl/6j Mice (<i>N</i> = 6/treatment) were fasted overnight, then dosed intravenously (iv) at 5 mg/kg or by oral gavage at 20 mg/kg with drugs (in 10% PEG400/10% solutol–H<sub>2</sub>O). Food was returned at 4 h post dose. Blood samples (0.25 mL) were collected post dose into tubes containing an appropriate anticoagulant. Blood samples are centrifuged for cell removal and were transferred to a clean vial, placed on dry ice, and subsequently stored in a −70 °C freezer prior to analysis. Plasma samples were normally prepared as follows. Two volumes of acetonitrile containing internal standard is added to one volume of plasma to precipitate proteins. Samples are centrifuged and supernatant removed for analysis by LC-MS-MS.</div></div><div id="sec5_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> DIO Mouse Food Intake Study</h4><div class="NLM_p last">Male DIO C57BL/6J mice from Taconic were given Research Diet no. D12492 for 8–9 weeks before arriving at 14–15 weeks old. The animals were housed one mouse per cage with nestled in a temperature-controlled room with 12 h light/dark cycle. The animals were allowed ad libitum access to water and fed with high fat diet (Research Diet no. D12492). The test compound was formulated in 10% PEG400 and 10% solutol. For the 5 day study, DIO mice (each group <i>N</i> = 10) received vehicle and test compound (@ 30 mg/kg) daily. Body weight and food weight (food intake) were monitored daily. Fed blood glucose and fed insulin was measured at day 4. At the end of the experiment, plasma samples are obtained via retro-orbital sinus under anesthesia and analyzed for compound concentration. Three mice from the drug treated group were anesthetized, perfused with heparinized saline through the left ventricle of the heart, and the brains were then removed and homogenized in PBS for ADME analysis. For the chronic study, DIO mice (each group <i>N</i> = 10) received vehicle and test compound (@ 0.3, 1, 3, and 10 mg/kg) daily. Body weight and food weight (food intake) were monitored daily for first 5 days and then every other day. At day 26, the necropsy procedure was conducted. Blood glucose was measured from the tail vein with a Lifescan glucometer. Plasma insulin was measured with an ELISA or HTRF kit (Cisbio). Total cholesterol was measured on Olympus. Liver fat content was assessed by Bruker. For the PK arms, the blood samples were collected in day 1 and day 22. Brain perfusion was performed and brain tissues were collected in day 2 and day 23 for PK analysis.</div></div><div id="sec5_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> CB<sub>1</sub>R Brain Receptor Occupancy (RO) Study</h4><div class="NLM_p last">Brain receptor occupancy assay was conducted with nonperfused brain tissue from the 5 day DIO mouse FI study. Brain slices were thaw-mounted onto microslides. Receptor binding assay was initiated by incubating the brain sections in the binding buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl<sub>2</sub>, 2 mM EDTA, and 0.5% BSA containing 1 nM [<sup>3</sup>H]CP-55940 for 10 min at rt. Nonspecific binding was defined by similar incubation conditions in the presence of 10 μM AM251. Next, brain sections were washed 3 × 10 min in 300 mL of ice-cold wash buffer (50 mM Tris-HCl, pH 7.4 and 1% BSA) and then rinsed briefly in ice-cold distilled water. Imaging data were collected for 2 h using β-imager 2000 and Beta Acquisition software. The radioligand signal in the region of interest is expressed as counts per minute per square millimeter (cpm/mm2). Specific binding is determined by subtracting nonspecific binding from total binding. The percentage inhibition of specific binding is calculated as follows: 1 – (individual specific binding/average of vehicle binding) × 100.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i166"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01467" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51110" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51110" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01467" class="ext-link">10.1021/acs.jmedchem.8b01467</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Open field locomotor activity study of <b>6a</b> in rat; additional data of mouse full PK study for compound <b>6a</b>; liver microsome stability of compounds <b>5l</b>, <b>6a</b>, <b>6c</b>, <b>6g</b>, and <b>6h</b>; analytical HPLC methods; HPLC traces and <sup>1</sup>H NMR spectra of the key target compounds <b>5m</b>, <b>5p</b>, <b>6a</b>, and <b>9l</b>; NOESY spectra of compounds <b>7b</b> and <b>8h</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">PBD file of CB<sub>1</sub>R and compound <b>6a</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf">jm8b01467_si_001.pdf (1.23 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_002.pdb">jm8b01467_si_002.pdb (525.87 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_003.csv">jm8b01467_si_003.csv (5.21 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01467" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43866" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43866" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yue-Mei Zhang</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6052-8120" title="Orcid link">http://orcid.org/0000-0001-6052-8120</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#eb9291838a858cdeab829f98c5818581c5888486"><span class="__cf_email__" data-cfemail="2a5350424b444d1f6a435e590440444004494547">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael N. Greco</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span>; 
    <span>Present Address:
                        The authors were Janssen Research & Development employees when this work was conducted</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark J. Macielag</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher A. Teleha</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renee L. DesJarlais</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuting Tang</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span>; 
    <span>Present Address:
                        The authors were Janssen Research & Development employees when this work was conducted</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Ho</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cuifen Hou</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span>; 
    <span>Present Address:
                        The authors were Janssen Research & Development employees when this work was conducted</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cailin Chen</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuyuan Zhao</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jack Kauffman</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span>; 
    <span>Present Address:
                        The authors were Janssen Research & Development employees when this work was conducted</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raul Camacho</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jenson Qi</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William Murray</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span>; 
    <span>Present Address:
                        The authors were Janssen Research & Development employees when this work was conducted</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith Demarest</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span>; 
    <span>Present Address:
                        The authors were Janssen Research & Development employees when this work was conducted</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Leonard</span> - <span class="hlFld-Affiliation affiliation">Janssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477-0776, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i168">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Wenying Jian for her kind support on HRMS analysis of the final target compounds, Dr. Xun Li<sup>†</sup> and Dr. Scott Ballentine for their support on scale-up synthesis of compound <b>6a</b>.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">CB<sub>1</sub>R</td><td class="NLM_def"><p class="first last">cannabinoid type 1 receptor</p></td></tr><tr><td class="NLM_term">CB<sub>1</sub>RIAs</td><td class="NLM_def"><p class="first last">CB<sub>1</sub>R inverse agonists</p></td></tr><tr><td class="NLM_term">tPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">dPEG</td><td class="NLM_def"><p class="first last">discrete polyethylene glycol</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i170">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devi, L. A.</span></span> <span> </span><span class="NLM_article-title">The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications</span>. <i>Pharmacological Reviews.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1124/pr.110.003491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1124%2Fpr.110.003491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=461-470&author=L.+K.+Millerauthor=L.+A.+Devi&title=The+highs+and+lows+of+cannabinoid+receptor+expression+in+disease%3A+mechanisms+and+their+therapeutic+implications&doi=10.1124%2Fpr.110.003491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications</span></div><div class="casAuthors">Miller, Lydia K.; Devi, Lakshmi A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-470</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Alterations in the endogenous cannabinoid system have been described in almost every category of disease.  These changes can alternatively be protective or maladaptive, such as producing antinociception in neuropathic pain or fibrogenesis in liver disease, making the system an attractive therapeutic target.  However, the challenge remains to selectively target the site of disease while sparing other areas, particularly mood and cognitive centers of the brain.  Identifying regional changes in cannabinoid receptor-1 and -2 (CB1R and CB2R) expression is particularly important when considering endocannabinoid system-based therapies, because regional increases in cannabinoid receptor expression have been shown to increase potency and efficacy of exogenous agonists at sites of disease.  Although there have been extensive descriptive studies of cannabinoid receptor expression changes in disease, the underlying mechanisms are only just beginning to unfold.  Understanding these mechanisms is important and potentially relevant to therapeutics.  In diseases for which cannabinoid receptors are protective, knowledge of the mechanisms of receptor up-regulation could be used to design therapies to regionally increase receptor expression and thus increase efficacy of an agonist.  Alternatively, inhibition of harmful cannabinoid up-regulation could be an attractive alternative to global antagonism of the system.  Here we review current findings on the mechanisms of cannabinoid receptor regulation in disease and discuss their therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBsKnefQ2N4rVg90H21EOLACvtfcHk0lgOIXIuodCdcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtbzL&md5=ed47f14e41dc66de83422e2e545275ab</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.003491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.003491%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DL.%2BK.%26aulast%3DDevi%26aufirst%3DL.%2BA.%26atitle%3DThe%2520highs%2520and%2520lows%2520of%2520cannabinoid%2520receptor%2520expression%2520in%2520disease%253A%2520mechanisms%2520and%2520their%2520therapeutic%2520implications%26jtitle%3DPharmacological%2520Reviews.%26date%3D2011%26volume%3D63%26spage%3D461%26epage%3D470%26doi%3D10.1124%2Fpr.110.003491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Despres, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjostrom, L.</span></span> <span> </span><span class="NLM_article-title">Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">2121</span>– <span class="NLM_lpage">2134</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1056%2FNEJMoa044537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=16291982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ajtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2121-2134&author=J.+P.+Despresauthor=A.+Golayauthor=L.+Sjostrom&title=Effects+of+rimonabant+on+metabolic+risk+factors+in+overweight+patients+with+dyslipidemia&doi=10.1056%2FNEJMoa044537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia</span></div><div class="casAuthors">Despres, Jean-Pierre; Golay, Alain; Sjoestroem, Lars</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2121-2134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body wt. and improve cardiovascular risk factors in obese patients.  The Rimonabant in Obesity-Lipids (RIO-Lipids) study examd. the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are over-wt. or obese and have dyslipidemia.  We randomly assigned 1036 overweight or obese patients (body-mass index [the wt. in kilograms divided by the square of the height in meters], 27 to 40) with untreated dyslipidemia (triglyceride levels > 1.69 to 7.90 mmol per L, or a ratio of cholesterol to high-d. lipoprotein [HDL] cholesterol of > 4.5 among women and > 5 among men) to double-blinded therapy with either placebo or rimonabant at a dose of 5 mg or 20 mg daily for 12 mo in addn. to a hypocaloric diet.  The rates of completion of the study were 62.6%, 60.3%, and 63.9% in the placebo group, the group receiving 5 mg of rimonabant, and the group receiving 20 mg of rimonabant, resp.  The most frequent adverse events resulting in discontinuation of the drug were depression, anxiety, and nausea.  As compared with placebo, rimonabant at a dose of 20 mg was assocd. with a significant (P < 0.001) mean wt. loss (repeated-measures method, -6.7 ± 0.5 kg, and last-observation-carried-forward analyses, -5.4 ± 0.4 kg), redn. in waist circumference (repeated-measures method, -5.8 ± 0.5 cm, and last-observation-carried-forward analyses, -4.7 ± 0.5 cm), increase in HDL cholesterol (repeated-measures method, +10.0 ± 1.6%, and last-observation-carried-forward analyses, +8.1 ± 1.5%), and redn. in triglycerides (repeated-measures method, -13.0 ± 3.5%, and last-observation-carried-forward analyses, -12.4 ± 3.2%).  Rimonabant at a dose of 20 mg also resulted in an increase in plasma adiponectin levels (repeated-measures method, 57.7%, and last-observation-carried-forward analyses, 46.2%; P < 0.001), for a change that was partly independent of wt. loss alone.  Selective CB1-receptor blockade with rimonabant significantly reduces body wt. and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTxwQs4CYJmrVg90H21EOLACvtfcHk0ljdi2LR1kLPRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ajtL3F&md5=6eff642cd942cd283ebff8606a469b96</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044537%26sid%3Dliteratum%253Aachs%26aulast%3DDespres%26aufirst%3DJ.%2BP.%26aulast%3DGolay%26aufirst%3DA.%26aulast%3DSjostrom%26aufirst%3DL.%26atitle%3DEffects%2520of%2520rimonabant%2520on%2520metabolic%2520risk%2520factors%2520in%2520overweight%2520patients%2520with%2520dyslipidemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2121%26epage%3D2134%26doi%3D10.1056%2FNEJMoa044537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gaal, L. F.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1660</span>– <span class="NLM_lpage">1672</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)69571-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2FS0140-6736%2806%2969571-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=17098084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtF2gurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1660-1672&author=A.+J.+Scheenauthor=N.+Finerauthor=P.+Hollanderauthor=M.+D.+Jensenauthor=L.+F.+Van+Gaal&title=Efficacy+and+tolerability+of+rimonabant+in+overweight+or+obese+patients+with+type+2+diabetes%3A+a+randomised+controlled+study&doi=10.1016%2FS0140-6736%2806%2969571-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study</span></div><div class="casAuthors">Scheen, Andre J.; Finer, Nick; Hollander, Priscilla; Jensen, Michael D.; Van Gaal, Luc F.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9548</span>),
    <span class="NLM_cas:pages">1660-1672</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients.  The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulfonylureas.  Of the 1047 overweight or obese type 2 diabetes patients (body-mass index 27-40 kg/m2) with a Hb A1c (HbA1c) concn. of 6.5-10.0% (mean 7.3% [SD 0.9] at baseline) already on metformin or sulfonylurea monotherapy were given a mild hypocaloric diet and advice for increased phys. activity, and randomly assigned placebo (n = 348), 5 mg/day rimonabant (360) or 20 mg/day rimonabant (339) for 1 yr.  Two individuals in the 5 mg/day group did not receive double-blind treatment and were thus not included in the final anal.  The primary endpoint was wt. change from baseline after 1 yr of treatment.  Analyses were done on an intention-to-treat basis.  This trial is registered at, no..  Of the 692 patients completed the 1 yr follow-up; nos. in each group after 1 yr were much the same.  Wt. loss was significantly greater after 1 yr in both rimonabant groups than in the placebo group (placebo: -1.4 kg [SD 3.6]; 5 mg/day: -2.3 kg [4.2], p = 0.01 vs placebo; 20 mg/day: -5.3 kg [5.2], p < 0.0001 vs. placebo).  Rimonabant was generally well tolerated.  The incidence of adverse events that led to discontinuation was slightly greater in the 20 mg/day rimonabant group, mainly due to depressed mood disorders, nausea, and dizziness.  These data indicate that 20 mg/day rimonabant, in combination with diet and exercise, can produce a clin. meaningful redn. in bodyweight and improve HbA1c and a no. of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulfonylureas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkVdBdGCd5xLVg90H21EOLACvtfcHk0ljdi2LR1kLPRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtF2gurvF&md5=9ab3b7ecadce3114a4ea3dbab54c8a15</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969571-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969571-8%26sid%3Dliteratum%253Aachs%26aulast%3DScheen%26aufirst%3DA.%2BJ.%26aulast%3DFiner%26aufirst%3DN.%26aulast%3DHollander%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DM.%2BD.%26aulast%3DVan%2BGaal%26aufirst%3DL.%2BF.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520rimonabant%2520in%2520overweight%2520or%2520obese%2520patients%2520with%2520type%25202%2520diabetes%253A%2520a%2520randomised%2520controlled%2520study%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1660%26epage%3D1672%26doi%3D10.1016%2FS0140-6736%2806%2969571-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_label">4. </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, R. B.</span></span> <span> </span><span class="NLM_article-title">Rimonabant redux and strategies to improve the future outlook of CB<sub>1</sub> receptor neutral-antagonist/inverse-agonist therapies</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1038/oby.2011.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1038%2Foby.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=21475141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnjt1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1325-1334&author=S.+J.+Wardauthor=R.+B.+Raffa&title=Rimonabant+redux+and+strategies+to+improve+the+future+outlook+of+CB1+receptor+neutral-antagonist%2Finverse-agonist+therapies&doi=10.1038%2Foby.2011.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44.</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies</span></div><div class="casAuthors">Ward Sara Jane; Raffa Robert B</div><div class="citationInfo"><span class="NLM_cas:title">Obesity (Silver Spring, Md.)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1325-34</span>
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTq32LoUyLn5Ptos8R3JUhXfW6udTcc2eY-r_527hKBv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnjt1OisQ%253D%253D&md5=17cafba99c5cc057e96c9bc3437f944a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Foby.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DS.%2BJ.%26aulast%3DRaffa%26aufirst%3DR.%2BB.%26atitle%3DRimonabant%2520redux%2520and%2520strategies%2520to%2520improve%2520the%2520future%2520outlook%2520of%2520CB1%2520receptor%2520neutral-antagonist%252Finverse-agonist%2520therapies%26jtitle%3DObesity%26date%3D2011%26volume%3D19%26spage%3D1325%26epage%3D1334%26doi%3D10.1038%2Foby.2011.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gaal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi-Sunyer, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Després, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheen, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the rimonabant in obesity (RIO) program</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">Suppl 2</span>),  <span class="NLM_fpage">S229</span>– <span class="NLM_lpage">S240</span>, <span class="refDoi"> DOI: 10.2337/dc08-s258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.2337%2Fdc08-s258" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=S229-S240&issue=Suppl+2&author=L.+Van+Gaalauthor=X.+Pi-Sunyerauthor=J.+P.+Despr%C3%A9sauthor=C.+McCarthyauthor=A.+Scheen&title=Efficacy+and+safety+of+rimonabant+for+improvement+of+multiple+cardiometabolic+risk+factors+in+overweight%2Fobese+patients%3A+pooled+1-year+data+from+the+rimonabant+in+obesity+%28RIO%29+program&doi=10.2337%2Fdc08-s258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.2337%2Fdc08-s258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc08-s258%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGaal%26aufirst%3DL.%26aulast%3DPi-Sunyer%26aufirst%3DX.%26aulast%3DDespr%25C3%25A9s%26aufirst%3DJ.%2BP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DScheen%26aufirst%3DA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520rimonabant%2520for%2520improvement%2520of%2520multiple%2520cardiometabolic%2520risk%2520factors%2520in%2520overweight%252Fobese%2520patients%253A%2520pooled%25201-year%2520data%2520from%2520the%2520rimonabant%2520in%2520obesity%2520%2528RIO%2529%2520program%26jtitle%3DDiabetes%2520Care%26date%3D2008%26volume%3D31%26issue%3DSuppl%25202%26spage%3DS229%26epage%3DS240%26doi%3D10.2337%2Fdc08-s258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span> <span> </span><span class="NLM_article-title">The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1431</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01352.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1111%2Fj.1476-5381.2011.01352.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=21434882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Sjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=1423-1431&author=G.+Kunosauthor=J.+Tam&title=The+case+for+peripheral+CB1+receptor+blockade+in+the+treatment+of+visceral+obesity+and+its+cardiometabolic+complications&doi=10.1111%2Fj.1476-5381.2011.01352.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications</span></div><div class="casAuthors">Kunos, George; Tam, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1423-1431</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In this review, we consider the role of endocannabinoids and cannabinoid-1 (CB1) cannabinoid receptors in metabolic regulation and as mediators of the thrifty phenotype that underlies the metabolic syndrome.  We survey the actions of endocannabinoids on food intake and body wt., as well as on the metabolic complications of visceral obesity, including fatty liver, insulin resistance and dyslipidemias.  Special emphasis is placed on weighing the relative importance of CB1 receptors located in peripheral tissues vs. the central nervous system in mediating the metabolic effects of endocannabinoids.  Finally, we review recent observations that indicate that peripherally restricted CB1 receptor antagonists retain efficacy in reducing wt. and improving metabolic abnormalities in mouse models of obesity without causing behavioral effects predictive of neuropsychiatric side effects in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoostFcUOY1jbVg90H21EOLACvtfcHk0ljRA60QtJ00VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Sjurk%253D&md5=69e13adbecefc8d113189de66f649bcd</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01352.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01352.x%26sid%3Dliteratum%253Aachs%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DTam%26aufirst%3DJ.%26atitle%3DThe%2520case%2520for%2520peripheral%2520CB1%2520receptor%2520blockade%2520in%2520the%2520treatment%2520of%2520visceral%2520obesity%2520and%2520its%2520cardiometabolic%2520complications%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D1423%26epage%3D1431%26doi%3D10.1111%2Fj.1476-5381.2011.01352.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nogueiras, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veyrat-Durebex, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchanek, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liposits, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reizes, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohner-Jeanrenaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschop, M. H.</span></span> <span> </span><span class="NLM_article-title">Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2977</span>– <span class="NLM_lpage">2991</span>, <span class="refDoi"> DOI: 10.2337/db08-0161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.2337%2Fdb08-0161" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2008&pages=2977-2991&author=R.+Nogueirasauthor=C.+Veyrat-Durebexauthor=P.+M.+Suchanekauthor=M.+Kleinauthor=J.+Tsch%C3%B6pauthor=C.+Caldwellauthor=S.+C.+Woodsauthor=G.+Wittmannauthor=M.+Watanabeauthor=Z.+Lipositsauthor=C.+Feketeauthor=O.+Reizesauthor=F.+Rohner-Jeanrenaudauthor=M.+H.+Tschop&title=Peripheral%2C+but+not+central%2C+CB1+antagonism+provides+food+intake-independent+metabolic+benefits+in+diet-induced+obese+rats&doi=10.2337%2Fdb08-0161"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.2337%2Fdb08-0161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb08-0161%26sid%3Dliteratum%253Aachs%26aulast%3DNogueiras%26aufirst%3DR.%26aulast%3DVeyrat-Durebex%26aufirst%3DC.%26aulast%3DSuchanek%26aufirst%3DP.%2BM.%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DJ.%26aulast%3DCaldwell%26aufirst%3DC.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DWittmann%26aufirst%3DG.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DLiposits%26aufirst%3DZ.%26aulast%3DFekete%26aufirst%3DC.%26aulast%3DReizes%26aufirst%3DO.%26aulast%3DRohner-Jeanrenaud%26aufirst%3DF.%26aulast%3DTschop%26aufirst%3DM.%2BH.%26atitle%3DPeripheral%252C%2520but%2520not%2520central%252C%2520CB1%2520antagonism%2520provides%2520food%2520intake-independent%2520metabolic%2520benefits%2520in%2520diet-induced%2520obese%2520rats%26jtitle%3DDiabetes%26date%3D2008%26volume%3D57%26spage%3D2977%26epage%3D2991%26doi%3D10.2337%2Fdb08-0161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gary-Bobo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elachouri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallas, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravinet-Trillou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruccioli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfersdorff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrié, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oury-Donat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maffrand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scatton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacheretz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Fur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensaid, M.</span></span> <span> </span><span class="NLM_article-title">Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1002/hep.21641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1002%2Fhep.21641" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=122-129&author=M.+Gary-Boboauthor=G.+Elachouriauthor=J.+F.+Gallasauthor=P.+Janiakauthor=P.+Mariniauthor=C.+Ravinet-Trillouauthor=M.+Chabbertauthor=N.+Cruccioliauthor=C.+Pfersdorffauthor=C.+Roqueauthor=M.+Arnoneauthor=T.+Crociauthor=P.+Soubri%C3%A9author=F.+Oury-Donatauthor=J.+P.+Maffrandauthor=B.+Scattonauthor=F.+Lacheretzauthor=G.+Le+Furauthor=J.+M.+Herbertauthor=M.+Bensaid&title=Rimonabant+reduces+obesity-associated+hepatic+steatosis+and+features+of+metabolic+syndrome+in+obese+Zucker+fa%2Ffa+rats&doi=10.1002%2Fhep.21641"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1002%2Fhep.21641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.21641%26sid%3Dliteratum%253Aachs%26aulast%3DGary-Bobo%26aufirst%3DM.%26aulast%3DElachouri%26aufirst%3DG.%26aulast%3DGallas%26aufirst%3DJ.%2BF.%26aulast%3DJaniak%26aufirst%3DP.%26aulast%3DMarini%26aufirst%3DP.%26aulast%3DRavinet-Trillou%26aufirst%3DC.%26aulast%3DChabbert%26aufirst%3DM.%26aulast%3DCruccioli%26aufirst%3DN.%26aulast%3DPfersdorff%26aufirst%3DC.%26aulast%3DRoque%26aufirst%3DC.%26aulast%3DArnone%26aufirst%3DM.%26aulast%3DCroci%26aufirst%3DT.%26aulast%3DSoubri%25C3%25A9%26aufirst%3DP.%26aulast%3DOury-Donat%26aufirst%3DF.%26aulast%3DMaffrand%26aufirst%3DJ.%2BP.%26aulast%3DScatton%26aufirst%3DB.%26aulast%3DLacheretz%26aufirst%3DF.%26aulast%3DLe%2BFur%26aufirst%3DG.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DBensaid%26aufirst%3DM.%26atitle%3DRimonabant%2520reduces%2520obesity-associated%2520hepatic%2520steatosis%2520and%2520features%2520of%2520metabolic%2520syndrome%2520in%2520obese%2520Zucker%2520fa%252Ffa%2520rats%26jtitle%3DHepatology%26date%3D2007%26volume%3D46%26spage%3D122%26epage%3D129%26doi%3D10.1002%2Fhep.21641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banasch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetze, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span> <span> </span><span class="NLM_article-title">Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis</span>. <i>Liver Int.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1155</span>, <span class="refDoi"> DOI: 10.1111/j.1478-3231.2007.01555.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1111%2Fj.1478-3231.2007.01555.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1152-1155&author=M.+Banaschauthor=O.+Goetzeauthor=W.+E.+Schmidtauthor=J.+J.+Meier&title=Rimonabant+as+a+novel+therapeutic+option+for+nonalcoholic+steatohepatitis&doi=10.1111%2Fj.1478-3231.2007.01555.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1478-3231.2007.01555.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1478-3231.2007.01555.x%26sid%3Dliteratum%253Aachs%26aulast%3DBanasch%26aufirst%3DM.%26aulast%3DGoetze%26aufirst%3DO.%26aulast%3DSchmidt%26aufirst%3DW.%2BE.%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26atitle%3DRimonabant%2520as%2520a%2520novel%2520therapeutic%2520option%2520for%2520nonalcoholic%2520steatohepatitis%26jtitle%3DLiver%2520Int.%26date%3D2007%26volume%3D27%26spage%3D1152%26epage%3D1155%26doi%3D10.1111%2Fj.1478-3231.2007.01555.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lecru, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desterke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassin-Delyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatziantoniou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devocelle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernochet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanovski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlicot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Said, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudreuil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpentier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giron-Michel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzarone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">François, H.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor 1 is a major mediator of renal fibrosis</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1038/ki.2015.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1038%2Fki.2015.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=25760323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSjtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=72-84&author=L.+Lecruauthor=C.+Desterkeauthor=S.+Grassin-Delyleauthor=C.+Chatziantoniouauthor=S.+Vandermeerschauthor=A.+Devocelleauthor=A.+Vernochetauthor=N.+Ivanovskiauthor=C.+Ledentauthor=S.+Ferlicotauthor=M.+Daliaauthor=M.+Saidauthor=S.+Beaudreuilauthor=B.+Charpentierauthor=A.+Vazquezauthor=J.+Giron-Michelauthor=B.+Azzaroneauthor=A.+Durrbachauthor=H.+Fran%C3%A7ois&title=Cannabinoid+receptor+1+is+a+major+mediator+of+renal+fibrosis&doi=10.1038%2Fki.2015.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor 1 is a major mediator of renal fibrosis</span></div><div class="casAuthors">Lecru, Lola; Desterke, Christophe; Grassin-Delyle, Stanislas; Chatziantoniou, Christos; Vandermeersch, Sophie; Devocelle, Aurore; Vernochet, Amelia; Ivanovski, Ninoslav; Ledent, Catherine; Ferlicot, Sophie; Dalia, Meriem; Said, Myriam; Beaudreuil, Severine; Charpentier, Bernard; Vazquez, Aime; Giron-Michel, Julien; Azzarone, Bruno; Durrbach, Antoine; Francois, Helene</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-84</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic kidney disease, secondary to renal fibrogenesis, is a burden on public health.  There is a need to explore new therapeutic pathways to reduce renal fibrogenesis.  To study this, we used unilateral ureteral obstruction (UUO) in mice as an exptl. model of renal fibrosis and microarray anal. to compare gene expression in fibrotic and normal kidneys.  The cannabinoid receptor 1 (CB1) was among the most upregulated genes in mice, and the main endogenous CB1 ligand (2-arachidonoylglycerol) was significantly increased in the fibrotic kidney.  Interestingly, CB1 expression was highly increased in kidney biopsies of patients with IgA nephropathy, diabetes, and acute interstitial nephritis.  Both genetic and pharmacol. knockout of CB1 induced a profound redn. in renal fibrosis during UUO.  While CB2 is also involved in renal fibrogenesis, it did not potentiate the role of CB1.  CB1 expression was significantly increased in myofibroblasts, the main effector cells in renal fibrogenesis, upon TGF-β1 stimulation.  The decrease in renal fibrosis during CB1 blockade could be explained by a direct action on myofibroblasts.  CB1 blockade reduced collagen expression in vitro.  Rimonabant, a selective CB1 endocannabinoid receptor antagonist, modulated the macrophage infiltrate responsible for renal fibrosis in UUO through a decrease in monocyte chemoattractant protein-1 synthesis.  Thus, CB1 has a major role in the activation of myofibroblasts and may be a new target for treating chronic kidney disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWhp5nvemySbVg90H21EOLACvtfcHk0lgdAPUcQHTyOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSjtL3P&md5=461047bd7498216d7e43186aae72ede9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fki.2015.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2015.63%26sid%3Dliteratum%253Aachs%26aulast%3DLecru%26aufirst%3DL.%26aulast%3DDesterke%26aufirst%3DC.%26aulast%3DGrassin-Delyle%26aufirst%3DS.%26aulast%3DChatziantoniou%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DS.%26aulast%3DDevocelle%26aufirst%3DA.%26aulast%3DVernochet%26aufirst%3DA.%26aulast%3DIvanovski%26aufirst%3DN.%26aulast%3DLedent%26aufirst%3DC.%26aulast%3DFerlicot%26aufirst%3DS.%26aulast%3DDalia%26aufirst%3DM.%26aulast%3DSaid%26aufirst%3DM.%26aulast%3DBeaudreuil%26aufirst%3DS.%26aulast%3DCharpentier%26aufirst%3DB.%26aulast%3DVazquez%26aufirst%3DA.%26aulast%3DGiron-Michel%26aufirst%3DJ.%26aulast%3DAzzarone%26aufirst%3DB.%26aulast%3DDurrbach%26aufirst%3DA.%26aulast%3DFran%25C3%25A7ois%26aufirst%3DH.%26atitle%3DCannabinoid%2520receptor%25201%2520is%2520a%2520major%2520mediator%2520of%2520renal%2520fibrosis%26jtitle%3DKidney%2520Int.%26date%3D2015%26volume%3D88%26spage%3D72%26epage%3D84%26doi%3D10.1038%2Fki.2015.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span> <span> </span><span class="NLM_article-title">The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases</span>. <i>J. Basic Clin. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1515/jbcpp-2015-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1515%2Fjbcpp-2015-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=26280171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVGhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=267-276&author=J.+Tam&title=The+emerging+role+of+the+endocannabinoid+system+in+the+pathogenesis+and+treatment+of+kidney+diseases&doi=10.1515%2Fjbcpp-2015-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases</span></div><div class="casAuthors">Tam, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Basic and Clinical Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-276</span>CODEN:
                <span class="NLM_cas:coden">JBPPES</span>;
        ISSN:<span class="NLM_cas:issn">0792-6855</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">Endocannabinoids (eCBs) are endogenous lipid ligands that bind to cannabinoid receptors that also mediate the effects of marijuana.  The eCB system is comprised of eCBs, anandamide, and 2-arachidonoyl glycerol, their cannabinoid-1 and cannabinoid-2 receptors (CB1 and CB2, resp.), and the enzymes involved in their biosynthesis and degrdn.  It is present in both the central nervous system and peripheral organs including the kidney.  The current review focuses on the role of the eCB system in normal kidney function and various diseases, such as diabetes and obesity, that directly contributes to the development of renal pathologies.  Normally, activation of the CB1 receptor regulates renal vascular hemodynamics and stimulates the transport of ions and proteins in different nephron compartments.  In various mouse and rat models of obesity and type 1 and 2 diabetes mellitus, eCBs generated in various renal cells activate CB1 receptors and contribute to the development of oxidative stress, inflammation, and renal fibrosis.  These effects can be chronically ameliorated by CB1 receptor blockers.  In contrast, activation of the renal CB2 receptors reduces the deleterious effects of these chronic diseases.  Because the therapeutic potential of globally acting CB1 receptor antagonists in these conditions is limited due to their neuropsychiatric adverse effects, the recent development of peripherally restricted CB1 receptor antagonists may represent a novel pharmacol. approach in treating renal diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo92JUqI8HqVrVg90H21EOLACvtfcHk0lgdAPUcQHTyOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVGhsLo%253D&md5=0cbe88dda65b050466a06ec4565618e0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1515%2Fjbcpp-2015-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fjbcpp-2015-0055%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26atitle%3DThe%2520emerging%2520role%2520of%2520the%2520endocannabinoid%2520system%2520in%2520the%2520pathogenesis%2520and%2520treatment%2520of%2520kidney%2520diseases%26jtitle%3DJ.%2520Basic%2520Clin.%2520Physiol.%2520Pharmacol.%26date%3D2016%26volume%3D27%26spage%3D267%26epage%3D276%26doi%3D10.1515%2Fjbcpp-2015-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraghithy, S.</span></span> <span> </span><span class="NLM_article-title">The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system</span>. <i>Eur. J. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.ejim.2018.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.ejim.2018.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=29336868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=23-29&author=J.+Tamauthor=L.+Hindenauthor=A.+Droriauthor=S.+Udiauthor=S.+Azarauthor=S.+Baraghithy&title=The+therapeutic+potential+of+targeting+the+peripheral+endocannabinoid%2FCB1+receptor+system&doi=10.1016%2Fj.ejim.2018.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system</span></div><div class="casAuthors">Tam, Joseph; Hinden, Liad; Drori, Adi; Udi, Shiran; Azar, Shahar; Baraghithy, Saja</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Internal Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-29</span>CODEN:
                <span class="NLM_cas:coden">EJIMEJ</span>;
        ISSN:<span class="NLM_cas:issn">0953-6205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Endocannabinoids (eCBs) are internal lipid mediators recognized by the cannabinoid-1 and -2 receptors (CB1R and CB2R, resp.), which also mediate the different physiol. effects of marijuana.  The endocannabinoid system, consisting of eCBs, their receptors, and the enzymes involved in their biosynthesis and degrdn., is present in a vast no. of peripheral organs.  In this review we describe the role of the eCB/CB1R system in modulating the metab. in several peripheral organs.  We assess how eCBs, via activating the CB1R, contribute to obesity and regulate food intake.  In addn., we describe their roles in modulating liver and kidney functions, as well as bone remodeling and mass.  Special importance is given to emphasizing the efficacy of the recently developed peripherally restricted CB1R antagonists, which were pre-clin. tested in the management of energy homeostasis, and in ameliorating both obesity- and diabetes-induced metabolic complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8f6fjglK3bVg90H21EOLACvtfcHk0lhIj8ryULFXIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKmtbY%253D&md5=e61e4a99661c7a49ded1ba82263c1f83</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejim.2018.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejim.2018.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DHinden%26aufirst%3DL.%26aulast%3DDrori%26aufirst%3DA.%26aulast%3DUdi%26aufirst%3DS.%26aulast%3DAzar%26aufirst%3DS.%26aulast%3DBaraghithy%26aufirst%3DS.%26atitle%3DThe%2520therapeutic%2520potential%2520of%2520targeting%2520the%2520peripheral%2520endocannabinoid%252FCB1%2520receptor%2520system%26jtitle%3DEur.%2520J.%2520Intern.%2520Med.%26date%3D2018%26volume%3D49%26spage%3D23%26epage%3D29%26doi%3D10.1016%2Fj.ejim.2018.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regnell, S. E.</span></span> <span> </span><span class="NLM_article-title">The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1111/bcp.12102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1111%2Fbcp.12102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=23452341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFym" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=21-30&author=M.+E.+Cooperauthor=S.+E.+Regnell&title=The+hepatic+cannabinoid+1+receptor+as+a+modulator+of+hepatic+energy+state+and+food+intake&doi=10.1111%2Fbcp.12102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake</span></div><div class="casAuthors">Cooper, Martin E.; Regnell, Simon E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The cannabinoid 1 receptor (CB1R) has a well-established role in appetite regulation.  Central CB1R antagonists, notably rimonabant, induced wt. loss and improved the metabolic profile in obese individuals, but were discontinued due to psychiatric side-effects.  The CB1R is also expressed peripherally, where its effects include promotion of liver fat accumulation, which consumes ATP.  Type 2 diabetes in obese subjects is linked to excess liver fat, while there is a neg. correlation between hepatic ATP content and insulin resistance.  A decreased hepatic ATP/AMP ratio increases food intake by signals via the vagus nerve to the brain.  The hepatic cannabinoid system is highly upregulated in obesity, and the effects of hepatic CB1R activation include increased activity of lipogenic and gluconeogenic transcription factors.  Thus, blockade of hepatic CB1Rs could contribute significantly to the wt.-reducing and insulin-sensitizing effects of CB1R antagonists.  Addnl., upregulation of the hepatic CB1R may contribute to chronic liver inflammation, fibrosis and cirrhosis from causes including obesity, alcoholism and viral hepatitis.  Peripheral CB1R antagonists induce wt. loss and metabolic improvements in obese rodents; however, as there is evidence that hepatic CB1Rs are predominately intracellular, due to high intrinsic clearance, many drugs may not effectively block these receptors and therefore have limited efficacy.  Hepatoselective CB1R antagonists may be effective at reducing hepatic steatosis, insulin resistance and bodyweight in obese, diabetic patients, with far fewer side-effects than first-generation CB1R antagonists.  Addnl., such compds. may be effective in treating inflammatory liver disease, such as non-alc. steatohepatitis, reducing the likelihood of disease progression to cirrhosis or cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIndQ0Bt4fG7Vg90H21EOLACvtfcHk0lhIj8ryULFXIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFym&md5=b2566fd49f273ea2243d64b90b7ba633</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12102%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3DRegnell%26aufirst%3DS.%2BE.%26atitle%3DThe%2520hepatic%2520cannabinoid%25201%2520receptor%2520as%2520a%2520modulator%2520of%2520hepatic%2520energy%2520state%2520and%2520food%2520intake%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2014%26volume%3D77%26spage%3D21%26epage%3D30%26doi%3D10.1111%2Fbcp.12102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hortala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadoun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finance, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span> <span> </span><span class="NLM_article-title">Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4573</span>– <span class="NLM_lpage">4577</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.bmcl.2010.06.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4573-4577&author=L.+Hortalaauthor=M.+Rinaldi-Carmonaauthor=C.+Congyauthor=L.+Bouluauthor=F.+Sadounauthor=G.+Fabreauthor=O.+Financeauthor=F.+Barth&title=Rational+design+of+a+novel+peripherally-restricted%2C+orally+active+CB1+cannabinoid+antagonist+containing+a+2%2C3-diarylpyrrole+motif&doi=10.1016%2Fj.bmcl.2010.06.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DHortala%26aufirst%3DL.%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DBoulu%26aufirst%3DL.%26aulast%3DSadoun%26aufirst%3DF.%26aulast%3DFabre%26aufirst%3DG.%26aulast%3DFinance%26aufirst%3DO.%26aulast%3DBarth%26aufirst%3DF.%26atitle%3DRational%2520design%2520of%2520a%2520novel%2520peripherally-restricted%252C%2520orally%2520active%2520CB1%2520cannabinoid%2520antagonist%2520containing%2520a%25202%252C3-diarylpyrrole%2520motif%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4573%26epage%3D4577%26doi%3D10.1016%2Fj.bmcl.2010.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2820</span>– <span class="NLM_lpage">2834</span>, <span class="refDoi"> DOI: 10.1021/jm201731z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201731z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVGju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2820-2834&author=A.+Fulpauthor=K.+Bortoffauthor=H.+Seltzmanauthor=Y.+Zhangauthor=J.+Mathewsauthor=R.+Snyderauthor=T.+Fennellauthor=R.+Maitra&title=Design+and+synthesis+of+cannabinoid+receptor+1+antagonists+for+peripheral+selectivity&doi=10.1021%2Fjm201731z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Cannabinoid Receptor 1 Antagonists for Peripheral Selectivity</span></div><div class="casAuthors">Fulp, Alan; Bortoff, Katherine; Seltzman, Herbert; Zhang, Yanan; Mathews, James; Snyder, Rodney; Fennell, Tim; Maitra, Rangan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2820-2834</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonists of cannabinoid receptor 1 (CB1) have potential for the treatment of several diseases such as obesity, liver disease, and diabetes.  Recently, development of several CB1 antagonists was halted because of adverse central nervous system (CNS) related side effects obsd. with rimonabant, the first clin. approved CB1 inverse agonist.  However, recent studies indicate that regulation of peripherally expressed CB1 with CNS-sparing compds. is a viable strategy to treat several important disorders.  The reported efforts aimed at rationally designing peripherally restricted CB1 antagonists have resulted in compds. that have limited blood-brain barrier (BBB) permeability and CNS exposure in preclin. in vitro and in vivo models.  Typically, compds. with high topol. polar surface areas (TPSAs) do not cross the BBB passively.  Compds. with TPSAs higher than that for rimonabant (rimonabant TPSA = 50) and excellent functional activity with limited CNS penetration were identified.  These compds. will serve as templates for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxIk0YtV78UbVg90H21EOLACvtfcHk0ljNAfGDkbJntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVGju74%253D&md5=95a56654ab10a8b238ee16949fc10e18</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fjm201731z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201731z%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMathews%26aufirst%3DJ.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520cannabinoid%2520receptor%25201%2520antagonists%2520for%2520peripheral%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2820%26epage%3D2834%26doi%3D10.1021%2Fjm201731z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiethe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Pyrazole antagonists of the CB1 receptor with reduced brain penetration</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1063</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.01.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.bmc.2016.01.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=26827137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1063-1070&author=A.+Fulpauthor=Y.+Zhangauthor=K.+Bortoffauthor=H.+Seltzmanauthor=R.+Snyderauthor=R.+Wietheauthor=G.+Amatoauthor=R.+Maitra&title=Pyrazole+antagonists+of+the+CB1+receptor+with+reduced+brain+penetration&doi=10.1016%2Fj.bmc.2016.01.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole antagonists of the CB1 receptor with reduced brain penetration</span></div><div class="casAuthors">Fulp, Alan; Zhang, Yanan; Bortoff, Katherine; Seltzman, Herbert; Snyder, Rodney; Wiethe, Robert; Amato, George; Maitra, Rangan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1063-1070</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Type 1 cannabinoid receptor (CB1) antagonists might be useful for treating obesity, liver disease, metabolic syndrome, and dyslipidemias.  Unfortunately, inhibition of CB1 in the central nervous system (CNS) produces adverse effects, including depression, anxiety and suicidal ideation in some patients, which led to withdrawal of the pyrazole inverse agonist rimonabant (SR141716A) from European markets.  Efforts are underway to produce peripherally selective CB1 antagonists to circumvent CNS-assocd. adverse effects.  In this study, novel analogs of rimonabant (1) were explored in which the 1-aminopiperidine group was switched to a 4-aminopiperidine, attached at the 4-amino position (5).  The piperidine nitrogen was functionalized with carbamates, amides, and sulfonamides, providing compds. that are potent inverse agonists of hCB1 with good selectivity for hCB1 over hCB2.  Select compds. were further studied using in vitro models of brain penetration, oral absorption and metabolic stability.  Several compds. were identified with predicted minimal brain penetration and good metabolic stability.  In vivo pharmacokinetic testing revealed that inverse agonist I is orally bioavailable and has vastly reduced brain penetration compared to rimonabant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQF0R_5pD887Vg90H21EOLACvtfcHk0ljNAfGDkbJntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyltL8%253D&md5=6cf6e50b077db6b1767f2397e3a5e017</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.01.033%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DWiethe%26aufirst%3DR.%26aulast%3DAmato%26aufirst%3DG.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DPyrazole%2520antagonists%2520of%2520the%2520CB1%2520receptor%2520with%2520reduced%2520brain%2520penetration%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1063%26epage%3D1070%26doi%3D10.1016%2Fj.bmc.2016.01.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marusich, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Peripherally selective diphenyl purine antagonist of the CB1 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8066</span>– <span class="NLM_lpage">8072</span>, <span class="refDoi"> DOI: 10.1021/jm401129n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401129n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8066-8072&author=A.+Fulpauthor=K.+Bortoffauthor=Y.+Zhangauthor=R.+Snyderauthor=T.+Fennellauthor=J.+A.+Marusichauthor=J.+L.+Wileyauthor=H.+Seltzmanauthor=R.+Maitra&title=Peripherally+selective+diphenyl+purine+antagonist+of+the+CB1+receptor&doi=10.1021%2Fjm401129n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1021%2Fjm401129n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401129n%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMarusich%26aufirst%3DJ.%2BA.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DPeripherally%2520selective%2520diphenyl%2520purine%2520antagonist%2520of%2520the%2520CB1%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8066%26epage%3D8072%26doi%3D10.1021%2Fjm401129n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10022</span>– <span class="NLM_lpage">10032</span>, <span class="refDoi"> DOI: 10.1021/jm301181r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301181r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOru7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10022-10032&author=A.+Fulpauthor=K.+Bortoffauthor=Y.+Zhangauthor=H.+Seltzmanauthor=J.+Mathewsauthor=R.+Snyderauthor=T.+Fennellauthor=R.+Maitra&title=Diphenyl+purine+derivatives+as+peripherally+selective+cannabinoid+receptor+1+antagonists&doi=10.1021%2Fjm301181r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Diphenyl Purine Derivatives as Peripherally Selective Cannabinoid Receptor 1 Antagonists</span></div><div class="casAuthors">Fulp, Alan; Bortoff, Katherine; Zhang, Yanan; Seltzman, Herbert; Mathews, James; Snyder, Rodney; Fennell, Tim; Maitra, Rangan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10022-10032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) antagonists are potentially useful for the treatment of several diseases.  However, clin. development of several CB1 antagonists was halted due to central nervous system (CNS)-related side effects including depression and suicidal ideation in some users.  Recently, studies have indicated that selective regulation of CB1 receptors in the periphery is a viable strategy for treating several important disorders.  Past efforts to develop peripherally selective antagonists of CB1 have largely targeted rimonabant, an inverse agonist of CB1.  Reported here are our efforts toward developing a peripherally selective CB1 antagonist based on the otenabant scaffold.  Even though otenabant penetrates the CNS, it is unique among CB1 antagonists that have been clin. tested because it has properties that are normally assocd. with peripherally selective compds.  Our efforts have resulted in an orally absorbed compd. that is a potent and selective CB1 antagonist with limited penetration into the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7vr0lo9pHgrVg90H21EOLACvtfcHk0ljNAfGDkbJntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOru7bK&md5=d844f7199d7689707b6e633076b86436</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1021%2Fjm301181r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301181r%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DMathews%26aufirst%3DJ.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DDiphenyl%2520purine%2520derivatives%2520as%2520peripherally%2520selective%2520cannabinoid%2520receptor%25201%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10022%26epage%3D10032%26doi%3D10.1021%2Fjm301181r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4 ((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl) ethynyl)thiophene-2-yl)-1H-pyrazole-3- carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in Diet-Induced Obese mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9920</span>– <span class="NLM_lpage">9933</span>, <span class="refDoi"> DOI: 10.1021/jm401158e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401158e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9920-9933&author=C.+Changauthor=C.+Wuauthor=J.+Songauthor=M.+Chouauthor=Y.+Wongauthor=Y.+Linauthor=T.+Yehauthor=A.+A.+Sadaniauthor=M.+Ouauthor=K.+Chenauthor=P.+Chenauthor=P.+C.+Kuoauthor=S.+L.+Tsengauthor=K.+Changauthor=S.+Tsengauthor=Y.+Chaoauthor=M.+Hungauthor=K.+Shia&title=Discovery+of+1-%282%2C4-dichlorophenyl%29-N-%28piperidin-1-yl%29-4+%28%28pyrrolidine-1-sulfonamido%29methyl%29-5-%285-%28%284-%28trifluoromethyl%29phenyl%29+ethynyl%29thiophene-2-yl%29-1H-pyrazole-3-+carboxamide+as+a+novel+peripherally+restricted+cannabinoid-1+receptor+antagonist+with+significant+weight-loss+efficacy+in+Diet-Induced+Obese+mice&doi=10.1021%2Fjm401158e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.1021%2Fjm401158e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401158e%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYeh%26aufirst%3DT.%26aulast%3DSadani%26aufirst%3DA.%2BA.%26aulast%3DOu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DKuo%26aufirst%3DP.%2BC.%26aulast%3DTseng%26aufirst%3DS.%2BL.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DS.%26aulast%3DChao%26aufirst%3DY.%26aulast%3DHung%26aufirst%3DM.%26aulast%3DShia%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25201-%25282%252C4-dichlorophenyl%2529-N-%2528piperidin-1-yl%2529-4%2520%2528%2528pyrrolidine-1-sulfonamido%2529methyl%2529-5-%25285-%2528%25284-%2528trifluoromethyl%2529phenyl%2529%2520ethynyl%2529thiophene-2-yl%2529-1H-pyrazole-3-%2520carboxamide%2520as%2520a%2520novel%2520peripherally%2520restricted%2520cannabinoid-1%2520receptor%2520antagonist%2520with%2520significant%2520weight-loss%2520efficacy%2520in%2520Diet-Induced%2520Obese%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9920%26epage%3D9933%26doi%3D10.1021%2Fjm401158e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdelyi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel, non-brain- penetrant, hybrid cannabinoid CB1R inverse agonist/inducible nitric oxide synthase (iNOS) inhibitors for the treatment of liver fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">–1141</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1126-%E2%80%931141&author=M.+R.+Iyerauthor=R.+Cinarauthor=A.+Katzauthor=M.+Gaoauthor=K.+Erdelyiauthor=T.+Jourdanauthor=N.+J.+Coffeyauthor=P.+Pacherauthor=G.+Kunos&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel%2C+non-brain-+penetrant%2C+hybrid+cannabinoid+CB1R+inverse+agonist%2Finducible+nitric+oxide+synthase+%28iNOS%29+inhibitors+for+the+treatment+of+liver+fibrosis&doi=10.1021%2Facs.jmedchem.6b01504"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01504%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DKatz%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DErdelyi%26aufirst%3DK.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DCoffey%26aufirst%3DN.%2BJ.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%252C%2520non-brain-%2520penetrant%252C%2520hybrid%2520cannabinoid%2520CB1R%2520inverse%2520agonist%252Finducible%2520nitric%2520oxide%2520synthase%2520%2528iNOS%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520liver%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1126%26epage%3D%25E2%2580%25931141%26doi%3D10.1021%2Facs.jmedchem.6b01504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyás, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnäs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noerregaard, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elling, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span> <span> </span><span class="NLM_article-title">Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1002/syn.21721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1002%2Fsyn.21721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=24293119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGgsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2014&pages=89-97&author=A.+Takanoauthor=B.+Guly%C3%A1sauthor=K.+Varn%C3%A4sauthor=P.+B.+Littleauthor=P.+K.+Noerregaardauthor=N.+O.+Jensenauthor=C.+E.+Ellingauthor=C.+Halldin&title=Low+brain+CB1+receptor+occupancy+by+a+second+generation+CB1+receptor+antagonist+TM38837+in+comparison+with+rimonabant+in+nonhuman+primates%3A+a+PET+study&doi=10.1002%2Fsyn.21721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: A PET study</span></div><div class="casAuthors">Takano, Akihiro; Gulyas, Balazs; Varnaes, Katarina; Little, Paul Brian; Noerregaard, Pia K.; Jensen, Niels Ole; Elling, Christian E.; Halldin, Christer</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">89-97</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Both central and peripheral cannabinoid receptor type 1 (CB1R) have been considered to be among the key targets for obesity treatment.  First generation CB1R antagonists/inverse agonists such as rimonabant and taranabant exhibited severe CNS side effects such as anxiety and depression, which are considered to be related to the compds.' ability to access central CB1R.  Recently, several compds. have been developed as second generation antagonists with a profile of restriction to peripheral CB1R.  We evaluated the distribution of TM38837, a second generation CB1R antagonist, using brain and whole body PET in three cynomolgus monkeys, and established the relationship between CB1R occupancy and dose/plasma concn. of TM38837 in comparison with rimonabant.  A brain PET study was performed using [11C]MePPEP, a PET radioligand for CB1R, to evaluate the brain CB1R occupancy of TM38837 at various plasma concns. in comparison with rimonabant at known efficacious plasma concns.  A whole body PET study was performed to investigate the change of peripheral distribution of [11C]MePPEP by TM38837 administration, which indirectly estd. the effects to the peripheral CB1R by TM38837.  CB1R occupancy by both TM38837 and rimonabant increased in a dose/plasma concn.-dependent manner.  However, in vivo affinity by plasma level was more than 100 times lower for TM38837.  Peripherally, [11C]MePPEP accumulation decreased in gall bladder and brown adipose tissue by TM38837 administration.  TM38837 showed rather lower CB1R occupancy than rimonabant at the expected therapeutic plasma level, which is expected to reduce CNS side effects in clin. situations.  Further clin. development of TM38837 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWO09xJ4aW2LVg90H21EOLACvtfcHk0lgHCd4iH5AKxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGgsb7N&md5=126673597feb5f59338815bc5ac9ace4</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1002%2Fsyn.21721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.21721%26sid%3Dliteratum%253Aachs%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DGuly%25C3%25A1s%26aufirst%3DB.%26aulast%3DVarn%25C3%25A4s%26aufirst%3DK.%26aulast%3DLittle%26aufirst%3DP.%2BB.%26aulast%3DNoerregaard%26aufirst%3DP.%2BK.%26aulast%3DJensen%26aufirst%3DN.%2BO.%26aulast%3DElling%26aufirst%3DC.%2BE.%26aulast%3DHalldin%26aufirst%3DC.%26atitle%3DLow%2520brain%2520CB1%2520receptor%2520occupancy%2520by%2520a%2520second%2520generation%2520CB1%2520receptor%2520antagonist%2520TM38837%2520in%2520comparison%2520with%2520rimonabant%2520in%2520nonhuman%2520primates%253A%2520a%2520PET%2520study%26jtitle%3DSynapse%26date%3D2014%26volume%3D68%26spage%3D89%26epage%3D97%26doi%3D10.1002%2Fsyn.21721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpers, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kam, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinloog, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elling, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gerven, J. M.</span></span> <span> </span><span class="NLM_article-title">Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">857</span>, <span class="refDoi"> DOI: 10.1111/bcp.12141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1111%2Fbcp.12141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=23601084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVamtLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=846-857&author=L.+E.+Klumpersauthor=M.+Fridbergauthor=M.+L.+de+Kamauthor=P.+B.+Littleauthor=N.+O.+Jensenauthor=H.+D.+Kleinloogauthor=C.+E.+Ellingauthor=J.+M.+van+Gerven&title=Peripheral+selectivity+of+the+novel+cannabinoid+receptor+antagonist+TM38837+in+healthy+subjects&doi=10.1111%2Fbcp.12141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects</span></div><div class="casAuthors">Klumpers, Linda E.; Fridberg, Marianne; de Kam, Marieke L.; Little, Paul B.; Jensen, Niels Ole; Kleinloog, Hendrik D.; Elling, Christian E.; van Gerven, Joop M. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">846-857</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: Cannabinoid receptor type 1 (CB1) antagonists show central side effects, whereas beneficial effects are most likely peripherally mediated.  In this study, the peripherally selective CB1 antagonist TM38837 was studied in humans.  Methods : This was a double-blind, randomized, placebo-controlled, crossover study.  On occasions 1-4, 24 healthy subjects received 5 × 4 mg THC with TM38837 100 mg, 500 mg or placebo, or placebos only.  During occasion 5, subjects received placebo TM38837 + THC with rimonabant 60 mg or placebo in parallel groups.  Blood collections and pharmacodynamic (PD) effects were assessed frequently.  Pharmacokinetics (PK) and PD were quantified using population PK-PD modeling.  Results : The TM38837 plasma concn. profile was relatively flat compared with rimonabant.  TM38837 showed an estd. terminal half-life of 771 h.  THC induced effects on VAS feeling high, body sway and heart rate were partly antagonized by rimonabant 60 mg [-26.70% [90% confidence interval (CI) -40.9, -12.6%]; -7.10%, (90%CI -18.1, 5.3%); -7.30%, (90% CI -11.5%, -3.0%) resp.] and TM38837 500 mg [-22.10% (90% CI -34.9, -9.4%); -12.20% (90% CI -21.6%, -1.7%); -8.90% (90% CI -12.8%, -5.1%) resp.].  TM38837 100 mg had no measurable feeling high or body sway effects and limited heart rate effects.  Conclusions : Rimonabant showed larger effects than TM38837, but the heart rate effects were similar.  TM38837 100 mg had no impact on CNS effects, suggesting that this dose does not penetrate the brain.  This TM38837 dose is predicted to be at least equipotent to rimonabant with regard to metabolic disorders in rodent models.  These results provide support for further development of TM38837 as a peripherally selective CB1 antagonist for indications such as metabolic disorders, with a reduced propensity for psychiatric side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqWgvk1WZZbVg90H21EOLACvtfcHk0lgRsMnq_eHF0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVamtLfJ&md5=e0bec67afbb53e471e53fc803c9ab3d4</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12141%26sid%3Dliteratum%253Aachs%26aulast%3DKlumpers%26aufirst%3DL.%2BE.%26aulast%3DFridberg%26aufirst%3DM.%26aulast%3Dde%2BKam%26aufirst%3DM.%2BL.%26aulast%3DLittle%26aufirst%3DP.%2BB.%26aulast%3DJensen%26aufirst%3DN.%2BO.%26aulast%3DKleinloog%26aufirst%3DH.%2BD.%26aulast%3DElling%26aufirst%3DC.%2BE.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%2BM.%26atitle%3DPeripheral%2520selectivity%2520of%2520the%2520novel%2520cannabinoid%2520receptor%2520antagonist%2520TM38837%2520in%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D846%26epage%3D857%26doi%3D10.1111%2Fbcp.12141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chorvat, R.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berbaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seriacki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, J. F.</span></span> <span> </span><span class="NLM_article-title">JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6173</span>– <span class="NLM_lpage">6180</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.bmcl.2012.08.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6173-6180&author=R.%0AJ.+Chorvatauthor=J.+Berbaumauthor=K.+Seriackiauthor=J.+F.+McElroy&title=JD-5006+and+JD-5037%3A+peripherally+restricted+%28PR%29+cannabinoid-1+receptor+blockers+related+to+SLV-319+%28Ibipinabant%29+as+metabolic+disorder+therapeutics+devoid+of+CNS+liabilities&doi=10.1016%2Fj.bmcl.2012.08.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DBerbaum%26aufirst%3DJ.%26aulast%3DSeriacki%26aufirst%3DK.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26atitle%3DJD-5006%2520and%2520JD-5037%253A%2520peripherally%2520restricted%2520%2528PR%2529%2520cannabinoid-1%2520receptor%2520blockers%2520related%2520to%2520SLV-319%2520%2528Ibipinabant%2529%2520as%2520metabolic%2520disorder%2520therapeutics%2520devoid%2520of%2520CNS%2520liabilities%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6173%26epage%3D6180%26doi%3D10.1016%2Fj.bmcl.2012.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chorvat, R. J.</span></span> <span> </span><span class="NLM_article-title">Peripherally restricted CB1 receptor blockers</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4751</span>– <span class="NLM_lpage">4760</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.bmcl.2013.06.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=23902803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Sjtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4751-4760&author=R.+J.+Chorvat&title=Peripherally+restricted+CB1+receptor+blockers&doi=10.1016%2Fj.bmcl.2013.06.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Peripherally restricted CB1 receptor blockers</span></div><div class="casAuthors">Chorvat, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4751-4760</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antagonists (inverse agonists) of the cannabinoid-1 (CB1) receptor showed promise as new therapies for controlling obesity and related metabolic function/liver disease.  These agents, representing diverse chem. series, shared the property of brain penetration due to the initial belief that therapeutic benefit was mainly based on brain receptor interaction.  However, undesirable CNS-based side effects of the only marketed agent in this class, rimonabant, led to its removal, and termination of the development of other clin. candidates soon followed.  Re-evaluation of this approach has focused on neutral or peripherally restricted (PR) antagonists.  Supporting these strategies, pharmacol. evidence indicates most if not all of the properties of globally acting agents may be captured by mols. with little brain presence.  Methodol. that can be used to eliminate BBB penetration and the means (in vitro assays, tissue distribution and receptor occupancy detns., behavioral paradigms) to identify potential agents with little brain presence is discussed.  Focus will be on the pharmacol. supporting the contention that reported agents are truly peripherally restricted.  Notable examples of these types of compds. are: TM38837 (structure not disclosed); AM6545 (8); JD5037 (15b); RTI-12 (19).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVjNs61m-GtLVg90H21EOLACvtfcHk0lgRsMnq_eHF0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Sjtb3O&md5=b124aabace6d82a2fd23fa75681786d4</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.066%26sid%3Dliteratum%253Aachs%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26atitle%3DPeripherally%2520restricted%2520CB1%2520receptor%2520blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4751%26epage%3D4760%26doi%3D10.1016%2Fj.bmcl.2013.06.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <i>PS CB1 Receptor Inverse Agonist
Program</i>; <span class="NLM_publisher-name">Jenrin Discovery</span>, <span class="NLM_year">2018</span>; <a href="http://www.jenrindiscovery.com/pscb1.html" class="extLink">http://www.jenrindiscovery.com/pscb1.html</a> (accessed Oct 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PS+CB1+Receptor+Inverse+Agonist%0AProgram%3B+Jenrin+Discovery%2C+2018%3B+http%3A%2F%2Fwww.jenrindiscovery.com%2Fpscb1.html+%28accessed+Oct+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPS%2520CB1%2520Receptor%2520Inverse%2520Agonist%250AProgram%26pub%3DJenrin%2520Discovery%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <i>Jenrin Discovery’s IND
application for its peripherally restricted cannabinoid-1 receptor
inverse agonist NASH compound was cleared by the FDA to begin phase
1 clinical trials</i>; <span class="NLM_publisher-name">Jenrin Discoery</span>, December 17, <span class="NLM_year">2017</span>; <a href="https://www.businesswire.com/news/home/20171214005128/en/" class="extLink">https://www.businesswire.com/news/home/20171214005128/en/</a> (accessed Oct 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Jenrin+Discovery%E2%80%99s+IND%0Aapplication+for+its+peripherally+restricted+cannabinoid-1+receptor%0Ainverse+agonist+NASH+compound+was+cleared+by+the+FDA+to+begin+phase%0A1+clinical+trials%3B+Jenrin+Discoery%2C+December+17%2C+2017%3B+https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20171214005128%2Fen%2F+%28accessed+Oct+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DJenrin%2520Discovery%25E2%2580%2599s%2520IND%250Aapplication%2520for%2520its%2520peripherally%2520restricted%2520cannabinoid-1%2520receptor%250Ainverse%2520agonist%2520NASH%2520compound%2520was%2520cleared%2520by%2520the%2520FDA%2520to%2520begin%2520phase%250A1%2520clinical%2520trials%26pub%3DJenrin%2520Discoery%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Testa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cytochrome P-450s and their mechanism of action</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.3109/03602538109011082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.3109%2F03602538109011082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=7028434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADyaL3MXkslGru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1981&pages=1-117&author=B.+Testaauthor=P.+Jenner&title=Inhibitors+of+cytochrome+P-450s+and+their+mechanism+of+action&doi=10.3109%2F03602538109011082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cytochrome P-450s and their mechanism of action</span></div><div class="casAuthors">Testa, Bernard; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-117</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    </div><div class="casAbstract">A review with 236 refs., of inhibitors of cytochrome P 450-dependent monooxygenase systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeDqU6i1SMN7Vg90H21EOLACvtfcHk0lgRsMnq_eHF0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXkslGru7g%253D&md5=8b08f336435114f8480cf96cadd0805a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3109%2F03602538109011082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602538109011082%26sid%3Dliteratum%253Aachs%26aulast%3DTesta%26aufirst%3DB.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DInhibitors%2520of%2520cytochrome%2520P-450s%2520and%2520their%2520mechanism%2520of%2520action%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1981%26volume%3D12%26spage%3D1%26epage%3D117%26doi%3D10.3109%2F03602538109011082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span>The intermediates <b>2</b>, <b>13</b>, <b>20</b>, and <b>24</b> were prepared according to
the procedures described
in<span class="NLM_contrib-group"><span class="NLM_string-name">Macielag, M. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Chemically Modified Quinoline and Quinolone Derivatives Useful as CB-1 Inverse Agonists</span>. WO Patent <span class="NLM_patent">WO 2017034877</span>, <span class="NLM_year">2017</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+J.+Macielag&title=Preparation+of+Chemically+Modified+Quinoline+and+Quinolone+Derivatives+Useful+as+CB-1+Inverse+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMacielag%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%2520Chemically%2520Modified%2520Quinoline%2520and%2520Quinolone%2520Derivatives%2520Useful%2520as%2520CB-1%2520Inverse%2520Agonists%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span> <span> </span><span class="NLM_article-title">Blood–brain barrier permeability considerations for CNS-targeted compound library design</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2008.03.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.cbpa.2008.03.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=18435937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1ers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=318-323&author=S.+A.+Hitchcock&title=Blood%E2%80%93brain+barrier+permeability+considerations+for+CNS-targeted+compound+library+design&doi=10.1016%2Fj.cbpa.2008.03.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-brain barrier permeability considerations for CNS-targeted compound library design</span></div><div class="casAuthors">Hitchcock, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-323</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A further refinement of the concept of drug-likeness is required for compd. libraries intended for central nervous system (CNS) targets to account for the limitations imposed by blood-brain barrier permeability.  This review describes criteria and processes that can be applied in the de novo design and assembly of libraries to increase the odds of compds. residing within CNS-accessible chem. space.  A no. of published examples where CNS activity and/or penetration characteristics have been a factor in library design are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorhMoAmlVhlrVg90H21EOLACvtfcHk0lg4PCiUf0TsLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1ers74%253D&md5=7b6962e237bc80c1d44053b54c5f3f40</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2008.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2008.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26atitle%3DBlood%25E2%2580%2593brain%2520barrier%2520permeability%2520considerations%2520for%2520CNS-targeted%2520compound%2520library%2520design%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D12%26spage%3D318%26epage%3D323%26doi%3D10.1016%2Fj.cbpa.2008.03.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockman, R. P.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of blood-brain barrier permeation</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">971</span>, <span class="refDoi"> DOI: 10.4155/tde.15.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.4155%2Ftde.15.32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=26305616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OqtLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=961-971&issue=7&author=J.+W.+Geldenhuysauthor=S.+A.+Mohammadauthor=C.+E.+Adkinsauthor=R.+P.+Lockman&title=Molecular+determinants+of+blood-brain+barrier+permeation&doi=10.4155%2Ftde.15.32"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of blood-brain barrier permeation</span></div><div class="casAuthors">Geldenhuys, Werner J.; Mohammad, Afroz S.; Adkins, Chris E.; Lockman, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">961-971</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The blood-brain barrier (BBB) is a microvascular unit which selectively regulates the permeability of drugs to the brain.  With the rise in CNS drug targets and diseases, there is a need to be able to accurately predict a priori which compds. in a company database should be pursued for favorable properties.  In this review, we will explore the different computational tools available today, as well as underpin these to the exptl. methods used to det. BBB permeability.  These include in vitro models and the in vivo models that yield the dataset we use to generate predictive models.  Understanding of how these models were exptl. derived dets. our accurate and predicted use for detg. a balance between activity and BBB distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeWXtbERlky7Vg90H21EOLACvtfcHk0lg4PCiUf0TsLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OqtLfF&md5=6f25f4b5b4fa37659b478517192fa09a</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.4155%2Ftde.15.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde.15.32%26sid%3Dliteratum%253Aachs%26aulast%3DGeldenhuys%26aufirst%3DJ.%2BW.%26aulast%3DMohammad%26aufirst%3DS.%2BA.%26aulast%3DAdkins%26aufirst%3DC.%2BE.%26aulast%3DLockman%26aufirst%3DR.%2BP.%26atitle%3DMolecular%2520determinants%2520of%2520blood-brain%2520barrier%2520permeation%26jtitle%3DTher.%2520Delivery%26date%3D2015%26volume%3D6%26issue%3D7%26spage%3D961%26epage%3D971%26doi%3D10.4155%2Ftde.15.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudkins, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallamo, J. P.</span></span> <span> </span><span class="NLM_article-title">Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1021/cn200100h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200100h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=50-68&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=J.+P.+Mallamo&title=Knowledge-based%2C+central+nervous+system+%28CNS%29+lead+selection+and+lead+optimization+for+CNS+drug+discovery&doi=10.1021%2Fcn200100h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Hudkins, Robert L.; Dorsey, Bruce D.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-68</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central nervous system (CNS) is the major area that is affected by aging.  Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment.  Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process.  On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochem. and structural differences between CNS and non-CNS drugs may assist both research areas.  Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena.  Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compds., we analyzed the physicochem. property and the chem. structural profiles of 317 CNS and 626 non-CNS oral drugs.  The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process.  A list of substructural units that may be useful for CNS drug design was also provided here.  A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs.  The combined anal. provided the following guidelines for designing high-quality CNS drugs: (i) topol. mol. polar surface area of <76 Å2 (25-60 Å2), (ii) at least one (one or two, including one aliph. amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) vol. of 740-970 Å3, (vi) solvent accessible surface area of 460-580 Å2, and (vii) pos. QikProp parameter CNS.  The ranges within parentheses may be used during lead optimization.  One violation to this proposed profile may be acceptable.  The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqfO0vq2i5bVg90H21EOLACvtfcHk0lg4PCiUf0TsLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO&md5=4c20ba34c3d5397170b50242975ce25d</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1021%2Fcn200100h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200100h%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge-based%252C%2520central%2520nervous%2520system%2520%2528CNS%2529%2520lead%2520selection%2520and%2520lead%2520optimization%2520for%2520CNS%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D50%26epage%3D68%26doi%3D10.1021%2Fcn200100h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Floettmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sostek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldon, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic profile of Naloxegol, a peripherally acting <i>m</i>-opioid receptor antagonist, for the treatment of opioid-induced constipation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.239061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1124%2Fjpet.116.239061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=28336575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A280%3ADC%252BC1cvgsFGjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2017&pages=280-291&author=E.+Floettmannauthor=K.+Buiauthor=M.+Sostekauthor=K.+Payzaauthor=M.+Eldon&title=Pharmacologic+profile+of+Naloxegol%2C+a+peripherally+acting+m-opioid+receptor+antagonist%2C+for+the+treatment+of+opioid-induced+constipation&doi=10.1124%2Fjpet.116.239061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic Profile of Naloxegol, a Peripherally Acting μ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation</span></div><div class="casAuthors">Floettmann Eike; Bui Khanh; Sostek Mark; Payza Kemal; Eldon Michael</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-291</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Opioid-induced constipation (OIC) is a common side effect of opioid pharmacotherapy for the management of pain because opioid agonists bind to μ-opioid receptors in the enteric nervous system (ENS).  Naloxegol, a polyethylene glycol derivative of naloxol, which is a derivative of naloxone and a peripherally acting μ-opioid receptor antagonist, targets the physiologic mechanisms that cause OIC.  Pharmacologic measures of opioid activity and pharmacokinetic measures of central nervous system (CNS) penetration were employed to characterize the mechanism of action of naloxegol.  At the human μ-opioid receptor in vitro, naloxegol was a potent inhibitor of binding (Ki = 7.42 nM) and a neutral competitive antagonist (pA2 - 7.95); agonist effects were <10% up to 30 μM and identical to those of naloxone.  The oral doses achieving 50% of the maximal effect in the rat for antagonism of morphine-induced inhibition of gastrointestinal transit and morphine-induced antinociception in the hot plate assay were 23.1 and 55.4 mg/kg for naloxegol and 0.69 and 1.14 mg/kg by for naloxone, respectively.  In the human colon adenocarcinoma cell transport assay, naloxegol was a substrate for the P-glycoprotein transporter, with low apparent permeability in the apical to basolateral direction, and penetrated the CNS 15-fold slower than naloxone in a rat brain perfusion model.  Naloxegol-derived radioactivity was poorly distributed throughout the rat CNS and was eliminated from most tissues within 24 hours.  These findings corroborate phase 3 clinical studies demonstrating that naloxegol relieves OIC-associated symptoms in patients with chronic noncancer pain by antagonizing the μ-opioid receptor in the ENS while preserving CNS-mediated analgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLhQuSZuN9W02yPDyEFiigfW6udTcc2eZy1tkNYXEfi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvgsFGjtQ%253D%253D&md5=93a41d3adcbe252c1b37fc57f2bd9135</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.239061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.239061%26sid%3Dliteratum%253Aachs%26aulast%3DFloettmann%26aufirst%3DE.%26aulast%3DBui%26aufirst%3DK.%26aulast%3DSostek%26aufirst%3DM.%26aulast%3DPayza%26aufirst%3DK.%26aulast%3DEldon%26aufirst%3DM.%26atitle%3DPharmacologic%2520profile%2520of%2520Naloxegol%252C%2520a%2520peripherally%2520acting%2520m-opioid%2520receptor%2520antagonist%252C%2520for%2520the%2520treatment%2520of%2520opioid-induced%2520constipation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D361%26spage%3D280%26epage%3D291%26doi%3D10.1124%2Fjpet.116.239061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="ref20_1"><span> <i>Molecular Operating Environment
(MOE)</i>, <span class="NLM_edition">2010.10</span>; <span class="NLM_publisher-name">Chemical
Computing Group ULC</span>: <span class="NLM_publisher-loc">1010 Sherbooke
St. West, Suite #910, Montreal, QC, Canada, H3A 2R7</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Molecular+Operating+Environment%0A%28MOE%29%2C+2010.10%3B+Chemical%0AComputing+Group+ULC%3A+1010+Sherbooke%0ASt.+West%2C+Suite+%23910%2C+Montreal%2C+QC%2C+Canada%2C+H3A+2R7%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref20_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Operating%2520Environment%250A%2528MOE%2529%26pub%3DChemical%250AComputing%2520Group%2520ULC%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span> <span> </span><span class="NLM_article-title">Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7216</span>– <span class="NLM_lpage">7233</span>, <span class="refDoi"> DOI: 10.1021/jm800843r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800843r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7216-7233&author=S.+H.+Leeauthor=H.+J.+Seoauthor=S.-H.+Leeauthor=M.+E.+Jungauthor=J.-H.+Parkauthor=H.-J.+Parkauthor=J.+Yooauthor=H.+Yunauthor=J.+Naauthor=S.+Y.+Kangauthor=K.-S.+Songauthor=M.-A.+Kimauthor=C.-H.+Changauthor=J.+Kimauthor=J.+Lee&title=Biarylpyrazolyl+oxadiazole+as+potent%2C+selective%2C+orally+bioavailable+cannabinoid-1+receptor+antagonists+for+the+treatment+of+obesity&doi=10.1021%2Fjm800843r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm800843r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800843r%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DSeo%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DPark%26aufirst%3DH.-J.%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DNa%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DSong%26aufirst%3DK.-S.%26aulast%3DKim%26aufirst%3DM.-A.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DBiarylpyrazolyl%2520oxadiazole%2520as%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520cannabinoid-1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520obesity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7216%26epage%3D7233%26doi%3D10.1021%2Fjm800843r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human cannabinoid receptor CB1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.cell.2016.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=27768894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=750-762&author=T.+Huaauthor=K.+Vemuriauthor=M.+Puauthor=L.+Quauthor=G.+W.+Hanauthor=Y.+Wuauthor=S.+Zhaoauthor=W.+Shuiauthor=S.+Liauthor=A.+Kordeauthor=R.+B.+Laprairieauthor=E.+L.+Stahlauthor=J.-H.+Hoauthor=N.+Zvonokauthor=H.+Zhouauthor=I.+Kufarevaauthor=B.+Wuauthor=Q.+Zhaoauthor=M.+Hansonauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.-J.+Liu&title=Crystal+structure+of+the+human+cannabinoid+receptor+CB1&doi=10.1016%2Fj.cell.2016.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB1</span></div><div class="casAuthors">Hua, Tian; Vemuri, Kiran; Pu, Mengchen; Qu, Lu; Han, Gye Won; Wu, Yiran; Zhao, Suwen; Shui, Wenqing; Li, Shanshan; Korde, Anisha; Laprairie, Robert B.; Stahl, Edward L.; Ho, Jo-Hao; Zvonok, Nikolai; Zhou, Han; Kufareva, Irina; Wu, Beili; Zhao, Qiang; Hanson, Michael A.; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-762.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chem. from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use.  CB1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders.  Here, the authors present the 2.8 Å crystal structure of human CB1 in complex with AM6538, a stabilizing antagonist, synthesized and characterized for this structural study.  The structure of the CB1-AM6538 complex reveals key features of the receptor and crit. interactions for antagonist binding.  In combination with functional studies and mol. modeling, the structure provides insight into the binding mode of naturally occurring CB1 ligands, such as THC, and synthetic cannabinoids.  This enhances the understanding of the mol. basis for the physiol. functions of CB1 and provides new opportunities for the design of next-generation CB1-targeting pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAuMgAfmO22bVg90H21EOLACvtfcHk0lhHTuN7LkXU6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI&md5=f4862c31391550ee2b83ef198c9c7b17</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DShui%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKorde%26aufirst%3DA.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DHo%26aufirst%3DJ.-H.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DHanson%26aufirst%3DM.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB1%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D750%26epage%3D762%26doi%3D10.1016%2Fj.cell.2016.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzemska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, M. D.</span></span> <span> </span><span class="NLM_article-title">High-resolution crystal structure of the human CB1 cannabinoid receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>540</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1038/nature20613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1038%2Fnature20613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=27851727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=540&publication_year=2016&pages=602-606&author=Z.+Shaoauthor=J.+Yinauthor=K.+Chapmanauthor=M.+Grzemskaauthor=L.+Clarkauthor=J.+Wangauthor=M.+D.+Rosenbaum&title=High-resolution+crystal+structure+of+the+human+CB1+cannabinoid+receptor&doi=10.1038%2Fnature20613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of the human CB1 cannabinoid receptor</span></div><div class="casAuthors">Shao, Zhenhua; Yin, Jie; Chapman, Karen; Grzemska, Magdalena; Clark, Lindsay; Wang, Junmei; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">540</span>
        (<span class="NLM_cas:issue">7634</span>),
    <span class="NLM_cas:pages">602-606</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Δ9-tetrahydrocannabinol (THC).  The cannabinoid receptors have been the targets of intensive drug discovery efforts, because modulation of these receptors has therapeutic potential to control pain, epilepsy, obesity, and other disorders.  Although much progress in understanding the biophys. properties of GPCRs has recently been made, investigations of the mol. mechanisms of the cannabinoids and their receptors have lacked high-resoln. structural data.  Here we report the use of GPCR engineering and lipidic cubic phase crystn. to det. the structure of the human CB1 receptor bound to the inhibitor taranabant at 2.6-Å resoln.  We found that the extracellular surface of CB1, including the highly conserved membrane-proximal N-terminal region, is distinct from those of other lipid-activated GPCRs, forming a crit. part of the ligand-binding pocket.  Docking studies further demonstrate how this same pocket may accommodate the cannabinoid agonist THC.  Our CB1 structure provides an at. framework for studying cannabinoid receptor function and will aid the design and optimization of therapeutic modulators of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrry3sr0ztbEbVg90H21EOLACvtfcHk0ligu2ZkJQH1JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgtL3L&md5=cccd3a0e0d0ccf9795777e4b9e722102</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1038%2Fnature20613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature20613%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DGrzemska%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRosenbaum%26aufirst%3DM.%2BD.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520the%2520human%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DNature%26date%3D2016%26volume%3D540%26spage%3D602%26epage%3D606%26doi%3D10.1038%2Fnature20613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzer, P.</span></span> <span> </span><span class="NLM_article-title">Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3714</span>– <span class="NLM_lpage">3717</span>, <span class="refDoi"> DOI: 10.1021/jm000942e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+calculation+of+molecular+polar+surface+area+as+a+sum+of+fragment-based+contributions+and+its+application+to+the+prediction+of+drug+transport+properties&doi=10.1021%2Fjm000942e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0ligu2ZkJQH1JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520calculation%2520of%2520molecular%2520polar%2520surface%2520area%2520as%2520a%2520sum%2520of%2520fragment-based%2520contributions%2520and%2520its%2520application%2520to%2520the%2520prediction%2520of%2520drug%2520transport%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3714%26epage%3D3717%26doi%3D10.1021%2Fjm000942e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0ljRn1SFUp6qZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grootenhuis, P. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayada, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbressine, L. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploemen, J. P.</span></span> <span> </span><span class="NLM_article-title">Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1514</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1023/A:1015040217741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1023%2FA%3A1015040217741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10554091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADyaK1MXntVOhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=1514-1519&author=J.+Kelderauthor=P.+D.+J.+Grootenhuisauthor=D.+M.+Bayadaauthor=L.+P.+C.+Delbressineauthor=J.+P.+Ploemen&title=Polar+molecular+surface+as+a+dominating+determinant+for+oral+absorption+and+brain+penetration+of+drugs&doi=10.1023%2FA%3A1015040217741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs</span></div><div class="casAuthors">Kelder, Jan; Grootenhuis, Peter D. J.; Bayada, Denis M.; Delbressine, Leon P. C.; Ploemen, Jan-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1514-1519</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">Purpose: To study oral absorption and brain penetration as a function of polar mol. surface area.  Methods: Measured brain penetration data of 45 drug mols. were investigated.  The dynamic polar surface areas were calcd. and correlated with the brain penetration data.  Also the static polar surface areas of 776 orally administered CNS drugs that have reached at least Phase II efficacy studies were calcd.  The same was done for a series of 1590 orally administered non-CNS drugs that have reached at least Phase II efficacy studies.  Results: A linear relationship between brain penetration and dynamic polar surface area (A2) was found (n = 45, R = 0.917, F1,43 = 229).  Brain penetration decreases with increasing polar surface area.  A clear difference between the distribution of the polar surface area of the 776 CNS and 1590 non-CNS drugs was found.  It was deduced that orally active drugs that are transported passively by the transcellular route should not exceed a polar surface area of about 120 A2.  They can be tailored to brain penetration by decreasing the polar surface to <60-70 A2.  This conclusion is supported by the inverse linear relationship between exptl. brain penetration data and the dynamic polar surface area of 45 drug mols.  Conclusions: The polar mol. surface area is a dominating determinant for oral absorption and brain penetration of drugs that are transported by the transcellular route.  This property should be considered in the early phase of drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmc3v7TzWM4LVg90H21EOLACvtfcHk0ljRn1SFUp6qZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVOhtb8%253D&md5=868fe1e9491dd3b8b92b326d28ee48f9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015040217741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015040217741%26sid%3Dliteratum%253Aachs%26aulast%3DKelder%26aufirst%3DJ.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%2BJ.%26aulast%3DBayada%26aufirst%3DD.%2BM.%26aulast%3DDelbressine%26aufirst%3DL.%2BP.%2BC.%26aulast%3DPloemen%26aufirst%3DJ.%2BP.%26atitle%3DPolar%2520molecular%2520surface%2520as%2520a%2520dominating%2520determinant%2520for%2520oral%2520absorption%2520and%2520brain%2520penetration%2520of%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D1514%26epage%3D1519%26doi%3D10.1023%2FA%3A1015040217741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">Computational methods for the prediction of drug-likeness</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(99)01451-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2FS1359-6446%2899%2901451-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10652455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht12js7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=49-58&author=D.+E.+Clarkauthor=S.+D.+Pickett&title=Computational+methods+for+the+prediction+of+drug-likeness&doi=10.1016%2FS1359-6446%2899%2901451-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Computational methods for the prediction of "drug-likeness"</span></div><div class="casAuthors">Clark, David E.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">49-58</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 55 refs.  Recently, one of the key trends in the pharmaceutical industry has been the integration of what have traditionally been considered "development" activities into the early phases of drug discovery.  The aim of this paradigm shift is the prompt identification and elimination of candidate mols. that are unlikely to survive later stages of discovery and development.  In this review, the authors examine the growing role that is being played by computational methods in this filtering process, with a particular focus on the prediction of intestinal absorption and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZMw4QBryVB7Vg90H21EOLACvtfcHk0ljRn1SFUp6qZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht12js7s%253D&md5=6b79763582f94aeb8f05a495afdbffad</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2899%2901451-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252899%252901451-8%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DD.%2BE.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DComputational%2520methods%2520for%2520the%2520prediction%2520of%2520drug-likeness%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2000%26volume%3D5%26spage%3D49%26epage%3D58%26doi%3D10.1016%2FS1359-6446%2899%2901451-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Loscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potschka, H.</span></span> <span> </span><span class="NLM_article-title">Drug resistance in brain diseases and the role of drug efflux transporters</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrn1728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1038%2Fnrn1728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=16025095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A280%3ADC%252BD2MvgtFKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=591-602&author=W.+Loscherauthor=H.+Potschka&title=Drug+resistance+in+brain+diseases+and+the+role+of+drug+efflux+transporters&doi=10.1038%2Fnrn1728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Drug resistance in brain diseases and the role of drug efflux transporters</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">591-602</span>
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    </div><div class="casAbstract">Resistance to drug treatment is an important hurdle in the therapy of many brain disorders, including brain cancer, epilepsy, schizophrenia, depression and infection of the brain with HIV.  Consequently, there is a pressing need to develop new and more effective treatment strategies.  Mechanisms of resistance that operate in cancer and infectious diseases might also be relevant in drug-resistant brain disorders.  In particular, drug efflux transporters that are expressed at the blood-brain barrier limit the ability of many drugs to access the brain.  There is increasing evidence that drug efflux transporters have an important role in drug-resistant brain disorders, and this information should allow more efficacious treatment strategies to be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBI4VWCsjP46-9TkgmBqTqfW6udTcc2earCKmEXlZkubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvgtFKisg%253D%253D&md5=26af8b7a7f5b210decf788b837e52b3e</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1038%2Fnrn1728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1728%26sid%3Dliteratum%253Aachs%26aulast%3DLoscher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DDrug%2520resistance%2520in%2520brain%2520diseases%2520and%2520the%2520role%2520of%2520drug%2520efflux%2520transporters%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2005%26volume%3D6%26spage%3D591%26epage%3D602%26doi%3D10.1038%2Fnrn1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeque, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A. J.</span></span> <span> </span><span class="NLM_article-title">Increased drug delivery to the brain by P-glycoprotein inhibition</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1067/mcp.2000.109156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1067%2Fmcp.2000.109156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=11014404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFOgtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2000&pages=231-237&author=A.+J.+Sadequeauthor=C.+Wandelauthor=H.+Heauthor=S.+Shahauthor=A.+J.+Wood&title=Increased+drug+delivery+to+the+brain+by+P-glycoprotein+inhibition&doi=10.1067%2Fmcp.2000.109156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Increased drug delivery to the brain by P-glycoprotein inhibition</span></div><div class="casAuthors">Sadeque, Abu J. M.; Wandel, Christoph; He, Hauibing; Shah, Selina; Wood, Alastair J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">231-237</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Although the antidiarrheal loperamide is a potent opiate, it does not produce opioid central nervous system effects at usual doses in patients.  On the basis of in vitro studies demonstrating that loperamide is a substrate for the ATP-dependent efflux membrane transporter P-glycoprotein, the authors postulated that inhibition of P-glycoprotein with quinidine would increase entry of loperamide into the central nervous system with resultant respiratory depression.  To test this hypothesis, a 16-mg dose of loperamide was administered to 8 healthy male volunteers in the presence of either 600 mg quinidine, a known inhibitor of P-glycoprotein, or placebo.  Central nervous system effects were measured by evaluation of the respiratory response to CO2 rebreathing as a measure of opiate-induced respiratory depression.  Loperamide produced no respiratory depression when administered alone, but respiratory depression occurred when loperamide (16 mg) was given with quinidine at a dose of 600 mg.  These changes were not explained by increased plasma loperamide concns.  This study therefore demonstrates 1st the potential for important drug interactions to occur by a new mechanism, namely, inhibition of P-glycoprotein, and 2nd that the lack of respiratory depression produced by loperamide, which allows it to be safely used therapeutically, can be reversed by a drug causing P-glycoprotein inhibition, resulting in serious toxic and abuse potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqankLtAzcwrrVg90H21EOLACvtfcHk0lgvlqF1vysIZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFOgtb8%253D&md5=8dec48b4ca58f5bebce92082ba604fd1</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2000.109156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2000.109156%26sid%3Dliteratum%253Aachs%26aulast%3DSadeque%26aufirst%3DA.%2BJ.%26aulast%3DWandel%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DA.%2BJ.%26atitle%3DIncreased%2520drug%2520delivery%2520to%2520the%2520brain%2520by%2520P-glycoprotein%2520inhibition%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2000%26volume%3D68%26spage%3D231%26epage%3D237%26doi%3D10.1067%2Fmcp.2000.109156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span> <span> </span><span class="NLM_article-title">Minimizing drug exposure in the CNS while maintaining good oral absorption</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1021/ml300378n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300378n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1OltLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=948-950&author=S.+K.+Bagalauthor=P.+J.+Bungay&title=Minimizing+drug+exposure+in+the+CNS+while+maintaining+good+oral+absorption&doi=10.1021%2Fml300378n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Minimizing Drug Exposure in the CNS while Maintaining Good Oral Absorption</span></div><div class="casAuthors">Bagal, Sharan K.; Bungay, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">948-950</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In some drug discovery approaches, it is advantageous to restrict the access of compds. to the CNS to minimize the risk of side effects.  By choosing appropriate physicochem. properties and building in the ability to act as substrates for active efflux transporters, it is possible to achieve CNS restriction and still retain sufficient absorption through the intestinal epithelium to retain good oral bioavailability.  Potential risks in employing this approach are considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhbO_d5Zr_JrVg90H21EOLACvtfcHk0lgvlqF1vysIZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1OltLvE&md5=04e328be4df50c3af37b6ad1d610933b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fml300378n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300378n%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26atitle%3DMinimizing%2520drug%2520exposure%2520in%2520the%2520CNS%2520while%2520maintaining%2520good%2520oral%2520absorption%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D948%26epage%3D950%26doi%3D10.1021%2Fml300378n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wittgen, G. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greupink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Heuvel, J. J.
M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Broek, P. H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinter-Heidorn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenderink, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, F. G. M.</span></span> <span> </span><span class="NLM_article-title">Exploiting transport activity of P-glycoprotein at the blood–brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1351</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.1021/mp200617z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200617z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1351-1360&author=G.+M.+H.+Wittgenauthor=R.+Greupinkauthor=J.+J.%0AM.+W.+van+den%0AHeuvelauthor=P.+H.+H.+van+den%0ABroekauthor=H.+Dinter-Heidornauthor=J.+B.+Koenderinkauthor=F.+G.+M.+Russel&title=Exploiting+transport+activity+of+P-glycoprotein+at+the+blood%E2%80%93brain+barrier+for+the+development+of+peripheral+cannabinoid+type+1+receptor+antagonists&doi=10.1021%2Fmp200617z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting Transport Activity of P-Glycoprotein at the Blood-Brain Barrier for the Development of Peripheral Cannabinoid Type 1 Receptor Antagonists</span></div><div class="casAuthors">Wittgen, Hanneke G. M.; Greupink, Rick; van den Heuvel, Jeroen J. M. W.; van den Broek, Petra H. H.; Dinter-Heidorn, Heike; Koenderink, Jan B.; Russel, Frans G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1351-1360</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although the CB1 receptor antagonist/inverse agonist rimonabant has pos. effects on wt. loss and cardiometabolic risk factors, neuropsychiatric side effects have prompted researchers to develop peripherally acting derivs.  Here, we investigated for a series of 3,4-diarylpyrazoline CB1 receptor antagonists if transport by the brain efflux transporter P-gp could be used as a selection criterion in the development of such drugs.  All 3,4-diarylpyrazolines and rimonabant inhibited P-gp transport activity in membrane vesicles isolated from HEK293 cells overexpressing the transporter, but only the 1,1-dioxo-thiomorpholino analog 23 exhibited a reduced accumulation (-38 ± 2%) in these cells, which could be completely reversed by the P-gp/BCRP inhibitor elacridar.  In addn., 23 appeared to be a BCRP substrate, whereas rimonabant was not.  In rats, the in vivo brain/plasma concn. ratio of 23 was significantly lower than for rimonabant (0.4 ± 0.1 vs 6.2 ± 1.6, p < 0.001).  Coadministration of elacridar resulted in an 11-fold increase of the brain/plasma ratio for 23 (p < 0.01) and only 1.4-fold for rimonabant (p < 0.05), confirming the involvement of P-gp and possibly BCRP in limiting the brain entrance of 23in vivo.  In conclusion, these data support the conception that efflux via transporters such as P-gp and BCRP can limit the brain penetration of CB1 receptor antagonists, and that this property could be used in the development of peripheral antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5CThRb0gfe7Vg90H21EOLACvtfcHk0lhpUa80CsxYjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFWht7k%253D&md5=a6404a4934cc6a24cae353840a44d114</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fmp200617z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200617z%26sid%3Dliteratum%253Aachs%26aulast%3DWittgen%26aufirst%3DG.%2BM.%2BH.%26aulast%3DGreupink%26aufirst%3DR.%26aulast%3Dvan%2Bden%2BHeuvel%26aufirst%3DJ.%2BJ.%2BM.%2BW.%26aulast%3Dvan%2Bden%2BBroek%26aufirst%3DP.%2BH.%2BH.%26aulast%3DDinter-Heidorn%26aufirst%3DH.%26aulast%3DKoenderink%26aufirst%3DJ.%2BB.%26aulast%3DRussel%26aufirst%3DF.%2BG.%2BM.%26atitle%3DExploiting%2520transport%2520activity%2520of%2520P-glycoprotein%2520at%2520the%2520blood%25E2%2580%2593brain%2520barrier%2520for%2520the%2520development%2520of%2520peripheral%2520cannabinoid%2520type%25201%2520receptor%2520antagonists%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D1351%26epage%3D1360%26doi%3D10.1021%2Fmp200617z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein recognition of substrates and circumvention through rational drug design</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1021/mp0500871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp0500871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlagu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=3-25&author=T.+J.+Raub&title=P-Glycoprotein+recognition+of+substrates+and+circumvention+through+rational+drug+design&doi=10.1021%2Fmp0500871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">P-Glycoprotein Recognition of Substrates and Circumvention through Rational Drug Design</span></div><div class="casAuthors">Raub, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now well recognized that membrane efflux transporters, esp. P-glycoprotein (P-gp; ABCB1), play a role in detg. the absorption, distribution, metab., excretion, and toxicol. behaviors of some drugs and mols. in development.  An investment in screening structure-activity relation (SAR) is warranted in early discovery when exposure and/or target activity in an in vivo efficacy model is not achieved and P-gp efflux is identified as a rate-limiting factor.  However, the amt. of investment in SAR must be placed into perspective by assessing the risks assocd. with the intended therapeutic target, the potency and margin of safety of the compd., the intended patient population(s), and the market competition.  The task of rationally designing a chem. strategy for circumventing a limiting P-gp interaction can be daunting.  The necessity of retaining biol. potency and metabolic stability places restrictions on what can be done, and the factors for P-gp recognition of substrates are complicated and poorly understood.  The parameters within the assays that affect overall pump efficiency or net efflux, such as passive diffusion, membrane partitioning, and mol. interaction between pump and substrate, should be understood when interpreting data sets assocd. with chem. around a scaffold.  No single, functional group alone is often the cause, but one group can accentuate the recognition points existing within a scaffold.  This can be likened to a rheostat, rather than an on/off switch, where addn. or removal of a key group can increase or decrease the pumping efficiency.  The most practical approach to de-emphasize the limiting effects of P-gp on a particular scaffold is to increase passive diffusion.  Efflux pumping efficiency may be overcome when passive diffusion is fast enough.  Eliminating, or substituting with fewer, groups that solvate in water, or decreasing their hydrogen bonding capacity, and adding halogen groups can increase passive diffusion.  Reducing mol. size, replacing electroneg. atoms, blocking or masking H-bond donors with N-alkylation or bulky flanking groups, introducing constrained conformation, or by promoting intramol. hydrogen bonds are all examples of steps to take.  This review discusses our understanding of how P-gp recognizes and pumps compds. as substrates and describes cases where structural changes were made in a chem. scaffold to circumvent the effects of P-gp interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRbEgPosNnxrVg90H21EOLACvtfcHk0lhpUa80CsxYjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlagu7%252FP&md5=cc89be920dfa0e32edb994be94626aa5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fmp0500871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0500871%26sid%3Dliteratum%253Aachs%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26atitle%3DP-Glycoprotein%2520recognition%2520of%2520substrates%2520and%2520circumvention%2520through%2520rational%2520drug%2520design%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2006%26volume%3D3%26spage%3D3%26epage%3D25%26doi%3D10.1021%2Fmp0500871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tingley, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajiji, S. M.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein efflux at the blood–brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists</span>. <i>J. Pharmacol. Exp.Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=11504828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtFKmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2001&pages=1252-1259&author=B.+J.+Smithauthor=A.+D.+Doranauthor=S.+McLeanauthor=F.+D.+Tingleyauthor=T.+Brianauthor=B.+T.+O%E2%80%99Neillauthor=S.+M.+Kajiji&title=P-Glycoprotein+efflux+at+the+blood%E2%80%93brain+barrier+mediates+differences+in+brain+disposition+and+pharmacodynamics+between+two+structurally+related+neurokinin-1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists</span></div><div class="casAuthors">Smith, Bill J.; Doran, Angela C.; McLean, Stafford; Tingley, F. David, III; O'Neill, Brian T.; Kajiji, Shama M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1259</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CP-122721 and CP-141938 are potent and selective neurokinin-1 (NK1) receptor antagonists with very different brain disposition and potency in models of centrally mediated activity.  These investigations sought to det. whether differences in potency were related to differences in P-glycoprotein (P-gp) transport at the blood-brain barrier.  Both compds. stimulated ATPase activity of human recombinant MDR1 with similar kinetic parameters.  Cell-assocd. drug concns. of CP-141938 were 9.4-fold lower in KBV1 cells expressing P-gp compared with KB3.1 control cells.  In Madin-Darby canine kidney (MDCK) cells expressing human MDR1, asym. transport of CP-141938 was 5-fold higher than in wild-type MDCK cells, whereas no asymmetry was obsd. with CP-122721.  In agreement with these differences in cellular transport, the differences in brain/plasma ratio between mdr1a/b(-/-) and FVB mice 1 h following a 3 mg/kg s.c. dose were 3- and 50-fold for CP-122721 and CP-141938, resp.  The effect of inhibiting P-gp efflux on the effects of these agents was evaluated using GR73632-induced foot tapping in gerbils as a model to measure centrally mediated NK1 antagonism.  When gerbils were pretreated with the P-gp inhibitor MS-073 (50 mg/kg s.c.), there was no effect on the activity of CP-122721 (0.05 mg/kg), whereas the percent reversal for CP-141938 (10 mg/kg) increased from 60 to 100%.  In gerbils, the brain/plasma ratio for CP-122721 was unaffected by MS-073 pretreatment, whereas the brain/plasma ratio for CP-141938 brain concns. increased 13-fold.  This suggested that P-gp efflux influences the brain disposition and pharmacol. activity of CP-141938, but not CP-122721.  Complete response curves for CP-141938 were then detd. with respect to dose, and drug concn. in the plasma and brain in the presence and absence of MS-073 pretreatment.  The dose and plasma concn.-response curves of CP-141938 were shifted to the left in the presence of MS-073, yet brain concns. assocd. with the response were unchanged.  This suggested that once in the brain the interaction of CP-141938 with the NK1 receptor was not affected by P-gp transport.  In conclusion, these studies show that brain disposition and centrally mediated in vivo activity of NK1 antagonists can be profoundly affected by P-gp transport and that such transport should be considered during the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozSRvdzBMaP7Vg90H21EOLACvtfcHk0liiHJ-qB2-hpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtFKmtbg%253D&md5=ca44f3c8d9e83a8f9486e805e95af1f6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DDoran%26aufirst%3DA.%2BD.%26aulast%3DMcLean%26aufirst%3DS.%26aulast%3DTingley%26aufirst%3DF.%2BD.%26aulast%3DBrian%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DKajiji%26aufirst%3DS.%2BM.%26atitle%3DP-Glycoprotein%2520efflux%2520at%2520the%2520blood%25E2%2580%2593brain%2520barrier%2520mediates%2520differences%2520in%2520brain%2520disposition%2520and%2520pharmacodynamics%2520between%2520two%2520structurally%2520related%2520neurokinin-1%2520receptor%2520antagonists%26jtitle%3DJ.%2520Pharmacol.%2520Exp.Ther.%26date%3D2001%26volume%3D298%26spage%3D1252%26epage%3D1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quarta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braulke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latorre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heldmaier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leste-Lassere, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisoli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cota, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagotto, U.</span></span> <span> </span><span class="NLM_article-title">CB1 Signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2010.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.cmet.2010.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=20374960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVajtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=273-285&author=C.+Quartaauthor=L.+Bellocchioauthor=G.+Manciniauthor=R.+Mazzaauthor=C.+Cervinoauthor=L.+J.+Braulkeauthor=C.+Feketeauthor=R.+Latorreauthor=C.+Nanniauthor=M.+Bucciauthor=L.+E.+Clemensauthor=G.+Heldmaierauthor=M.+Watanabeauthor=T.+Leste-Lassereauthor=M.+Maitreauthor=L.+Tedescoauthor=F.+Fanelliauthor=S.+Reussauthor=S.+Klausauthor=R.+K.+Srivastavaauthor=K.+Monoryauthor=A.+Valerioauthor=A.+Grandisauthor=R.+De+Giorgioauthor=R.+Pasqualiauthor=E.+Nisoliauthor=E.+Cotaauthor=B.+Lutzauthor=G.+Marsicanoauthor=U.+Pagotto&title=CB1+Signaling+in+forebrain+and+sympathetic+neurons+is+a+key+determinant+of+endocannabinoid+actions+on+energy+balance&doi=10.1016%2Fj.cmet.2010.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">CB1 signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance</span></div><div class="casAuthors">Quarta, Carmelo; Bellocchio, Luigi; Mancini, Giacomo; Mazza, Roberta; Cervino, Cristina; Braulke, Luzie J.; Fekete, Csaba; Latorre, Rocco; Nanni, Cristina; Bucci, Marco; Clemens, Laura E.; Heldmaier, Gerhard; Watanabe, Masahiko; Leste-Lassere, Thierry; Maitre, Marlene; Tedesco, Laura; Fanelli, Flaminia; Reuss, Stefan; Klaus, Susanne; Srivastava, Raj Kamal; Monory, Krisztina; Valerio, Alessandra; Grandis, Annamaria; De Giorgio, Roberto; Pasquali, Renato; Nisoli, Enzo; Cota, Daniela; Lutz, Beat; Marsicano, Giovanni; Pagotto, Uberto</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-285</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The endocannabinoid system (ECS) plays a crit. role in obesity development.  The pharmacol. blockade of cannabinoid receptor type 1 (CB1) has been shown to reduce body wt. and to alleviate obesity-related metabolic disorders.  An unsolved question is at which anatomical level CB1 modulates energy balance and the mechanisms involved in its action.  Here, we demonstrate that CB1 receptors expressed in forebrain and sympathetic neurons play a key role in the pathophysiol. development of diet-induced obesity.  Conditional mutant mice lacking CB1 expression in neurons known to control energy balance, but not in nonneuronal peripheral organs, displayed a lean phenotype and resistance to diet-induced obesity.  This phenotype results from an increase in lipid oxidn. and thermogenesis as a consequence of an enhanced sympathetic tone and a decrease in energy absorption.  In conclusion, CB1 signaling in the forebrain and sympathetic neurons is a key determinant of the ECS control of energy balance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKwboAUEBgwrVg90H21EOLACvtfcHk0liiHJ-qB2-hpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVajtbY%253D&md5=6bef1e482829fac3871b4e47f3cedd0e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2010.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2010.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DQuarta%26aufirst%3DC.%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DMancini%26aufirst%3DG.%26aulast%3DMazza%26aufirst%3DR.%26aulast%3DCervino%26aufirst%3DC.%26aulast%3DBraulke%26aufirst%3DL.%2BJ.%26aulast%3DFekete%26aufirst%3DC.%26aulast%3DLatorre%26aufirst%3DR.%26aulast%3DNanni%26aufirst%3DC.%26aulast%3DBucci%26aufirst%3DM.%26aulast%3DClemens%26aufirst%3DL.%2BE.%26aulast%3DHeldmaier%26aufirst%3DG.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DLeste-Lassere%26aufirst%3DT.%26aulast%3DMaitre%26aufirst%3DM.%26aulast%3DTedesco%26aufirst%3DL.%26aulast%3DFanelli%26aufirst%3DF.%26aulast%3DReuss%26aufirst%3DS.%26aulast%3DKlaus%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DR.%2BK.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DValerio%26aufirst%3DA.%26aulast%3DGrandis%26aufirst%3DA.%26aulast%3DDe%2BGiorgio%26aufirst%3DR.%26aulast%3DPasquali%26aufirst%3DR.%26aulast%3DNisoli%26aufirst%3DE.%26aulast%3DCota%26aufirst%3DE.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DPagotto%26aufirst%3DU.%26atitle%3DCB1%2520Signaling%2520in%2520forebrain%2520and%2520sympathetic%2520neurons%2520is%2520a%2520key%2520determinant%2520of%2520endocannabinoid%2520actions%2520on%2520energy%2520balance%26jtitle%3DCell%2520Metab.%26date%3D2010%26volume%3D11%26spage%3D273%26epage%3D285%26doi%3D10.1016%2Fj.cmet.2010.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria-Gómez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metna-Laurent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delamarre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Fontecha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leste-Lasserre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartsch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaouloff, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagotto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span> <span> </span><span class="NLM_article-title">Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB1 receptor blockade</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">4786</span>– <span class="NLM_lpage">4791</span>, <span class="refDoi"> DOI: 10.1073/pnas.1218573110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1073%2Fpnas.1218573110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=4786-4791&author=L.+Bellocchioauthor=E.+Soria-G%C3%B3mezauthor=C.+Quartaauthor=M.+Metna-Laurentauthor=P.+Cardinalauthor=E.+Binderauthor=A.+Cannichauthor=A.+Delamarreauthor=M.+H%C3%A4ringauthor=M.+Mart%C3%ADn-Fontechaauthor=D.+Vegaauthor=T.+Leste-Lasserreauthor=D.+Bartschauthor=K.+Monoryauthor=B.+Lutzauthor=F.+Chaouloffauthor=U.+Pagottoauthor=M.+Guzmanauthor=D.+Cotaauthor=G.+Marsicano&title=Activation+of+the+sympathetic+nervous+system+mediates+hypophagic+and+anxiety-like+effects+of+CB1+receptor+blockade&doi=10.1073%2Fpnas.1218573110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1218573110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1218573110%26sid%3Dliteratum%253Aachs%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DSoria-G%25C3%25B3mez%26aufirst%3DE.%26aulast%3DQuarta%26aufirst%3DC.%26aulast%3DMetna-Laurent%26aufirst%3DM.%26aulast%3DCardinal%26aufirst%3DP.%26aulast%3DBinder%26aufirst%3DE.%26aulast%3DCannich%26aufirst%3DA.%26aulast%3DDelamarre%26aufirst%3DA.%26aulast%3DH%25C3%25A4ring%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn-Fontecha%26aufirst%3DM.%26aulast%3DVega%26aufirst%3DD.%26aulast%3DLeste-Lasserre%26aufirst%3DT.%26aulast%3DBartsch%26aufirst%3DD.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DChaouloff%26aufirst%3DF.%26aulast%3DPagotto%26aufirst%3DU.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DCota%26aufirst%3DD.%26aulast%3DMarsicano%26aufirst%3DG.%26atitle%3DActivation%2520of%2520the%2520sympathetic%2520nervous%2520system%2520mediates%2520hypophagic%2520and%2520anxiety-like%2520effects%2520of%2520CB1%2520receptor%2520blockade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D4786%26epage%3D4791%26doi%3D10.1073%2Fpnas.1218573110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godlewski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chedester, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liow, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorvat, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2012.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.cmet.2012.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=22841573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=167-179&author=J.+Tamauthor=R.+Cinarauthor=J.+Liuauthor=G.+Godlewskiauthor=D.+Wesleyauthor=T.+Jourdanauthor=G.+Szandaauthor=B.+Mukhopadhyayauthor=L.+Chedesterauthor=J.-S.+Liowauthor=R.+B.+Innisauthor=K.+Chengauthor=K.+C.+Riceauthor=J.+R.+Deschampsauthor=R.+J.+Chorvatauthor=J.+F.+McElroyauthor=G.+Kunos&title=Peripheral+cannabinoid-1+receptor+inverse+agonism+reduces+obesity+by+reversing+leptin+resistance&doi=10.1016%2Fj.cmet.2012.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance</span></div><div class="casAuthors">Tam, Joseph; Cinar, Resat; Liu, Jie; Godlewski, Grzegorz; Wesley, Daniel; Jourdan, Tony; Szanda, Gergo; Mukhopadhyay, Bani; Chedester, Lee; Liow, Jeih-San; Innis, Robert B.; Cheng, Kejun; Rice, Kenner C.; Deschamps, Jeffrey R.; Chorvat, Robert J.; McElroy, John F.; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-179</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Obesity-related leptin resistance manifests in loss of leptin's ability to reduce appetite and increase energy expenditure.  Obesity is also assocd. with increased activity of the endocannabinoid system, and CB1 receptor (CB1R) inverse agonists reduce body wt. and the assocd. metabolic complications, although adverse neuropsychiatric effects halted their therapeutic development.  In mice with diet-induced obesity (DIO), the peripherally restricted CB1R inverse agonist JD5037 is equieffective with its brain-penetrant parent compd. in reducing appetite, body wt., hepatic steatosis, and insulin resistance, even though it does not occupy central CB1R or induce related behaviors.  Appetite and wt. redn. by JD5037 are mediated by resensitizing DIO mice to endogenous leptin through reversing the hyperleptinemia by decreasing leptin expression and secretion by adipocytes and increasing leptin clearance via the kidney.  Thus, inverse agonism at peripheral CB1R not only improves cardiometabolic risk in obesity but has antiobesity effects by reversing leptin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXZCRIXdM8qLVg90H21EOLACvtfcHk0ljY56NBhbGyqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahsL%252FO&md5=412b24018a9a1620ebf533f5195b1659</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2012.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2012.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DWesley%26aufirst%3DD.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DChedester%26aufirst%3DL.%26aulast%3DLiow%26aufirst%3DJ.-S.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520cannabinoid-1%2520receptor%2520inverse%2520agonism%2520reduces%2520obesity%2520by%2520reversing%2520leptin%2520resistance%26jtitle%3DCell%2520Metab.%26date%3D2012%26volume%3D16%26spage%3D167%26epage%3D179%26doi%3D10.1016%2Fj.cmet.2012.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashiwaya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1113</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.1016/j.molmet.2017.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.molmet.2017.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=29031713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=1113-1125&author=J.+Tamauthor=G.+Szandaauthor=A.+Droriauthor=Z.+Liuauthor=R.+Cinarauthor=Y.+Kashiwayaauthor=M.+L.+Reitmanauthor=G.+Kunos&title=Peripheral+cannabinoid-1+receptor+blockade+restores+hypothalamic+leptin+signaling&doi=10.1016%2Fj.molmet.2017.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling</span></div><div class="casAuthors">Tam, Joseph; Szanda, Gergo; Drori, Adi; Liu, Ziyi; Cinar, Resat; Kashiwaya, Yoshihiro; Reitman, Marc L.; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1113-1125</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">In visceral obesity, an overactive endocannabinoid/CB1 receptor (CB1R) system promotes increased caloric intake and decreases energy expenditure, which are mitigated by global or peripheral CB1R blockade.  In mice with diet-induced obesity (DIO), inhibition of food intake by the peripherally restricted CB1R antagonist JD5037 could be attributed to endogenous leptin due to the rapid reversal of hyperleptinemia that maintains leptin resistance, but the signaling pathway engaged by leptin has remained to be detd.We analyzed the hypothalamic circuitry targeted by leptin following chronic treatment of DIO mice with JD5037.Leptin treatment or an increase in endogenous leptin following fasting/refeeding induced STAT3 phosphorylation in neurons in the arcuate nucleus (ARC) in lean and JD5037-treated DIO mice, but not in vehicle-treated DIO animals.  Co-localization of pSTAT3 in leptin-treated mice was significantly less common with NPY+ than with POMC+ ARC neurons.  The hypophagic effect of JD5037 was absent in melanocortin-4 receptor (MC4R) deficient obese mice or DIO mice treated with a MC4R antagonist, but was maintained in NPY-/- mice kept on a high-fat diet.Peripheral CB1R blockade in DIO restores sensitivity to endogenous leptin, which elicits hypophagia via the re-activation of melanocortin signaling in the ARC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokTnwUe56m1LVg90H21EOLACvtfcHk0lid3T4NUcOR1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7rI&md5=50be1d443a5e97c67cf85e466d7b2a48</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2017.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2017.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DDrori%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DKashiwaya%26aufirst%3DY.%26aulast%3DReitman%26aufirst%3DM.%2BL.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520cannabinoid-1%2520receptor%2520blockade%2520restores%2520hypothalamic%2520leptin%2520signaling%26jtitle%3DMol.%2520Metab.%26date%3D2017%26volume%3D6%26spage%3D1113%26epage%3D1125%26doi%3D10.1016%2Fj.molmet.2017.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz
de Azua, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zingaretti, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwitter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettschureck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez-Lago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindila, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offermanns, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisoli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagotto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span> <span> </span><span class="NLM_article-title">Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">4148</span>– <span class="NLM_lpage">4162</span>, <span class="refDoi"> DOI: 10.1172/JCI83626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1172%2FJCI83626" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=4148-4162&author=I.+Ruiz%0Ade+Azuaauthor=G.+Manciniauthor=R.+K.+Srivastavaauthor=A.+A.+Reyauthor=P.+Cardinalauthor=L.+Tedescoauthor=C.+M.+Zingarettiauthor=A.+Sassmannauthor=C.+Quartaauthor=C.+Schwitterauthor=A.+Conradauthor=N.+Wettschureckauthor=V.+K.+Vemuriauthor=A.+Makriyannisauthor=J.+Hartwigauthor=M.+Mendez-Lagoauthor=L.+Bindilaauthor=K.+Monoryauthor=A.+Giordanoauthor=S.+Cintiauthor=G.+Marsicanoauthor=S.+Offermannsauthor=E.+Nisoliauthor=U.+Pagottoauthor=D.+Cotaauthor=B.+Lutz&title=Adipocyte+cannabinoid+receptor+CB1+regulates+energy+homeostasis+and+alternatively+activated+macrophages&doi=10.1172%2FJCI83626"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1172%2FJCI83626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI83626%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz%2Bde%2BAzua%26aufirst%3DI.%26aulast%3DMancini%26aufirst%3DG.%26aulast%3DSrivastava%26aufirst%3DR.%2BK.%26aulast%3DRey%26aufirst%3DA.%2BA.%26aulast%3DCardinal%26aufirst%3DP.%26aulast%3DTedesco%26aufirst%3DL.%26aulast%3DZingaretti%26aufirst%3DC.%2BM.%26aulast%3DSassmann%26aufirst%3DA.%26aulast%3DQuarta%26aufirst%3DC.%26aulast%3DSchwitter%26aufirst%3DC.%26aulast%3DConrad%26aufirst%3DA.%26aulast%3DWettschureck%26aufirst%3DN.%26aulast%3DVemuri%26aufirst%3DV.%2BK.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DHartwig%26aufirst%3DJ.%26aulast%3DMendez-Lago%26aufirst%3DM.%26aulast%3DBindila%26aufirst%3DL.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DGiordano%26aufirst%3DA.%26aulast%3DCinti%26aufirst%3DS.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DOffermanns%26aufirst%3DS.%26aulast%3DNisoli%26aufirst%3DE.%26aulast%3DPagotto%26aufirst%3DU.%26aulast%3DCota%26aufirst%3DD.%26aulast%3DLutz%26aufirst%3DB.%26atitle%3DAdipocyte%2520cannabinoid%2520receptor%2520CB1%2520regulates%2520energy%2520homeostasis%2520and%2520alternatively%2520activated%2520macrophages%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D4148%26epage%3D4162%26doi%3D10.1172%2FJCI83626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit44'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11a','cit11b','cit11c','cit11d','cit11e','cit11f'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b','cit18c'],'ref19':['cit19'],'ref20':['ref20_1'],'ref21':['cit21'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34a','cit34b'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yue-Mei Zhang, Michael Greco, Tonya Le Blanc, Wensheng Lang, Jack Kauffman, John Masucci, William V. Murray, Keith Demarest, <span class="NLM_string-name hlFld-ContribAuthor">Mark Joseph Macielag</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB1R Inverse Agonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2504-2509. <a href="https://doi.org/10.1021/acsmedchemlett.0c00495" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00495</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00495%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPEGylated%252B6-Benzhydryl-4-amino-quinazolines%252Bas%252BPeripherally%252BRestricted%252BCB1R%252BInverse%252BAgonists%26aulast%3DZhang%26aufirst%3DYue-Mei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10092020%26date%3D02112020%26date%3D03112020%26volume%3D11%26issue%3D12%26spage%3D2504%26epage%3D2509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Piotr  Schulz</span>, <span class="hlFld-ContribAuthor ">Szymon  Hryhorowicz</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Rychter</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Zawada</span>, <span class="hlFld-ContribAuthor ">Ryszard  Słomski</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Dobrowolska</span>, <span class="hlFld-ContribAuthor ">Iwona  Krela-Kaźmierczak</span>. </span><span class="cited-content_cbyCitation_article-title">What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?. </span><span class="cited-content_cbyCitation_journal-name">Nutrients</span><span> <strong>2021,</strong> <em>13 </em>
                                    (2)
                                     , 373. <a href="https://doi.org/10.3390/nu13020373" title="DOI URL">https://doi.org/10.3390/nu13020373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/nu13020373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fnu13020373%26sid%3Dliteratum%253Aachs%26jtitle%3DNutrients%26atitle%3DWhat%252BRole%252BDoes%252Bthe%252BEndocannabinoid%252BSystem%252BPlay%252Bin%252Bthe%252BPathogenesis%252Bof%252BObesity%25253F%26aulast%3DSchulz%26aufirst%3DPiotr%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D2%26spage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carmelo  Quarta</span>, <span class="hlFld-ContribAuthor ">Daniela  Cota</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Obesity</span><span> <strong>2020,</strong> <em>44 </em>
                                    (11)
                                     , 2179-2193. <a href="https://doi.org/10.1038/s41366-020-0577-8" title="DOI URL">https://doi.org/10.1038/s41366-020-0577-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41366-020-0577-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41366-020-0577-8%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Obesity%26atitle%3DAnti-obesity%252Btherapy%252Bwith%252Bperipheral%252BCB1%252Bblockers%25253A%252Bfrom%252Bpromise%252Bto%252Bsafe%252528%25253F%252529%252Bpractice%26aulast%3DQuarta%26aufirst%3DCarmelo%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D11%26spage%3D2179%26epage%3D2193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Murphy</span>, <span class="hlFld-ContribAuthor ">Bernard  Le Foll</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (6)
                                     , 855. <a href="https://doi.org/10.3390/biom10060855" title="DOI URL">https://doi.org/10.3390/biom10060855</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10060855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10060855%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DTargeting%252Bthe%252BEndocannabinoid%252BCB1%252BReceptor%252Bto%252BTreat%252BBody%252BWeight%252BDisorders%25253A%252BA%252BPreclinical%252Band%252BClinical%252BReview%252Bof%252Bthe%252BTherapeutic%252BPotential%252Bof%252BPast%252Band%252BPresent%252BCB1%252BDrugs%26aulast%3DMurphy%26aufirst%3DThomas%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D6%26spage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suo-Suo  Qi</span>, <span class="hlFld-ContribAuthor ">Zhen-Hui  Jiang</span>, <span class="hlFld-ContribAuthor ">Ming-Ming  Chu</span>, <span class="hlFld-ContribAuthor ">Yi-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Xue-Yang  Chen</span>, <span class="hlFld-ContribAuthor ">Wan-Zhen  Ju</span>, <span class="hlFld-ContribAuthor ">Dan-Qian  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective catalytic asymmetric
              N
              -alkylation of isoxazol-5-ones with
              para
              -quinone methides. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (13)
                                     , 2398-2404. <a href="https://doi.org/10.1039/D0OB00393J" title="DOI URL">https://doi.org/10.1039/D0OB00393J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00393J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00393J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRegioselective%252Bcatalytic%252Basymmetric%252BN%252B-alkylation%252Bof%252Bisoxazol-5-ones%252Bwith%252Bpara%252B-quinone%252Bmethides%26aulast%3DQi%26aufirst%3DSuo-Suo%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D13%26spage%3D2398%26epage%3D2404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prashant  Dhiman</span>, <span class="hlFld-ContribAuthor ">Nidhi  Arora</span>, <span class="hlFld-ContribAuthor ">Punniyakoti Veeraveedu  Thanikachalam</span>, <span class="hlFld-ContribAuthor ">Vikramdeep  Monga</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the synthetic and medicinal perspective of quinolones: A review. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>92 </em>, 103291. <a href="https://doi.org/10.1016/j.bioorg.2019.103291" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103291%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bsynthetic%252Band%252Bmedicinal%252Bperspective%252Bof%252Bquinolones%25253A%252BA%252Breview%26aulast%3DDhiman%26aufirst%3DPrashant%26date%3D2019%26volume%3D92%26spage%3D103291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shira  Hirsch</span>, <span class="hlFld-ContribAuthor ">Joseph  Tam</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome. </span><span class="cited-content_cbyCitation_journal-name">Toxins</span><span> <strong>2019,</strong> <em>11 </em>
                                    (5)
                                     , 275. <a href="https://doi.org/10.3390/toxins11050275" title="DOI URL">https://doi.org/10.3390/toxins11050275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/toxins11050275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Ftoxins11050275%26sid%3Dliteratum%253Aachs%26jtitle%3DToxins%26atitle%3DCannabis%25253A%252BFrom%252Ba%252BPlant%252BThat%252BModulates%252BFeeding%252BBehaviors%252Btoward%252BDeveloping%252BSelective%252BInhibitors%252Bof%252Bthe%252BPeripheral%252BEndocannabinoid%252BSystem%252Bfor%252Bthe%252BTreatment%252Bof%252BObesity%252Band%252BMetabolic%252BSyndrome%26aulast%3DHirsch%26aufirst%3DShira%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D5%26spage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George  Amato</span>, <span class="hlFld-ContribAuthor ">Nayaab S  Khan</span>, <span class="hlFld-ContribAuthor ">Rangan  Maitra</span>. </span><span class="cited-content_cbyCitation_article-title">A patent update on cannabinoid receptor 1 antagonists (2015-2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (4)
                                     , 261-269. <a href="https://doi.org/10.1080/13543776.2019.1597851" title="DOI URL">https://doi.org/10.1080/13543776.2019.1597851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1597851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1597851%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Bupdate%252Bon%252Bcannabinoid%252Breceptor%252B1%252Bantagonists%252B%2525282015-2018%252529%26aulast%3DAmato%26aufirst%3DGeorge%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D4%26spage%3D261%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of rimonabant, quinoline-2-one-based HTS hit <b>1a</b>, and the generic scaffold <b>1</b> with sites of modification labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Compounds in Series <b>5</b>, <b>6</b>, <b>7</b>, <b>8</b>, and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) R<sup>4</sup>Li or R<sup>4</sup> MgBr, −78 °C, THF; (b) SnCl<sub>2</sub>·2H<sub>2</sub>O, HCl, AcOH; (c) Pd(OAc)<sub>2</sub>, SPhos, K<sub>3</sub>PO<sub>4</sub>, 35 °C, THF; (d) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, 100 °C, Cs<sub>2</sub>CO<sub>3</sub>, dioxane; (e) Et<sub>3</sub>SiH, TFA/CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) 48% HBr, 100 °C, 96%; (g) ClSO<sub>2</sub>R′, BrR′, TEA, CH<sub>2</sub>Cl<sub>2</sub>; or R′CHO, NaBH<sub>3</sub>CN, MeOH, AcOH; (h) aq NaOH, THF/MeOH; (i) NH<sub>4</sub>Cl, DIEA, HATU, DMF, 47%; (j) R<sup>1</sup>Br or R<sup>1</sup>OTs, Cs<sub>2</sub>CO<sub>3</sub>, 80 °C, CH<sub>3</sub>CN.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Compounds in Series <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:5), rt, 92%; (b) NaBH<sub>4</sub>, MeOH, 92%; (c) R<sup>3</sup>B(OH)<sub>2</sub> or R<sup>3</sup>Bpin, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 80 °C, dioxane/H<sub>2</sub>O; (d) Imidazole, CDI, rt, CH<sub>2</sub>Cl<sub>2</sub>; (e) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, 100 °C, Cs<sub>2</sub>CO<sub>3</sub>, dioxane.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>5h</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BnBr, Ag<sub>2</sub>CO<sub>3</sub>, 100 °C, toluene, 65%; (b) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 100%; (c) TsCl, K<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 60–80%; (d) NaBH<sub>4</sub>, MeOH, rt, 84–91%; (e) imidazole, CDI, rt, CH<sub>2</sub>Cl<sub>2</sub>; (f) PBr<sub>3</sub>, DMF, rt, 80%; (g) PhCONH<sub>2</sub>, CuI, <i>trans</i>-<i>N</i>,<i>N</i>-dimethylcyclohexane-1,2-diamine, K<sub>3</sub>PO<sub>4</sub>, 100 °C, toluene, 54%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>6b</b>, <b>6i</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, 99%; (b) 4-ClPhOH, PPh<sub>3</sub>, DEAD, CH<sub>2</sub>Cl<sub>2</sub>; (c) TFA, CH<sub>2</sub>Cl<sub>2,</sub> rt; (d) SOCl<sub>2</sub>; (e) 1-phenylpiperazine, TEA, CH<sub>2</sub>Cl<sub>2</sub>; (f) Et<sub>3</sub>SiH, TFA/CH<sub>2</sub>Cl<sub>2</sub>, rt; (g) 4-F-BnMgBr, −78 °C, THF; (h) PtO<sub>2</sub>, MeOH, H<sub>2</sub>, rt; 22%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>7c</b>, <b>7e</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) KOBu<sup>t</sup> or NaOMe, 65 °C, toluene; (b) 4-ClPhMgBr, 0 °C, THF; (c) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, 85–100 °C, Cs<sub>2</sub>CO<sub>3</sub>, dioxane; (d) Et<sub>3</sub>SiH, TFA/CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 80 °C, dioxane/H<sub>2</sub>O, 66%; (f) PtO<sub>2</sub>, H<sub>2</sub>, rt, 70%; (g) 4 N HCl, 100 °C, 59%; (h) aq NaOH, THF/MeOH.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>8a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-ClPhMgBr, THF, reflux, 63%; (b) Et<sub>3</sub>SiH, TFA/CH<sub>2</sub>Cl<sub>2</sub>, rt, 90%; (c) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C, 48%; (d) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, 72%; (e) R<sup>5</sup>Br or R<sup>5</sup>OTs, Cs<sub>2</sub>CO<sub>3,</sub> 60 °C, DMF; (f) aq NaOH, THF/MeOH; (g) NH<sub>4</sub>Cl, HATU, DIEA, DMF, rt, 29%; (h) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:10), rt.</p></p></figure><figure data-id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0003.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Overlay model of rimonabant (cyan carbons) and compound <b>6a</b> (pink carbons). Arrows indicate positions on the 4-aminoquinolinone scaffold that were explored to increase peripheral restriction. (B) The same overlay, with minor adjustments as described in the text, in the context of the CB<sub>1</sub>R-AM6538 crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TGZ">5TGZ</a>). CB<sub>1</sub>R is shown with white carbons, AM6538 with purple carbons, and compound <b>6a</b> with pink carbons. The blue arrow indicates the C8 position and the tunnel toward solvent. (C) Atoms in red were used to superimpose the rimonabant conformation from the flexible overlay onto AM6538 from the cocrystal structure with CB<sub>1</sub>R (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TGZ">5TGZ</a>)<a onclick="showRef(event, 'cit22a'); return false;" href="javascript:void(0);" class="ref cit22a">(22a)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0004.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Efficacy of compound <b>6a</b> (30 mg/kg, daily) in DIO mice. (A) Daily food intake. (B) Percent body weight change.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/medium/jm-2018-01467p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0005.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Dose–response DIO mouse efficacy of compound <b>6a</b> over 23-day treatment. (A) Food intake was measured daily for 5 days, twice weekly thereafter until 17 days, and every 3 days for the last 6 days. Data for last 6 days not shown. (B) Body weight was measured daily for 5 days and twice weekly thereafter for 10 days with oral dosing of 1, 3, and 10 mpk. (C) Fasting insulin at day 26. (D) liver fat. (E) cholesterol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01467/20181119/images/large/jm-2018-01467p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01467&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i170">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devi, L. A.</span></span> <span> </span><span class="NLM_article-title">The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications</span>. <i>Pharmacological Reviews.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1124/pr.110.003491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1124%2Fpr.110.003491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=461-470&author=L.+K.+Millerauthor=L.+A.+Devi&title=The+highs+and+lows+of+cannabinoid+receptor+expression+in+disease%3A+mechanisms+and+their+therapeutic+implications&doi=10.1124%2Fpr.110.003491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications</span></div><div class="casAuthors">Miller, Lydia K.; Devi, Lakshmi A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-470</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Alterations in the endogenous cannabinoid system have been described in almost every category of disease.  These changes can alternatively be protective or maladaptive, such as producing antinociception in neuropathic pain or fibrogenesis in liver disease, making the system an attractive therapeutic target.  However, the challenge remains to selectively target the site of disease while sparing other areas, particularly mood and cognitive centers of the brain.  Identifying regional changes in cannabinoid receptor-1 and -2 (CB1R and CB2R) expression is particularly important when considering endocannabinoid system-based therapies, because regional increases in cannabinoid receptor expression have been shown to increase potency and efficacy of exogenous agonists at sites of disease.  Although there have been extensive descriptive studies of cannabinoid receptor expression changes in disease, the underlying mechanisms are only just beginning to unfold.  Understanding these mechanisms is important and potentially relevant to therapeutics.  In diseases for which cannabinoid receptors are protective, knowledge of the mechanisms of receptor up-regulation could be used to design therapies to regionally increase receptor expression and thus increase efficacy of an agonist.  Alternatively, inhibition of harmful cannabinoid up-regulation could be an attractive alternative to global antagonism of the system.  Here we review current findings on the mechanisms of cannabinoid receptor regulation in disease and discuss their therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBsKnefQ2N4rVg90H21EOLACvtfcHk0lgdgtbPjflprQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtbzL&md5=ed47f14e41dc66de83422e2e545275ab</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.003491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.003491%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DL.%2BK.%26aulast%3DDevi%26aufirst%3DL.%2BA.%26atitle%3DThe%2520highs%2520and%2520lows%2520of%2520cannabinoid%2520receptor%2520expression%2520in%2520disease%253A%2520mechanisms%2520and%2520their%2520therapeutic%2520implications%26jtitle%3DPharmacological%2520Reviews.%26date%3D2011%26volume%3D63%26spage%3D461%26epage%3D470%26doi%3D10.1124%2Fpr.110.003491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Despres, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjostrom, L.</span></span> <span> </span><span class="NLM_article-title">Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">2121</span>– <span class="NLM_lpage">2134</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1056%2FNEJMoa044537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=16291982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ajtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2121-2134&author=J.+P.+Despresauthor=A.+Golayauthor=L.+Sjostrom&title=Effects+of+rimonabant+on+metabolic+risk+factors+in+overweight+patients+with+dyslipidemia&doi=10.1056%2FNEJMoa044537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia</span></div><div class="casAuthors">Despres, Jean-Pierre; Golay, Alain; Sjoestroem, Lars</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2121-2134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body wt. and improve cardiovascular risk factors in obese patients.  The Rimonabant in Obesity-Lipids (RIO-Lipids) study examd. the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are over-wt. or obese and have dyslipidemia.  We randomly assigned 1036 overweight or obese patients (body-mass index [the wt. in kilograms divided by the square of the height in meters], 27 to 40) with untreated dyslipidemia (triglyceride levels > 1.69 to 7.90 mmol per L, or a ratio of cholesterol to high-d. lipoprotein [HDL] cholesterol of > 4.5 among women and > 5 among men) to double-blinded therapy with either placebo or rimonabant at a dose of 5 mg or 20 mg daily for 12 mo in addn. to a hypocaloric diet.  The rates of completion of the study were 62.6%, 60.3%, and 63.9% in the placebo group, the group receiving 5 mg of rimonabant, and the group receiving 20 mg of rimonabant, resp.  The most frequent adverse events resulting in discontinuation of the drug were depression, anxiety, and nausea.  As compared with placebo, rimonabant at a dose of 20 mg was assocd. with a significant (P < 0.001) mean wt. loss (repeated-measures method, -6.7 ± 0.5 kg, and last-observation-carried-forward analyses, -5.4 ± 0.4 kg), redn. in waist circumference (repeated-measures method, -5.8 ± 0.5 cm, and last-observation-carried-forward analyses, -4.7 ± 0.5 cm), increase in HDL cholesterol (repeated-measures method, +10.0 ± 1.6%, and last-observation-carried-forward analyses, +8.1 ± 1.5%), and redn. in triglycerides (repeated-measures method, -13.0 ± 3.5%, and last-observation-carried-forward analyses, -12.4 ± 3.2%).  Rimonabant at a dose of 20 mg also resulted in an increase in plasma adiponectin levels (repeated-measures method, 57.7%, and last-observation-carried-forward analyses, 46.2%; P < 0.001), for a change that was partly independent of wt. loss alone.  Selective CB1-receptor blockade with rimonabant significantly reduces body wt. and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTxwQs4CYJmrVg90H21EOLACvtfcHk0lgdgtbPjflprQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ajtL3F&md5=6eff642cd942cd283ebff8606a469b96</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044537%26sid%3Dliteratum%253Aachs%26aulast%3DDespres%26aufirst%3DJ.%2BP.%26aulast%3DGolay%26aufirst%3DA.%26aulast%3DSjostrom%26aufirst%3DL.%26atitle%3DEffects%2520of%2520rimonabant%2520on%2520metabolic%2520risk%2520factors%2520in%2520overweight%2520patients%2520with%2520dyslipidemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2121%26epage%3D2134%26doi%3D10.1056%2FNEJMoa044537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gaal, L. F.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1660</span>– <span class="NLM_lpage">1672</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)69571-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2FS0140-6736%2806%2969571-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=17098084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtF2gurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1660-1672&author=A.+J.+Scheenauthor=N.+Finerauthor=P.+Hollanderauthor=M.+D.+Jensenauthor=L.+F.+Van+Gaal&title=Efficacy+and+tolerability+of+rimonabant+in+overweight+or+obese+patients+with+type+2+diabetes%3A+a+randomised+controlled+study&doi=10.1016%2FS0140-6736%2806%2969571-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study</span></div><div class="casAuthors">Scheen, Andre J.; Finer, Nick; Hollander, Priscilla; Jensen, Michael D.; Van Gaal, Luc F.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9548</span>),
    <span class="NLM_cas:pages">1660-1672</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients.  The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulfonylureas.  Of the 1047 overweight or obese type 2 diabetes patients (body-mass index 27-40 kg/m2) with a Hb A1c (HbA1c) concn. of 6.5-10.0% (mean 7.3% [SD 0.9] at baseline) already on metformin or sulfonylurea monotherapy were given a mild hypocaloric diet and advice for increased phys. activity, and randomly assigned placebo (n = 348), 5 mg/day rimonabant (360) or 20 mg/day rimonabant (339) for 1 yr.  Two individuals in the 5 mg/day group did not receive double-blind treatment and were thus not included in the final anal.  The primary endpoint was wt. change from baseline after 1 yr of treatment.  Analyses were done on an intention-to-treat basis.  This trial is registered at, no..  Of the 692 patients completed the 1 yr follow-up; nos. in each group after 1 yr were much the same.  Wt. loss was significantly greater after 1 yr in both rimonabant groups than in the placebo group (placebo: -1.4 kg [SD 3.6]; 5 mg/day: -2.3 kg [4.2], p = 0.01 vs placebo; 20 mg/day: -5.3 kg [5.2], p < 0.0001 vs. placebo).  Rimonabant was generally well tolerated.  The incidence of adverse events that led to discontinuation was slightly greater in the 20 mg/day rimonabant group, mainly due to depressed mood disorders, nausea, and dizziness.  These data indicate that 20 mg/day rimonabant, in combination with diet and exercise, can produce a clin. meaningful redn. in bodyweight and improve HbA1c and a no. of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulfonylureas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkVdBdGCd5xLVg90H21EOLACvtfcHk0liSZ5rQemc94A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtF2gurvF&md5=9ab3b7ecadce3114a4ea3dbab54c8a15</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969571-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969571-8%26sid%3Dliteratum%253Aachs%26aulast%3DScheen%26aufirst%3DA.%2BJ.%26aulast%3DFiner%26aufirst%3DN.%26aulast%3DHollander%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DM.%2BD.%26aulast%3DVan%2BGaal%26aufirst%3DL.%2BF.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520rimonabant%2520in%2520overweight%2520or%2520obese%2520patients%2520with%2520type%25202%2520diabetes%253A%2520a%2520randomised%2520controlled%2520study%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1660%26epage%3D1672%26doi%3D10.1016%2FS0140-6736%2806%2969571-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_label">4. </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, R. B.</span></span> <span> </span><span class="NLM_article-title">Rimonabant redux and strategies to improve the future outlook of CB<sub>1</sub> receptor neutral-antagonist/inverse-agonist therapies</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1038/oby.2011.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1038%2Foby.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=21475141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnjt1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1325-1334&author=S.+J.+Wardauthor=R.+B.+Raffa&title=Rimonabant+redux+and+strategies+to+improve+the+future+outlook+of+CB1+receptor+neutral-antagonist%2Finverse-agonist+therapies&doi=10.1038%2Foby.2011.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44.</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies</span></div><div class="casAuthors">Ward Sara Jane; Raffa Robert B</div><div class="citationInfo"><span class="NLM_cas:title">Obesity (Silver Spring, Md.)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1325-34</span>
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTq32LoUyLn5Ptos8R3JUhXfW6udTcc2ebt5VYxnOStWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnjt1OisQ%253D%253D&md5=17cafba99c5cc057e96c9bc3437f944a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Foby.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DS.%2BJ.%26aulast%3DRaffa%26aufirst%3DR.%2BB.%26atitle%3DRimonabant%2520redux%2520and%2520strategies%2520to%2520improve%2520the%2520future%2520outlook%2520of%2520CB1%2520receptor%2520neutral-antagonist%252Finverse-agonist%2520therapies%26jtitle%3DObesity%26date%3D2011%26volume%3D19%26spage%3D1325%26epage%3D1334%26doi%3D10.1038%2Foby.2011.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gaal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi-Sunyer, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Després, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheen, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the rimonabant in obesity (RIO) program</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">Suppl 2</span>),  <span class="NLM_fpage">S229</span>– <span class="NLM_lpage">S240</span>, <span class="refDoi"> DOI: 10.2337/dc08-s258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.2337%2Fdc08-s258" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=S229-S240&issue=Suppl+2&author=L.+Van+Gaalauthor=X.+Pi-Sunyerauthor=J.+P.+Despr%C3%A9sauthor=C.+McCarthyauthor=A.+Scheen&title=Efficacy+and+safety+of+rimonabant+for+improvement+of+multiple+cardiometabolic+risk+factors+in+overweight%2Fobese+patients%3A+pooled+1-year+data+from+the+rimonabant+in+obesity+%28RIO%29+program&doi=10.2337%2Fdc08-s258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.2337%2Fdc08-s258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc08-s258%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGaal%26aufirst%3DL.%26aulast%3DPi-Sunyer%26aufirst%3DX.%26aulast%3DDespr%25C3%25A9s%26aufirst%3DJ.%2BP.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DScheen%26aufirst%3DA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520rimonabant%2520for%2520improvement%2520of%2520multiple%2520cardiometabolic%2520risk%2520factors%2520in%2520overweight%252Fobese%2520patients%253A%2520pooled%25201-year%2520data%2520from%2520the%2520rimonabant%2520in%2520obesity%2520%2528RIO%2529%2520program%26jtitle%3DDiabetes%2520Care%26date%3D2008%26volume%3D31%26issue%3DSuppl%25202%26spage%3DS229%26epage%3DS240%26doi%3D10.2337%2Fdc08-s258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span> <span> </span><span class="NLM_article-title">The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1431</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01352.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1111%2Fj.1476-5381.2011.01352.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=21434882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Sjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=1423-1431&author=G.+Kunosauthor=J.+Tam&title=The+case+for+peripheral+CB1+receptor+blockade+in+the+treatment+of+visceral+obesity+and+its+cardiometabolic+complications&doi=10.1111%2Fj.1476-5381.2011.01352.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications</span></div><div class="casAuthors">Kunos, George; Tam, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1423-1431</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In this review, we consider the role of endocannabinoids and cannabinoid-1 (CB1) cannabinoid receptors in metabolic regulation and as mediators of the thrifty phenotype that underlies the metabolic syndrome.  We survey the actions of endocannabinoids on food intake and body wt., as well as on the metabolic complications of visceral obesity, including fatty liver, insulin resistance and dyslipidemias.  Special emphasis is placed on weighing the relative importance of CB1 receptors located in peripheral tissues vs. the central nervous system in mediating the metabolic effects of endocannabinoids.  Finally, we review recent observations that indicate that peripherally restricted CB1 receptor antagonists retain efficacy in reducing wt. and improving metabolic abnormalities in mouse models of obesity without causing behavioral effects predictive of neuropsychiatric side effects in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoostFcUOY1jbVg90H21EOLACvtfcHk0lhGZQOd9HQXcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Sjurk%253D&md5=69e13adbecefc8d113189de66f649bcd</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01352.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01352.x%26sid%3Dliteratum%253Aachs%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DTam%26aufirst%3DJ.%26atitle%3DThe%2520case%2520for%2520peripheral%2520CB1%2520receptor%2520blockade%2520in%2520the%2520treatment%2520of%2520visceral%2520obesity%2520and%2520its%2520cardiometabolic%2520complications%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D1423%26epage%3D1431%26doi%3D10.1111%2Fj.1476-5381.2011.01352.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nogueiras, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veyrat-Durebex, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchanek, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liposits, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reizes, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohner-Jeanrenaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschop, M. H.</span></span> <span> </span><span class="NLM_article-title">Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2977</span>– <span class="NLM_lpage">2991</span>, <span class="refDoi"> DOI: 10.2337/db08-0161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.2337%2Fdb08-0161" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2008&pages=2977-2991&author=R.+Nogueirasauthor=C.+Veyrat-Durebexauthor=P.+M.+Suchanekauthor=M.+Kleinauthor=J.+Tsch%C3%B6pauthor=C.+Caldwellauthor=S.+C.+Woodsauthor=G.+Wittmannauthor=M.+Watanabeauthor=Z.+Lipositsauthor=C.+Feketeauthor=O.+Reizesauthor=F.+Rohner-Jeanrenaudauthor=M.+H.+Tschop&title=Peripheral%2C+but+not+central%2C+CB1+antagonism+provides+food+intake-independent+metabolic+benefits+in+diet-induced+obese+rats&doi=10.2337%2Fdb08-0161"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.2337%2Fdb08-0161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb08-0161%26sid%3Dliteratum%253Aachs%26aulast%3DNogueiras%26aufirst%3DR.%26aulast%3DVeyrat-Durebex%26aufirst%3DC.%26aulast%3DSuchanek%26aufirst%3DP.%2BM.%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DJ.%26aulast%3DCaldwell%26aufirst%3DC.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DWittmann%26aufirst%3DG.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DLiposits%26aufirst%3DZ.%26aulast%3DFekete%26aufirst%3DC.%26aulast%3DReizes%26aufirst%3DO.%26aulast%3DRohner-Jeanrenaud%26aufirst%3DF.%26aulast%3DTschop%26aufirst%3DM.%2BH.%26atitle%3DPeripheral%252C%2520but%2520not%2520central%252C%2520CB1%2520antagonism%2520provides%2520food%2520intake-independent%2520metabolic%2520benefits%2520in%2520diet-induced%2520obese%2520rats%26jtitle%3DDiabetes%26date%3D2008%26volume%3D57%26spage%3D2977%26epage%3D2991%26doi%3D10.2337%2Fdb08-0161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gary-Bobo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elachouri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallas, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravinet-Trillou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruccioli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfersdorff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrié, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oury-Donat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maffrand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scatton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacheretz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Fur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensaid, M.</span></span> <span> </span><span class="NLM_article-title">Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1002/hep.21641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1002%2Fhep.21641" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=122-129&author=M.+Gary-Boboauthor=G.+Elachouriauthor=J.+F.+Gallasauthor=P.+Janiakauthor=P.+Mariniauthor=C.+Ravinet-Trillouauthor=M.+Chabbertauthor=N.+Cruccioliauthor=C.+Pfersdorffauthor=C.+Roqueauthor=M.+Arnoneauthor=T.+Crociauthor=P.+Soubri%C3%A9author=F.+Oury-Donatauthor=J.+P.+Maffrandauthor=B.+Scattonauthor=F.+Lacheretzauthor=G.+Le+Furauthor=J.+M.+Herbertauthor=M.+Bensaid&title=Rimonabant+reduces+obesity-associated+hepatic+steatosis+and+features+of+metabolic+syndrome+in+obese+Zucker+fa%2Ffa+rats&doi=10.1002%2Fhep.21641"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1002%2Fhep.21641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.21641%26sid%3Dliteratum%253Aachs%26aulast%3DGary-Bobo%26aufirst%3DM.%26aulast%3DElachouri%26aufirst%3DG.%26aulast%3DGallas%26aufirst%3DJ.%2BF.%26aulast%3DJaniak%26aufirst%3DP.%26aulast%3DMarini%26aufirst%3DP.%26aulast%3DRavinet-Trillou%26aufirst%3DC.%26aulast%3DChabbert%26aufirst%3DM.%26aulast%3DCruccioli%26aufirst%3DN.%26aulast%3DPfersdorff%26aufirst%3DC.%26aulast%3DRoque%26aufirst%3DC.%26aulast%3DArnone%26aufirst%3DM.%26aulast%3DCroci%26aufirst%3DT.%26aulast%3DSoubri%25C3%25A9%26aufirst%3DP.%26aulast%3DOury-Donat%26aufirst%3DF.%26aulast%3DMaffrand%26aufirst%3DJ.%2BP.%26aulast%3DScatton%26aufirst%3DB.%26aulast%3DLacheretz%26aufirst%3DF.%26aulast%3DLe%2BFur%26aufirst%3DG.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DBensaid%26aufirst%3DM.%26atitle%3DRimonabant%2520reduces%2520obesity-associated%2520hepatic%2520steatosis%2520and%2520features%2520of%2520metabolic%2520syndrome%2520in%2520obese%2520Zucker%2520fa%252Ffa%2520rats%26jtitle%3DHepatology%26date%3D2007%26volume%3D46%26spage%3D122%26epage%3D129%26doi%3D10.1002%2Fhep.21641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banasch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetze, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span> <span> </span><span class="NLM_article-title">Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis</span>. <i>Liver Int.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1155</span>, <span class="refDoi"> DOI: 10.1111/j.1478-3231.2007.01555.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1111%2Fj.1478-3231.2007.01555.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1152-1155&author=M.+Banaschauthor=O.+Goetzeauthor=W.+E.+Schmidtauthor=J.+J.+Meier&title=Rimonabant+as+a+novel+therapeutic+option+for+nonalcoholic+steatohepatitis&doi=10.1111%2Fj.1478-3231.2007.01555.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1478-3231.2007.01555.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1478-3231.2007.01555.x%26sid%3Dliteratum%253Aachs%26aulast%3DBanasch%26aufirst%3DM.%26aulast%3DGoetze%26aufirst%3DO.%26aulast%3DSchmidt%26aufirst%3DW.%2BE.%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26atitle%3DRimonabant%2520as%2520a%2520novel%2520therapeutic%2520option%2520for%2520nonalcoholic%2520steatohepatitis%26jtitle%3DLiver%2520Int.%26date%3D2007%26volume%3D27%26spage%3D1152%26epage%3D1155%26doi%3D10.1111%2Fj.1478-3231.2007.01555.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lecru, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desterke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassin-Delyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatziantoniou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devocelle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernochet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanovski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlicot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Said, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudreuil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpentier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giron-Michel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzarone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">François, H.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptor 1 is a major mediator of renal fibrosis</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1038/ki.2015.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1038%2Fki.2015.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=25760323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSjtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=72-84&author=L.+Lecruauthor=C.+Desterkeauthor=S.+Grassin-Delyleauthor=C.+Chatziantoniouauthor=S.+Vandermeerschauthor=A.+Devocelleauthor=A.+Vernochetauthor=N.+Ivanovskiauthor=C.+Ledentauthor=S.+Ferlicotauthor=M.+Daliaauthor=M.+Saidauthor=S.+Beaudreuilauthor=B.+Charpentierauthor=A.+Vazquezauthor=J.+Giron-Michelauthor=B.+Azzaroneauthor=A.+Durrbachauthor=H.+Fran%C3%A7ois&title=Cannabinoid+receptor+1+is+a+major+mediator+of+renal+fibrosis&doi=10.1038%2Fki.2015.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor 1 is a major mediator of renal fibrosis</span></div><div class="casAuthors">Lecru, Lola; Desterke, Christophe; Grassin-Delyle, Stanislas; Chatziantoniou, Christos; Vandermeersch, Sophie; Devocelle, Aurore; Vernochet, Amelia; Ivanovski, Ninoslav; Ledent, Catherine; Ferlicot, Sophie; Dalia, Meriem; Said, Myriam; Beaudreuil, Severine; Charpentier, Bernard; Vazquez, Aime; Giron-Michel, Julien; Azzarone, Bruno; Durrbach, Antoine; Francois, Helene</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-84</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic kidney disease, secondary to renal fibrogenesis, is a burden on public health.  There is a need to explore new therapeutic pathways to reduce renal fibrogenesis.  To study this, we used unilateral ureteral obstruction (UUO) in mice as an exptl. model of renal fibrosis and microarray anal. to compare gene expression in fibrotic and normal kidneys.  The cannabinoid receptor 1 (CB1) was among the most upregulated genes in mice, and the main endogenous CB1 ligand (2-arachidonoylglycerol) was significantly increased in the fibrotic kidney.  Interestingly, CB1 expression was highly increased in kidney biopsies of patients with IgA nephropathy, diabetes, and acute interstitial nephritis.  Both genetic and pharmacol. knockout of CB1 induced a profound redn. in renal fibrosis during UUO.  While CB2 is also involved in renal fibrogenesis, it did not potentiate the role of CB1.  CB1 expression was significantly increased in myofibroblasts, the main effector cells in renal fibrogenesis, upon TGF-β1 stimulation.  The decrease in renal fibrosis during CB1 blockade could be explained by a direct action on myofibroblasts.  CB1 blockade reduced collagen expression in vitro.  Rimonabant, a selective CB1 endocannabinoid receptor antagonist, modulated the macrophage infiltrate responsible for renal fibrosis in UUO through a decrease in monocyte chemoattractant protein-1 synthesis.  Thus, CB1 has a major role in the activation of myofibroblasts and may be a new target for treating chronic kidney disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWhp5nvemySbVg90H21EOLACvtfcHk0ljO2DFYYAhm1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSjtL3P&md5=461047bd7498216d7e43186aae72ede9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fki.2015.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2015.63%26sid%3Dliteratum%253Aachs%26aulast%3DLecru%26aufirst%3DL.%26aulast%3DDesterke%26aufirst%3DC.%26aulast%3DGrassin-Delyle%26aufirst%3DS.%26aulast%3DChatziantoniou%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DS.%26aulast%3DDevocelle%26aufirst%3DA.%26aulast%3DVernochet%26aufirst%3DA.%26aulast%3DIvanovski%26aufirst%3DN.%26aulast%3DLedent%26aufirst%3DC.%26aulast%3DFerlicot%26aufirst%3DS.%26aulast%3DDalia%26aufirst%3DM.%26aulast%3DSaid%26aufirst%3DM.%26aulast%3DBeaudreuil%26aufirst%3DS.%26aulast%3DCharpentier%26aufirst%3DB.%26aulast%3DVazquez%26aufirst%3DA.%26aulast%3DGiron-Michel%26aufirst%3DJ.%26aulast%3DAzzarone%26aufirst%3DB.%26aulast%3DDurrbach%26aufirst%3DA.%26aulast%3DFran%25C3%25A7ois%26aufirst%3DH.%26atitle%3DCannabinoid%2520receptor%25201%2520is%2520a%2520major%2520mediator%2520of%2520renal%2520fibrosis%26jtitle%3DKidney%2520Int.%26date%3D2015%26volume%3D88%26spage%3D72%26epage%3D84%26doi%3D10.1038%2Fki.2015.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span> <span> </span><span class="NLM_article-title">The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases</span>. <i>J. Basic Clin. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1515/jbcpp-2015-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1515%2Fjbcpp-2015-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=26280171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVGhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=267-276&author=J.+Tam&title=The+emerging+role+of+the+endocannabinoid+system+in+the+pathogenesis+and+treatment+of+kidney+diseases&doi=10.1515%2Fjbcpp-2015-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases</span></div><div class="casAuthors">Tam, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Basic and Clinical Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-276</span>CODEN:
                <span class="NLM_cas:coden">JBPPES</span>;
        ISSN:<span class="NLM_cas:issn">0792-6855</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">Endocannabinoids (eCBs) are endogenous lipid ligands that bind to cannabinoid receptors that also mediate the effects of marijuana.  The eCB system is comprised of eCBs, anandamide, and 2-arachidonoyl glycerol, their cannabinoid-1 and cannabinoid-2 receptors (CB1 and CB2, resp.), and the enzymes involved in their biosynthesis and degrdn.  It is present in both the central nervous system and peripheral organs including the kidney.  The current review focuses on the role of the eCB system in normal kidney function and various diseases, such as diabetes and obesity, that directly contributes to the development of renal pathologies.  Normally, activation of the CB1 receptor regulates renal vascular hemodynamics and stimulates the transport of ions and proteins in different nephron compartments.  In various mouse and rat models of obesity and type 1 and 2 diabetes mellitus, eCBs generated in various renal cells activate CB1 receptors and contribute to the development of oxidative stress, inflammation, and renal fibrosis.  These effects can be chronically ameliorated by CB1 receptor blockers.  In contrast, activation of the renal CB2 receptors reduces the deleterious effects of these chronic diseases.  Because the therapeutic potential of globally acting CB1 receptor antagonists in these conditions is limited due to their neuropsychiatric adverse effects, the recent development of peripherally restricted CB1 receptor antagonists may represent a novel pharmacol. approach in treating renal diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo92JUqI8HqVrVg90H21EOLACvtfcHk0li5oypjTpoU8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVGhsLo%253D&md5=0cbe88dda65b050466a06ec4565618e0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1515%2Fjbcpp-2015-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fjbcpp-2015-0055%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26atitle%3DThe%2520emerging%2520role%2520of%2520the%2520endocannabinoid%2520system%2520in%2520the%2520pathogenesis%2520and%2520treatment%2520of%2520kidney%2520diseases%26jtitle%3DJ.%2520Basic%2520Clin.%2520Physiol.%2520Pharmacol.%26date%3D2016%26volume%3D27%26spage%3D267%26epage%3D276%26doi%3D10.1515%2Fjbcpp-2015-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraghithy, S.</span></span> <span> </span><span class="NLM_article-title">The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system</span>. <i>Eur. J. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.ejim.2018.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.ejim.2018.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=29336868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKmtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=23-29&author=J.+Tamauthor=L.+Hindenauthor=A.+Droriauthor=S.+Udiauthor=S.+Azarauthor=S.+Baraghithy&title=The+therapeutic+potential+of+targeting+the+peripheral+endocannabinoid%2FCB1+receptor+system&doi=10.1016%2Fj.ejim.2018.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system</span></div><div class="casAuthors">Tam, Joseph; Hinden, Liad; Drori, Adi; Udi, Shiran; Azar, Shahar; Baraghithy, Saja</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Internal Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-29</span>CODEN:
                <span class="NLM_cas:coden">EJIMEJ</span>;
        ISSN:<span class="NLM_cas:issn">0953-6205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Endocannabinoids (eCBs) are internal lipid mediators recognized by the cannabinoid-1 and -2 receptors (CB1R and CB2R, resp.), which also mediate the different physiol. effects of marijuana.  The endocannabinoid system, consisting of eCBs, their receptors, and the enzymes involved in their biosynthesis and degrdn., is present in a vast no. of peripheral organs.  In this review we describe the role of the eCB/CB1R system in modulating the metab. in several peripheral organs.  We assess how eCBs, via activating the CB1R, contribute to obesity and regulate food intake.  In addn., we describe their roles in modulating liver and kidney functions, as well as bone remodeling and mass.  Special importance is given to emphasizing the efficacy of the recently developed peripherally restricted CB1R antagonists, which were pre-clin. tested in the management of energy homeostasis, and in ameliorating both obesity- and diabetes-induced metabolic complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8f6fjglK3bVg90H21EOLACvtfcHk0li5oypjTpoU8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKmtbY%253D&md5=e61e4a99661c7a49ded1ba82263c1f83</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejim.2018.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejim.2018.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DHinden%26aufirst%3DL.%26aulast%3DDrori%26aufirst%3DA.%26aulast%3DUdi%26aufirst%3DS.%26aulast%3DAzar%26aufirst%3DS.%26aulast%3DBaraghithy%26aufirst%3DS.%26atitle%3DThe%2520therapeutic%2520potential%2520of%2520targeting%2520the%2520peripheral%2520endocannabinoid%252FCB1%2520receptor%2520system%26jtitle%3DEur.%2520J.%2520Intern.%2520Med.%26date%3D2018%26volume%3D49%26spage%3D23%26epage%3D29%26doi%3D10.1016%2Fj.ejim.2018.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regnell, S. E.</span></span> <span> </span><span class="NLM_article-title">The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1111/bcp.12102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1111%2Fbcp.12102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=23452341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFym" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=21-30&author=M.+E.+Cooperauthor=S.+E.+Regnell&title=The+hepatic+cannabinoid+1+receptor+as+a+modulator+of+hepatic+energy+state+and+food+intake&doi=10.1111%2Fbcp.12102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake</span></div><div class="casAuthors">Cooper, Martin E.; Regnell, Simon E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The cannabinoid 1 receptor (CB1R) has a well-established role in appetite regulation.  Central CB1R antagonists, notably rimonabant, induced wt. loss and improved the metabolic profile in obese individuals, but were discontinued due to psychiatric side-effects.  The CB1R is also expressed peripherally, where its effects include promotion of liver fat accumulation, which consumes ATP.  Type 2 diabetes in obese subjects is linked to excess liver fat, while there is a neg. correlation between hepatic ATP content and insulin resistance.  A decreased hepatic ATP/AMP ratio increases food intake by signals via the vagus nerve to the brain.  The hepatic cannabinoid system is highly upregulated in obesity, and the effects of hepatic CB1R activation include increased activity of lipogenic and gluconeogenic transcription factors.  Thus, blockade of hepatic CB1Rs could contribute significantly to the wt.-reducing and insulin-sensitizing effects of CB1R antagonists.  Addnl., upregulation of the hepatic CB1R may contribute to chronic liver inflammation, fibrosis and cirrhosis from causes including obesity, alcoholism and viral hepatitis.  Peripheral CB1R antagonists induce wt. loss and metabolic improvements in obese rodents; however, as there is evidence that hepatic CB1Rs are predominately intracellular, due to high intrinsic clearance, many drugs may not effectively block these receptors and therefore have limited efficacy.  Hepatoselective CB1R antagonists may be effective at reducing hepatic steatosis, insulin resistance and bodyweight in obese, diabetic patients, with far fewer side-effects than first-generation CB1R antagonists.  Addnl., such compds. may be effective in treating inflammatory liver disease, such as non-alc. steatohepatitis, reducing the likelihood of disease progression to cirrhosis or cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIndQ0Bt4fG7Vg90H21EOLACvtfcHk0likHFiZWFv9-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFym&md5=b2566fd49f273ea2243d64b90b7ba633</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12102%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DM.%2BE.%26aulast%3DRegnell%26aufirst%3DS.%2BE.%26atitle%3DThe%2520hepatic%2520cannabinoid%25201%2520receptor%2520as%2520a%2520modulator%2520of%2520hepatic%2520energy%2520state%2520and%2520food%2520intake%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2014%26volume%3D77%26spage%3D21%26epage%3D30%26doi%3D10.1111%2Fbcp.12102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hortala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi-Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadoun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finance, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span> <span> </span><span class="NLM_article-title">Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4573</span>– <span class="NLM_lpage">4577</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.bmcl.2010.06.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4573-4577&author=L.+Hortalaauthor=M.+Rinaldi-Carmonaauthor=C.+Congyauthor=L.+Bouluauthor=F.+Sadounauthor=G.+Fabreauthor=O.+Financeauthor=F.+Barth&title=Rational+design+of+a+novel+peripherally-restricted%2C+orally+active+CB1+cannabinoid+antagonist+containing+a+2%2C3-diarylpyrrole+motif&doi=10.1016%2Fj.bmcl.2010.06.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DHortala%26aufirst%3DL.%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DBoulu%26aufirst%3DL.%26aulast%3DSadoun%26aufirst%3DF.%26aulast%3DFabre%26aufirst%3DG.%26aulast%3DFinance%26aufirst%3DO.%26aulast%3DBarth%26aufirst%3DF.%26atitle%3DRational%2520design%2520of%2520a%2520novel%2520peripherally-restricted%252C%2520orally%2520active%2520CB1%2520cannabinoid%2520antagonist%2520containing%2520a%25202%252C3-diarylpyrrole%2520motif%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4573%26epage%3D4577%26doi%3D10.1016%2Fj.bmcl.2010.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2820</span>– <span class="NLM_lpage">2834</span>, <span class="refDoi"> DOI: 10.1021/jm201731z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201731z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVGju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2820-2834&author=A.+Fulpauthor=K.+Bortoffauthor=H.+Seltzmanauthor=Y.+Zhangauthor=J.+Mathewsauthor=R.+Snyderauthor=T.+Fennellauthor=R.+Maitra&title=Design+and+synthesis+of+cannabinoid+receptor+1+antagonists+for+peripheral+selectivity&doi=10.1021%2Fjm201731z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Cannabinoid Receptor 1 Antagonists for Peripheral Selectivity</span></div><div class="casAuthors">Fulp, Alan; Bortoff, Katherine; Seltzman, Herbert; Zhang, Yanan; Mathews, James; Snyder, Rodney; Fennell, Tim; Maitra, Rangan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2820-2834</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonists of cannabinoid receptor 1 (CB1) have potential for the treatment of several diseases such as obesity, liver disease, and diabetes.  Recently, development of several CB1 antagonists was halted because of adverse central nervous system (CNS) related side effects obsd. with rimonabant, the first clin. approved CB1 inverse agonist.  However, recent studies indicate that regulation of peripherally expressed CB1 with CNS-sparing compds. is a viable strategy to treat several important disorders.  The reported efforts aimed at rationally designing peripherally restricted CB1 antagonists have resulted in compds. that have limited blood-brain barrier (BBB) permeability and CNS exposure in preclin. in vitro and in vivo models.  Typically, compds. with high topol. polar surface areas (TPSAs) do not cross the BBB passively.  Compds. with TPSAs higher than that for rimonabant (rimonabant TPSA = 50) and excellent functional activity with limited CNS penetration were identified.  These compds. will serve as templates for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxIk0YtV78UbVg90H21EOLACvtfcHk0likHFiZWFv9-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVGju74%253D&md5=95a56654ab10a8b238ee16949fc10e18</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1021%2Fjm201731z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201731z%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMathews%26aufirst%3DJ.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520cannabinoid%2520receptor%25201%2520antagonists%2520for%2520peripheral%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2820%26epage%3D2834%26doi%3D10.1021%2Fjm201731z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiethe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Pyrazole antagonists of the CB1 receptor with reduced brain penetration</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1063</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.01.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.bmc.2016.01.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=26827137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1063-1070&author=A.+Fulpauthor=Y.+Zhangauthor=K.+Bortoffauthor=H.+Seltzmanauthor=R.+Snyderauthor=R.+Wietheauthor=G.+Amatoauthor=R.+Maitra&title=Pyrazole+antagonists+of+the+CB1+receptor+with+reduced+brain+penetration&doi=10.1016%2Fj.bmc.2016.01.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole antagonists of the CB1 receptor with reduced brain penetration</span></div><div class="casAuthors">Fulp, Alan; Zhang, Yanan; Bortoff, Katherine; Seltzman, Herbert; Snyder, Rodney; Wiethe, Robert; Amato, George; Maitra, Rangan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1063-1070</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Type 1 cannabinoid receptor (CB1) antagonists might be useful for treating obesity, liver disease, metabolic syndrome, and dyslipidemias.  Unfortunately, inhibition of CB1 in the central nervous system (CNS) produces adverse effects, including depression, anxiety and suicidal ideation in some patients, which led to withdrawal of the pyrazole inverse agonist rimonabant (SR141716A) from European markets.  Efforts are underway to produce peripherally selective CB1 antagonists to circumvent CNS-assocd. adverse effects.  In this study, novel analogs of rimonabant (1) were explored in which the 1-aminopiperidine group was switched to a 4-aminopiperidine, attached at the 4-amino position (5).  The piperidine nitrogen was functionalized with carbamates, amides, and sulfonamides, providing compds. that are potent inverse agonists of hCB1 with good selectivity for hCB1 over hCB2.  Select compds. were further studied using in vitro models of brain penetration, oral absorption and metabolic stability.  Several compds. were identified with predicted minimal brain penetration and good metabolic stability.  In vivo pharmacokinetic testing revealed that inverse agonist I is orally bioavailable and has vastly reduced brain penetration compared to rimonabant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQF0R_5pD887Vg90H21EOLACvtfcHk0lg05OGzPLdzJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyltL8%253D&md5=6cf6e50b077db6b1767f2397e3a5e017</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.01.033%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DWiethe%26aufirst%3DR.%26aulast%3DAmato%26aufirst%3DG.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DPyrazole%2520antagonists%2520of%2520the%2520CB1%2520receptor%2520with%2520reduced%2520brain%2520penetration%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1063%26epage%3D1070%26doi%3D10.1016%2Fj.bmc.2016.01.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marusich, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Peripherally selective diphenyl purine antagonist of the CB1 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8066</span>– <span class="NLM_lpage">8072</span>, <span class="refDoi"> DOI: 10.1021/jm401129n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401129n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8066-8072&author=A.+Fulpauthor=K.+Bortoffauthor=Y.+Zhangauthor=R.+Snyderauthor=T.+Fennellauthor=J.+A.+Marusichauthor=J.+L.+Wileyauthor=H.+Seltzmanauthor=R.+Maitra&title=Peripherally+selective+diphenyl+purine+antagonist+of+the+CB1+receptor&doi=10.1021%2Fjm401129n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1021%2Fjm401129n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401129n%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMarusich%26aufirst%3DJ.%2BA.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DPeripherally%2520selective%2520diphenyl%2520purine%2520antagonist%2520of%2520the%2520CB1%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8066%26epage%3D8072%26doi%3D10.1021%2Fjm401129n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10022</span>– <span class="NLM_lpage">10032</span>, <span class="refDoi"> DOI: 10.1021/jm301181r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301181r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOru7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10022-10032&author=A.+Fulpauthor=K.+Bortoffauthor=Y.+Zhangauthor=H.+Seltzmanauthor=J.+Mathewsauthor=R.+Snyderauthor=T.+Fennellauthor=R.+Maitra&title=Diphenyl+purine+derivatives+as+peripherally+selective+cannabinoid+receptor+1+antagonists&doi=10.1021%2Fjm301181r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11eR"><div class="casContent"><span class="casTitleNuber">11e</span><div class="casTitle"><span class="NLM_cas:atitle">Diphenyl Purine Derivatives as Peripherally Selective Cannabinoid Receptor 1 Antagonists</span></div><div class="casAuthors">Fulp, Alan; Bortoff, Katherine; Zhang, Yanan; Seltzman, Herbert; Mathews, James; Snyder, Rodney; Fennell, Tim; Maitra, Rangan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10022-10032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) antagonists are potentially useful for the treatment of several diseases.  However, clin. development of several CB1 antagonists was halted due to central nervous system (CNS)-related side effects including depression and suicidal ideation in some users.  Recently, studies have indicated that selective regulation of CB1 receptors in the periphery is a viable strategy for treating several important disorders.  Past efforts to develop peripherally selective antagonists of CB1 have largely targeted rimonabant, an inverse agonist of CB1.  Reported here are our efforts toward developing a peripherally selective CB1 antagonist based on the otenabant scaffold.  Even though otenabant penetrates the CNS, it is unique among CB1 antagonists that have been clin. tested because it has properties that are normally assocd. with peripherally selective compds.  Our efforts have resulted in an orally absorbed compd. that is a potent and selective CB1 antagonist with limited penetration into the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7vr0lo9pHgrVg90H21EOLACvtfcHk0lg05OGzPLdzJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOru7bK&md5=d844f7199d7689707b6e633076b86436</span></div><a href="/servlet/linkout?suffix=cit11e&amp;dbid=16384&amp;doi=10.1021%2Fjm301181r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301181r%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DMathews%26aufirst%3DJ.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DDiphenyl%2520purine%2520derivatives%2520as%2520peripherally%2520selective%2520cannabinoid%2520receptor%25201%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10022%26epage%3D10032%26doi%3D10.1021%2Fjm301181r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4 ((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl) ethynyl)thiophene-2-yl)-1H-pyrazole-3- carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in Diet-Induced Obese mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9920</span>– <span class="NLM_lpage">9933</span>, <span class="refDoi"> DOI: 10.1021/jm401158e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401158e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9920-9933&author=C.+Changauthor=C.+Wuauthor=J.+Songauthor=M.+Chouauthor=Y.+Wongauthor=Y.+Linauthor=T.+Yehauthor=A.+A.+Sadaniauthor=M.+Ouauthor=K.+Chenauthor=P.+Chenauthor=P.+C.+Kuoauthor=S.+L.+Tsengauthor=K.+Changauthor=S.+Tsengauthor=Y.+Chaoauthor=M.+Hungauthor=K.+Shia&title=Discovery+of+1-%282%2C4-dichlorophenyl%29-N-%28piperidin-1-yl%29-4+%28%28pyrrolidine-1-sulfonamido%29methyl%29-5-%285-%28%284-%28trifluoromethyl%29phenyl%29+ethynyl%29thiophene-2-yl%29-1H-pyrazole-3-+carboxamide+as+a+novel+peripherally+restricted+cannabinoid-1+receptor+antagonist+with+significant+weight-loss+efficacy+in+Diet-Induced+Obese+mice&doi=10.1021%2Fjm401158e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11f&amp;dbid=16384&amp;doi=10.1021%2Fjm401158e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401158e%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYeh%26aufirst%3DT.%26aulast%3DSadani%26aufirst%3DA.%2BA.%26aulast%3DOu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DKuo%26aufirst%3DP.%2BC.%26aulast%3DTseng%26aufirst%3DS.%2BL.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DS.%26aulast%3DChao%26aufirst%3DY.%26aulast%3DHung%26aufirst%3DM.%26aulast%3DShia%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25201-%25282%252C4-dichlorophenyl%2529-N-%2528piperidin-1-yl%2529-4%2520%2528%2528pyrrolidine-1-sulfonamido%2529methyl%2529-5-%25285-%2528%25284-%2528trifluoromethyl%2529phenyl%2529%2520ethynyl%2529thiophene-2-yl%2529-1H-pyrazole-3-%2520carboxamide%2520as%2520a%2520novel%2520peripherally%2520restricted%2520cannabinoid-1%2520receptor%2520antagonist%2520with%2520significant%2520weight-loss%2520efficacy%2520in%2520Diet-Induced%2520Obese%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9920%26epage%3D9933%26doi%3D10.1021%2Fjm401158e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdelyi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel, non-brain- penetrant, hybrid cannabinoid CB1R inverse agonist/inducible nitric oxide synthase (iNOS) inhibitors for the treatment of liver fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">–1141</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1126-%E2%80%931141&author=M.+R.+Iyerauthor=R.+Cinarauthor=A.+Katzauthor=M.+Gaoauthor=K.+Erdelyiauthor=T.+Jourdanauthor=N.+J.+Coffeyauthor=P.+Pacherauthor=G.+Kunos&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel%2C+non-brain-+penetrant%2C+hybrid+cannabinoid+CB1R+inverse+agonist%2Finducible+nitric+oxide+synthase+%28iNOS%29+inhibitors+for+the+treatment+of+liver+fibrosis&doi=10.1021%2Facs.jmedchem.6b01504"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01504%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DKatz%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DErdelyi%26aufirst%3DK.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DCoffey%26aufirst%3DN.%2BJ.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%252C%2520non-brain-%2520penetrant%252C%2520hybrid%2520cannabinoid%2520CB1R%2520inverse%2520agonist%252Finducible%2520nitric%2520oxide%2520synthase%2520%2528iNOS%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520liver%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1126%26epage%3D%25E2%2580%25931141%26doi%3D10.1021%2Facs.jmedchem.6b01504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyás, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnäs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noerregaard, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elling, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span> <span> </span><span class="NLM_article-title">Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1002/syn.21721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1002%2Fsyn.21721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=24293119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGgsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2014&pages=89-97&author=A.+Takanoauthor=B.+Guly%C3%A1sauthor=K.+Varn%C3%A4sauthor=P.+B.+Littleauthor=P.+K.+Noerregaardauthor=N.+O.+Jensenauthor=C.+E.+Ellingauthor=C.+Halldin&title=Low+brain+CB1+receptor+occupancy+by+a+second+generation+CB1+receptor+antagonist+TM38837+in+comparison+with+rimonabant+in+nonhuman+primates%3A+a+PET+study&doi=10.1002%2Fsyn.21721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: A PET study</span></div><div class="casAuthors">Takano, Akihiro; Gulyas, Balazs; Varnaes, Katarina; Little, Paul Brian; Noerregaard, Pia K.; Jensen, Niels Ole; Elling, Christian E.; Halldin, Christer</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">89-97</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Both central and peripheral cannabinoid receptor type 1 (CB1R) have been considered to be among the key targets for obesity treatment.  First generation CB1R antagonists/inverse agonists such as rimonabant and taranabant exhibited severe CNS side effects such as anxiety and depression, which are considered to be related to the compds.' ability to access central CB1R.  Recently, several compds. have been developed as second generation antagonists with a profile of restriction to peripheral CB1R.  We evaluated the distribution of TM38837, a second generation CB1R antagonist, using brain and whole body PET in three cynomolgus monkeys, and established the relationship between CB1R occupancy and dose/plasma concn. of TM38837 in comparison with rimonabant.  A brain PET study was performed using [11C]MePPEP, a PET radioligand for CB1R, to evaluate the brain CB1R occupancy of TM38837 at various plasma concns. in comparison with rimonabant at known efficacious plasma concns.  A whole body PET study was performed to investigate the change of peripheral distribution of [11C]MePPEP by TM38837 administration, which indirectly estd. the effects to the peripheral CB1R by TM38837.  CB1R occupancy by both TM38837 and rimonabant increased in a dose/plasma concn.-dependent manner.  However, in vivo affinity by plasma level was more than 100 times lower for TM38837.  Peripherally, [11C]MePPEP accumulation decreased in gall bladder and brown adipose tissue by TM38837 administration.  TM38837 showed rather lower CB1R occupancy than rimonabant at the expected therapeutic plasma level, which is expected to reduce CNS side effects in clin. situations.  Further clin. development of TM38837 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWO09xJ4aW2LVg90H21EOLACvtfcHk0lgeioT_2649ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGgsb7N&md5=126673597feb5f59338815bc5ac9ace4</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1002%2Fsyn.21721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.21721%26sid%3Dliteratum%253Aachs%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DGuly%25C3%25A1s%26aufirst%3DB.%26aulast%3DVarn%25C3%25A4s%26aufirst%3DK.%26aulast%3DLittle%26aufirst%3DP.%2BB.%26aulast%3DNoerregaard%26aufirst%3DP.%2BK.%26aulast%3DJensen%26aufirst%3DN.%2BO.%26aulast%3DElling%26aufirst%3DC.%2BE.%26aulast%3DHalldin%26aufirst%3DC.%26atitle%3DLow%2520brain%2520CB1%2520receptor%2520occupancy%2520by%2520a%2520second%2520generation%2520CB1%2520receptor%2520antagonist%2520TM38837%2520in%2520comparison%2520with%2520rimonabant%2520in%2520nonhuman%2520primates%253A%2520a%2520PET%2520study%26jtitle%3DSynapse%26date%3D2014%26volume%3D68%26spage%3D89%26epage%3D97%26doi%3D10.1002%2Fsyn.21721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpers, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kam, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinloog, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elling, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gerven, J. M.</span></span> <span> </span><span class="NLM_article-title">Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">857</span>, <span class="refDoi"> DOI: 10.1111/bcp.12141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1111%2Fbcp.12141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=23601084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVamtLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=846-857&author=L.+E.+Klumpersauthor=M.+Fridbergauthor=M.+L.+de+Kamauthor=P.+B.+Littleauthor=N.+O.+Jensenauthor=H.+D.+Kleinloogauthor=C.+E.+Ellingauthor=J.+M.+van+Gerven&title=Peripheral+selectivity+of+the+novel+cannabinoid+receptor+antagonist+TM38837+in+healthy+subjects&doi=10.1111%2Fbcp.12141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects</span></div><div class="casAuthors">Klumpers, Linda E.; Fridberg, Marianne; de Kam, Marieke L.; Little, Paul B.; Jensen, Niels Ole; Kleinloog, Hendrik D.; Elling, Christian E.; van Gerven, Joop M. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">846-857</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: Cannabinoid receptor type 1 (CB1) antagonists show central side effects, whereas beneficial effects are most likely peripherally mediated.  In this study, the peripherally selective CB1 antagonist TM38837 was studied in humans.  Methods : This was a double-blind, randomized, placebo-controlled, crossover study.  On occasions 1-4, 24 healthy subjects received 5 × 4 mg THC with TM38837 100 mg, 500 mg or placebo, or placebos only.  During occasion 5, subjects received placebo TM38837 + THC with rimonabant 60 mg or placebo in parallel groups.  Blood collections and pharmacodynamic (PD) effects were assessed frequently.  Pharmacokinetics (PK) and PD were quantified using population PK-PD modeling.  Results : The TM38837 plasma concn. profile was relatively flat compared with rimonabant.  TM38837 showed an estd. terminal half-life of 771 h.  THC induced effects on VAS feeling high, body sway and heart rate were partly antagonized by rimonabant 60 mg [-26.70% [90% confidence interval (CI) -40.9, -12.6%]; -7.10%, (90%CI -18.1, 5.3%); -7.30%, (90% CI -11.5%, -3.0%) resp.] and TM38837 500 mg [-22.10% (90% CI -34.9, -9.4%); -12.20% (90% CI -21.6%, -1.7%); -8.90% (90% CI -12.8%, -5.1%) resp.].  TM38837 100 mg had no measurable feeling high or body sway effects and limited heart rate effects.  Conclusions : Rimonabant showed larger effects than TM38837, but the heart rate effects were similar.  TM38837 100 mg had no impact on CNS effects, suggesting that this dose does not penetrate the brain.  This TM38837 dose is predicted to be at least equipotent to rimonabant with regard to metabolic disorders in rodent models.  These results provide support for further development of TM38837 as a peripherally selective CB1 antagonist for indications such as metabolic disorders, with a reduced propensity for psychiatric side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrqWgvk1WZZbVg90H21EOLACvtfcHk0lgEZPxQtrAyOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVamtLfJ&md5=e0bec67afbb53e471e53fc803c9ab3d4</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12141%26sid%3Dliteratum%253Aachs%26aulast%3DKlumpers%26aufirst%3DL.%2BE.%26aulast%3DFridberg%26aufirst%3DM.%26aulast%3Dde%2BKam%26aufirst%3DM.%2BL.%26aulast%3DLittle%26aufirst%3DP.%2BB.%26aulast%3DJensen%26aufirst%3DN.%2BO.%26aulast%3DKleinloog%26aufirst%3DH.%2BD.%26aulast%3DElling%26aufirst%3DC.%2BE.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%2BM.%26atitle%3DPeripheral%2520selectivity%2520of%2520the%2520novel%2520cannabinoid%2520receptor%2520antagonist%2520TM38837%2520in%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D846%26epage%3D857%26doi%3D10.1111%2Fbcp.12141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chorvat, R.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berbaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seriacki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, J. F.</span></span> <span> </span><span class="NLM_article-title">JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6173</span>– <span class="NLM_lpage">6180</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.bmcl.2012.08.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6173-6180&author=R.%0AJ.+Chorvatauthor=J.+Berbaumauthor=K.+Seriackiauthor=J.+F.+McElroy&title=JD-5006+and+JD-5037%3A+peripherally+restricted+%28PR%29+cannabinoid-1+receptor+blockers+related+to+SLV-319+%28Ibipinabant%29+as+metabolic+disorder+therapeutics+devoid+of+CNS+liabilities&doi=10.1016%2Fj.bmcl.2012.08.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DBerbaum%26aufirst%3DJ.%26aulast%3DSeriacki%26aufirst%3DK.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26atitle%3DJD-5006%2520and%2520JD-5037%253A%2520peripherally%2520restricted%2520%2528PR%2529%2520cannabinoid-1%2520receptor%2520blockers%2520related%2520to%2520SLV-319%2520%2528Ibipinabant%2529%2520as%2520metabolic%2520disorder%2520therapeutics%2520devoid%2520of%2520CNS%2520liabilities%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6173%26epage%3D6180%26doi%3D10.1016%2Fj.bmcl.2012.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chorvat, R. J.</span></span> <span> </span><span class="NLM_article-title">Peripherally restricted CB1 receptor blockers</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4751</span>– <span class="NLM_lpage">4760</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.bmcl.2013.06.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=23902803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Sjtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4751-4760&author=R.+J.+Chorvat&title=Peripherally+restricted+CB1+receptor+blockers&doi=10.1016%2Fj.bmcl.2013.06.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Peripherally restricted CB1 receptor blockers</span></div><div class="casAuthors">Chorvat, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4751-4760</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antagonists (inverse agonists) of the cannabinoid-1 (CB1) receptor showed promise as new therapies for controlling obesity and related metabolic function/liver disease.  These agents, representing diverse chem. series, shared the property of brain penetration due to the initial belief that therapeutic benefit was mainly based on brain receptor interaction.  However, undesirable CNS-based side effects of the only marketed agent in this class, rimonabant, led to its removal, and termination of the development of other clin. candidates soon followed.  Re-evaluation of this approach has focused on neutral or peripherally restricted (PR) antagonists.  Supporting these strategies, pharmacol. evidence indicates most if not all of the properties of globally acting agents may be captured by mols. with little brain presence.  Methodol. that can be used to eliminate BBB penetration and the means (in vitro assays, tissue distribution and receptor occupancy detns., behavioral paradigms) to identify potential agents with little brain presence is discussed.  Focus will be on the pharmacol. supporting the contention that reported agents are truly peripherally restricted.  Notable examples of these types of compds. are: TM38837 (structure not disclosed); AM6545 (8); JD5037 (15b); RTI-12 (19).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVjNs61m-GtLVg90H21EOLACvtfcHk0lhRe4HC8RLXww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Sjtb3O&md5=b124aabace6d82a2fd23fa75681786d4</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.066%26sid%3Dliteratum%253Aachs%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26atitle%3DPeripherally%2520restricted%2520CB1%2520receptor%2520blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4751%26epage%3D4760%26doi%3D10.1016%2Fj.bmcl.2013.06.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <i>PS CB1 Receptor Inverse Agonist
Program</i>; <span class="NLM_publisher-name">Jenrin Discovery</span>, <span class="NLM_year">2018</span>; <a href="http://www.jenrindiscovery.com/pscb1.html" class="extLink">http://www.jenrindiscovery.com/pscb1.html</a> (accessed Oct 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+PS+CB1+Receptor+Inverse+Agonist%0AProgram%3B+Jenrin+Discovery%2C+2018%3B+http%3A%2F%2Fwww.jenrindiscovery.com%2Fpscb1.html+%28accessed+Oct+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPS%2520CB1%2520Receptor%2520Inverse%2520Agonist%250AProgram%26pub%3DJenrin%2520Discovery%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <i>Jenrin Discovery’s IND
application for its peripherally restricted cannabinoid-1 receptor
inverse agonist NASH compound was cleared by the FDA to begin phase
1 clinical trials</i>; <span class="NLM_publisher-name">Jenrin Discoery</span>, December 17, <span class="NLM_year">2017</span>; <a href="https://www.businesswire.com/news/home/20171214005128/en/" class="extLink">https://www.businesswire.com/news/home/20171214005128/en/</a> (accessed Oct 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Jenrin+Discovery%E2%80%99s+IND%0Aapplication+for+its+peripherally+restricted+cannabinoid-1+receptor%0Ainverse+agonist+NASH+compound+was+cleared+by+the+FDA+to+begin+phase%0A1+clinical+trials%3B+Jenrin+Discoery%2C+December+17%2C+2017%3B+https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20171214005128%2Fen%2F+%28accessed+Oct+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DJenrin%2520Discovery%25E2%2580%2599s%2520IND%250Aapplication%2520for%2520its%2520peripherally%2520restricted%2520cannabinoid-1%2520receptor%250Ainverse%2520agonist%2520NASH%2520compound%2520was%2520cleared%2520by%2520the%2520FDA%2520to%2520begin%2520phase%250A1%2520clinical%2520trials%26pub%3DJenrin%2520Discoery%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Testa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cytochrome P-450s and their mechanism of action</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.3109/03602538109011082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.3109%2F03602538109011082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=7028434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADyaL3MXkslGru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1981&pages=1-117&author=B.+Testaauthor=P.+Jenner&title=Inhibitors+of+cytochrome+P-450s+and+their+mechanism+of+action&doi=10.3109%2F03602538109011082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cytochrome P-450s and their mechanism of action</span></div><div class="casAuthors">Testa, Bernard; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-117</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    </div><div class="casAbstract">A review with 236 refs., of inhibitors of cytochrome P 450-dependent monooxygenase systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeDqU6i1SMN7Vg90H21EOLACvtfcHk0lhRe4HC8RLXww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXkslGru7g%253D&md5=8b08f336435114f8480cf96cadd0805a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3109%2F03602538109011082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602538109011082%26sid%3Dliteratum%253Aachs%26aulast%3DTesta%26aufirst%3DB.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DInhibitors%2520of%2520cytochrome%2520P-450s%2520and%2520their%2520mechanism%2520of%2520action%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1981%26volume%3D12%26spage%3D1%26epage%3D117%26doi%3D10.3109%2F03602538109011082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span>The intermediates <b>2</b>, <b>13</b>, <b>20</b>, and <b>24</b> were prepared according to
the procedures described
in<span class="NLM_contrib-group"><span class="NLM_string-name">Macielag, M. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Chemically Modified Quinoline and Quinolone Derivatives Useful as CB-1 Inverse Agonists</span>. WO Patent <span class="NLM_patent">WO 2017034877</span>, <span class="NLM_year">2017</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+J.+Macielag&title=Preparation+of+Chemically+Modified+Quinoline+and+Quinolone+Derivatives+Useful+as+CB-1+Inverse+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMacielag%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%2520Chemically%2520Modified%2520Quinoline%2520and%2520Quinolone%2520Derivatives%2520Useful%2520as%2520CB-1%2520Inverse%2520Agonists%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span> <span> </span><span class="NLM_article-title">Blood–brain barrier permeability considerations for CNS-targeted compound library design</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2008.03.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.cbpa.2008.03.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=18435937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1ers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=318-323&author=S.+A.+Hitchcock&title=Blood%E2%80%93brain+barrier+permeability+considerations+for+CNS-targeted+compound+library+design&doi=10.1016%2Fj.cbpa.2008.03.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-brain barrier permeability considerations for CNS-targeted compound library design</span></div><div class="casAuthors">Hitchcock, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-323</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A further refinement of the concept of drug-likeness is required for compd. libraries intended for central nervous system (CNS) targets to account for the limitations imposed by blood-brain barrier permeability.  This review describes criteria and processes that can be applied in the de novo design and assembly of libraries to increase the odds of compds. residing within CNS-accessible chem. space.  A no. of published examples where CNS activity and/or penetration characteristics have been a factor in library design are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorhMoAmlVhlrVg90H21EOLACvtfcHk0lhm6MVD7ngsiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1ers74%253D&md5=7b6962e237bc80c1d44053b54c5f3f40</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2008.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2008.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26atitle%3DBlood%25E2%2580%2593brain%2520barrier%2520permeability%2520considerations%2520for%2520CNS-targeted%2520compound%2520library%2520design%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D12%26spage%3D318%26epage%3D323%26doi%3D10.1016%2Fj.cbpa.2008.03.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockman, R. P.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of blood-brain barrier permeation</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">961</span>– <span class="NLM_lpage">971</span>, <span class="refDoi"> DOI: 10.4155/tde.15.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.4155%2Ftde.15.32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=26305616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OqtLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=961-971&issue=7&author=J.+W.+Geldenhuysauthor=S.+A.+Mohammadauthor=C.+E.+Adkinsauthor=R.+P.+Lockman&title=Molecular+determinants+of+blood-brain+barrier+permeation&doi=10.4155%2Ftde.15.32"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of blood-brain barrier permeation</span></div><div class="casAuthors">Geldenhuys, Werner J.; Mohammad, Afroz S.; Adkins, Chris E.; Lockman, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">961-971</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The blood-brain barrier (BBB) is a microvascular unit which selectively regulates the permeability of drugs to the brain.  With the rise in CNS drug targets and diseases, there is a need to be able to accurately predict a priori which compds. in a company database should be pursued for favorable properties.  In this review, we will explore the different computational tools available today, as well as underpin these to the exptl. methods used to det. BBB permeability.  These include in vitro models and the in vivo models that yield the dataset we use to generate predictive models.  Understanding of how these models were exptl. derived dets. our accurate and predicted use for detg. a balance between activity and BBB distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeWXtbERlky7Vg90H21EOLACvtfcHk0lhm6MVD7ngsiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OqtLfF&md5=6f25f4b5b4fa37659b478517192fa09a</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.4155%2Ftde.15.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde.15.32%26sid%3Dliteratum%253Aachs%26aulast%3DGeldenhuys%26aufirst%3DJ.%2BW.%26aulast%3DMohammad%26aufirst%3DS.%2BA.%26aulast%3DAdkins%26aufirst%3DC.%2BE.%26aulast%3DLockman%26aufirst%3DR.%2BP.%26atitle%3DMolecular%2520determinants%2520of%2520blood-brain%2520barrier%2520permeation%26jtitle%3DTher.%2520Delivery%26date%3D2015%26volume%3D6%26issue%3D7%26spage%3D961%26epage%3D971%26doi%3D10.4155%2Ftde.15.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbertz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudkins, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallamo, J. P.</span></span> <span> </span><span class="NLM_article-title">Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1021/cn200100h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200100h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=50-68&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=J.+P.+Mallamo&title=Knowledge-based%2C+central+nervous+system+%28CNS%29+lead+selection+and+lead+optimization+for+CNS+drug+discovery&doi=10.1021%2Fcn200100h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Hudkins, Robert L.; Dorsey, Bruce D.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-68</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central nervous system (CNS) is the major area that is affected by aging.  Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment.  Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process.  On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochem. and structural differences between CNS and non-CNS drugs may assist both research areas.  Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena.  Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compds., we analyzed the physicochem. property and the chem. structural profiles of 317 CNS and 626 non-CNS oral drugs.  The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process.  A list of substructural units that may be useful for CNS drug design was also provided here.  A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs.  The combined anal. provided the following guidelines for designing high-quality CNS drugs: (i) topol. mol. polar surface area of <76 Å2 (25-60 Å2), (ii) at least one (one or two, including one aliph. amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) vol. of 740-970 Å3, (vi) solvent accessible surface area of 460-580 Å2, and (vii) pos. QikProp parameter CNS.  The ranges within parentheses may be used during lead optimization.  One violation to this proposed profile may be acceptable.  The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqfO0vq2i5bVg90H21EOLACvtfcHk0ljwEnn7oW44rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO&md5=4c20ba34c3d5397170b50242975ce25d</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1021%2Fcn200100h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200100h%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge-based%252C%2520central%2520nervous%2520system%2520%2528CNS%2529%2520lead%2520selection%2520and%2520lead%2520optimization%2520for%2520CNS%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D50%26epage%3D68%26doi%3D10.1021%2Fcn200100h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Floettmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sostek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldon, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic profile of Naloxegol, a peripherally acting <i>m</i>-opioid receptor antagonist, for the treatment of opioid-induced constipation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.239061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1124%2Fjpet.116.239061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=28336575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A280%3ADC%252BC1cvgsFGjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2017&pages=280-291&author=E.+Floettmannauthor=K.+Buiauthor=M.+Sostekauthor=K.+Payzaauthor=M.+Eldon&title=Pharmacologic+profile+of+Naloxegol%2C+a+peripherally+acting+m-opioid+receptor+antagonist%2C+for+the+treatment+of+opioid-induced+constipation&doi=10.1124%2Fjpet.116.239061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic Profile of Naloxegol, a Peripherally Acting μ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation</span></div><div class="casAuthors">Floettmann Eike; Bui Khanh; Sostek Mark; Payza Kemal; Eldon Michael</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-291</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Opioid-induced constipation (OIC) is a common side effect of opioid pharmacotherapy for the management of pain because opioid agonists bind to μ-opioid receptors in the enteric nervous system (ENS).  Naloxegol, a polyethylene glycol derivative of naloxol, which is a derivative of naloxone and a peripherally acting μ-opioid receptor antagonist, targets the physiologic mechanisms that cause OIC.  Pharmacologic measures of opioid activity and pharmacokinetic measures of central nervous system (CNS) penetration were employed to characterize the mechanism of action of naloxegol.  At the human μ-opioid receptor in vitro, naloxegol was a potent inhibitor of binding (Ki = 7.42 nM) and a neutral competitive antagonist (pA2 - 7.95); agonist effects were <10% up to 30 μM and identical to those of naloxone.  The oral doses achieving 50% of the maximal effect in the rat for antagonism of morphine-induced inhibition of gastrointestinal transit and morphine-induced antinociception in the hot plate assay were 23.1 and 55.4 mg/kg for naloxegol and 0.69 and 1.14 mg/kg by for naloxone, respectively.  In the human colon adenocarcinoma cell transport assay, naloxegol was a substrate for the P-glycoprotein transporter, with low apparent permeability in the apical to basolateral direction, and penetrated the CNS 15-fold slower than naloxone in a rat brain perfusion model.  Naloxegol-derived radioactivity was poorly distributed throughout the rat CNS and was eliminated from most tissues within 24 hours.  These findings corroborate phase 3 clinical studies demonstrating that naloxegol relieves OIC-associated symptoms in patients with chronic noncancer pain by antagonizing the μ-opioid receptor in the ENS while preserving CNS-mediated analgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLhQuSZuN9W02yPDyEFiigfW6udTcc2eaFtAeZp6QrIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvgsFGjtQ%253D%253D&md5=93a41d3adcbe252c1b37fc57f2bd9135</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.239061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.239061%26sid%3Dliteratum%253Aachs%26aulast%3DFloettmann%26aufirst%3DE.%26aulast%3DBui%26aufirst%3DK.%26aulast%3DSostek%26aufirst%3DM.%26aulast%3DPayza%26aufirst%3DK.%26aulast%3DEldon%26aufirst%3DM.%26atitle%3DPharmacologic%2520profile%2520of%2520Naloxegol%252C%2520a%2520peripherally%2520acting%2520m-opioid%2520receptor%2520antagonist%252C%2520for%2520the%2520treatment%2520of%2520opioid-induced%2520constipation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D361%26spage%3D280%26epage%3D291%26doi%3D10.1124%2Fjpet.116.239061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-ref20_1"><span> <i>Molecular Operating Environment
(MOE)</i>, <span class="NLM_edition">2010.10</span>; <span class="NLM_publisher-name">Chemical
Computing Group ULC</span>: <span class="NLM_publisher-loc">1010 Sherbooke
St. West, Suite #910, Montreal, QC, Canada, H3A 2R7</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Molecular+Operating+Environment%0A%28MOE%29%2C+2010.10%3B+Chemical%0AComputing+Group+ULC%3A+1010+Sherbooke%0ASt.+West%2C+Suite+%23910%2C+Montreal%2C+QC%2C+Canada%2C+H3A+2R7%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref20_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Operating%2520Environment%250A%2528MOE%2529%26pub%3DChemical%250AComputing%2520Group%2520ULC%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span> <span> </span><span class="NLM_article-title">Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7216</span>– <span class="NLM_lpage">7233</span>, <span class="refDoi"> DOI: 10.1021/jm800843r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800843r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7216-7233&author=S.+H.+Leeauthor=H.+J.+Seoauthor=S.-H.+Leeauthor=M.+E.+Jungauthor=J.-H.+Parkauthor=H.-J.+Parkauthor=J.+Yooauthor=H.+Yunauthor=J.+Naauthor=S.+Y.+Kangauthor=K.-S.+Songauthor=M.-A.+Kimauthor=C.-H.+Changauthor=J.+Kimauthor=J.+Lee&title=Biarylpyrazolyl+oxadiazole+as+potent%2C+selective%2C+orally+bioavailable+cannabinoid-1+receptor+antagonists+for+the+treatment+of+obesity&doi=10.1021%2Fjm800843r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm800843r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800843r%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DSeo%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DPark%26aufirst%3DJ.-H.%26aulast%3DPark%26aufirst%3DH.-J.%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DNa%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DS.%2BY.%26aulast%3DSong%26aufirst%3DK.-S.%26aulast%3DKim%26aufirst%3DM.-A.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26atitle%3DBiarylpyrazolyl%2520oxadiazole%2520as%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520cannabinoid-1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520obesity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7216%26epage%3D7233%26doi%3D10.1021%2Fjm800843r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human cannabinoid receptor CB1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.cell.2016.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=27768894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2016&pages=750-762&author=T.+Huaauthor=K.+Vemuriauthor=M.+Puauthor=L.+Quauthor=G.+W.+Hanauthor=Y.+Wuauthor=S.+Zhaoauthor=W.+Shuiauthor=S.+Liauthor=A.+Kordeauthor=R.+B.+Laprairieauthor=E.+L.+Stahlauthor=J.-H.+Hoauthor=N.+Zvonokauthor=H.+Zhouauthor=I.+Kufarevaauthor=B.+Wuauthor=Q.+Zhaoauthor=M.+Hansonauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.-J.+Liu&title=Crystal+structure+of+the+human+cannabinoid+receptor+CB1&doi=10.1016%2Fj.cell.2016.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB1</span></div><div class="casAuthors">Hua, Tian; Vemuri, Kiran; Pu, Mengchen; Qu, Lu; Han, Gye Won; Wu, Yiran; Zhao, Suwen; Shui, Wenqing; Li, Shanshan; Korde, Anisha; Laprairie, Robert B.; Stahl, Edward L.; Ho, Jo-Hao; Zvonok, Nikolai; Zhou, Han; Kufareva, Irina; Wu, Beili; Zhao, Qiang; Hanson, Michael A.; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-762.e14</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chem. from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use.  CB1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders.  Here, the authors present the 2.8 Å crystal structure of human CB1 in complex with AM6538, a stabilizing antagonist, synthesized and characterized for this structural study.  The structure of the CB1-AM6538 complex reveals key features of the receptor and crit. interactions for antagonist binding.  In combination with functional studies and mol. modeling, the structure provides insight into the binding mode of naturally occurring CB1 ligands, such as THC, and synthetic cannabinoids.  This enhances the understanding of the mol. basis for the physiol. functions of CB1 and provides new opportunities for the design of next-generation CB1-targeting pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAuMgAfmO22bVg90H21EOLACvtfcHk0ljH5obXRaU7bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCrsrbI&md5=f4862c31391550ee2b83ef198c9c7b17</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DShui%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKorde%26aufirst%3DA.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DHo%26aufirst%3DJ.-H.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DHanson%26aufirst%3DM.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520cannabinoid%2520receptor%2520CB1%26jtitle%3DCell%26date%3D2016%26volume%3D167%26spage%3D750%26epage%3D762%26doi%3D10.1016%2Fj.cell.2016.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzemska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, M. D.</span></span> <span> </span><span class="NLM_article-title">High-resolution crystal structure of the human CB1 cannabinoid receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>540</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1038/nature20613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1038%2Fnature20613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=27851727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=540&publication_year=2016&pages=602-606&author=Z.+Shaoauthor=J.+Yinauthor=K.+Chapmanauthor=M.+Grzemskaauthor=L.+Clarkauthor=J.+Wangauthor=M.+D.+Rosenbaum&title=High-resolution+crystal+structure+of+the+human+CB1+cannabinoid+receptor&doi=10.1038%2Fnature20613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of the human CB1 cannabinoid receptor</span></div><div class="casAuthors">Shao, Zhenhua; Yin, Jie; Chapman, Karen; Grzemska, Magdalena; Clark, Lindsay; Wang, Junmei; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">540</span>
        (<span class="NLM_cas:issue">7634</span>),
    <span class="NLM_cas:pages">602-606</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Δ9-tetrahydrocannabinol (THC).  The cannabinoid receptors have been the targets of intensive drug discovery efforts, because modulation of these receptors has therapeutic potential to control pain, epilepsy, obesity, and other disorders.  Although much progress in understanding the biophys. properties of GPCRs has recently been made, investigations of the mol. mechanisms of the cannabinoids and their receptors have lacked high-resoln. structural data.  Here we report the use of GPCR engineering and lipidic cubic phase crystn. to det. the structure of the human CB1 receptor bound to the inhibitor taranabant at 2.6-Å resoln.  We found that the extracellular surface of CB1, including the highly conserved membrane-proximal N-terminal region, is distinct from those of other lipid-activated GPCRs, forming a crit. part of the ligand-binding pocket.  Docking studies further demonstrate how this same pocket may accommodate the cannabinoid agonist THC.  Our CB1 structure provides an at. framework for studying cannabinoid receptor function and will aid the design and optimization of therapeutic modulators of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrry3sr0ztbEbVg90H21EOLACvtfcHk0lhsrcy9psCdfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgtL3L&md5=cccd3a0e0d0ccf9795777e4b9e722102</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1038%2Fnature20613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature20613%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DGrzemska%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRosenbaum%26aufirst%3DM.%2BD.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520the%2520human%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DNature%26date%3D2016%26volume%3D540%26spage%3D602%26epage%3D606%26doi%3D10.1038%2Fnature20613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzer, P.</span></span> <span> </span><span class="NLM_article-title">Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3714</span>– <span class="NLM_lpage">3717</span>, <span class="refDoi"> DOI: 10.1021/jm000942e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+calculation+of+molecular+polar+surface+area+as+a+sum+of+fragment-based+contributions+and+its+application+to+the+prediction+of+drug+transport+properties&doi=10.1021%2Fjm000942e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0lhsrcy9psCdfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520calculation%2520of%2520molecular%2520polar%2520surface%2520area%2520as%2520a%2520sum%2520of%2520fragment-based%2520contributions%2520and%2520its%2520application%2520to%2520the%2520prediction%2520of%2520drug%2520transport%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3714%26epage%3D3717%26doi%3D10.1021%2Fjm000942e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0lgY3l1AZaMg7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grootenhuis, P. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayada, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbressine, L. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploemen, J. P.</span></span> <span> </span><span class="NLM_article-title">Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1514</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1023/A:1015040217741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1023%2FA%3A1015040217741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10554091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADyaK1MXntVOhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=1514-1519&author=J.+Kelderauthor=P.+D.+J.+Grootenhuisauthor=D.+M.+Bayadaauthor=L.+P.+C.+Delbressineauthor=J.+P.+Ploemen&title=Polar+molecular+surface+as+a+dominating+determinant+for+oral+absorption+and+brain+penetration+of+drugs&doi=10.1023%2FA%3A1015040217741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs</span></div><div class="casAuthors">Kelder, Jan; Grootenhuis, Peter D. J.; Bayada, Denis M.; Delbressine, Leon P. C.; Ploemen, Jan-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1514-1519</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">Purpose: To study oral absorption and brain penetration as a function of polar mol. surface area.  Methods: Measured brain penetration data of 45 drug mols. were investigated.  The dynamic polar surface areas were calcd. and correlated with the brain penetration data.  Also the static polar surface areas of 776 orally administered CNS drugs that have reached at least Phase II efficacy studies were calcd.  The same was done for a series of 1590 orally administered non-CNS drugs that have reached at least Phase II efficacy studies.  Results: A linear relationship between brain penetration and dynamic polar surface area (A2) was found (n = 45, R = 0.917, F1,43 = 229).  Brain penetration decreases with increasing polar surface area.  A clear difference between the distribution of the polar surface area of the 776 CNS and 1590 non-CNS drugs was found.  It was deduced that orally active drugs that are transported passively by the transcellular route should not exceed a polar surface area of about 120 A2.  They can be tailored to brain penetration by decreasing the polar surface to <60-70 A2.  This conclusion is supported by the inverse linear relationship between exptl. brain penetration data and the dynamic polar surface area of 45 drug mols.  Conclusions: The polar mol. surface area is a dominating determinant for oral absorption and brain penetration of drugs that are transported by the transcellular route.  This property should be considered in the early phase of drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmc3v7TzWM4LVg90H21EOLACvtfcHk0lgY3l1AZaMg7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVOhtb8%253D&md5=868fe1e9491dd3b8b92b326d28ee48f9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015040217741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015040217741%26sid%3Dliteratum%253Aachs%26aulast%3DKelder%26aufirst%3DJ.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%2BJ.%26aulast%3DBayada%26aufirst%3DD.%2BM.%26aulast%3DDelbressine%26aufirst%3DL.%2BP.%2BC.%26aulast%3DPloemen%26aufirst%3DJ.%2BP.%26atitle%3DPolar%2520molecular%2520surface%2520as%2520a%2520dominating%2520determinant%2520for%2520oral%2520absorption%2520and%2520brain%2520penetration%2520of%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D1514%26epage%3D1519%26doi%3D10.1023%2FA%3A1015040217741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">Computational methods for the prediction of drug-likeness</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(99)01451-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2FS1359-6446%2899%2901451-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10652455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht12js7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=49-58&author=D.+E.+Clarkauthor=S.+D.+Pickett&title=Computational+methods+for+the+prediction+of+drug-likeness&doi=10.1016%2FS1359-6446%2899%2901451-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Computational methods for the prediction of "drug-likeness"</span></div><div class="casAuthors">Clark, David E.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">49-58</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 55 refs.  Recently, one of the key trends in the pharmaceutical industry has been the integration of what have traditionally been considered "development" activities into the early phases of drug discovery.  The aim of this paradigm shift is the prompt identification and elimination of candidate mols. that are unlikely to survive later stages of discovery and development.  In this review, the authors examine the growing role that is being played by computational methods in this filtering process, with a particular focus on the prediction of intestinal absorption and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZMw4QBryVB7Vg90H21EOLACvtfcHk0lgY3l1AZaMg7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht12js7s%253D&md5=6b79763582f94aeb8f05a495afdbffad</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2899%2901451-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252899%252901451-8%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DD.%2BE.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DComputational%2520methods%2520for%2520the%2520prediction%2520of%2520drug-likeness%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2000%26volume%3D5%26spage%3D49%26epage%3D58%26doi%3D10.1016%2FS1359-6446%2899%2901451-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Loscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potschka, H.</span></span> <span> </span><span class="NLM_article-title">Drug resistance in brain diseases and the role of drug efflux transporters</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrn1728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1038%2Fnrn1728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=16025095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A280%3ADC%252BD2MvgtFKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=591-602&author=W.+Loscherauthor=H.+Potschka&title=Drug+resistance+in+brain+diseases+and+the+role+of+drug+efflux+transporters&doi=10.1038%2Fnrn1728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Drug resistance in brain diseases and the role of drug efflux transporters</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">591-602</span>
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    </div><div class="casAbstract">Resistance to drug treatment is an important hurdle in the therapy of many brain disorders, including brain cancer, epilepsy, schizophrenia, depression and infection of the brain with HIV.  Consequently, there is a pressing need to develop new and more effective treatment strategies.  Mechanisms of resistance that operate in cancer and infectious diseases might also be relevant in drug-resistant brain disorders.  In particular, drug efflux transporters that are expressed at the blood-brain barrier limit the ability of many drugs to access the brain.  There is increasing evidence that drug efflux transporters have an important role in drug-resistant brain disorders, and this information should allow more efficacious treatment strategies to be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBI4VWCsjP46-9TkgmBqTqfW6udTcc2ebES0Gbvy_kRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvgtFKisg%253D%253D&md5=26af8b7a7f5b210decf788b837e52b3e</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1038%2Fnrn1728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1728%26sid%3Dliteratum%253Aachs%26aulast%3DLoscher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DDrug%2520resistance%2520in%2520brain%2520diseases%2520and%2520the%2520role%2520of%2520drug%2520efflux%2520transporters%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2005%26volume%3D6%26spage%3D591%26epage%3D602%26doi%3D10.1038%2Fnrn1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeque, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A. J.</span></span> <span> </span><span class="NLM_article-title">Increased drug delivery to the brain by P-glycoprotein inhibition</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1067/mcp.2000.109156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1067%2Fmcp.2000.109156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=11014404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFOgtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2000&pages=231-237&author=A.+J.+Sadequeauthor=C.+Wandelauthor=H.+Heauthor=S.+Shahauthor=A.+J.+Wood&title=Increased+drug+delivery+to+the+brain+by+P-glycoprotein+inhibition&doi=10.1067%2Fmcp.2000.109156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Increased drug delivery to the brain by P-glycoprotein inhibition</span></div><div class="casAuthors">Sadeque, Abu J. M.; Wandel, Christoph; He, Hauibing; Shah, Selina; Wood, Alastair J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">231-237</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Although the antidiarrheal loperamide is a potent opiate, it does not produce opioid central nervous system effects at usual doses in patients.  On the basis of in vitro studies demonstrating that loperamide is a substrate for the ATP-dependent efflux membrane transporter P-glycoprotein, the authors postulated that inhibition of P-glycoprotein with quinidine would increase entry of loperamide into the central nervous system with resultant respiratory depression.  To test this hypothesis, a 16-mg dose of loperamide was administered to 8 healthy male volunteers in the presence of either 600 mg quinidine, a known inhibitor of P-glycoprotein, or placebo.  Central nervous system effects were measured by evaluation of the respiratory response to CO2 rebreathing as a measure of opiate-induced respiratory depression.  Loperamide produced no respiratory depression when administered alone, but respiratory depression occurred when loperamide (16 mg) was given with quinidine at a dose of 600 mg.  These changes were not explained by increased plasma loperamide concns.  This study therefore demonstrates 1st the potential for important drug interactions to occur by a new mechanism, namely, inhibition of P-glycoprotein, and 2nd that the lack of respiratory depression produced by loperamide, which allows it to be safely used therapeutically, can be reversed by a drug causing P-glycoprotein inhibition, resulting in serious toxic and abuse potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqankLtAzcwrrVg90H21EOLACvtfcHk0lhicC5pe_3whQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFOgtb8%253D&md5=8dec48b4ca58f5bebce92082ba604fd1</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2000.109156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2000.109156%26sid%3Dliteratum%253Aachs%26aulast%3DSadeque%26aufirst%3DA.%2BJ.%26aulast%3DWandel%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DA.%2BJ.%26atitle%3DIncreased%2520drug%2520delivery%2520to%2520the%2520brain%2520by%2520P-glycoprotein%2520inhibition%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2000%26volume%3D68%26spage%3D231%26epage%3D237%26doi%3D10.1067%2Fmcp.2000.109156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span> <span> </span><span class="NLM_article-title">Minimizing drug exposure in the CNS while maintaining good oral absorption</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1021/ml300378n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300378n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1OltLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=948-950&author=S.+K.+Bagalauthor=P.+J.+Bungay&title=Minimizing+drug+exposure+in+the+CNS+while+maintaining+good+oral+absorption&doi=10.1021%2Fml300378n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Minimizing Drug Exposure in the CNS while Maintaining Good Oral Absorption</span></div><div class="casAuthors">Bagal, Sharan K.; Bungay, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">948-950</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In some drug discovery approaches, it is advantageous to restrict the access of compds. to the CNS to minimize the risk of side effects.  By choosing appropriate physicochem. properties and building in the ability to act as substrates for active efflux transporters, it is possible to achieve CNS restriction and still retain sufficient absorption through the intestinal epithelium to retain good oral bioavailability.  Potential risks in employing this approach are considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhbO_d5Zr_JrVg90H21EOLACvtfcHk0lhhSxmfQ7SH_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1OltLvE&md5=04e328be4df50c3af37b6ad1d610933b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fml300378n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300378n%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26atitle%3DMinimizing%2520drug%2520exposure%2520in%2520the%2520CNS%2520while%2520maintaining%2520good%2520oral%2520absorption%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D948%26epage%3D950%26doi%3D10.1021%2Fml300378n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wittgen, G. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greupink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Heuvel, J. J.
M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Broek, P. H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinter-Heidorn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenderink, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, F. G. M.</span></span> <span> </span><span class="NLM_article-title">Exploiting transport activity of P-glycoprotein at the blood–brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1351</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.1021/mp200617z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200617z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1351-1360&author=G.+M.+H.+Wittgenauthor=R.+Greupinkauthor=J.+J.%0AM.+W.+van+den%0AHeuvelauthor=P.+H.+H.+van+den%0ABroekauthor=H.+Dinter-Heidornauthor=J.+B.+Koenderinkauthor=F.+G.+M.+Russel&title=Exploiting+transport+activity+of+P-glycoprotein+at+the+blood%E2%80%93brain+barrier+for+the+development+of+peripheral+cannabinoid+type+1+receptor+antagonists&doi=10.1021%2Fmp200617z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting Transport Activity of P-Glycoprotein at the Blood-Brain Barrier for the Development of Peripheral Cannabinoid Type 1 Receptor Antagonists</span></div><div class="casAuthors">Wittgen, Hanneke G. M.; Greupink, Rick; van den Heuvel, Jeroen J. M. W.; van den Broek, Petra H. H.; Dinter-Heidorn, Heike; Koenderink, Jan B.; Russel, Frans G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1351-1360</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although the CB1 receptor antagonist/inverse agonist rimonabant has pos. effects on wt. loss and cardiometabolic risk factors, neuropsychiatric side effects have prompted researchers to develop peripherally acting derivs.  Here, we investigated for a series of 3,4-diarylpyrazoline CB1 receptor antagonists if transport by the brain efflux transporter P-gp could be used as a selection criterion in the development of such drugs.  All 3,4-diarylpyrazolines and rimonabant inhibited P-gp transport activity in membrane vesicles isolated from HEK293 cells overexpressing the transporter, but only the 1,1-dioxo-thiomorpholino analog 23 exhibited a reduced accumulation (-38 ± 2%) in these cells, which could be completely reversed by the P-gp/BCRP inhibitor elacridar.  In addn., 23 appeared to be a BCRP substrate, whereas rimonabant was not.  In rats, the in vivo brain/plasma concn. ratio of 23 was significantly lower than for rimonabant (0.4 ± 0.1 vs 6.2 ± 1.6, p < 0.001).  Coadministration of elacridar resulted in an 11-fold increase of the brain/plasma ratio for 23 (p < 0.01) and only 1.4-fold for rimonabant (p < 0.05), confirming the involvement of P-gp and possibly BCRP in limiting the brain entrance of 23in vivo.  In conclusion, these data support the conception that efflux via transporters such as P-gp and BCRP can limit the brain penetration of CB1 receptor antagonists, and that this property could be used in the development of peripheral antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5CThRb0gfe7Vg90H21EOLACvtfcHk0lhhSxmfQ7SH_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFWht7k%253D&md5=a6404a4934cc6a24cae353840a44d114</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fmp200617z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200617z%26sid%3Dliteratum%253Aachs%26aulast%3DWittgen%26aufirst%3DG.%2BM.%2BH.%26aulast%3DGreupink%26aufirst%3DR.%26aulast%3Dvan%2Bden%2BHeuvel%26aufirst%3DJ.%2BJ.%2BM.%2BW.%26aulast%3Dvan%2Bden%2BBroek%26aufirst%3DP.%2BH.%2BH.%26aulast%3DDinter-Heidorn%26aufirst%3DH.%26aulast%3DKoenderink%26aufirst%3DJ.%2BB.%26aulast%3DRussel%26aufirst%3DF.%2BG.%2BM.%26atitle%3DExploiting%2520transport%2520activity%2520of%2520P-glycoprotein%2520at%2520the%2520blood%25E2%2580%2593brain%2520barrier%2520for%2520the%2520development%2520of%2520peripheral%2520cannabinoid%2520type%25201%2520receptor%2520antagonists%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D1351%26epage%3D1360%26doi%3D10.1021%2Fmp200617z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raub, T. J.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein recognition of substrates and circumvention through rational drug design</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1021/mp0500871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp0500871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlagu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=3-25&author=T.+J.+Raub&title=P-Glycoprotein+recognition+of+substrates+and+circumvention+through+rational+drug+design&doi=10.1021%2Fmp0500871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">P-Glycoprotein Recognition of Substrates and Circumvention through Rational Drug Design</span></div><div class="casAuthors">Raub, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now well recognized that membrane efflux transporters, esp. P-glycoprotein (P-gp; ABCB1), play a role in detg. the absorption, distribution, metab., excretion, and toxicol. behaviors of some drugs and mols. in development.  An investment in screening structure-activity relation (SAR) is warranted in early discovery when exposure and/or target activity in an in vivo efficacy model is not achieved and P-gp efflux is identified as a rate-limiting factor.  However, the amt. of investment in SAR must be placed into perspective by assessing the risks assocd. with the intended therapeutic target, the potency and margin of safety of the compd., the intended patient population(s), and the market competition.  The task of rationally designing a chem. strategy for circumventing a limiting P-gp interaction can be daunting.  The necessity of retaining biol. potency and metabolic stability places restrictions on what can be done, and the factors for P-gp recognition of substrates are complicated and poorly understood.  The parameters within the assays that affect overall pump efficiency or net efflux, such as passive diffusion, membrane partitioning, and mol. interaction between pump and substrate, should be understood when interpreting data sets assocd. with chem. around a scaffold.  No single, functional group alone is often the cause, but one group can accentuate the recognition points existing within a scaffold.  This can be likened to a rheostat, rather than an on/off switch, where addn. or removal of a key group can increase or decrease the pumping efficiency.  The most practical approach to de-emphasize the limiting effects of P-gp on a particular scaffold is to increase passive diffusion.  Efflux pumping efficiency may be overcome when passive diffusion is fast enough.  Eliminating, or substituting with fewer, groups that solvate in water, or decreasing their hydrogen bonding capacity, and adding halogen groups can increase passive diffusion.  Reducing mol. size, replacing electroneg. atoms, blocking or masking H-bond donors with N-alkylation or bulky flanking groups, introducing constrained conformation, or by promoting intramol. hydrogen bonds are all examples of steps to take.  This review discusses our understanding of how P-gp recognizes and pumps compds. as substrates and describes cases where structural changes were made in a chem. scaffold to circumvent the effects of P-gp interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRbEgPosNnxrVg90H21EOLACvtfcHk0lhhSxmfQ7SH_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlagu7%252FP&md5=cc89be920dfa0e32edb994be94626aa5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fmp0500871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp0500871%26sid%3Dliteratum%253Aachs%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26atitle%3DP-Glycoprotein%2520recognition%2520of%2520substrates%2520and%2520circumvention%2520through%2520rational%2520drug%2520design%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2006%26volume%3D3%26spage%3D3%26epage%3D25%26doi%3D10.1021%2Fmp0500871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tingley, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajiji, S. M.</span></span> <span> </span><span class="NLM_article-title">P-Glycoprotein efflux at the blood–brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists</span>. <i>J. Pharmacol. Exp.Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=11504828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtFKmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2001&pages=1252-1259&author=B.+J.+Smithauthor=A.+D.+Doranauthor=S.+McLeanauthor=F.+D.+Tingleyauthor=T.+Brianauthor=B.+T.+O%E2%80%99Neillauthor=S.+M.+Kajiji&title=P-Glycoprotein+efflux+at+the+blood%E2%80%93brain+barrier+mediates+differences+in+brain+disposition+and+pharmacodynamics+between+two+structurally+related+neurokinin-1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists</span></div><div class="casAuthors">Smith, Bill J.; Doran, Angela C.; McLean, Stafford; Tingley, F. David, III; O'Neill, Brian T.; Kajiji, Shama M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1259</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CP-122721 and CP-141938 are potent and selective neurokinin-1 (NK1) receptor antagonists with very different brain disposition and potency in models of centrally mediated activity.  These investigations sought to det. whether differences in potency were related to differences in P-glycoprotein (P-gp) transport at the blood-brain barrier.  Both compds. stimulated ATPase activity of human recombinant MDR1 with similar kinetic parameters.  Cell-assocd. drug concns. of CP-141938 were 9.4-fold lower in KBV1 cells expressing P-gp compared with KB3.1 control cells.  In Madin-Darby canine kidney (MDCK) cells expressing human MDR1, asym. transport of CP-141938 was 5-fold higher than in wild-type MDCK cells, whereas no asymmetry was obsd. with CP-122721.  In agreement with these differences in cellular transport, the differences in brain/plasma ratio between mdr1a/b(-/-) and FVB mice 1 h following a 3 mg/kg s.c. dose were 3- and 50-fold for CP-122721 and CP-141938, resp.  The effect of inhibiting P-gp efflux on the effects of these agents was evaluated using GR73632-induced foot tapping in gerbils as a model to measure centrally mediated NK1 antagonism.  When gerbils were pretreated with the P-gp inhibitor MS-073 (50 mg/kg s.c.), there was no effect on the activity of CP-122721 (0.05 mg/kg), whereas the percent reversal for CP-141938 (10 mg/kg) increased from 60 to 100%.  In gerbils, the brain/plasma ratio for CP-122721 was unaffected by MS-073 pretreatment, whereas the brain/plasma ratio for CP-141938 brain concns. increased 13-fold.  This suggested that P-gp efflux influences the brain disposition and pharmacol. activity of CP-141938, but not CP-122721.  Complete response curves for CP-141938 were then detd. with respect to dose, and drug concn. in the plasma and brain in the presence and absence of MS-073 pretreatment.  The dose and plasma concn.-response curves of CP-141938 were shifted to the left in the presence of MS-073, yet brain concns. assocd. with the response were unchanged.  This suggested that once in the brain the interaction of CP-141938 with the NK1 receptor was not affected by P-gp transport.  In conclusion, these studies show that brain disposition and centrally mediated in vivo activity of NK1 antagonists can be profoundly affected by P-gp transport and that such transport should be considered during the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozSRvdzBMaP7Vg90H21EOLACvtfcHk0lhff2pg9x6iuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtFKmtbg%253D&md5=ca44f3c8d9e83a8f9486e805e95af1f6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DDoran%26aufirst%3DA.%2BD.%26aulast%3DMcLean%26aufirst%3DS.%26aulast%3DTingley%26aufirst%3DF.%2BD.%26aulast%3DBrian%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DKajiji%26aufirst%3DS.%2BM.%26atitle%3DP-Glycoprotein%2520efflux%2520at%2520the%2520blood%25E2%2580%2593brain%2520barrier%2520mediates%2520differences%2520in%2520brain%2520disposition%2520and%2520pharmacodynamics%2520between%2520two%2520structurally%2520related%2520neurokinin-1%2520receptor%2520antagonists%26jtitle%3DJ.%2520Pharmacol.%2520Exp.Ther.%26date%3D2001%26volume%3D298%26spage%3D1252%26epage%3D1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quarta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braulke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latorre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heldmaier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leste-Lassere, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valerio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisoli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cota, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagotto, U.</span></span> <span> </span><span class="NLM_article-title">CB1 Signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2010.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.cmet.2010.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=20374960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVajtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=273-285&author=C.+Quartaauthor=L.+Bellocchioauthor=G.+Manciniauthor=R.+Mazzaauthor=C.+Cervinoauthor=L.+J.+Braulkeauthor=C.+Feketeauthor=R.+Latorreauthor=C.+Nanniauthor=M.+Bucciauthor=L.+E.+Clemensauthor=G.+Heldmaierauthor=M.+Watanabeauthor=T.+Leste-Lassereauthor=M.+Maitreauthor=L.+Tedescoauthor=F.+Fanelliauthor=S.+Reussauthor=S.+Klausauthor=R.+K.+Srivastavaauthor=K.+Monoryauthor=A.+Valerioauthor=A.+Grandisauthor=R.+De+Giorgioauthor=R.+Pasqualiauthor=E.+Nisoliauthor=E.+Cotaauthor=B.+Lutzauthor=G.+Marsicanoauthor=U.+Pagotto&title=CB1+Signaling+in+forebrain+and+sympathetic+neurons+is+a+key+determinant+of+endocannabinoid+actions+on+energy+balance&doi=10.1016%2Fj.cmet.2010.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">CB1 signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance</span></div><div class="casAuthors">Quarta, Carmelo; Bellocchio, Luigi; Mancini, Giacomo; Mazza, Roberta; Cervino, Cristina; Braulke, Luzie J.; Fekete, Csaba; Latorre, Rocco; Nanni, Cristina; Bucci, Marco; Clemens, Laura E.; Heldmaier, Gerhard; Watanabe, Masahiko; Leste-Lassere, Thierry; Maitre, Marlene; Tedesco, Laura; Fanelli, Flaminia; Reuss, Stefan; Klaus, Susanne; Srivastava, Raj Kamal; Monory, Krisztina; Valerio, Alessandra; Grandis, Annamaria; De Giorgio, Roberto; Pasquali, Renato; Nisoli, Enzo; Cota, Daniela; Lutz, Beat; Marsicano, Giovanni; Pagotto, Uberto</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-285</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The endocannabinoid system (ECS) plays a crit. role in obesity development.  The pharmacol. blockade of cannabinoid receptor type 1 (CB1) has been shown to reduce body wt. and to alleviate obesity-related metabolic disorders.  An unsolved question is at which anatomical level CB1 modulates energy balance and the mechanisms involved in its action.  Here, we demonstrate that CB1 receptors expressed in forebrain and sympathetic neurons play a key role in the pathophysiol. development of diet-induced obesity.  Conditional mutant mice lacking CB1 expression in neurons known to control energy balance, but not in nonneuronal peripheral organs, displayed a lean phenotype and resistance to diet-induced obesity.  This phenotype results from an increase in lipid oxidn. and thermogenesis as a consequence of an enhanced sympathetic tone and a decrease in energy absorption.  In conclusion, CB1 signaling in the forebrain and sympathetic neurons is a key determinant of the ECS control of energy balance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKwboAUEBgwrVg90H21EOLACvtfcHk0lhff2pg9x6iuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVajtbY%253D&md5=6bef1e482829fac3871b4e47f3cedd0e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2010.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2010.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DQuarta%26aufirst%3DC.%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DMancini%26aufirst%3DG.%26aulast%3DMazza%26aufirst%3DR.%26aulast%3DCervino%26aufirst%3DC.%26aulast%3DBraulke%26aufirst%3DL.%2BJ.%26aulast%3DFekete%26aufirst%3DC.%26aulast%3DLatorre%26aufirst%3DR.%26aulast%3DNanni%26aufirst%3DC.%26aulast%3DBucci%26aufirst%3DM.%26aulast%3DClemens%26aufirst%3DL.%2BE.%26aulast%3DHeldmaier%26aufirst%3DG.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DLeste-Lassere%26aufirst%3DT.%26aulast%3DMaitre%26aufirst%3DM.%26aulast%3DTedesco%26aufirst%3DL.%26aulast%3DFanelli%26aufirst%3DF.%26aulast%3DReuss%26aufirst%3DS.%26aulast%3DKlaus%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DR.%2BK.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DValerio%26aufirst%3DA.%26aulast%3DGrandis%26aufirst%3DA.%26aulast%3DDe%2BGiorgio%26aufirst%3DR.%26aulast%3DPasquali%26aufirst%3DR.%26aulast%3DNisoli%26aufirst%3DE.%26aulast%3DCota%26aufirst%3DE.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DPagotto%26aufirst%3DU.%26atitle%3DCB1%2520Signaling%2520in%2520forebrain%2520and%2520sympathetic%2520neurons%2520is%2520a%2520key%2520determinant%2520of%2520endocannabinoid%2520actions%2520on%2520energy%2520balance%26jtitle%3DCell%2520Metab.%26date%3D2010%26volume%3D11%26spage%3D273%26epage%3D285%26doi%3D10.1016%2Fj.cmet.2010.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria-Gómez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metna-Laurent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delamarre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Fontecha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leste-Lasserre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartsch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaouloff, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagotto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span> <span> </span><span class="NLM_article-title">Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB1 receptor blockade</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">4786</span>– <span class="NLM_lpage">4791</span>, <span class="refDoi"> DOI: 10.1073/pnas.1218573110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1073%2Fpnas.1218573110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=4786-4791&author=L.+Bellocchioauthor=E.+Soria-G%C3%B3mezauthor=C.+Quartaauthor=M.+Metna-Laurentauthor=P.+Cardinalauthor=E.+Binderauthor=A.+Cannichauthor=A.+Delamarreauthor=M.+H%C3%A4ringauthor=M.+Mart%C3%ADn-Fontechaauthor=D.+Vegaauthor=T.+Leste-Lasserreauthor=D.+Bartschauthor=K.+Monoryauthor=B.+Lutzauthor=F.+Chaouloffauthor=U.+Pagottoauthor=M.+Guzmanauthor=D.+Cotaauthor=G.+Marsicano&title=Activation+of+the+sympathetic+nervous+system+mediates+hypophagic+and+anxiety-like+effects+of+CB1+receptor+blockade&doi=10.1073%2Fpnas.1218573110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1218573110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1218573110%26sid%3Dliteratum%253Aachs%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DSoria-G%25C3%25B3mez%26aufirst%3DE.%26aulast%3DQuarta%26aufirst%3DC.%26aulast%3DMetna-Laurent%26aufirst%3DM.%26aulast%3DCardinal%26aufirst%3DP.%26aulast%3DBinder%26aufirst%3DE.%26aulast%3DCannich%26aufirst%3DA.%26aulast%3DDelamarre%26aufirst%3DA.%26aulast%3DH%25C3%25A4ring%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn-Fontecha%26aufirst%3DM.%26aulast%3DVega%26aufirst%3DD.%26aulast%3DLeste-Lasserre%26aufirst%3DT.%26aulast%3DBartsch%26aufirst%3DD.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DChaouloff%26aufirst%3DF.%26aulast%3DPagotto%26aufirst%3DU.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DCota%26aufirst%3DD.%26aulast%3DMarsicano%26aufirst%3DG.%26atitle%3DActivation%2520of%2520the%2520sympathetic%2520nervous%2520system%2520mediates%2520hypophagic%2520and%2520anxiety-like%2520effects%2520of%2520CB1%2520receptor%2520blockade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D4786%26epage%3D4791%26doi%3D10.1073%2Fpnas.1218573110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godlewski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chedester, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liow, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorvat, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2012.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.cmet.2012.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=22841573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=167-179&author=J.+Tamauthor=R.+Cinarauthor=J.+Liuauthor=G.+Godlewskiauthor=D.+Wesleyauthor=T.+Jourdanauthor=G.+Szandaauthor=B.+Mukhopadhyayauthor=L.+Chedesterauthor=J.-S.+Liowauthor=R.+B.+Innisauthor=K.+Chengauthor=K.+C.+Riceauthor=J.+R.+Deschampsauthor=R.+J.+Chorvatauthor=J.+F.+McElroyauthor=G.+Kunos&title=Peripheral+cannabinoid-1+receptor+inverse+agonism+reduces+obesity+by+reversing+leptin+resistance&doi=10.1016%2Fj.cmet.2012.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance</span></div><div class="casAuthors">Tam, Joseph; Cinar, Resat; Liu, Jie; Godlewski, Grzegorz; Wesley, Daniel; Jourdan, Tony; Szanda, Gergo; Mukhopadhyay, Bani; Chedester, Lee; Liow, Jeih-San; Innis, Robert B.; Cheng, Kejun; Rice, Kenner C.; Deschamps, Jeffrey R.; Chorvat, Robert J.; McElroy, John F.; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-179</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Obesity-related leptin resistance manifests in loss of leptin's ability to reduce appetite and increase energy expenditure.  Obesity is also assocd. with increased activity of the endocannabinoid system, and CB1 receptor (CB1R) inverse agonists reduce body wt. and the assocd. metabolic complications, although adverse neuropsychiatric effects halted their therapeutic development.  In mice with diet-induced obesity (DIO), the peripherally restricted CB1R inverse agonist JD5037 is equieffective with its brain-penetrant parent compd. in reducing appetite, body wt., hepatic steatosis, and insulin resistance, even though it does not occupy central CB1R or induce related behaviors.  Appetite and wt. redn. by JD5037 are mediated by resensitizing DIO mice to endogenous leptin through reversing the hyperleptinemia by decreasing leptin expression and secretion by adipocytes and increasing leptin clearance via the kidney.  Thus, inverse agonism at peripheral CB1R not only improves cardiometabolic risk in obesity but has antiobesity effects by reversing leptin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXZCRIXdM8qLVg90H21EOLACvtfcHk0lhf3s8u-DBvcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahsL%252FO&md5=412b24018a9a1620ebf533f5195b1659</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2012.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2012.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DWesley%26aufirst%3DD.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DChedester%26aufirst%3DL.%26aulast%3DLiow%26aufirst%3DJ.-S.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520cannabinoid-1%2520receptor%2520inverse%2520agonism%2520reduces%2520obesity%2520by%2520reversing%2520leptin%2520resistance%26jtitle%3DCell%2520Metab.%26date%3D2012%26volume%3D16%26spage%3D167%26epage%3D179%26doi%3D10.1016%2Fj.cmet.2012.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szanda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashiwaya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1113</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.1016/j.molmet.2017.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1016%2Fj.molmet.2017.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=29031713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=1113-1125&author=J.+Tamauthor=G.+Szandaauthor=A.+Droriauthor=Z.+Liuauthor=R.+Cinarauthor=Y.+Kashiwayaauthor=M.+L.+Reitmanauthor=G.+Kunos&title=Peripheral+cannabinoid-1+receptor+blockade+restores+hypothalamic+leptin+signaling&doi=10.1016%2Fj.molmet.2017.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling</span></div><div class="casAuthors">Tam, Joseph; Szanda, Gergo; Drori, Adi; Liu, Ziyi; Cinar, Resat; Kashiwaya, Yoshihiro; Reitman, Marc L.; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1113-1125</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">In visceral obesity, an overactive endocannabinoid/CB1 receptor (CB1R) system promotes increased caloric intake and decreases energy expenditure, which are mitigated by global or peripheral CB1R blockade.  In mice with diet-induced obesity (DIO), inhibition of food intake by the peripherally restricted CB1R antagonist JD5037 could be attributed to endogenous leptin due to the rapid reversal of hyperleptinemia that maintains leptin resistance, but the signaling pathway engaged by leptin has remained to be detd.We analyzed the hypothalamic circuitry targeted by leptin following chronic treatment of DIO mice with JD5037.Leptin treatment or an increase in endogenous leptin following fasting/refeeding induced STAT3 phosphorylation in neurons in the arcuate nucleus (ARC) in lean and JD5037-treated DIO mice, but not in vehicle-treated DIO animals.  Co-localization of pSTAT3 in leptin-treated mice was significantly less common with NPY+ than with POMC+ ARC neurons.  The hypophagic effect of JD5037 was absent in melanocortin-4 receptor (MC4R) deficient obese mice or DIO mice treated with a MC4R antagonist, but was maintained in NPY-/- mice kept on a high-fat diet.Peripheral CB1R blockade in DIO restores sensitivity to endogenous leptin, which elicits hypophagia via the re-activation of melanocortin signaling in the ARC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokTnwUe56m1LVg90H21EOLACvtfcHk0ljZFM5DWzEGFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7rI&md5=50be1d443a5e97c67cf85e466d7b2a48</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2017.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2017.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DDrori%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DKashiwaya%26aufirst%3DY.%26aulast%3DReitman%26aufirst%3DM.%2BL.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520cannabinoid-1%2520receptor%2520blockade%2520restores%2520hypothalamic%2520leptin%2520signaling%26jtitle%3DMol.%2520Metab.%26date%3D2017%26volume%3D6%26spage%3D1113%26epage%3D1125%26doi%3D10.1016%2Fj.molmet.2017.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz
de Azua, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zingaretti, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quarta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwitter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettschureck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez-Lago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bindila, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offermanns, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisoli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagotto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span> <span> </span><span class="NLM_article-title">Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">4148</span>– <span class="NLM_lpage">4162</span>, <span class="refDoi"> DOI: 10.1172/JCI83626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;key=10.1172%2FJCI83626" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=4148-4162&author=I.+Ruiz%0Ade+Azuaauthor=G.+Manciniauthor=R.+K.+Srivastavaauthor=A.+A.+Reyauthor=P.+Cardinalauthor=L.+Tedescoauthor=C.+M.+Zingarettiauthor=A.+Sassmannauthor=C.+Quartaauthor=C.+Schwitterauthor=A.+Conradauthor=N.+Wettschureckauthor=V.+K.+Vemuriauthor=A.+Makriyannisauthor=J.+Hartwigauthor=M.+Mendez-Lagoauthor=L.+Bindilaauthor=K.+Monoryauthor=A.+Giordanoauthor=S.+Cintiauthor=G.+Marsicanoauthor=S.+Offermannsauthor=E.+Nisoliauthor=U.+Pagottoauthor=D.+Cotaauthor=B.+Lutz&title=Adipocyte+cannabinoid+receptor+CB1+regulates+energy+homeostasis+and+alternatively+activated+macrophages&doi=10.1172%2FJCI83626"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1172%2FJCI83626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI83626%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz%2Bde%2BAzua%26aufirst%3DI.%26aulast%3DMancini%26aufirst%3DG.%26aulast%3DSrivastava%26aufirst%3DR.%2BK.%26aulast%3DRey%26aufirst%3DA.%2BA.%26aulast%3DCardinal%26aufirst%3DP.%26aulast%3DTedesco%26aufirst%3DL.%26aulast%3DZingaretti%26aufirst%3DC.%2BM.%26aulast%3DSassmann%26aufirst%3DA.%26aulast%3DQuarta%26aufirst%3DC.%26aulast%3DSchwitter%26aufirst%3DC.%26aulast%3DConrad%26aufirst%3DA.%26aulast%3DWettschureck%26aufirst%3DN.%26aulast%3DVemuri%26aufirst%3DV.%2BK.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DHartwig%26aufirst%3DJ.%26aulast%3DMendez-Lago%26aufirst%3DM.%26aulast%3DBindila%26aufirst%3DL.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DGiordano%26aufirst%3DA.%26aulast%3DCinti%26aufirst%3DS.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DOffermanns%26aufirst%3DS.%26aulast%3DNisoli%26aufirst%3DE.%26aulast%3DPagotto%26aufirst%3DU.%26aulast%3DCota%26aufirst%3DD.%26aulast%3DLutz%26aufirst%3DB.%26atitle%3DAdipocyte%2520cannabinoid%2520receptor%2520CB1%2520regulates%2520energy%2520homeostasis%2520and%2520alternatively%2520activated%2520macrophages%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D4148%26epage%3D4162%26doi%3D10.1172%2FJCI83626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TGZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5TGZ','PDB','5TGZ'); return false;">PDB: 5TGZ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i166"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01467">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_52782"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01467">10.1021/acs.jmedchem.8b01467</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Open field locomotor activity study of <b>6a</b> in rat; additional data of mouse full PK study for compound <b>6a</b>; liver microsome stability of compounds <b>5l</b>, <b>6a</b>, <b>6c</b>, <b>6g</b>, and <b>6h</b>; analytical HPLC methods; HPLC traces and <sup>1</sup>H NMR spectra of the key target compounds <b>5m</b>, <b>5p</b>, <b>6a</b>, and <b>9l</b>; NOESY spectra of compounds <b>7b</b> and <b>8h</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf">PDF</a>)</p></li><li><p class="inline">PBD file of CB<sub>1</sub>R and compound <b>6a</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_001.pdf">jm8b01467_si_001.pdf (1.23 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_002.pdb">jm8b01467_si_002.pdb (525.87 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01467/suppl_file/jm8b01467_si_003.csv">jm8b01467_si_003.csv (5.21 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01467&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-22%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01467%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01467" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799313c8abb24cb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
